Walker Chandiok & Co LLP

21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Report

To the Members of Integris Medtech Limited (formerly known as Integris Health Private Limited)

Report on the Audit of the Standalone Financial Statements

Opinion

1. We have audited the accompanying standalone financial statements of **Integris Medtech Limited (formerly known as Integris Health Private Limited)** ('the Company'), which comprise the Standalone Balance Sheet as at 31 March 2026, the Standalone Statement of Profit and Loss (including Other Comprehensive Income), the Standalone Statement of Cash Flow and the Standalone Statement of Changes in Equity for the year then ended, and notes to the standalone financial statements, including material accounting policy information and other explanatory information.

2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards ('Ind AS') specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2026, and its profit (including other comprehensive income), its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Standalone Financial Statements and Auditor's Report thereon

4. The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Director's report, but does not include the standalone financial statements and our auditor's report thereon.

   Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

   In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

   The Director's report is not made available to us at the date of this auditor's report. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

5. The accompanying standalone financial statements have been approved by the Company's Board of Directors. The Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation and presentation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS specified under section 133 of the Act and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

6. In preparing the standalone financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

7. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

8. Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

9. As part of an audit in accordance with Standards on Auditing, specified under section 143(10) of the Act we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(I) of the Act we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;

- Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

11. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

12. As required by section 197(16) of the Act, based on our audit, we report that the Company has paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.

13. As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act we give in the Annexure A a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

14. Further to our comments in Annexure A, as required by section 143(3) of the Act based on our audit, we report, to the extent applicable, that:

    a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the accompanying standalone financial statements;

b) Except for the matters stated in paragraph 14(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

c) The standalone financial statements dealt with by this report are in agreement with the books of account;

d) In our opinion, the aforesaid standalone financial statements comply with Ind AS specified under section 133 of the Act;

e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2026 from being appointed as a director in terms of section 164(2) of the Act;

f) The qualification relating to the maintenance of accounts and other matters connected therewith are as stated in paragraph 14(b) above on reporting under section 143(3)(b) of the Act and paragraph 14(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended);

g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company as on 31 March 2026 and the operating effectiveness of such controls, refer to our separate report in Annexure B wherein we have expressed an unmodified opinion; and

h) With respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position as at 31 March 2026;

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2026;

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended 31 March 2026;

iv.

a. The management has represented that, to the best of its knowledge and belief, as disclosed in note 48(vi) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or securities premium or any other sources or kind of funds) by the Company to or in any person(s) or entity(ices), including foreign entities ('the intermediaries'), with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ('the Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf the Ultimate Beneficiaries;

b. The management has represented that, to the best of its knowledge and belief, as disclosed in note 48(vii) to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ices), including foreign entities ('the Funding Parties'), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

c. Based on such audit procedures performed as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the management representations under sub-clauses iv(a) and iv(b) above contain any material misstatement.

v. The Company has not declared or paid any dividend during the year ended 31 March 2026.

vi. As stated in note 47 to the standalone financial statements and based on our examination which included test checks, except for matters mentioned below, the Company, in respect of financial year commencing on 1 April 2025, has used an accounting software for maintaining its books of account and payroll records which have a feature of recording audit trail (edit log) facility and the same have been operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with other than the consequential impact of the exception given below. Furthermore, the audit trail has been preserved by the Company as per the statutory requirements for record retention.

Nature of exception noted	Details of Exception
Instances of accounting software for maintaining books of accounts for which the feature of recording audit trail (edit log) facility was not operated throughout the year for all relevant transactions recorded in the software	The audit trail feature was not enabled at the database level for accounting software to log any direct data changes, used for maintenance of all accounting records by the Company.

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No.: 001076N/N500013

Kartik Gogia
Partner
Membership No.: 512371
UDIN: 26512371BXZOSI8062

Place: Gurugram
Date: 29 June 2026

Annexure A referred to in paragraph 13 of the Independent Auditor's Report of even date to the members of Integris Medtech Limited (formerly known as Integris Health Private Limited) on the Standalone Financial Statements for the year ended 31 March 2026

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit, and to the best of our knowledge and belief, we report that:

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment and relevant details of right-of-use assets.

(B) The Company does not have any intangible assets and accordingly, reporting under clause 3(i)(a)(B) of the Order is not applicable to the Company.

(b) The property, plant and equipment have been physically verified by the management during the year and no material discrepancies were noticed on such verification. In our opinion, the frequency of physical verification programme adopted by the Company, is reasonable having regard to the size of the Company and the nature of its assets.

(c) The Company does not own any immovable property (other than properties where the Company is a lessee), disclosed in Note 4 to the standalone financial statements. For properties where the Company is a lessee, the lease arrangements have been duly executed in favour of the Company except in following cases:

Description of property	Right-of-Use Assets Value *(₹ million)*	Location	Details of Lessor	Period held	Reason for non-execution of lease agreement
Buildings	147.02	Gurugram	Fairleaf Real Estate Private Limited	February 2026	In the process of registration of lease agreement with the lessor.

Further, for properties where the Company is a lessee and the lease agreements are duly executed in favour of the lessee, the Company has entered into sub-leasing arrangements with its subsidiary company.

(d) The Company has adopted cost model for its property, plant and equipment (including right-of-use assets) and intangible assets. Accordingly, reporting under clause 3(i)(d) of the Order is not applicable to the Company.

(e) No proceedings have been initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended) and rules made thereunder.

(ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year, except inventory lying with third parties. In our opinion, the coverage and procedure of such verification by the management is appropriate and no discrepancies of 10% or more in the aggregate for each class of inventory were noticed as compared to book records. In respect of inventory lying with third parties, these have substantially been confirmed by the third parties.

(b) As disclosed in Note 46 to the standalone financial statements, the Company has been sanctioned a working capital limit in excess of Rs. 5 crores by banks based on the security of current assets. The quarterly returns/statements, in respect of the working capital limits have been filed by the Company with such banks and such returns/statements are in agreement with the books of account of the Company for the respective periods, which were not subject to audit/reviews. Further, pursuant to the terms of the sanction letter, the Company is not required to file any quarterly return or statement with Citi Bank.

Annexure A referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Integris Medtech Limited (formerly known as Integris Health Private Limited) on the Standalone Financial Statements for the year ended 31 March 2026

(iii) The Company has not provided any security or granted any advances in the nature of loans to companies, firms, limited liability partnerships or any other parties during the year. Further, the Company has made investments in, provided guarantee and granted unsecured loans to companies and employees during the year, in respect of which:

(a) The Company has provided loans, or guarantee to companies and employees during the year as per details given below:

Amount in ₹ million

Particulars	**Guarantees***	**Loans**
Aggregate amount provided/granted during the year:		
- Subsidiaries	3,123.60	3,682.70
- Employees	-	1.80
Balance outstanding as at balance sheet date:		
- Subsidiaries	3,123.60	4,049.23
- Employees	-	1.80

* Renewal of existing Guarantees have been considered as "guarantees granted during the year" for the purpose of reporting under this clause.

(b) In our opinion, and according to the information and explanations given to us, the investments made, guarantees provided and terms and conditions of the grant of all loans and guarantees provided are, prima facie, not prejudicial to the interest of the Company.

(c) In respect of loans and advances in the nature of loans granted by the Company, the schedule of repayment of principal and payment of interest has been stipulated and the repayments/receipts of principal and interest are regular.

(d) There is no amount which is overdue for more than 90 days in respect of loans or advances in the nature of loans granted to such companies, or other parties.

(e) The Company has granted loans which had fallen due during the year and such loan was renewed during the year. The details of the same has been given below:

Amount in ₹ million

Name of the party	**Total loan amount granted during the year***	**Aggregate amount of overdues of existing loans renewed or extended or settled by fresh loans**	**Nature of extension (i.e., renewed/ extended/ fresh loan provided)**	**Percentage of the aggregate to the total loans or advances in the nature of loans granted during the year**
Translumina GmbH	655.41	272.60	Extended	41.59%

*Loans renewed or extended have been considered as "loans granted during the year" for the purpose of reporting under this clause.

(f) The Company has not granted any loans, which are repayable on demand or without specifying any terms or period of repayment.

(iv) In our opinion, and according to the information and explanations given to us, the Company has complied with the provisions of section 186 of the Act in respect of loans, investments made and guarantees provided, as applicable. Further, the Company has not entered into any transaction covered under section 185 and section 186 of the Act in respect of security provided by it.

Annexure A referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Integris Medtech Limited (formerly known as Integris Health Private Limited) on the Standalone Financial Statements for the year ended 31 March 2026

(v) In our opinion, and according to the information and explanations given to us, the Company has not accepted any deposits or there are no amounts which have been deemed to be deposits within the meaning of sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, reporting under clause 3(v) of the Order is not applicable to the Company.

(vi) The Central Government has not specified maintenance of cost records under sub-section (1) of section 148 of the Act, in respect of Company's products/ services / business activities. Accordingly, reporting under clause 3(vi) of the Order is not applicable.

(vii)(a) In our opinion and according to the information and explanations given to us, undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and other material statutory dues, as applicable, have generally been regularly deposited with the appropriate authorities by the Company, though there have been slight delays in a few cases. Further, no undisputed amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us, we report that there are no statutory dues referred in sub-clause (a) which have not been deposited with the appropriate authorities on account of any dispute except for the following:

Name of the statute	**Nature of dues**	**Gross Amount *(₹ million)***	**Amount paid under Protest *(₹ million)***	**Period to which the amount relates**	**Forum where dispute is pending**
Income Tax Act, 1961	Income Tax	2.40	0.48	AY 2023-2024	Commissioner of Income-Tax (Appeals)

(viii) According to the information and explanations given to us, we report that no transactions were surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961) which have not been previously recorded in the books of accounts.

(ix) (a) In our opinion and according to the information and explanations given to us, the Company has not defaulted in repayment of its loans or borrowings or in the payment of interest thereon to any lender.

(b) According to the information and explanations given to us including confirmations received from banks representation received from the management of the Company, and on the basis of our audit procedures, we report that the Company has not been declared a willful defaulter by any bank or financial institution or government or any government authority.

(c) In our opinion and according to the information and explanations given to us, the Company has not raised any money by way of term loans during the year and did not have any term loans outstanding at the beginning of the current year. Accordingly, reporting under clause 3(ix)(c) of the Order is not applicable to the Company.

(d) In our opinion and according to the information and explanations given to us, and on an overall examination of the financial statements of the Company, funds raised by the Company on short term basis have, prima facie, not been utilised for long term purposes.

(e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries and associates.

Annexure A referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Integris Medtech Limited (formerly known as Integris Health Private Limited) on the Standalone Financial Statements for the year ended 31 March 2026

(f) In our opinion and according to the information and explanations given to us, the Company has not raised any loans during the year on the pledge of securities held in its subsidiaries or associate companies.

(x) (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments), during the year. Accordingly, reporting under clause 3(x)(a) of the Order is not applicable to the Company.

(b) During the year, the Company has made preferential allotment of shares. In our opinion and according to the information and explanations given to us, the Company has complied with the requirements of section 42 and section 62 of the Act and the rules framed there under with respect to the same. No amounts have been raised from the preferential allotment of shares as the allotment was in lieu of acquisition of Everlife Holdings Pte. Ltd. as further explained in Note 5A and 14(a) to the standalone financial statements and hence, the reporting on utilisation of funds is not applicable. Further, the Company has not made any preferential allotment or private placement of convertible debentures during the year. Furthermore, in regards to money raised towards private placement of shares towards end of the previous year and which was unutilised till 31 March 2025, have been partially utilised during the current year for the purposes for which these funds were raised by the Company, though surplus funds which were not required for immediate utilisation had been invested in readily realizable liquid investments.

(xi) (a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or no fraud on the Company has been noticed or reported during the period covered by our audit.

(b) According to the information and explanations given to us including the representation made to us by the management of the Company, no report under sub-section 12 of section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014, with the Central Government for the period covered by our audit.

(c) According to the information and explanations given to us including the representation made to us by the management of the Company, there are no whistle-blower complaints received by the Company during the year.

(xii) The Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it. Accordingly, reporting under clause 3(xii) of the Order is not applicable to the Company.

(xiii) In our opinion and according to the information and explanations given to us, all transactions entered into by the Company with the related parties are in compliance with sections 177 and 188 of the Act, where applicable. Further, the details of such related party transactions have been disclosed in the standalone financial statements, as required under Indian Accounting Standard (Ind AS) 24, Related Party Disclosures specified in Companies (Indian Accounting Standards) Rules 2015 as prescribed under section 133 of the Act.

(xiv) According to the information and explanations given to us, the Company is not required to and consequently, does not have an internal audit system as per the provisions of section 138 of the Act. Accordingly, reporting under clause 3(xiv) of the Order is not applicable to the Company.

(xv) According to the information and explanation given to us, the Company has not entered into any non-cash transactions with its directors or persons connected with its directors and accordingly, reporting under clause 3(xv) of the Order with respect to compliance with the provisions of section 192 of the Act are not applicable to the Company.

(xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, reporting under clauses 3(xvi)(a), (b) and (c) of the Order are not applicable to the Company.

Annexure A referred to in Paragraph 13 of the Independent Auditor's Report of even date to the members of Integris Medtech Limited (formerly known as Integris Health Private Limited) on the Standalone Financial Statements for the year ended 31 March 2026

(d) Based on the information and explanations given to us and as represented by the management of the Company, the Group (as defined in Core Investment Companies (Reserve Bank) Directions, 2016) does not have any Core Investment Company (CIC).

(xvii) The Company has not incurred any cash losses in the current financial year as well as the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, reporting under clause 3(xviii) of the Order is not applicable to the Company.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information in the standalone financial statements, our knowledge of the plans of the Board of Directors and management and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) (a) In our opinion and according to the information and explanations given to us, there are no unspent amounts towards Corporate Social Responsibility pertaining to other than ongoing projects as at end of the current financial year. Accordingly, reporting under clause 3(xx)(a) of the Order is not applicable to the Company.

(b) In our opinion and according to the information and explanations given to us, the Company has transferred the remaining unspent amounts towards Corporate Social Responsibility (CSR) under sub-section (5) of section 135 of the Act, in respect of ongoing project, within a period of 30 days from the end of financial year to a special account in compliance with the provision of sub-section (6) of section 135 of the Act.

(xxi) The reporting under clause 3(xxi) of the Order is not applicable in respect of audit of standalone financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report.

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No.: 001076N/N500013

Kartik Gogia
Partner
Membership No.: 512371
UDIN: 26512371BXZOSI8062

Place: Gurugram
Date: 29 June 2026

Annexure B

Independent Auditor's Report on the internal financial controls with reference to the Standalone Financial Statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the standalone financial statements of **Integris Medtech Limited (formerly known as Integris Health Private Limited)** ('the Company') as at and for the year ended 31 March 2026, we have audited the internal financial controls with reference to financial statements of the Company as at that date.

Responsibilities of Management and Those Charged with Governance for Internal Financial Controls

2. The Company's Board of Directors is responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements

3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the ICAI prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with Reference to Financial Statements

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of

management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2026, based on the internal financial controls with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No.: 001076N/N500013

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Kartik Gogia
Partner
Membership No.: 512371
UDIN: 26512371BXZOSI8062

Place: Gurugram
Date: 29 June 2026

Integris Medtech Limited (formerly known as Integris Health Private Limited)
CIN: U85110DL2008PLC177230
Standalone Balance Sheet as at 31 March 2026
(All amounts in ₹ million except number of shares and per share data, unless otherwise stated)

Particulars	Notes	As at 31 March 2026	As at 31 March 2025
Assets			
Non-current assets			
Property, plant and equipment	4	2.31	0.20
Right-of-use assets	4A	145.80	9.61
Intangible assets under development	4B	37.62	-
Financial assets			
(i) Investments	5A	37,811.63	5,175.62
(ii) Loans	6	4,039.23	784.99
(iii) Other financial assets	7	477.07	330.84
Non-current tax assets (net)	8	2.62	1.99
Other non-current assets	9	30.45	-
Total non-current assets		**42,546.73**	**6,303.25**
Current assets			
Inventories	10	49.26	25.49
Financial assets			
(i) Investments	5B	1,426.15	3,276.23
(ii) Trade receivables	11	151.90	298.66
(iii) Cash and cash equivalents	12	75.03	98.15
(iv) Bank balances other than (iii) above	13	3.41	2,118.68
(v) Loans	6	11.80	-
(vi) Other financial assets	7	659.21	138.58
Other current assets	9	275.50	169.30
Total current assets		**2,652.26**	**6,125.09**
Total assets		**45,198.99**	**12,428.34**
Equity and liabilities			
Equity			
Equity share capital	14	108.34	19.66
Other equity	15	44,297.13	12,145.89
Total equity		**44,405.47**	**12,165.55**
Liabilities			
Non-current liabilities			
Financial liabilities			
(i) Lease liabilities	16	302.03	169.20
(ii) Other financial liabilities	17	65.71	-
Deferred tax liabilities (net)	18	62.00	17.32
Provisions	19	0.90	0.35
Total non-current liabilities		**430.64**	**186.87**
Current liabilities			
Financial liabilities			
(i) Borrowings	20	-	6.94
(ii) Lease liabilities	16	12.51	8.62
(iii) Trade payables	21		
-Total outstanding dues of micro enterprises and small enterprises		4.92	0.04
-Total outstanding dues of creditors other than micro enterprises and small enterprises		165.23	37.33
(iv) Other financial liabilities	17	102.27	11.41
Other current liabilities	22	37.54	11.31
Provisions	19	3.50	0.27
Current tax liabilities (net)	23	36.91	-
Total current liabilities		**362.88**	**75.92**
Total equity and liabilities		**45,198.99**	**12,428.34**

Summary of material accounting policies 3
The accompanying notes form an integral part of the Standalone Financial Statements.

As per our report of even date attached

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm Registration No: 001076N/N500013

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Kartik Gogia
Partner
Membership No: 512371

Place: Gurugram
Date: 29 June 2026

Probir Das
Executive Director and Group CEO
DIN: 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No: ACS 15719

Place: Noida
Date: 29 June 2026

Integris Medtech Limited (formerly known as Integris Health Private Limited)
CIN: U85110DL2008PLC177230
Standalone Statement of Profit and Loss for the year ended 31 March 2026
(All amounts in ₹ million except number of shares and per share data, unless otherwise stated)

Particulars	Notes	For the year ended 31 March 2026	For the year ended 31 March 2025
Income			
Revenue from operations	24	651.09	383.41
Other income	25	958.25	525.66
Total Income		**1,609.34**	**909.07**
Expenses			
Purchases of stock-in-trade	26	622.77	371.58
Changes in inventories of stock-in-trade	27	(23.77)	(18.63)
Employee benefits expense	28	240.53	34.61
Finance costs	29	20.84	8.47
Depreciation and amortisation expenses	30	8.97	1.39
Other expenses	31	134.30	63.53
Total expenses		**1,003.64**	**460.95**
Profit before exceptional items and tax		**605.70**	**448.12**
Exceptional items	45	82.89	45.78
Profit before tax		**522.81**	**402.34**
Tax expense	33		
Current tax (including earlier years)		104.12	28.13
Deferred tax expense		44.64	19.79
Total tax expense		**148.76**	**47.92**
Profit after tax		**374.05**	**354.42**
Other comprehensive income			
Items that will not be reclassified to profit or loss			
Re-measurements of the defined benefit plans		0.17	(0.18)
Income tax relating to above item		(0.04)	0.05
Total other comprehensive income/(loss) for the year		**0.13**	**(0.13)**
Total comprehensive income for the year		**374.18**	**354.29**
Earnings per equity share ₹ 1 per share	34		
Basic (₹)		3.85	6.33
Diluted (₹)		3.83	6.18
Summary of material accounting policies	3		

The accompanying notes form an integral part of the Standalone Financial Statements.

As per our report of even date attached

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm Registration No: 001076N/N500013

Kartik Gogia
Partner
Membership No: 512371

Place: Gurugram
Date: 29 June 2026

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Probir Das
Executive Director and Group CEO
DIN: 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No: ACS 15719

Place: Noida
Date: 29 June 2026

Integris Medtech Limited (formerly known as Integris Health Private Limited)
CIN: U85110DL2008PLC177230
Standalone Statement of Changes in Equity for the year ended 31 March 2026
(All amounts in ₹ million except number of shares and per share data, unless otherwise stated)

A Equity share capital*

Particulars	As at 1 April 2024	Issued during the year	As at 31 March 2025	Issued during the year	As at 31 March 2026
Equity share capital	16.70	2.96	19.66	88.68	108.34

B Other equity**

Particulars	Other equity				Total
	Equity Component of CCPS	Securities Premium	Retained earnings	Shared based compensation reserve	
Balance as at 1 April 2024	**634.65**	**5,652.79**	**979.65**	**-**	**7,267.09**
Profit for the year	-	-	354.42	-	354.42
Other comprehensive income for the year (net of tax)	-	-	(0.13)	-	(0.13)
Security premium on equity shares issued during the year	-	4,979.88	-	-	4,979.88
Transaction cost arising on issue of equity shares	-	(42.76)	-	-	(42.76)
Conversion of compulsorily convertible preference shares	(634.65)	-	-	-	(634.65)
Share based payment expenses (refer note 44)	-	-	-	222.04	222.04
Balance as at 31 March 2025	**-**	**10,589.91**	**1,333.94**	**222.04**	**12,145.89**
Profit for the year	-	-	374.05	-	374.05
Other comprehensive income for the year (net of tax)	-	-	0.13	-	0.13
Security premium on equity shares issued during the year	-	31,753.40	-	-	31,753.40
Bonus shares issued during the year	-	(72.22)	-	-	(72.22)
Share based payment expenses (refer note 44)	-	-	-	186.13	186.13
Transfer from shared based compensation reserve to retained earnings on cancellation of options (refer note 44)	-	-	90.25	(90.25)	-
Employee stock options settlement on cancellation of options (refer note 44)	-	-	(90.25)	-	(90.25)
Balance as at 31 March 2026	**-**	**42,271.09**	**1,708.12**	**317.92**	**44,297.13**

**Refer note 14 for details*
***Refer note 15 for details*

The accompanying notes form an integral part of the Standalone Financial Statements.

As per our report of even date attached

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm Registration No: 001076N/N500013

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Kartik Gogia
Partner
Membership No: 512371

Place: Gurugram
Date: 29 June 2026

Probir Das
Executive Director and Group CEO
DIN: 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No: ACS 15719

Place: Noida
Date: 29 June 2026

Standalone Statement of Cash Flows for the year ended 31 March 2026
(All amounts in ₹ million except number of shares and per share data, unless otherwise stated)

	Particulars		For the year ended 31 March 2026	For the year ended 31 March 2025
A	**Cash flow from operating activities**			
	Profit before tax		**522.81**	**402.34**
	Adjustments for:			
	Depreciation and amortisation expenses		8.97	1.39
	Finance costs		20.84	8.47
	Interest income		(320.90)	(202.45)
	Share of profit from investment in Limited Liability Partnership ('LLP')		-	(180.50)
	Unrealised gain on exchange rate fluctuations (net)		(218.55)	(16.85)
	(Reversal)/Allowance for expected credit loss on trade receivables (net)		(0.53)	8.04
	Allowance for impairment on financial assets		-	0.43
	Gain on termination of right-of-use assets and lease liabilities		(1.02)	-
	Liability no longer required, written back		(0.50)	(0.39)
	Fair value gains on investments measured at fair value through profit or loss		(22.11)	(72.35)
	Gain on disposal of investment in mutual funds		(145.64)	(7.25)
	Share based payment expenses		74.30	8.99
	Operating loss before working capital changes		**(82.33)**	**(50.13)**
	Movement in working capital			
	Increase/(decrease) in trade payables		133.18	(140.95)
	Increase in provisions		3.91	0.71
	Increase/(decrease) in other liabilities		26.23	(8.12)
	Increase/(decrease)in other financial liabilities		89.54	(19.30)
	(Increase)/decrease in trade receivables		147.29	(200.60)
	Increase in inventories		(23.77)	(18.64)
	Increase in other assets		(134.46)	(169.53)
	Increase in other financial assets		(509.97)	(24.40)
	Cash used in operating activities post working capital changes		**(350.38)**	**(630.96)**
	Income tax paid (net)		(67.84)	(29.70)
	Net cash used in operating activities	**A**	**(418.22)**	**(660.66)**
B	**Cash flows from investing activities**			
	Purchase of property, plant and equipment (including intangible assets under development, capital advances, and capital creditors)		(40.86)	(2.44)
	Investments in subsidiaries and associates		(838.62)	-
	Share of profit from investment in Limited Liability Partnership ('LLP')		-	180.50
	Purchase of investments in quoted mutual funds		(300.00)	(3,500.00)
	Sale of investments in quoted mutual funds		2,317.83	303.37
	Movement in bank deposits (net)		2,117.72	(1,670.27)
	Loans given/ (repayments received) (net)		(3,063.50)	1,801.21
	Interest received		236.06	124.03
	Net cash generated from/(used) in investing activities	**B**	**428.63**	**(2,763.60)**
C	**Cash flows from financing activities**			
	Proceeds from issue of equity shares (net of transaction costs)		-	3,540.09
	Payment of principal portion of lease liabilities		(5.72)	(1.43)
	Payment of interest portion of lease liabilities		(18.96)	(0.52)
	Repayment of current borrowings (net)		(6.94)	(14.93)
	Finance costs paid		(1.90)	(1.28)
	Net cash generated from/(used) in financing activities	**C**	**(33.52)**	**3,521.93**
	Net change in cash and cash equivalents (A+B+C)		**(23.11)**	**97.67**
	Cash and cash equivalents at the beginning of the year		98.14	0.48
	Cash and cash equivalents at the end of the year		**75.03**	**98.15**
	Cash and cash equivalents includes (refer note 12)			
	Cash on hand		-	4.25
	Balances with banks in current accounts		10.18	3.90
	Deposits with maturity of less than three months		64.85	90.00
			75.03	**98.15**
	Notes:			
	Significant non-cash investing activities:			
	Conversion of investment in LLP into loan (refer note 5A)		-	1,647.58
	Deemed investment in group companies (refer note 5A and 41)		27.53	41.15
	Conversion of CCPS into equity shares (refer note 4(a)(iii)(c))		-	634.65
	Investment in subsidiaries and issuance of equity shares including premium (refer note 5A and 14(a)(iii)(d))		31,769.86	-
	Bonus shares issued during the year		72.22	-
	Net investment in the sub-lease of right-of-use assets		-	163.84
	Acquisition of right-of-use assets		147.02	170.70

The accompanying notes form an integral part of the Standalone Financial Statements.

As per our report of even date attached

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm Registration No: 001076N/N500013

Kartik Gogia
Partner
Membership No: 512371

Place: Gurugram
Date: 29 June 2026

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Probir Das
Executive Director and Group CEO
DIN: 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No: ACS 15719

Place: Noida
Date: 29 June 2026

4 Property, plant and equipment

Particulars	Office equipments	Computers	Total
Gross block			
Balance as at 1 April 2024	0.26	-	**0.26**
Additions during the year	-	0.16	0.16
Balance as at 31 March 2025	**0.26**	**0.16**	**0.42**
Additions during the year	0.25	2.11	2.36
Balance as at 31 March 2026	**0.51**	**2.27**	**2.78**
Accumulated depreciation			
Balance as at 1 April 2024	**0.17**	**-**	**0.17**
Depreciation charge for the year	0.04	0.01	0.05
Balance as at 31 March 2025	**0.21**	**0.01**	**0.22**
Depreciation charge for the year	0.06	0.19	0.25
Balance as at 31 March 2026	**0.27**	**0.20**	**0.47**
Carrying amount (net)			
Net block as at 31 March 2025	**0.05**	**0.15**	**0.20**
Net block as at 31 March 2026	**0.24**	**2.07**	**2.31**

Notes:
1.The Company has not revalued property, plant and equipment during the year ended 31 March 2026 and 31 March 2025.
2. No property, plant and equipment have been taken on lease.
3. The Company does not have any immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee except as disclosed in note 4A).

4A Right-of-use assets

Particulars	Buildings*	Total
Gross block		
Balance as at 1 April 2024	8.29	**8.29**
Additions during the year	170.70	170.70
Derecognition on account of investment in sub-lease of right-of-use assets^	(163.84)	(163.84)
Balance as at 31 March 2025	**15.15**	**15.15**
Additions during the year	147.02	147.02
Adjustment for lease termination	(5.80)	(5.80)
Balance as at 31 March 2026	**156.37**	**156.37**
Accumulated depreciation		
Balance as at 1 April 2024	**4.21**	**4.21**
Depreciation charge for the year	1.33	1.33
Balance as at 31 March 2025	**5.54**	**5.54**
Depreciation charge for the year	8.72	8.72
Adjustment for lease termination	(3.69)	(3.69)
Balance as at 31 March 2026	**10.57**	**10.57**
Carrying amount (net)		
Net block as at 31 March 2025	**9.61**	**9.61**
Net block as at 31 March 2026	**145.80**	**145.80**

* The immovable properties (buildings) where the Company is a lessee, the lease arrangements have been duly executed in favour of the Company except in following cases:

Details of Lessor	Amount	Location	Period held	Reason for non-execution of lease
Fairleaf Real Estate Private Limited	147.02	Gurugram	February 2026	In the process of registration of lease agreement with the lessor.

^ The immovable properties (buildings) where the Company is a lessee and the lease agreements are duly executed in favour of the lessee, the Company has entered into sub-leasing arrangements with its subsidiary company.

Note: Refer note 42 for details.

(This space has been intentionally left blank)

4B Intangible assets under development

Particulars	As at 31 March 2026	As at 31 March 2025
Opening balance	**-**	**-**
Additions during the year	37.62	-
Capitalised during the year	-	-
Closing balance	**37.62**	**-**

Intangible assets under development ageing schedule as at 31 March 2026

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in progress	37.62	-	-	-	37.62
Total	**37.62**	**-**	**-**	**-**	**37.62**

Intangible assets under development ageing schedule as at 31 March 2025

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Project in progress	-	-	-	-	-
Total	**-**	**-**	**-**	**-**	**-**

(i) There are no projects whose completion is either overdue or has exceeded its cost compared to its original plan.
(ii) Intangible assets under development does not include any project temporarily suspended.

(This space has been intentionally left blank)

5A Investments

Particulars	**As at 31 March 2026**	**As at 31 March 2025**
Non-current investments:		
A) Investment in equity instruments - carried at amortised cost		
(I) Investment in subsidiaries (unquoted):		
25,000 (31 March 2025: 25,000) fully paid-up equity shares of face value Euro 1 each in Artic GmbH, Munich, Germany	77.81	77.81
Less: Impairment in value of Investment in Artic GmbH, Munich, Germany	(77.81)	(77.81)
805,000 (31 March 2025: 805,000) fully paid-up equity shares of face value Euro 1 each in Translumina GmbH, Germany	1,212.66	1,212.66
3,000,000 (31 March 2025: 3,000,000) fully paid-up equity shares of face value ₹ 10 each in Transhealth Private Limited, India	30.00	30.00
2,000,000 (31 March 2025: 2,000,000) fully paid-up equity shares of face value ₹ 10 each in Transvalve Health Private Limited, India	20.00	20.00
101,003 (31 March 2025: 101,003) fully paid-up equity shares of face value ₹ 1 each in Translumina Therapeutics Private Limited, India (Converted from LLP to Private Limited Company from 25 January 2025)*	3,871.81	3,871.81
10,000 (31 March 2025: Nil) fully paid-up equity shares of face value ₹ 10 each in Halemed Medical Private Limited, India (refer note (iv) below)	42.66	-
21,668,546 (31 March 2025: Nil) fully paid-up equity shares of face value USD 1 each; 31,876,940 (31 March 2025: Nil) fully paid-up class C CCPS of face value USD 4.317 each; 32,502,819 (31 March 2025: Nil) fully paid-up class C CCPS of face value USD 1 in Everlife Holdings Pte. Ltd., Singapore (refer note (v) below)	31,769.86	-
65,196 (31 March 2025: Nil) fully paid-up equity shares of face value ₹ 100 each in CPC Diagnostics Private Limited, India (refer note (vi) below)	502.01	-
Deemed investment in group companies for share based payment arrangements (refer note (iii) below)	68.68	41.15
	37,517.68	**5,175.62**
(II) Investment in associates		
1,771,210 (31 March 2025: Nil) fully paid-up Series A preference stock of face value USD 0.0001 each in Laguna Tech USA, Inc. (refer note (vii) below)	293.95	-
	293.95	**-**
B) Interest in LLP - carried at amortised cost		
I) Interest in Translumina Therapeutics LLP ('TTLLP') (till 25 January 2025):		
Partnership interest in TTLLP, India (refer note (ii) below)	-	3,871.81
Reduction of interest in TTLLP on the account of conversion to Private limited Company (refer note (ii) below)	-	(3,871.81)
	-	**-**
	37,811.63	**5,175.62**
Aggregate value of unquoted investments	37,889.44	5,253.43
Aggregate amount of impairment in value of investments	77.81	77.81

(i) Investment in subsidiaries are stated at cost using principles of Ind AS 27 'Separate Financial Statements'.

(ii) As per the partnership deed, the Company has subscribed to 99% interest in TTLLP, however, its share in profits/loss of TTLLP is 100%. During the year ended 31 March 2025, the investment in TTLLP amounting ₹ 1,647.58 million was converted into loan on 15 November 2024. Subsequently, loan amounting ₹ 1,647.58 million has been repaid by TTLLP on 27 December 2024. Further, TTLLP was converted in Private Limited Company w.e.f. 25 January 2025.

(iii) The Company has Employee Stock Option Plan (ESOP) in force. Based on such ESOP scheme, the Company has granted options to acquire equity shares of the Company that would vest in a graded manner to certain employees of subsidiaries. To the extent that the Company has not charged and recovered the fair value of such stock options from its subsidiaries, it has been included in the above carrying value of investment in the those subsidiaries.

(iv) On 24 June 2025, the Company has also acquired 100% ownership interest in Halemed Medical Private Limited and has paid a purchase consideration of ₹ 42.66 million.

(v) On 23 June 2025, the Company has acquired 100% ownership interest in Everlife Holdings Pte. Ltd. (Everlife) under common control. The acquisition of Everlife has been done through swap of shares of Everlife and the Company for a total consideration of ₹ 31,769.86 million by issuing of fresh equity shares of the Company.

(vi) During the year ended 31 March 2026, pursuant to resolution dated 07 January 2026, passed by Board of Directors of the Company, the Company has agreed to acquire the balance 35.39% stake (64.61% stake is held by Everlife Holdings Pte. Ltd.) in CPC Diagnostics Private Limited ("CPC") for a consideration of ₹ 1,813.92 million, consequent to which CPC shall become, directly and indirectly, wholly owned subsidiary of the Company. Out of the total consideration, an amount of ₹ 502.01 million has been paid till 31 March 2026 to acquire 10.61% stake in CPC and the balance would be paid in due course of time.

(vii) On 11 December 2025, the Company has invested ₹ 293.95 million to acquire a 13.98% equity interest in Laguna Tech USA, Inc. by purchasing its 1,771,210 Series A Preference Stock. The investment provides the Company with one board seat out of total 5 on the board of directors, enabling active participation in key policy making processes of Laguna Tech USA, Inc., including review of financial plans, strategic initiatives, and operational decisions. Based on these rights and representation, the management has concluded that the Company is able to exercise significant influence over Laguna Tech USA, Inc.

*Further, the total amount (in absolute) of equity share capital of Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP w.e.f. 25 January 2025) by the Company (including through nominees) is as under:

Particulars	**As at 31 March 2026**	**As at 31 March 2025**
Share capital amounts:		
Integris Medtech Limited	1,00,001	1,00,000
Avnish Mehra (Nominee of Integris Medtech Limited)	999	999
Punita Sharma (Nominee of Integris Medtech Limited)	1	1
Vishal Sharma (Nominee of Integris Medtech Limited)	1	1
Indranil Mukherjee (Nominee of Integris Medtech Limited)	-	1
Vishal Omprakash Goenka (Nominee of Integris Medtech Limited)	1	1
Total share capital of Translumina Therapeutics Private Limited	**1,01,003**	**1,01,003**

5B Investments

Particulars	**As at 31 March 2026**	**As at 31 March 2025**
Current investments		
Investment in quoted mutual funds measured at fair value through profit or loss (FVTPL)		
387,368.06 (31 March 2025 - 1,112,427.86) units in ABSL Money Manager Fund - Direct - Growth plan	151.91	409.01
Nil (31 March 2025 - 289,126.26) units in Axis Money Market Fund - Direct - Growth plan	-	409.39
Nil (31 March 2025 - 53,660.29) units in HDFC Money Market Fund - Direct - Growth plan	-	306.77
7,234.02 (31 March 2025 - 68,998.38) units in Kotak Money Market Fund - Direct - Growth plan	34.32	306.73
Nil (31 March 2025 - 49,613.61) units in Nippon India Money Market Fund - Direct - Growth plan	-	204.50
77,554.15 (31 March 2025 - 133,734.70) units in UTI Money Market Fund - Direct - Growth plan	253.32	409.34
9,835,582.55 (31 March 2025 - 6,683,820.77) units in Nippon India Corporate Bond Fund - Direct - Growth plan**	640.63	410.81
10,135,691.86 (31 March 2025 - 12,564,040.58) units in HDFC Corporate Bond Fund - Direct - Growth plan*	345.97	408.85
Nil (31 March 2025 - 3,653,390.32) units in ABSL Corporate Bond Fund - Direct - Growth plan	-	410.83
	1,426.15	**3,276.23**
Aggregate amount of quoted investments and market value thereof	1,426.15	3,276.23
Aggregate amount of impairment in the value of investments	-	-

Current investments (cont'd)

*As at 31 March 2026, mutual funds investment of the Company namely 9,122,610 units in "HDFC Corporate Bond Fund - Direct - Growth plan" (31 March 2025: 52,000 units in "HDFC Money Market Fund-Direct- Growth plan") have been pledged to HDFC Bank as a guarantee against against letter of credit amounting to ₹ 1,380.00 million to one of its wholly owned subsidiary company (Translumina GmbH) and cash credit/working capital facility of ₹ 20.00 million of the Company.

** As at 31 March 2026, mutual funds investment of 2,084,000 units (31 March 2025 : Nil) in "Nippon India Corporate Bond Fund - Direct - Growth plan" have been pledged to CITI Bank as a guarantee against working capital facility of ₹ 120.00 million.

6 Loans

Particulars	As at 31 March 2026		As at 31 March 2025	
	Non-current	Current	Non-current	Current
(Unsecured, considered good at amortised cost)				
Loan to related parties*	4,039.23	10.00	784.99	-
Loan to employees**	-	1.80	-	-
	4,039.23	**11.80**	**784.99**	**-**

*Particulars of which are displayed below as required by Section 186(4) of Companies Act, 2013. Loan to related parties are given for working capital/business purposes.

Name of Loanee	Maturity date	Rate of Interest	As at 31 March 2026	As at 31 March 2025
Translumina GmbH	31 March 2028	5.15% (31 March 2025 - 7.5%)	539.75	457.00
Translumina GmbH	31 March 2029	5.15% (31 March 2025 - 7.5%)	272.60	230.83
Translumina GmbH	26 January 2031	5.15% (31 March 2025 - NA)	130.85	-
Translumina GmbH	14 July 2032	5.15% (31 March 2025 - NA)	272.60	-
Transhealth Private Limited	03 October 2027	10% (31 March 2025 - 10%)	18.36	31.36
Transhealth Private Limited	09 May 2032	10% (31 March 2025 - NA)	475.00	-
Transvalve health Private Limited	31 December 2026	10% (31 March 2025 - 10%)	10.00	10.00
Transvalve health Private Limited	03 October 2027	10% (31 March 2025 - 10%)	56.00	55.80
Translumina Therapeutics Private Limited	23 April 2030	10% (31 March 2025 - NA)	1,398.19	-
Halemed Medical Private Limited	23 June 2030	10% (31 March 2025 - NA)	88.60	-
Halemed Medical Private Limited	23 June 2030	10% (31 March 2025 - NA)	66.90	-
Halemed Medical Private Limited	15 July 2030	10% (31 March 2025 - NA)	3.60	-
Halemed Medical Private Limited	30 September 2030	10% (31 March 2025 - NA)	15.13	-
Halemed Medical Private Limited	27 October 2030	10% (31 March 2025 - NA)	14.00	-
Everlife Holdings Pte. Ltd.	24 June 2028	7.4% (31 March 2025 - NA)	379.36	-
Everlife Holdings Pte. Ltd.	16 July 2028	7.4% (31 March 2025 - NA)	113.87	-
Everlife Holdings Pte. Ltd.	28 October 2030	7.4% (31 March 2025 - NA)	194.42	-
			4,049.23	**784.99**

** In line with Circular No 04/2015 issued by Ministry of Corporate Affairs dated 10 March, 2015, loans given to employees as per the Company's policy are not considered for the purposes of disclosure under Section 186(4) of the Companies Act, 2013.

Notes:
(i) There are no loans or advances in the nature of loans granted to Promoters, Key Managerial Personnel (KMPs), Directors of the Company, or to firms/ companies in which any Director is a partner, director, or member, or to their related parties (as defined under the Companies Act, 2013), either severally or jointly with any other person.
(ii) Refer note 41 for details of loan given and received back from related parties during the year.
(iii) There are no loans which have significant increase in credit risk and which are credit impaired.

7 Other financial assets

Particulars	As at 31 March 2026		As at 31 March 2025	
	Non-current	Current	Non-current	Current
(Unsecured, considered good at amortised cost)				
Security deposits	6.70	3.41	5.15	-
Fixed deposits with banks with maturity period of more than 12 months	-	-	1.69	-
Share based payment expenses recoverable from group companies (Refer note below and note 41)	253.78	-	176.86	-
Net investment in sub-lease of right-of-use assets (refer note 42)	155.28	8.02	147.14	23.48
Interest accrued but not due on fixed deposits with banks	-	0.20	-	41.71
Interest accrued but not due on loan to related parties (refer note 41)	61.31	104.85	-	39.97
Other recoverables*	-	542.73	-	33.42
(Unsecured, considered doubtful at amortised cost)				
Security deposits	0.43	-	0.43	-
Less: Allowance for impairment on financial assets	(0.43)	-	(0.43)	-
	477.07	**659.21**	**330.84**	**138.58**

* Other recoverables mainly includes the following:
(a) The Company has incurred share issue expenses in connection with proposed public offer of equity shares amounting to ₹ 432.14 million, recoverable from selling shareholders or adjustable against securities premium portion of the Initial Public Offer (IPO) proceeds and accordingly ₹ 246.16 million (including GST recoverable from selling shareholders amounting to ₹ 30.09 million) has been included under other recoverable above and ₹ 216.07 million has been disclosed under other current assets.
(b) Recoverable from subsidiary companies on account of business support services and expenses incurred on behalf of subsidiaries amounting ₹ 296.57 million (31 March 2025: ₹ 31.04 million).

Note: The Company has issued employee stock options to the employees of the Company and certain eligible employees of subsidiary companies that would vest in a graded manner. Based on the group policy/arrangement, the Company has charged the fair value of such stock options from subsidiary companies classified as share based payment expense recoverable from group companies and the present value of such recoverable has been classified as deemed investment in subsidiaries.

8 Non-current tax assets (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Income tax assets (net of provisions for tax)	2.62	1.99
	2.62	**1.99**

9 Other assets

Particulars	As at 31 March 2026		As at 31 March 2025	
	Non-current	Current	Non-current	Current
Advances to suppliers	-	14.99	-	149.21
Prepaid expenses	-	1.47	-	0.08
Balance with government authorities	27.77	42.97	-	12.44
Deposits under protest*	0.48	-	-	-
Capital advances	2.20	-	-	-
Others**	-	216.07	-	7.57
	30.45	**275.50**	**-**	**169.30**

* Deposits under protest represents 20% of the disputed income tax demand deposited by the Company against a rectification order u/s 154, which is currently under appeal before the CIT(A).
** Share issue expenses relating to incremental costs that are directly attributable to proposed issue of equity shares on account of Initial Public offer (IPO).

10 Inventories

Particulars	As at 31 March 2026	As at 31 March 2025
(valued at lower of cost or net realisable value)		
Traded goods*	49.26	25.49
	49.26	**25.49**

*Traded goods includes inventories lying with third parties amounting to ₹ 2.15 million (31 March 2025: ₹ 5.70 million).

11 Trade receivables

Particulars	As at 31 March 2026	As at 31 March 2025
Trade receivables		
Unsecured, considered good	151.90	298.66
Unsecured, considered impaired	13.59	18.71
	165.49	**317.37**
Less: Expected credit loss on trade receivables	(13.59)	(18.71)
	151.90	**298.66**

Trade receivables ageing schedule as at 31 March 2026

S.No.	Particulars	Outstanding for following periods from due date of payment						
		Not due	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
	Undisputed trade receivables:							
1	considered good	64.36	33.29	28.20	26.05	-	-	**151.90**
2	which have significant increase in credit risk	-	-	-	-	-	-	**-**
3	credit impaired	0.60	0.82	0.70	2.03	1.21	8.23	**13.59**
	Disputed trade receivables:							
1	considered good	-	-	-	-	-	-	**-**
2	which have significant increase in credit risk	-	-	-	-	-	-	**-**
3	credit impaired	-	-	-	-	-	-	**-**
	Total	**64.96**	**34.11**	**28.90**	**28.08**	**1.21**	**8.23**	**165.49**

Trade receivables ageing schedule as at 31 March 2025

S.No.	Particulars	Outstanding for following periods from due date of payment						
		Not due	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
	Undisputed trade receivables:							
1	considered good	174.47	114.84	0.81	6.58	1.96	-	**298.66**
2	which have significant increase in credit risk	-	-	-	-	-	-	**-**
3	credit impaired	3.64	4.76	0.25	0.91	1.13	8.02	**18.71**
	Disputed trade receivables:							
1	considered good	-	-	-	-	-	-	**-**
2	which have significant increase in credit risk	-	-	-	-	-	-	**-**
3	credit impaired	-	-	-	-	-	-	**-**
	Total	**178.11**	**119.60**	**1.06**	**7.49**	**3.09**	**8.02**	**317.37**

Note :
(i) No trade receivables are due from directors or other officers of the Company either severally or jointly with any other person.
(ii) The Company does not have any disputed trade receivables as at 31 March 2026 and 31 March 2025.
(iii) Trade receivables are non-interest bearing and are generally on payment terms of 0 to 180 days.
(iv) There are no unbilled trade receivables as at 31 March 2026 and 31 March 2025.

12 Cash and cash equivalents

Particulars	As at 31 March 2026	As at 31 March 2025
Cash on hand	-	4.25
Balance with banks in current accounts	10.18	3.90
Deposits with original maturity of less than three months	64.85	90.00
	75.03	**98.15**

There are no repatriation restrictions with regard to cash and cash equivalents as at the end of the current and previous year.

13 Other bank balances

Particulars	As at 31 March 2026	As at 31 March 2025
Fixed deposits with banks with original maturity period of more than 3 months but remaining maturity of less than 12 months*	2.66	2,118.68
Earmarked accounts - Unspent corporate social responsibility account	0.75	-
	3.41	**2,118.68**

* includes bank deposits pledged with banks as margin money for issuance of bank guarantees or borrowing facilities amounting to ₹ 2.66 million (31 March 2025: ₹ 238.07 million).

14 a) Equity share capital

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
i Authorised				
Equity shares of ₹ 1 each (31 March 2025: ₹ 1 each) with voting rights	17,00,00,000	170.00	4,00,00,000	40.00
	17,00,00,000	**170.00**	**4,00,00,000**	**40.00**
ii Issued, subscribed and fully paid up				
Equity shares of ₹ 1 each (31 March 2025: ₹ 1 each) with voting rights	10,83,38,049	108.34	1,96,56,969	19.66
	10,83,38,049	**108.34**	**1,96,56,969**	**19.66**

iii Reconciliation of number of equity shares outstanding at the beginning and at the end of the year

	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
Balance at the beginning of the year	**1,96,56,989**	**19.66**	**16,70,078**	**16.70**
Equity shares arising on shares split from ₹ 10 to ₹ 1 per share (refer note (a) below)	-	-	1,50,30,702	-
Conversion of 7% Compulsory Convertible Preference Shares into equity shares (refer note (b) below)	-	-	8,30,585	0.83
Issued during the year (Refer note (c) and (d) below)	1,64,55,694	16.46	21,25,624	2.13
Issue of bonus equity shares in the ratio of 2:1 (refer note (e) below)	7,22,25,366	72.22	-	-
Balance at the end of the year	**10,83,38,049**	**108.34**	**1,96,56,989**	**19.66**

(a) Pursuant to the approval of the shareholders in extra ordinary general meeting held on 26 April 2024, each equity share of the Company having face value of ₹ 10 per share was sub-divided into ten equity shares of face value of ₹ 1 per share.

(b) On 27 November 2024, the Company had converted its 162,790 7% Compulsorily Convertible Preference Shares (CCPS) into fully paid up 830,585 equity shares in accordance with the terms of issuance.

(c) On 17 December 2024, the Company had issued 2,125,624 equity shares of face value ₹ 1 each through private placement at a premium of ₹ 1,685.55 each. Each equity share carries equal rights with respect to dividends, repayment of capital, and entities the holder to one vote at the Company's shareholders' meetings.

(d) On 23 June 2025, the Company has acquired 100% ownership interest in Everlife Holdings Pte. Ltd. (Everlife) under common control. The acquisition of Everlife has been done through swap of shares of Everlife and the Company for a total consideration of ₹ 31,769.86 million (USD 371.47 million) by issuing of equity shares of the Company.

(e) On 27 August 2025, pursuant to the approval of the shareholders in extra ordinary general meeting held on 26 August 2025, the company had allotted 72,225,366 equity shares of face value of ₹ 1 each through bonus share in the proportion of 2 bonus equity share for every 1 fully paid-up equity share to eligible shareholders whose names appeared in the Register of Members/ beneficial owners as at 25 August 2025, being the record date fixed for this purpose. The said bonus equity shares rank pari passu in all respects with the existing equity shares of the Company. The paid-up capital on account of bonus issue of ₹ 72.22 million has been appropriated from securities premium.

iv Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity shares having the par value of ₹ 1 per share. Each holder of equity share is entitled to one vote per share. The Company declares and pays dividend in Indian rupees. All shareholders are equally entitled to dividends.

As per the Articles of Association (the 'AOA') of the Company, in the event of liquidation, dissolution or admission of winding up proceedings by an appropriate court or tribunal, either voluntary or involuntary, the Evercure Holding Pte. Limited (the 'Investor') shall have the right in preference to any other shareholders of the Company to require the Company, and Mr. Gurmit Singh Chugh and Ms. Punita Sharma (the 'Founders') (on a reasonable efforts basis) to ensure that the liquidator is appointed to liquidate the Company in order to distribute the proceeds from the liquidation of the Company, which remains after discharging the liabilities of the Company to the Investor, such that the Investor receives the Liquidation Price (as defined in the AOA) subject to applicable laws, in priority over any amounts received by any other existing shareholders of the Company.

Except with the prior written consent of the Investor, the Founders shall not transfer any of the securities of the Company held by them to any person, including competitors. However, the shares held by the Investor shall, subject to the transferee executing a Deed of Adherence, be freely transferable without any restrictions of any nature whatsoever.

v Details of shareholder holding more than 5% share capital*/ Details of equity shares held by the promoters as defined in the Companies Act, 2013 :

Name of the equity shareholders	As at 31 March 2026		% Change
	Number	%	during the year
Mr. Gurmit Singh Chugh	1,11,89,331	10.33%	-7.51%
Ms. Punita Sharma	1,11,89,331	10.33%	-7.51%
Evercure Holding Pte. Ltd. (Immediate Holding Company till 22 June 2025)	3,15,56,433	29.13%	-24.38%
Medicore Holdings Pte. Ltd. (formerly known as Integris Holding Pte Ltd.)	3,71,15,679	34.26%	34.26%
Total	**9,10,50,774**		

Name of the equity shareholders	As at 31 March 2025		% Change
	Number	%	during the year
Mr. Gurmit Singh Chugh	35,06,277	17.84%	-2.16%
Ms. Punita Sharma	35,06,277	17.84%	-2.16%
Evercure Holding Pte. Ltd. (Immediate Holding Company till 22 June 2025)	1,05,18,811	53.51%	-6.49%
Total	**1,75,31,365**		

Details of shares held by holding/ ultimate holding company and/ or their subsidiaries/ associates

Name of the equity shareholders	As at 31 March 2026		As at 31 March 2025	
	Number	%	Number	%
Evercure Holding Pte. Ltd. (Immediate Holding Company till 22 June 2025)	3,15,56,433	29.13%	1,05,18,811	53.51%
Medicore Holdings Pte. Ltd. (formerly known as Integris Holding Pte Ltd.)*	3,71,15,679	34.26%	-	-

* entity having significant influence w.e.f. 23 June 2025.

Note: 'Promoters' for the purpose of this disclosure means promoters as defined under section 2(69) of Companies Act, 2013.

*As per records of the Company, including its register of shareholders/members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

vi Aggregate number and class of shares allotted as fully paid up pursuant to contract(s) without payment being received in cash, by way of bonus shares and shares bought back for the period of 5 years immediately preceding the balance sheet date:

Particulars	As at 31 March 2026	As at 31 March 2025
Equity share allotted as fully paid up pursuant to contract for consideration other than cash:		
- equity shares arising on shares split from ₹ 10 to ₹ 1 per share (refer note 14(a)(iii)(a) above)	1,50,30,702	1,50,30,702
- conversion of 7% Compulsory Convertible Preference Shares into equity shares (refer note 14(a)(iii)(c) above)	8,30,585	8,30,585
- for acquisition of Everlife Holdings Pte. Ltd. (refer note 14(a)(iii)(d) above)	1,64,55,694	-
- issue of bonus equity shares in the ratio of 2:1 (refer note 14(a)(iii)(e) above)	7,22,25,366	-
	10,45,42,347	**1,58,61,287**

b) Preference share capital

Particulars	As at31 March 2026		As at31 March 2025	
	Number	Amount	Number	Amount
i Authorised				
7% Compulsory Convertible Preference Shares of ₹ 8,600 each (CCPS)	1,62,790	1,399.99	1,62,790	1,399.99
	1,62,790	**1,399.99**	**1,62,790**	**1,399.99**
ii Issued, subscribed and fully paid up				
7% Compulsory Convertible Preference Shares of ₹ 8,600 each (CCPS)	-	-	-	-
	-	-	-	-

iii Rights, preferences and restrictions attached to compulsory convertible preference shares

Compulsorily convertible cumulative preference shares were issued at par in May 2023 and each share is convertible into equity shares after a period of 10 years and can be converted at any time prior to expiry of 10 years at the option of the Company, convertible at the Fair Market Value of equity shares prevailing as on the date of conversion. The holders of these shares are entitled to fixed cumulative dividend at the rate of 7% on the capital for the time being paid-up thereon and shall be payable, as and when declared by the Board. In the event of winding up, preference shareholders have a preferential right over equity shareholders to be repaid to the extent of capital paid-up and dividend in arrears on such shares.

Except with the prior written consent of the Investor, the Founders shall not transfer any of the securities of the Company held by them to any person, including competitor. However, the shares held by the Investor shall, subject to the transferee executing a Deed of Adherence, be freely transferable without any restrictions of any nature whatsoever.

iv No shares have been issued pursuant to contract without payment being received in cash, allotted as fully paid-up shares by way of bonus issues nor has any bought back of shares happened during the period of five years immediately preceding the reporting date.

15 Other equity

Particulars	As at 31 March 2026	As at 31 March 2025
Securities premium	42,271.09	10,589.91
Retained earnings	1,708.12	1,333.94
7% Compulsory Convertible Preference Shares (Equity Component)	-	-
Shared based compensation reserve	317.92	222.04
	44,297.13	**12,145.89**
A. Securities premium		
Opening balance	10,589.91	5,652.79
Security premium on equity shares issued	31,753.40	4,979.88
Transaction cost arising on issue of equity shares	-	(42.76)
Bonus shares issued during the year	(72.22)	-
Closing balance	**42,271.09**	**10,589.91**
B. Retained earnings		
Opening balance	1,333.94	979.65
Profit for the year	374.05	354.42
Other comprehensive income for the year (net of tax impact)	0.13	(0.13)
Transfer from shared based compensation reserve to retained earnings on cancellation of options	90.25	-
Employee stock options settlement on cancellation of options (refer note 44)	(90.25)	-
Closing balance	**1,708.12**	**1,333.94**
C. 7% Compulsory Convertible Preference Shares (Equity Component)		
Opening balance	-	634.65
Conversion in equity shares during the year	-	(634.65)
Closing balance	-	-
D. Shared based compensation reserve		
Opening balance	**222.04**	-
Share based payment expenses (refer note 44)	186.13	222.04
Transfer to retained earnings on cancellation of options	(90.25)	-
Closing balance	**317.92**	**222.04**
Total other equity (A+B+C+D)	**44,297.13**	**12,145.89**

Nature and purpose of other reserves:

Securities premium

Securities premium represents premium received on issue of shares. The amount is utilised in accordance with the provisions of the Companies Act, 2013.

Retained earnings

Retained earnings are used to record the profit/(loss) earned by the Company. The reserve is utilised in accordance with the provisions of the Act. It includes impact of remeasurement gain/(loss) net of taxes on defined benefit plans on account of change in actuarial assumption or experience adjustments within the plan.

Equity component of compulsorily convertible preference shares

Compulsory Convertible Preference Shares (equity component) represents the fair value of financial liability on account of net proceeds received from the issue of Compulsory Convertible Preference Shares.

Shared based compensation reserve

Shared based compensation reserve is used to record share based payment expense for options issued to employees of the Company and its subsidiaries under Employee Stock Option

16 Lease liabilities

Particulars	As at 31 March 2026		As at 31 March 2025	
	Non-current	Current	Non-current	Current
Lease liabilities (refer note 42)	302.03	12.51	169.20	8.62
	302.03	**12.51**	**169.20**	**8.62**

17 Other financial liabilities

Particulars	As at 31 March 2026		As at 31 March 2025	
	Non-current	Current	Non-current	Current
Capital creditors	-	1.32	-	-
Employee related payables	-	56.74	-	7.61
Interest accrued but not due on borrowings	-	-	-	0.02
Other payables (refer note 41)*	65.71	44.21	-	3.78
	65.71	**102.27**	**-**	**11.41**

* includes amount payable to employee of a subsidiary company in respect of equity linked incentive plan amounting ₹ 65.71 million (31 March 2025: Nil) (refer note 44) and payable to subsidiaries towards expenses incurred by them on behalf of the Company amounting ₹ 40.88 million (31 March 2025: ₹ 3.78 million) and payable to independent directors amounting ₹ 3.33 million (31 March 2025: Nil).

18 Deferred tax liabilities (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Deferred tax assets arising on account of		
Provision for employee benefits	13.66	0.21
Property, plant and equipment	0.18	0.26
Expected credit loss on trade receivables	3.70	5.11
Right-of-use assets and lease liabilities	3.08	-
Others	0.40	0.40
Deferred tax liabilities arising on account of		
Right-of-use assets and lease liabilities	-	(0.84)
Fair value gain on investments in quoted mutual funds	(23.78)	(18.21)
Gain on exchange rate fluctuations (net)	(59.24)	(4.25)
Deferred tax assets/(liabilities) (net)	**(62.00)**	**(17.32)**

Movement in deferred tax assets and liabilities during the year ended 31 March 2026:

Particulars	As at 1 April 2025	Recognised in profit or loss	Recognised in other comprehensive income	As at 31 March 2026
Provision for employee benefits	0.21	13.49	(0.04)	13.66
Property, plant and equipment	0.26	(0.08)	-	0.18
Expected credit loss on trade receivables	5.10	(1.40)	-	3.70
Right-of-use assets and lease liabilities	(0.84)	3.92	-	3.08
Fair value gain on investments in quoted mutual funds	(18.21)	(5.57)	-	(23.78)
Gain on exchange rate fluctuation (net)	(4.24)	(55.00)	-	(59.24)
Others	0.40	-	-	0.40
Deferred tax assets/(liabilities) (net)	**(17.32)**	**(44.64)**	**(0.04)**	**(62.00)**

Movement in deferred tax assets and liabilities during the year ended 31 March 2025:

Particulars	As at 1 April 2024	Recognised in profit or loss	Recognised in other comprehensive income	As at 31 March 2025
Provision for employee benefits	0.01	0.15	0.05	0.21
Property, plant and equipment	0.25	0.01	-	0.26
Expected credit loss on trade receivable	2.97	2.13	-	5.10
Right-of-use assets and lease liabilities	(0.81)	(0.03)	-	(0.84)
Fair value gain on investments in quoted mutual funds	-	(18.21)	-	(18.21)
Gain on exchange rate fluctuation (net)	-	(4.24)	-	(4.24)
Others	-	0.40	-	0.40
Deferred tax assets/(liabilities) (net)	**2.42**	**(19.79)**	**0.05**	**(17.32)**

19 Provisions

Particulars	As at 31 March 2026		As at 31 March 2025	
	Non-current	Current	Non-current	Current
Provision for employee benefits				
- Provision for gratuity (refer note 38)	0.90	0.03	0.35	-
- Provision for compensated absences	-	3.47	-	0.27
	0.90	**3.50**	**0.35**	**0.27**

(This space has been intentionally left blank)

20 Borrowings

Particulars	As at 31 March 2026	As at 31 March 2025
"Secured, at amortised cost"		
Cash credit limit from bank	-	6.94
	-	**6.94**

(a) The Company had availed cash credit/working capital facility and SBLC limit (letter of credit) from HDFC Bank of ₹ 20.00 million and ₹ 1,380.00 million respectively, bearing an average interest rate of 8.77% p.a. The outstanding balance is Nil (31 March 2025: ₹ 6.94 million).

Primary Security: Cash collateral ₹ 170.00 million, inventories and trade receivables.
Guarantees: 1) Corporate guarantee of Translumina Therapeutics Private Limited.
2) Mutual funds investment of the Company namely 9,122,610 units in "HDFC Corporate Bond Fund - Direct - Growth Plan" (31 March 2025: 52,000 units in "HDFC Money Market Fund - Direct - Growth Plan").

(b) The Company had availed working capital credit facility of ₹ 120.00 million from Citi Bank. The outstanding balance is Nil (31 March 2025: ₹ Nil). The facility carries a floating rate of interest, which is agreed mutually between the Company and the bank at the time of utilization of the limit.

Guarantee: Mutual funds investment of the Company namely 2,084,000 units of "Nippon India Corporate Bond Fund – Direct - Growth Plan" as primary security against the working capital credit facility.

(c) The Company has undrawn facility amounting to ₹ 1,520.00 million (31 March 2025: ₹ 1,520.00 million).

21 Trade payables

Particulars	As at 31 March 2026	As at 31 March 2025
Total outstanding dues of micro enterprises and small enterprises*	4.92	0.04
Total outstanding dues of creditors other than micro enterprises and small enterprises	165.23	37.33
	170.15	**37.37**

Notes:
(i) All amounts are short-term. The carrying values of trade payables are considered to be a reasonable approximation of their fair value.
(ii) Trade payables are non-interest bearing and are normally settled on 15-60 days terms.

Trade payables ageing schedule as at 31 March 2026

S.No.	Particulars	Unbilled	Not due	Outstanding for following periods from due date of payment: Less than 1 Year	1-2 years	2-3 years	More than 3 years	Total
	Undisputed trade payables:							
a)	Micro enterprises and small enterprises	-	0.03	4.89	-	-	-	**4.92**
b)	Others	83.68	34.72	46.83	-	-	-	**165.23**
	Disputed trade payables:							
a)	Micro enterprises and small enterprises	-	-	-	-	-	-	**-**
b)	Others	-	-	-	-	-	-	**-**
	Total	**83.68**	**34.75**	**51.72**	**-**	**-**	**-**	**170.15**

Trade payables ageing schedule as at 31 March 2025

S.No.	Particulars	Unbilled	Not due	Outstanding for following periods from due date of payment: Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
	Undisputed trade payables:							
a)	Micro enterprises and smallenterprises	-	0.02	0.01	0.01	-	-	**0.04**
b)	Others	28.08	5.66	3.59	-	-	-	**37.33**
	Disputed trade payables:							
a)	Micro enterprises and small enterprises	-	-	-	-	-	-	**-**
b)	Others	-	-	-	-	-	-	**-**
	Total	**28.08**	**5.68**	**3.60**	**0.01**	**-**	**-**	**37.37**

*The management has identified enterprises which have provided goods and services to the Company and which qualifies under the definition of micro enterprises and small enterprises, as defined under Micro, Small and Medium Enterprises Development Act, 2006 ("MSMED Act, 2006"). Accordingly, the disclosure in respect of the amount payable to such enterprises has been made in the financials statements based on information received and available with the Company. Further, the Company has not paid any interest to any micro enterprises and small enterprises during the current year.
Disclosure under the Micro Enterprise and Small Enterprises Development Act, 2006 ("MSMED Act, 2006"):

	Particulars	As at 31 March 2026	As at 31 March 2025
i	Principal amount remaining unpaid to any supplier as at the end of the accounting year;	4.92	0.04
ii	Interest due thereon remaining unpaid to any supplier as at the end of the accounting year;	-	0.01
iii	The amount of interest paid by the buyer in terms of Section 16, along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year;	-	-
iv	The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act;	-	-
v	The amount of interest accrued and remaining unpaid at the end of each accounting year; and	0.02	0.02
vi	The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23.	0.02	0.02

22 Other current liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Statutory dues payable	21.14	2.97
Advance from customers	10.03	8.34
Other payables*	6.37	-
	37.54	**11.31**

*Amount payable towards liability of CSR expenses.

23 Current tax liabilities (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for income tax (net of taxes paid)	36.91	-
	36.91	**-**

24 Revenue from operations*

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of products		
Traded goods (refer note below)	651.09	383.41
Total revenue from contract with customers	**651.09**	**383.41**
Disaggregation of revenue information		
Details of traded goods		
Wires/catheters	606.82	357.34
Coronary stents	37.00	21.79
Other accessories	7.27	4.28
	651.09	**383.41**

*Refer note 43 for revenue related disclosures.

25 Other income

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Share of profit from investment in LLP	-	180.50
Interest income earned		
- on fixed deposits with banks at amortised cost	17.72	59.63
- on loan to related parties at amortised cost	266.55	61.08
- on sub-lease of right-of-use assets	16.16	6.78
- on discounting of share based payment expenses	20.47	4.96
- on 7% Compulsory Convertible Preference Shares	-	69.99
Liability no longer required, written back	0.50	0.39
Gain on termination of right-of-use assets and lease liabilities	1.02	-
Reversal of allowance for expected credit loss on trade receivables	0.53	-
Gain on foreign exchange fluctuations (net)	224.85	16.87
Business support services to subsidiaries*	225.11	31.19
Gain on disposal of investment in quoted mutual funds	145.64	7.25
Fair value gains on investment measured at fair value through profit or loss	22.11	72.35
Miscellaneous income	17.59	14.67
	958.25	**525.66**

*Certain central administrative and management support costs are incurred by the Company and cross charged to subsidiaries. These costs are cross charged to subsidiaries based on appropriate allocation methodology i.e. external revenue contribution. The policy ensures that each entity bears its fair share of group-wise expenses. All cross-charges are conducted at cost plus a margin as per transfer pricing guidelines.

26 Purchases of traded goods

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Purchases of traded goods	622.77	371.58
	622.77	**371.58**

27 Changes in inventories of traded goods

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Inventories at the end of the year: (B)		
Traded goods	49.26	25.49
Inventories at the beginning of the year: (A)		
Traded goods	25.49	6.86
Changes in inventories of traded goods (A)-(B)	**(23.77)**	**(18.63)**

28 Employee benefits expense

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Salaries, wages and bonus	165.50	25.55
Contribution to provident funds	0.73	0.07
Share based payment expenses (refer note 44)	251.84	222.04
Share based payment for employees of subsidiaries (refer note 44)	(177.54)	(213.05)
	240.53	**34.61**

29 Finance costs

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest expense		
- on lease liabilities (refer note 42)	18.96	7.27
- on cash credit facilities at amortised cost	0.39	1.18
- on delayed payment of statutory dues	0.09	0.01
- on delayed payment to MSME	-	0.01
Loan processing charges	1.40	-
	20.84	**8.47**

30 Depreciation and amortisation expense

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation on property, plant and equipment (refer note 4)	0.25	0.06
Depreciation on right-of-use assets (refer note 4A)	8.72	1.33
	8.97	**1.39**

31 Other expenses

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Rent	12.00	-
Rates and taxes	1.87	1.25
Travelling and conveyance	18.03	0.03
Legal and professional expenses*	39.34	28.17
Allowance for expected credit loss on trade receivables (refer note 11)	-	8.04
Allowance for impairment on financial assets (refer note 7)	-	0.43
Recruitment expenses	17.36	-
Bank charges	4.64	1.39
Corporate social responsibility expenses (refer note 32)	9.37	5.52
Directors remuneration**	5.84	-
Insurance	0.41	0.19
Management support charges (refer note 41)	19.27	17.44
Miscellaneous expenses	6.17	1.07
	134.30	**63.53**

***Legal and professional expenses includes remuneration to auditors as:**

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Statutory audit fees	3.60	4.40
Certification services	0.45	0.21
Reimbursement of expenses	0.39	0.35
	4.44	**4.96**
Other services (IPO related)^	155.60	-
	160.04	**4.96**

^ IPO related expenses (including reimbursements) are reclassed from legal and professional expense to 'other receivables' under other financial assets and 'others' under other assets (refer note 7 and 9).

** remuneration to independent directors.

32 Details of CSR expenditure:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
(a) Gross amount required to be spent by the Company during the year	5.62	6.14
(b) Amount approved by the board to be spent during the year	5.62	6.14
(c) Movement :		
Opening balance		
With Company (Budget)	5.62	6.14
In Separate CSR unspent Account	3.75	3.13
Total (A)	**9.37**	**9.27**
Amount required to be spent during the year (Budget for FY 26)	5.62	6.14
Amount spent during the year		
From Company's Bank Account	-	2.73
From unspent CSR Account	3.00	2.79
Total (B)	**3.00**	**5.52**
Closing Balance		
With Company	5.62	-
In Separate CSR unspent Account	0.75	3.75
Closing balance to be spent (A-B)	**6.37**	**3.75**
(d) Excess amount spent on CSR as per Section 135(5) of Companies Act, 2013	-	-
(e) Total of previous year shortfall	-	-
(f) Reason for shortfall	NA	NA
(g) Nature of CSR activities	Social welfare for promoting health care	Social welfare for promoting health care

Note: Closing balance with the Company for unspent CSR expenditure has been deposited in 'unspent CSR account' on 30 April 2026.

(This space has been intentionally left blank)

33 Income tax

(a) Amounts recognised in the statement of profit and loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Current tax (including earlier years)	104.12	28.13
Deferred tax expense	44.68	19.74
Income tax expense reported in the statement of profit and loss	**148.80**	**47.87**

The Company has opted for taxation under Section 115BAA of the Income Tax Act, 1961. The major components of income tax expense and the reconciliation of expected tax expense based on the domestic tax rate of the Company at 25.168% and the reported tax expense in profit or loss are as follows:

(b) Reconciliation of effective tax rate

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Accounting profit before income tax	**522.81**	**402.34**
At India's income-tax rate of 25.168%	131.58	101.26
Tax effect of amounts which are not deductible/(taxable) in calculating taxable income:		
Income not chargeable to tax	(5.15)	(64.29)
Expenses not deductible for tax purposes	20.86	10.03
Corporate social responsibility expenses	2.36	1.39
Tax related to earlier years	(0.54)	(0.89)
Others	(0.31)	0.37
Income tax expense	**148.80**	**47.87**

34 Earnings per share

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Calculation of Basic EPS		
Net profit attributable to equity shareholders (A)	**374.18**	**354.29**
Nominal value of equity share (₹)	1.00	1.00
Weighted average number of equity shares	3,23,70,703	1,75,96,708
Add: Number of equity shares issued under bonus issue (2 bonus shares for each equity share)	6,47,41,406	3,51,93,416
Add: Weighted average number of potential equity share to be issued on account of conversion of Compulsory Convertible Preference Shares at the end of year^	-	32,11,200
Total weighted average number of equity shares (B)*	**9,71,12,109**	**5,60,01,324**
Basic earnings per share (A/B)	**3.85**	**6.33**
Calculation of Diluted EPS		
Adjusted net profits profit attributable to equity shareholders (C)	**374.18**	**354.29**
Weighted average number of equity shares	3,23,70,703	1,75,96,708
Add: Number of equity shares issued under bonus issue (2 bonus shares for each equity share)	6,47,41,406	3,51,93,416
Add: Weighted average number of potential equity share to be issued on account of conversion of Compulsory Convertible Preference Shares at the end of year^	-	32,11,200
Add: Weighted average number of shares from share-based payment arrangements (including bonus shares)	5,16,708	13,21,790
Total weighted average number of equity shares (D)*	**9,76,28,817**	**5,73,23,114**
Diluted earnings per share (C/D)	**3.83**	**6.18**

*weighted average number of shares outstanding have been retrospective adjusted to give impact of the issuance of bonus shares and stock split in accordance with Ind AS 33 - Earnings per Share.

^ Calculated on the basis of fair value on the date of issue of Compulsory Convertible Preference Shares.

(This space has been intentionally left blank)

35 Financial instruments

i) Financial assets and liabilities

The carrying amounts of financial instruments by category are as follows:

Particulars	Note	31 March 2026 Fair value through profit or loss (FVTPL)	31 March 2026 Amortised cost	31 March 2025 Fair value through profit or loss (FVTPL)	31 March 2025 Amortised cost
Financial assets					
Trade receivables	11	-	151.90	-	298.66
Cash and cash equivalents	12	-	75.03	-	98.15
Other bank balances	13	-	3.41	-	2,118.68
Loans	6	-	4,051.03	-	784.99
Other financial assets	7	-	1,136.28	-	469.43
Investments	5B	1,426.15	-	3,276.23	-
Total financial assets		**1,426.15**	**5,417.65**	**3,276.23**	**3,769.91**
Financial liabilities					
Borrowings	20	-	-	-	6.94
Trade payables	21	-	170.15	-	37.37
Lease liabilities	16	-	314.54	-	177.82
Other financial liabilities	17	-	167.98	-	11.41
Total financial liabilities		**-**	**652.67**	**-**	**233.54**

Investment in subsidiaries and associates are measured at cost as per Ind AS 27, 'Separate financial statements' and hence, not presented here.

ii) Fair values hierarchy

The carrying value and fair values of financial instruments by categories are as follows:
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).
Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

Fair value of instruments measured at amortised cost and fair value through profit or loss

Particulars	Level	Note	31 March 2026 FVTPL	31 March 2026 Amortised cost	31 March 2025 FVTPL	31 March 2025 Amortised cost
Financial assets						
Loans	Level 3	6	-	4,051.03		784.99
Trade receivables	Level 3	11	-	151.90		298.66
Cash and cash equivalents	Level 3	12	-	75.03		98.15
Other bank balances	Level 3	13	-	3.41		2,118.68
Other financial assets	Level 3	7	-	1,136.28		469.43
Investments	Level 1	5B	1,426.15	-	3,276.23	-
Total financial assets			**1,426.15**	**5,417.65**	**3,276.23**	**3,769.91**
Financial liabilities						
Borrowings	Level 3	20	-	-	-	6.94
Trade payables	Level 3	21	-	170.15	-	37.37
Lease liabilities	Level 3	16	-	314.54	-	177.82
Other financial liabilities	Level 3	17	-	167.98	-	11.41
Total financial liabilities			**-**	**652.67**	**-**	**233.54**

Cash and cash equivalents, other bank balances, loans, trade receivables, trade payables, lease liabilities and borrowings approximate their carrying amounts largely due to the short-term maturities of these instruments. The fair value of the financial assets and liabilities is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. There are no financial assets and liabilities which are measured at fair value through other comprehensive income.

Financial risk management

The Company is exposed to various risks in relation to financial instruments. The main types of financial risks are market risk, credit risk and liquidity risk.

The management of the Company monitors and manages the financial risks relating to the operations of the Company on a continuous basis. The Company does not engage in the trading of financial assets for speculative purposes. The most significant financial risks to which the Company is exposed are described below:

Risk	Exposure arising from	Measurement	Management
Credit risk	Trade receivables, cash and cash equivalents, other bank balances, loans and other financial assets measured at amortised cost	Ageing analysis	Diversification of bank deposits and regular monitoring
Liquidity risk	Borrowings, lease liabilities and other financial liabilities	Cash flow forecasts	Availability of funds and credit facilities.
Market risk - foreign exchange	Recognised financial assets and liabilities not denominated in Indian rupee	Fluctuation in foreign exchange rates	Monitoring of exposure levels at regular internal

A) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial asset fails to meet its contractual obligations. The Company's exposure to credit risk is influenced mainly by the individual characteristics of each financial asset. The carrying amounts of financial assets represent the maximum credit risk exposure. The Company monitors its exposure to credit risk on an ongoing basis.

(This space has been intentionally left blank)

Financial instruments (cont'd)

Provision for expected credit losses
The Company provides for 12 month expected credit losses for following financial assets:

As at 31 March 2026

Particulars	Estimated gross carrying amount at default	Expected credit losses	Carrying amount net of impairment provision
Cash and cash equivalents	75.03	-	75.03
Other bank balances	3.41	-	3.41
Trade receivables	165.49	13.59	151.90
Loans	4,051.03	-	4,051.03
Other financial assets	1,136.28	-	1,136.28
Investments (other than in subsidiaries and associates)	1,426.15		1,426.15

As at 31 March 2025

Particulars	Estimated gross carrying amount at default	Expected credit losses	Carrying amount net of impairment provision
Cash and cash equivalents	98.15	-	98.15
Other bank balances	2,118.68	-	2,118.68
Trade receivables	317.37	18.71	298.66
Loans	784.99	-	784.99
Other financial assets	469.43	-	469.43
Investments (other than in subsidiaries and associates)	3,276.23	-	3,276.23

Reconciliation of expected credit losses on trade receivables

Particulars	Amount
Expected credit loss on trade receivables as at 01 April 2025	**18.71**
Expected credit loss utilised against bad-debts	(4.59)
Expected credit loss reversed	(0.53)
Expected credit loss on trade receivables as at 31 March 2026	**13.59**

B) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due.

Maturities of financial liabilities & financial assets
As at 31 March 2026, the Company's financial assets and financial liabilities have undiscounted contractual maturities as summarised below:
As at 31 March 2026

Particulars	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Financial liabilities					
Borrowings	-	-	-	-	-
Trade payables	170.15	-	-	-	170.15
Lease liabilities	42.09	47.76	50.95	336.68	477.48
Other financial liabilities	102.27	65.71	-	-	167.98
Total	**314.51**	**113.47**	**50.95**	**336.68**	**815.61**
Financial assets					
Loans	2,826.00	6,921.14	4,932.41	24,912.69	39,592.24
Trade receivables	1,258.49	260.58	-	-	1,519.07
Cash and cash equivalents	75.03	-	-	-	75.03
Other bank balances	3.41	-	-	-	3.41
Other financial assets	659.21	103.95	2,499.90	1,312.19	4,575.25
Total	**4,822.14**	**7,285.67**	**7,432.31**	**26,224.88**	**45,765.00**

As at 31 March 2025

Particulars	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Financial liabilities					
Borrowings	6.94	-	-	-	**6.94**
Trade payables	37.33	-	-	-	**37.33**
Lease liabilities	25.39	25.24	26.41	203.13	**280.17**
Other financial liabilities	11.41	-	-	-	**11.41**
Total	**81.07**	**25.24**	**26.41**	**203.13**	**335.85**
Financial assets					
Loans	-	-	7849.88	-	**7,849.88**
Trade receivables	298.66	-	-	-	**298.66**
Cash and cash equivalents	98.15	-	-	-	**98.15**
Other bank balances	2,118.68	-	-	-	**2,118.68**
Other financial assets	138.58	-	330.84	-	**469.42**
Total	**2,654.07**	**-**	**8,180.72**	**-**	**10,834.79**

C) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. The Company is exposed to market risk through its use of financial instruments and specifically to foreign currency risk and interest rate risk which result from its operating, investing and financing activities.

i) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to changes in market interest rates as some borrowings are at variable interest rates.

The following table illustrates the sensitivity of profit and equity to a reasonably possible change in interest rates of +/- 1%. These changes are considered to be reasonably possible based on management's assessment. The calculations are based on a change in the average market interest rate for each period, and the financial instruments held at each reporting date that are sensitive to changes in interest rates. All other variables are held constant.

Financial instruments (cont'd)

The exposure of Company's borrowing and interest rate at reporting period as following:

Particulars	As at 31 March 2026		As at 31 March 2025	
	Non current	Current	Non current	Current
(Secured - at amortised cost)				
Cash credit limit from bank	-	-	-	6.94
	-	**-**	**-**	**6.94**
1% Increase in basis points impact in profit	-	-	-	0.07
1% decrease in basis points impact in profit	-	-	-	(0.07)

ii) **Foreign exchange risk**

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The functional currency of the Company is INR. Most of the Company's transactions are carried out in INR. Exposures to currency exchange rates mainly arise from the Company's overseas purchases, which is primarily denominated in US Dollars ('USD').

The Company has limited exposure to foreign currency risk and outstanding foreign currency exposures are not being hedged against adverse currency fluctuation.

Foreign currency risk exposure:

Particulars	Currency	Amount in foreign currency		Amount in ₹	
		31 March 2026	31 March 2025	31 March 2026	31 March 2025
Receivables					
Loan to related parties (including interest accrued)	EUR	11.64	7.84	1,268.77	724.03
Loan to related parties (including interest accrued)	USD	7.59	-	719.84	-
ESOP recoverable	EUR	0.74	-	80.71	-
Other recoverable	USD	1.30	-	122.95	-
Other Payable	USD	0.05	-	5.17	-
Other Payable	THB	4.69	-	12.81	-
Other Payable	SG	0.16	-	9.76	-
Other Payable	INDO	965.21	-	5.18	-
Other Payable	MYR	0.29	-	6.16	-
Other recoverable	EUR	0.91	-	99.72	-

The following table illustrates the foreign currency sensitivity of profit and equity with regards to the Company's financial assets and financial liabilities considering 'all other things being equal' and ignoring the impact of taxation. It assumes a +/- 1% change of the Euro/USD exchange rate for the period ended at 31 March 2026. These are the sensitivity rates used when reporting foreign currency exposures internally to the key management personnel and represents management's assessment of the reasonably possible changes in the foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items at end of each period reported upon. A positive number indicates an increase in profit or equity and vice-versa.

Sensitivity

If the Euro, USD, THB, SG, INDO and MYR had strengthened/ weekend against the INR by 1%, the following would have been the impact:

Particulars	Currency	Exchange rate change	Increase 31 March 2026	Decrease 31 March 2026	Increase 31 March 2025	Decrease 31 March 2025
Receivables						
Loan to related parties (including interest accrued)	EUR	1.00%	12.69	(12.69)	7.24	(7.24)
Loan to related parties (including interest accrued)	USD	1.00%	7.20	(7.20)	-	-
ESOP recoverable	EUR	1.00%	0.81	(0.81)	-	-
Other recoverable	USD	1.00%	1.23	(1.23)	-	-
Other Payable	USD	1.00%	0.05	(0.05)	-	-
Other Payable	TBH	1.00%	0.13	(0.13)	-	-
Other Payable	SG	1.00%	0.10	(0.10)	-	-
Other Payable	INDO	1.00%	0.05	(0.05)	-	-
Other Payable	MYR	1.00%	0.06	(0.06)	-	-
Other recoverable	EUR	1.00%	1.00	(1.00)	-	-

D) **Capital management**

For the purpose of the Company's capital management, capital includes issued equity capital, securities premium and all other equity reserves attributable to the equity shareholders. The Company includes within net debt, borrowings less cash and cash equivalents, other bank balances and current investments. The primary objective of the Company's capital management is to maximise the shareholder value. The Company is not subject to any externally imposed capital requirements.

Particulars	As at 31 March 2026	As at 31 March 2025
Borrowings	-	6.94
Lease liabilities	314.54	177.82
Interest accrued and due on borrowings	-	0.02
Less : Current investments	(1,426.15)	(3,276.23)
Less : Cash and cash equivalents	(75.03)	(98.15)
Less : Bank balances other than cash and cash equivalents	(3.41)	(2,118.68)
Less : Interest accrued on above asset	(0.20)	(41.71)
Net debt	**(1,190.25)**	**(5,349.99)**
Total capital	44,405.47	12,165.55
Capital and net debt	43,215.22	6,815.56
Gearing ratio	NA	NA

E) **Reconciliation of movements of borrowings (current and non current) and interest accrued but not due to cash flows arising from financing activities:**

Particulars	Interest accrued but not due on borrowings	Borrowings
As at 01 April 2024	**0.12**	**21.87**
Cash flows	(1.28)	(14.93)
Interest expense	1.18	-
As at 31 March 2025	**0.02**	**6.94**
Cash flows	(0.41)	(6.94)
Interest expense/ adjustment	0.39	-
As at 31 March 2026	-	-

36 Additional information

Following are the analytical ratios for the year ended 31 March 2026 and 31 March 2025

Particulars	Numerator	Denominator	31 March 2026	31 March 2025	% Variance	Reasons for variance
Current ratio	Current assets	Current liabilities	7.31	80.68	-91%	Current ratio decreased since in the last financial year significant investment made in mutual funds and fixed deposits from the proceeeds raised on the account of issue of shares.

Ratios required to be disclosed as per Schedule III

Particulars	Numerator	Denominator	31 March 2026	31 March 2025	% Variance	Reasons for variance
Debt-equity ratio	Total Debt	Total Equity	-	0.00	0%	NA
Debt service coverage ratio	Earnings available for debt service = (Profit before exceptional items and tax + finance costs + depreciation and amortisation expenses)	Debt Service=Finance costs for the year	355.03	347.70	2%	NA
Return on equity ratio	Net Profits after taxes – Preference Dividend (if any)	Average Shareholder's Equity	0.01	0.04	-64%	Return on equity ratio decreased due to conversion of CCPS into equity shares and issue of bonus share in ratio of 2:1.
Inventory turnover ratio	Cost of goods sold	Average Inventory	16.03	21.82	-27%	Inventory turnover ratio decreased by 27% as compared to last year, due to increase in average inventory.
Trade receivables turnover ratio	Net Credit Sales	Average Accounts Receivable	2.89	1.89	53%	Trade receivables turnover ratio increased due to increase in sales compare to previous year.
Trade payables turnover ratio	Net Credit Purchases	Average Trade Payables	6.00	3.44	75%	Trade payables turnover ratio increased due to increase in purchases and average trade payable balance compare to previous year.
Net capital turnover ratio	Net Sales	Working Capital	0.28	0.06	349%	Sales for the current financials year increased from previous financial year. Further, significant investment made in mutual funds and fixed deposits from the proceeeds raised on the account of issue of shares which leads to increase in net capital turnover ratio.
Net profit ratio	Net Profit	Total Revenue	0.57	0.92	-38%	Net profit decreased due to increase in operating expenses during the year in comparison to previous year.
Return on capital employed	Earning before interest and taxes	Capital Employed	0.01	0.03	-58%	Return on capital employed decreased due to increase in capital employed on the account of issue of fresh shares and conversion of CCPS.
Return on investment	Interest income on fixed deposits	Fixed Deposits Balance	0.26	0.03	861%	Return on investments increased during the year since investments in fixed deposits made during the last of previous year.

Note: Since the change in ratio is less than 25%, reason is not warranted.
Earning for Debt Service = Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets etc.
Debt service = Interest & Lease Payments + Principal Repayments
"Net Profit after tax" means reported amount of "Profit / (loss) for the period" and it does not include items of other comprehensive income.
Average inventory is (Opening + Closing balance / 2)
Net credit sales consist of gross credit sales minus sales return. Trade receivables includes sundry debtors and bills receivables.
Average trade debtors = (Opening + Closing balance / 2)
Net credit purchases consist of gross credit purchases minus purchase return
Net sales shall be calculated as total sales minus sales returns.
Working capital shall be calculated as current assets minus current liabilities.
Net profit shall be after tax.
Net sales shall be calculated as total sales minus sales returns.
Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability

(This space has been intentionally left blank)

37 Commitments / Contingent liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Commitments		
Estimated amount of contracts remaining to be executed on capital account and not provided for (net of capital advances)	60.70	-
Contingent liabilities, not acknowledged as debt, includes:		
Corporate guarantees given on behalf of subsidiaries companies(Refer Note 41)	3,123.60	3,162.10
There are no contingent liabilities (under litigation) not acknowledged as debt as at 31 March 2026		

38 Employee benefits
Defined benefit plans
Gratuity

The Company has a defined benefit gratuity plan. Every employee is entitled to gratuity as per the provisions of the Payment of Gratuity Act. The liability of Gratuity is recognized on the basis of actuarial valuation.

Salary increases	Actual salary increases will increase the plan's liability. Increase in salary increase rate assumption in future valuations will also increase the liability.
Discount rate	Reduction in discount rate in subsequent valuations can increase the plan's liability.
Mortality & disability	Actual deaths and disability cases proving lower or higher than assumed in the valuation can impact the liabilities.
Withdrawals	Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can impact plan's liability.

Amounts recognised in the balance sheet:	**Gratuity**	
Particulars	**31 March 2026**	**31 March 2025**
Current liabilities	0.03	0.00
Non-current liabilities	0.90	3.54

Gain/Loss recognised in other comprehensive income:	**Gratuity**	
Actuarial (gain)/loss on defined benefit obligations	**31 March 2026**	**31 March 2025**
Actuarial losses from changes in demographic assumptions	-	(0.00)
Actuarial losses from changes in financial assumptions	(0.04)	0.09
Experience variance	(0.13)	0.09
Total income /(expenses) recognised in other comprehensive income	**(0.17)**	**0.18**

Expenses recognised in statement of profit and loss	**Gratuity**	
Particulars	**31 March 2026**	**31 March 2025**
Current service cost	0.61	0.14
Past service cost	0.11	-
Interest cost	0.03	0.00
Cost recognised during the year	**0.75**	**0.14**

Movement in the liability recognised in the balance sheet is as under:	**Gratuity**	
Particulars	**31 March 2026**	**31 March 2025**
Present value of defined benefit obligation at the beginning of the year	0.35	0.03
Current service cost	0.61	0.14
Past service cost	0.11	-
Interest cost	0.03	0.00
Actuarial (gain)/loss	(0.17)	0.18
Benefits paid	-	-
Present value of defined benefit obligation at the end of the year	**0.93**	**0.35**

(a) For determination of the liability of the Company the following actuarial assumptions were used:

	Gratuity	
Particulars	**31 March 2026**	**31 March 2025**
Discount rate	7.05%	6.70%
Salary escalation rate	10.00%	10.00%
Retirement age (years)	58 Years	58 Years
Withdrawal rate	10% PA	10% PA
Mortality rates	100% of IALM (2012–14)	10

inclusive of provision for disability -

(b) Maturity profile of defined benefit obligation:	**Gratuity**	
Particulars	**31 March 2026**	**31 March 2025**
1 year	0.03	-
2 to 5 years	0.26	-
6 year onwards	1.88	0.35

(This space has been intentionally left blank)

38 Employee benefits (Cont'd)

Sensitivity analysis for gratuity liability:	Gratuity	
Particulars	**31 March 2026**	**31 March 2025**
a) Impact of the change in discount rate		
Present value of obligation at the end of the year		
Impact due to increase of 1.00 %	(0.85)	(0.38)
Impact due to decrease of 1.00 %	0.99	0.44
b) Impact of the change in salary increase		
Present value of obligation at the end of the year		
Impact due to increase of 1.00 %	0.92	0.42
Impact due to decrease of 1.00 %	(0.82)	(0.37)
c) Impact of the change in attrition rate		
Present value of obligation at the end of the year		
Impact due to increase of 1.00 %	(0.03)	(0.01)
Impact due to decrease of 1.00 %	0.04	0.02

Sensitivities as to rate of inflation, rate of increase of pensions in payment, rate of increase of pensions before retirement and life expectancy are not applicable being a lump sum benefit on retirement

39 Segment information

The Company's primary business segment is reflected based on principal business activities carried on by the Company. Group Chief Executive officer has been identified as being the Chief Operating Decision Maker ('CODM') and evaluates the Company's performance and allocates resources based on analysis of the various performance indicators of the Company as a single unit. Therefore, there are no separate reportable business segments as per Ind AS 108 "Operating Segments". The Company operates in one reportable business segment, i.e. “Trading of products” and is primarily operating in India and hence, considered as single geographical segment.

Particulars	As at 31 March 2026	As at 31 March 2025
Revenue from Operations		
Within India	651.09	383.41
Outside India	-	-
Total	**651.09**	**383.41**
Non-current assets (other than financial instruments and deferred tax asset)		
Within India	218.80	11.80
Outside India	-	-
Total	**218.80**	**11.80**

40 Per transfer pricing legislation under section 92-92F of the Income Tax Act 1961, the Company is required to use certain specific methods in computing arm's length price of international transactions with associated enterprises and maintains adequate documentation in this respect. The legislations require that such information and documentation to be contemporaneous in nature. The Company has appointed independent consultants for conducting the Transfer Pricing Study to determine whether the transactions with associated enterprises undertake during the financial year are on an "arm's length basis". The Company is in the process of conducting a transfer pricing study for the current financial year and expects such records to be in existence latest by the due date as required by law. However, in the opinion of the management the update would not have a material impact on these financial statements. Accordingly, these financial statements do not include any adjustments for the transfer pricing implications, if any.

(This space has been intentionally left blank)

41 Related party disclosures

In accordance with the requirements of Ind AS 24, 'Related Party Disclosures', the names of the related party where control exists/ significant influence exists, along with the transactions and year-end balances with them as identified and certified by the management are given below:

A Names of related parties and related party relationship

Name of the related party

i. Ultimate Holding Company

Everstone Capital Partners III LP

ii. Intermediate Holding Company

ECP III Pte. Ltd., Singapore

iii. Entities having significant influence over the Company

Medicore Holdings Pte. Ltd. (formerly known as Integris Holding Pte Ltd.) (w.e.f. 23 June 2025)
Evercure Holding Pte. Ltd., Singapore (Immediate Holding Company till 22 June 2025)

iv. Entities under the control, joint control or significant influence of KMP or their relatives

Halemed Medical Private Limited (till 23 June 2025)

iv. Subsidiaries

Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP on 25 January 2025)
Transhealth Private Limited
Transvalve Health Private Limited
Translumina GmbH
Artic GmbH
Translumina France (refer note (i) below)
Blue Medical Devices B.V.
LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte
Translumina Medical Devices Trading L.L.C (incorporated w.e.f. 24 April 2024)
Everlife Holdings Pte. Ltd. (w.e.f. 23 June 2025)
Halemed Medical Private Limited (w.e.f. 24 June 2025)
Analisa Resources (M) Sdn. Bhd.(refer note (ii) below)
Biofrontier Technology Pte. Ltd (refer note (ii) below)
Bio-Rev Pte. Ltd (refer note (ii) below)
Chemoinformatics Sdn. Bhd (refer note (ii) below)
Chemopharm Sdn Bhd (refer note (ii) below)
Chemoresearch Sdn. Bhd (refer note (ii) and (iii) below)
Chemoresources Sdn. Bhd (refer note (ii) below)
Chemoscience (Malaysia) Sdn. Bhd (refer note (ii) and (iv) below)
Chemoscience Pte. Ltd (refer note (ii) below)
Chemoscience Philippines Inc.(refer note (ii) below)
CPC Diagnostics Private Limited (refer note (ii) below)
Everlife Philippines Holding Inc (w.e.f. 23 June 2025)
Lifeline Holdings Inc. (w.e.f. 23 June 2025)
Lifeline Diagnostics Supplies Inc. (w.e.f. 23 June 2025)
Medigene Sdn Bhd (refer note (ii) below)
PT Chemoscience Indonesia (refer note (ii) below)
Research Instrument Pte. Ltd (refer note (ii) below)
Research Instruments Sdn. Bhd (refer note (ii) below)
Research Instruments Vietnam Company Limited (refer note (ii) below)
Scientific Resources Pte Ltd (refer note (ii) below)
Hausen Bernstein Co., Ltd.(refer note (ii) below)
Neoscience Sdn Bhd (refer note (ii) below) (w.e.f. 24 June 2025)
Nevolution Engineering Sdn Bhd (refer note (ii) below) (w.e.f. 24 June 2025)

vi. Associate Company

R I Technologies Limited (refer note (ii) below)
Chemoscience (Thailand) Co Ltd (refer note (ii) below)
Laguna Tech USA, Inc. (w.e.f. 11 December 2025)

(This space has been intentionally left blank)

vii. Directors and Key Management Personnels ('KMPs')
Ms. Punita Sharma, Director
Mr. Gurmit Singh Chugh, Director
Mr. Vishal Sharma, Director (till 07 March 2025)
Mr. Avnish Mehra, Director
Mr. Arjun Oberoi, Director (refer note (v) below)
Mr. Vishal Omprakash Goenka, Director
Mr. Puggera Mandappa Devaiah, Director (w.e.f. 07 March 2025 till 21 July 2025)
Mr. Amit Manocha, Director (w.e.f. 07 March 2025 till 21 July 2025)
Mr. Indranil Mukherjee, Director (till 09 June 2025)
Mr. Kewal Jindal, Chief Financial Officer (till 25 August 2025)
Mr. Probir Das, (Executive Director - w.e.f. 10 June 2025 and Group CEO - w.e.f. 18 November 2024)
Mr. Hemant Sultania, Chief Financial Officer (w.e.f. 25 August 2025)
Ms. Rajani Kesari, Independent Director (w.e.f . 01 August 2025)
Mr. Ramesh Subrahmanian, Independent Director (w.e.f . 01 August 2025)
Mr. Annaswamy Vaidheesh, Independent Director (w.e.f . 26 August 2025)
Ms. Sonia, Company Secretary (w.e.f. 20 September 2024 till 09 March 2025)
Mr. Darpan Batra, Group General Counsel and Company Secretary (w.e.f. 26 September 2025)

Notes:
(i) Translumina France has been dissolved/strike off w.e.f. 31 July 2024.
(ii) Subsidiaries and associates of Everlife Holdings Pte. Ltd.
(iii) Chemoresearch Sdn Bhd has been dissolved/strike off w.e.f. 06 January 2025.
(iv) The management of Chemoscience (Malaysia) Sdn. Bhd is planning to submit an application to the concerned authorities for striking off the Company. Accordingly, the financial statements of subsidiary have been prepared on liquidation basis, wherein all the assets have been recognised at their net realisable value.
(v) Mr. Arjun Oberoi resigned on 07 March 2025 from the position of Director however subsequently resumed his position effective 21 July 2025.

B The following transactions were carried out with related parties in the ordinary course of business:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
i. Directors and Key Management Personnels ('KMPs')		
Punita Sharma		
Interest expense on lease liabilities	0.06	0.16
Depreciation on right-of-use assets	0.09	0.22
Rent expense	0.08	-
Equity shares issued on conversion of CCPS	-	280.00
Issue of equity shares	7.01	-
Gurmit Singh Chugh		
Interest expense on lease liabilities	0.09	0.26
Depreciation on right-of-use assets	0.15	0.35
Rent expense	0.08	-
Equity shares issued on conversion of CCPS	-	280.00
Issue of equity shares	7.01	-
Remuneration to Directors and Key Management Personnels		
Short-term employee benefits	118.81	17.00
Share based payment expense	12.19	135.44
Independent directors' remuneration and sitting fees	9.64	-
ii. Entities having significant influence over the Company		
Evercure Holding Pte. Ltd.		
Equity shares issued on conversion of CCPS	-	840.00
Issue of equity shares	21.04	-
Medicore Holdings Pte. Ltd. (formerly known as Integris Holding Pte Ltd.)		
Issue of equity shares	38.46	-
iii. Subsidiaries and associates		
Everlife Holdings Pte. Ltd.		
Loan given	630.24	-
Interest income on loan given	30.44	-
Business support services	118.22	-
Reimbursement of expenses	4.44	-
Investment made	31,769.86	-

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Translumina Therapeutics LLP		
Share of profit from investment in partnership received	-	180.50
Purchases of goods	-	189.70
Corporate guarantee given	-	1,400.00
Corporate guarantee received	-	1,400.00
Business support services	-	6.31
Interest income on loan given	-	12.01
Interest on discounting of share based payment expenses	-	3.64
Conversion of investment into loan	-	1,647.58
Repayment received in respect of the Investment converted into loan	-	1,647.58
Management support charges	-	7.35
ESOP cross charge on cost basis	-	156.12
Reimbursement of expenses	-	22.28
Translumina Therapeutics Private Limited		
Purchases of goods	622.77	181.88
Business support services	61.13	13.37
Management support charges	19.27	10.09
Cross charge expenses	16.38	3.96
ESOP cross charge on cost basis	97.72	42.28
Interest on discounting of share based payment expenses	18.01	0.98
Deemed investment	11.38	38.32
Rental Income	23.48	-
Expenses incurred on behalf of the Company	2.35	9.79
Investment in sub-lease of right-of-use assets	-	163.84
Corporate guarantee given	1,310.00	1,400.00
Corporate guarantee received	1,400.00	1,400.00
Loan given	2,006.22	-
Interest income on loan given	122.08	-
Translumina GmbH		
Business support services	8.84	2.87
ESOP cross charge on cost basis	0.90	0.71
Interest on discounting of share based payment expenses	0.06	0.02
Deemed investment	0.08	0.14
Cross charge expenses	11.03	14.61
Corporate guarantee commission income	7.96	6.75
Corporate guarantee given	1,380.00	1,380.00
Loan given	382.81	226.50
Interest income on loan given	50.10	35.51
Transvalve Health Private Limited		
Loan given	0.20	47.50
Interest income on loan given	6.59	2.84
Corporate guarantee received	-	1,400.00
Transhealth Private Limited		
Business support services	4.35	2.08
ESOP cross charge on cost basis	0.72	0.57
Interest on discounting of share based payment expenses	0.05	0.01
Deemed investment	0.06	0.11
Corporate guarantee given	433.60	382.10
Corporate guarantee received	-	1,400.00
Loan given	475.00	114.00
Interest income on loan given	44.71	10.72
LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte		
Business support services	21.78	5.55
ESOP cross charge on cost basis	77.59	12.93
Interest on discounting of share based payment expenses	2.31	0.30
Deemed Investment	15.59	2.50

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Blue Medical Devices B.V .		
Business support services	10.79	1.01
ESOP cross charge on cost basis	0.61	0.43
Interest on discounting of share based payment expenses	0.04	0.01
Deemed Investment	0.42	0.08
Halemed Medical Private Limited		
Investment made	42.66	-
Revenue from operations	1.26	2.34
Loan given	188.23	-
Interest income on loan given	12.63	-
CPC Diagnostics Private Limited		
Investment made	502.01	-
Analisa Resources (M) Sdn. Bhd.		
Expenses incurred on behalf of the company	6.05	-
Biofrontier Technology Pte. Ltd		
Expenses incurred on behalf of the company	4.23	-
Bio-Rev Pte. Ltd		
Expenses incurred on behalf of the company	1.53	-
Chemopharm Sdn. Bhd.		
Expenses incurred on behalf of the company	0.11	-
PT Chemoscience Indonesia		
Expenses incurred on behalf of the company	3.59	-
Chemoscience Pte. Ltd		
Expenses incurred on behalf of the company	0.04	-
Chemoscience (Thailand) Co Ltd		
Expenses incurred on behalf of the company	5.48	-
Hausen Bernstein Co., Ltd.		
Expenses incurred on behalf of the company	0.41	-
Scientific Resources Pte Ltd		
Expenses incurred on behalf of the company	3.81	-
R I Technologies Limited		
Expenses incurred on behalf of the company	6.92	-
Research Instrument Pte. Ltd		
Expenses incurred on behalf of the company	0.15	-
Research Instruments Vietnam Company Limited		
Expenses incurred on behalf of the company	1.59	-
Laguna Tech USA, Inc.		
Investment made	293.95	-

C The following balances were outstanding as at with related parties in the ordinary course of business

Particulars	As at 31 March 2026	As at 31 March 2025
i. Key Management Personnel		
Gurmit Singh Chugh		
Lease liabilities	-	1.25
Punita Sharma		
Lease liabilities	-	2.00

	Particulars	As at 31 March 2026	As at 31 March 2025
	Remuneration to Directors and Key Management Personnels		
	Short-term employee benefits payable	46.23	-
	Independent directors' remuneration and sitting fees payable	3.33	-
ii.	**Subsidiaries and associates**		
	Translumina Therapeutics Private Limited		
	Investment	3,871.81	3,871.81
	ESOP recoverable	175.78	164.71
	Other receivables	66.75	-
	Deemed investment	49.70	38.32
	Loan receivables	1,398.19	-
	Interest receivables	19.69	-
	Other payables	-	3.78
	Advnances given	13.49	149.21
	Corporate guarantee given	1,310.00	1,400.00
	Corporate guarantee received	1,400.00	1,400.00
	Transhealth Private Limited		
	Investment	30.00	30.00
	ESOP recoverable	1.20	0.47
	Other receivables	7.27	0.21
	Loan receivables	493.36	31.36
	Interest receivables	42.36	2.12
	Deemed investment	0.17	0.11
	Corporate guarantee given	433.60	382.10
	Corporate guarantee received	-	1,400.00
	Translumina GmbH		
	Investment	1,212.66	1,212.66
	ESOP recoverable	1.58	0.59
	Other receivables	59.19	24.23
	Loan receivables	1,215.80	687.83
	Interest receivables	52.98	36.21
	Deemed investment	0.24	0.14
	Corporate guarantee given	1,380.00	1,380.00
	Transvalve Health Private Limited		
	Investment	20.00	20.00
	Loan receivables	66.00	65.80
	Interest receivables	7.57	1.64
	Corporate guarantee given	-	-
	Corporate guarantee received	-	1,400.00
	LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte		
	ESOP recoverable	74.66	10.74
	Other receivables	29.27	5.59
	Deemed investment	18.06	2.50
	Blue Medical Devices B.V.		
	ESOP recoverable	0.56	0.35
	Other receivables	11.25	1.01
	Deemed investment	0.51	0.08
	Everlife Holdings Pte. Ltd.		
	Investment	31,769.86	-
	Other receivables	122.84	-
	Other payables	4.56	-
	Loan receivables	687.65	-
	Interest receivables	32.19	-
	Halemed Medical Private Limited		
	Investment	42.66	
	Trade receivables	5.17	2.66
	Loan receivables	188.23	-
	Interest receivables	11.37	-
	CPC Diagnostics Private Limited		
	Investment	502.01	-

Particulars	As at 31 March 2026	As at 31 March 2025
Analisa Resources (M) Sdn. Bhd.		
Other payables	6.05	-
Biofrontier Technology Pte. Ltd		
Other payables	4.23	-
Bio-Rev Pte. Ltd		
Other payables	1.53	-
Chemopharm Sdn Bhd		
Other payables	0.11	-
PT Chemoscience Indonesia		
Other payables	3.59	-
Chemoscience Pte. Ltd		
Other payables	0.04	-
Chemoscience (Thailand) Co Ltd		
Other payables	5.48	-
Hausen Bernstein Co., Ltd.		
Other payables	0.41	-
Scientific Resources Pte Ltd		
Other payables	3.81	-
Research Instrument Pte. Ltd		
Other payables	0.15	-
R I Technologies Limited		
Other payables	8.72	-
Research Instruments Vietnam Company Limited		
Other payables	1.59	-
Lifeline Diagnostics Supplies Inc.		
Other payables	0.61	-
Laguna Tech USA, Inc.		
Investment	293.95	-

Notes:

a) All the transactions with related parties are made on the terms equivalent to those that prevails in arm's length transactions and within the ordinary course of business. Outstanding balances at respective year ends are unsecured and settlement is generally done in cash.
b) The above information has been determined to the extent such parties have been identified on the basis of information available with the Company and relied upon by the auditors.
c) Liabilities for gratuity are provided on an actuarial basis for the Company, the amounts pertaining to the key management personnel is not included.
d) Corporate guarantee given to bank for arranging working capital facilities/terms loans to subsidiaries.
e) Outstanding balances are net of TDS and including GST as applicable.

(This space has been intentionally left blank)

42 Lease related disclosures

The Company has leases for office premises. With the exception of short-term lease underlying assets, each lease is reflected on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities are measured at the present value of the remaining lease payments, discounted using the incremental borrowing rate on the date of lease commencement that is ranging from 9.50% to 9.77% p.a. (31 March 2025: 9.50% to 9.77% p.a.).

Each lease generally imposes a restriction that, unless there is a contractual right to sublet the asset to another party, the right-of-use assets can only be used by the Company. Leases are either non-cancellable or may only be cancelled by incurring a substantive termination fee. Some leases contain an option to extend the lease for a further term. The Company is prohibited from selling or pledging the underlying leased assets as security against the Company other debts and liabilities.
The Company also has certain leases of office premises with lease terms of 12 months or less. The Company applies the 'short-term lease' recognition exemptions for these leases. The lease payments for such leases is being recognised on actual basis by applying paragraph 6 of Ind AS 116.

A Set out below are the carrying amounts of lease liabilities and the movements during the year:

Particulars	As at 31 March 2026	As at 31 March 2025
Opening Balance	**177.82**	**5.53**
Additions during the year	145.57	166.96
Adjustment for lease termination	(3.13)	-
Accretion of interest	18.96	7.27
Payments	(24.68)	(1.94)
Closing balance	**314.54**	**177.82**
- Current lease liabilities	12.51	8.62
- Non-current lease liabilities	302.03	169.20

B Total cash outflow for leases for the year ended 31 March 2026 was ₹ 24.68 million (31 March 2025: ₹ 1.94 million).

C Amounts recognised in statement of profit and loss:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest expense on lease liabilities	18.96	7.27
Depreciation on right-of-use assets	8.72	1.33
Rent	12.00	-
Gain on termination of right-of-use assets and lease liabilities	(1.02)	-
	38.66	**8.60**

D Maturity of lease liabilities

The lease liabilities are secured by the related underlying assets. Future minimum lease payments were as follows:

31 March 2026	Minimum lease payments due				
	Within 1 year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	42.09	47.76	50.95	336.68	**477.48**
Interest expense	29.58	27.92	25.70	79.74	**162.94**
Net present values	**12.51**	**19.84**	**25.25**	**256.94**	**314.54**

The lease liabilities are secured by the related underlying assets. Future minimum lease payments were as follows:

31 March 2025	Minimum lease payments due				
	Within 1 year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	25.39	25.24	26.41	203.13	**280.17**
Interest expense	16.77	15.90	14.93	54.75	**102.35**
Net present values	**8.62**	**9.34**	**11.48**	**148.38**	**177.82**

E Sub-Lease Arrangement

The Company has entered into sub-lease arrangements where it sub-lease certain leased premises to its wholly owned subsidiary company namely "Translumina Therapeutics Private Limited". These sub-leases have been classified as finance leases in accordance with Ind AS 116 – Leases, based on an evaluation of whether substantially all the risks and rewards incidental to the right-of-use assets have been transferred to the sub-lessee.

i. **Set out below are the carrying amount of net investment in the sub-lease and the movements during the year:**

Particulars	31 March 2026	31 March 2025
Less than one year	23.48	23.48
One to five year	107.62	102.41
More than five year	115.90	144.59
Gross investment in the sub-lease	**247.00**	**270.48**
Unearned finance income	(83.70)	(106.64)
Net investment in the lease	**163.30**	**163.84**
Interest income	22.94	6.78
Receipt	(22.94)	-
Closing balance	**163.30**	**170.62**
- Current	8.02	23.48
- Non-current	155.28	147.14

ii. The lease income from finance leases recognized during the year amounted to ₹ 16.16 million (31 March 2025: ₹ 6.78 million).

(This space has been intentionally left blank)

43 Revenue from contracts with customers

Ind AS 115, "Revenue from contracts with customers", establishes a framework for determining whether, how much and when revenue is recognised and requires disclosures about the nature, amount, timing and uncertainty of revenues and cashflows arising from customer contracts.

The Company supplies wires/catheters, coronary stents and other related accessories. The revenue is respect of the these recognised on point in time basis when the control of goods is transferred to the customer.

a) Assets related to contracts with customer

Particulars	As at 31 March 2026	As at 31 March 2025
Trade receivables	151.90	298.66
	151.90	**298.66**

b) Reconciliation of revenue recognised in statement of profit and loss with contract price:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Contract price	668.12	420.10
Less: discounts, rebates, credits etc.	(17.03)	(36.69)
Revenue from operations	**651.09**	**383.41**

c) The Company has not incurred any cost for obtaining contracts except administrative cost and the same is charged to statement of profit and loss.

d) Following table provides information about receivables and contract liabilities from contract with customers:

Particulars	As at 31 March 2026	As at 31 March 2025
Contract Liabilities		
Customer credit balances, advances and other payables	10.03	8.34
	10.03	**8.34**
Receivables		
Trade receivables	165.49	317.37
Less : Expected credit loss on trade receivables	(13.59)	(18.71)
Net receivables	**151.90**	**298.66**

e) Revenue recognised in the reporting period included in contract liability in the beginning of the year:

Particulars	As at 31 March 2026	As at 31 March 2025
Opening balance	8.34	190.23
Addition during the year	10.03	8.34
Revenue recognised during the year	(8.34)	(190.23)
	10.03	**8.34**

f) There are no unsatisfied obligation as at 31 March 2026 and 31 March 2025

44 Share-based payments

Employee Stock Option Scheme, 2024

Under the Employee Stock Option Scheme, 2024 (ESOP), stock options of the Company are granted to employees of the Company and eligible employees of subsidiary companies (group employees) as defined under Employee Stock Options Scheme, 2024 which is administered by the Nomination and Remuneration Committee of the Board of the Company. The maximum number of Shares which shall be subject to Options under the Scheme shall not exceed 10% (ten per cent) of the issued, subscribed and paid-up share capital of the Company, as of the Effective Date (“Ceiling”). The maximum number of Options that may be Granted in the aggregate under this Scheme shall not exceed 5,870,097.
The ESOPs provide a right to its holders (i.e., Group employees) to purchase one (Integris Medtech Limited - IML) share for each option at a pre-determined exercise price on the expiry of the vesting period. The stock options granted will not vest until performance condition is not met i.e., service. The ESOP hence represents an option that provides a right but not an obligation to the group employees to exercise the option by paying the exercise price at any time on completion of the vesting period, subject to an outer boundary on the exercise period. Based on group policy/ arrangement, the Company has charged the fair value of such stock options, subsidiary companies has accepted such cross charge and accordingly the recognised the recoverable amount as a reduction from the employee benefits expense (refer note 28). The recoverable amount is shown under head other financial assets in note 7 in the balance sheet.

The Company has granted ESOPs under the plan to its employees and employees of the subsidiaries (group employees) on an equity-settled basis. The fair value of the share options is estimated at the grant date using a Black Scholes pricing model, taking into account the terms and conditions upon which the share options were granted. Further, there are no cash settlement alternatives with respect to these options.

The vesting of options is subject to the employee’s continued employment with the IML group. The ESOPs shall vest in a graded manner over a period of 3 to 5 years.

The expense recognised for employee services received for the Company during the year is shown in the following table:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Share based payment expenses	251.84	222.04
Share based payment for employees of subsidiaries	(177.54)	(213.05)
Total	**74.30**	**8.99**

There were no cancellations or modifications to the awards other than as disclosed below.

Movements during the year

The following table illustrates the number and weighted average exercise prices (WAEP) of, and movements in, share options during the year:

	Number of shares	WAEP
Outstanding at 1 April 2025	**12,25,691**	**990.89**
Granted during the year	94,996	1,879.06
Forfeiture/ cancellation during the year (refer note (ii) below)	(9,30,888)	389.79
Bonus issue during the year	23,81,394	-
Outstanding at 31 March 2026	**27,71,193**	**371.75**

The following principal assumptions were used in the valuation:

Particulars	Grant I	Grant II	Grant III	Grant IV
Grant date	31 May 2024	21 February 2025	14 July 2025	25 Aug 2025
Vesting period ends	30 September 2027	17 November 2028 and 04 February 2029	31 March 2028 and 31 March 2029	25 August 2030
Fair value per option at grant date (in ₹)	301.35 - 758.72	269.52 - 688.82	555.98 - 874.25	441.97 - 911.89
Exercise price at date of grant	551 and 1,125	1,688	1,688	1,930
Risk–free interest rate (%)	6.75% - 6.82%	6.60% - 6.66%	5.42%-5.84%	5.42%-5.84%
Time to Expiration (years)	1.83 -3.84	1.50 -5.24	1.50 - 4.22	1.50 - 5.50
Dividend yield (%)	0%	0%	0%	0
Expected volatility (%)	35%	45%	40%	40.00%
Share price at date of grant (in ₹)	1,168.59	1,423.47	1,930.63	1,931.22

Notes:
(i) One of the employee of a subsidiary Company, has been granted ESOPs as per the Company's ESOP scheme. That employee has also been provided a right whereby the Company may allot additional stock options, or will pay a cash bonus, to ensure that the employee's total gain from exercising the stock options is not less than the annual bonus entitlement for the three years ending on 31 March 2025, 31 March 2026, and 31 March 2027.
Consequent to the above, the Company has recognized an expense of ₹ 65.71 million under share based payment expense and has recorded a corresponding liability under employee related payables within other financial liabilities (non-current).

(ii) Mr. Indranil Mukherjee resigned from the position of Chief Executive Officer (Cardiovascular) of Translumina Therapeutics Private Limited ("TTPL"), a subsidiary of the Company. Pursuant to the approval of the Nomination and Remuneration Committee of the Company on 24 January 2026, the Company approved the cancellation of all vested employee stock options held by Mr. Indranil Mukherjee as at the resignation date. In lieu of such cancellation, TTPL entered into an agreement (including an addendum thereto) with Mr. Indranil Mukherjee, under which TTPL agreed to pay a one time ESOP settlement amounting to ₹ 114.40 million, payable in two tranches.
Consequent to the above, the Company has transferred an amount of ₹ 90.25 million, representing the cumulative expense recognised in respect of vested employee stock options (i.e. 394,455 options, post bonus 788,910 options as included in forfeiture/ cancellation above), from the share based compensation reserve to retained earnings. The excess settlement amount of ₹ 24.15 million was charged directly to retained earnings within other equity of TTPL, in accordance with the principles of Ind AS 102 – Share-based Payment.

45 Exceptional items

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Acquisition/diligence cost (refer note (i) below)	39.86	45.78
Others (refer note (ii) below)	43.03	-
	82.89	**45.78**

(i) It represents expenditure incurred on technical, commercial, tax, legal and financial due diligences on new acquisitions.

(ii) (a) On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the incremental impact of these changes amounting to ₹ 0.11 million towards gratuity for the year ended 31 March 2026, on the basis of best information available, consistent with the guidance provided by Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact under "Exceptional Items" for the year ended 31 March 2026.

The Company continues to monitor the finalisation of Central/State Rules and clarifications from the Government on other aspects of the Labour Codes and would provide the appropriate accounting effect on the basis of such developments needed.

(b) During the year ended 31 March 2026, expenses amounting to ₹ 6.17 million primarily includes advertising and promotional expenses, website development and maintenance charges, branding and marketing expenses, and other related costs incurred for IPO preparedness and investor outreach activities that are non-recurring in nature.

(c) During the year ended 31 March 2026, an amount of ₹ 36.75 million has been paid to Securities and Exchange Board of India (SEBI), National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in relation to proposed listing of equity share of the Company.

46 The Company has been sanctioned a working capital limit in excess of ₹ 5 crores by banks based on the security of current assets. The quarterly returns, in respect of the working capital limits have been filed by the Company with such banks and such returns are in agreement with the books of account of the Company for the respective periods. Further, pursuant to the terms of the sanction letter, the Company is not required to file any quarterly return or statement with Citi Bank.

47 As per Section 128 of the Companies Act, 2013 read with proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 with reference to use of accounting software by the Company for maintaining its books of account, has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such change were made and ensuring that the audit trail cannot be disabled is applicable with effect from the financial year beginning on 1 April 2023. Further the audit trail shall be preserved by the Company as per the statutory requirements for record retention.

The Company, in respect of financial period commencing on 1 April 2025, has used an accounting software for maintaining its books of account which have a feature of recording audit trail (edit log) facility and the same have been operated throughout the period for all relevant transactions recorded in the software except that the audit trail feature was not enabled at the database level for accounting software to log any direct data changes, used for maintenance of all accounting records by the Company.

The Company uses another accounting software for maintenance of payroll records which is operated by a third-party software service provider. As per the 'Independent Service Auditor's Report on a Description of the Service Organization's System and the Suitability of the Design and Operating Effectiveness of Controls' SOC 2 Report, the audit trail (edit log) feature for any direct changes made at the database level and changes made at application level was operating throughout the period for all relevant transactions recorded in the software.

Further, there were no instances of audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention for all accounting softwares except for the accounting software used for maintenance of payroll records of the Company.

(This space has been intentionally left blank)

48 Other statutory information :

(i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
(ii) The Company has not traded or invested in crypto currency or virtual currency during the year ended 31 March 2026 and 31 March 2025.
(iii) The Company has not been declared a wilful defaulter by any bank or financial institution or other lender (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India.
(iv) The Company does not have any transactions with struck off companies under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956.
(v) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory year.
(vi) The Company has not advanced or loaned or invested funds to any other person or entity, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries); or
b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
(vii) The Company has not received any fund from any person or entity, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company
a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or
b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
(viii) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
(ix) The Company has complied with the relevant provisions of the Foreign Exchange Management Act, 1999 (Paragraph 42 of 1999) and Companies Act for transactions disclosed and the transactions are not violative of the Prevention of Money-Laundering Act, 2002 (Paragraph 15 of 2003).
(x) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

49 Subsequent events:

(i) The Board has approved the grant of 180,000 stock options w.e.f. 01 April 2026, under the Employee Stock Option Plan Scheme 2024, in accordance with the applicable terms and conditions.

As per our report of even date attached

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Kartik Gogia
Partner
Membership No: 512371

Place: Gurugram
Date: 29 June 2026

Probir Das
Executive Director and Group CEO
DIN: 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No: ACS 15719

Place: Noida
Date: 29 June 2026

Walker Chandiok & Co LLP

21st Floor, DLF Square
Jacaranda Marg, DLF Phase II,
Gurugram - 122 002
Haryana, India

T +91 124 462 8099
F +91 124 462 8001

Independent Auditor's Report

To the Members of Integris Medtech Limited (formerly known as Integris Health Private Limited)

Report on the Audit of the Consolidated Financial Statements

Opinion

1. We have audited the accompanying consolidated financial statements of Integris Medtech Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates, as listed in Annexure A, which comprise the Consolidated Balance Sheet as at 31 March 2026, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Cash Flows and the Consolidated Statement of Changes in Equity for the year then ended, and notes to the consolidated financial statements, including material accounting policy information and other explanatory information.

2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate financial statements and on the other financial information of the subsidiaries and associates the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards ('Ind AS') specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India of the consolidated state of affairs of the Group and its associates, as at 31 March 2026, and their consolidated profit (including other comprehensive income), consolidated cash flows and the consolidated changes in equity for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group and its associates in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 12 of the Other Matter section below, is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

4. We draw attention to Note 46(I)(D) to the accompanying consolidated financial statements which describes that pursuant to Share Purchase Agreement (SPA) dated 23 June 2025, the Holding Company has acquired Everlife Holdings Pte Ltd. The Holding Company's management has accounted the said business combination in accordance with the requirements of Appendix C to Ind AS 103 "Business Combination", applicable to common control business combination. Accordingly, the comparative financial information in respect of the year ended 31 March 2025 has been restated as if the business acquisition had occurred from the beginning of the preceding period i.e. 01 April 2024 as described in the said note. Our opinion is not modified in respect of this matter.

Information other than the Consolidated Financial Statements and Auditor's Report thereon

5. The Holding Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Director's Report, but does not include the consolidated financial statements and our auditor's report thereon.

   Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

   In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

   The Director's Report is not made available to us at the date of this auditor's report. We have nothing to report in this regard

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

6. The accompanying consolidated financial statements have been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation and presentation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated changes in equity and consolidated cash flows of the Group including its associates in accordance with the Ind AS specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India. The Holding Company's Board of Directors are also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of consolidated Ind AS financial statements. Further, in terms of the provisions of the Act the respective Board of Directors of the companies included in the Group, and its associate companies covered under the Act are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial statements have been used for the purpose of preparation of the consolidated financial statements by the Board of Directors of the Holding Company, as aforesaid.

7. In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group and of its associates are responsible for assessing the ability of the Group and of its associates to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

8. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group and of its associates.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

9. Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

10. As part of an audit in accordance with Standards on Auditing specified under section 143(10) of the Act we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

    - Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

    - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;

    - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;

    - Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates to cease to continue as a going concern;

    - Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation; and

    - Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group, and its associates, to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of financial statements of such entities included in the consolidated financial statements, of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

11. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Other Matter

12. We did not audit the financial statements of 18 subsidiaries, whose financial statements reflects total assets of ₹ 8,970.05 million as at 31 March 2026, total revenues of ₹ 5,358.14 million and net cash outflows amounting to ₹ 149.91 million for the year ended on that date, as considered in the consolidated financial statements. The consolidated financial statements also include the Group's share of net loss (including other comprehensive income) of ₹ 3.75 million for the year ended 31 March 2026 in respect of 4 associates whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Holding Company's management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, and our report in terms of sub-section (3) of section 143 of the Act in so far as it relates to the aforesaid subsidiaries and associates, are based solely on the reports of the other auditors.

    Further, of these subsidiaries and associates, 16 subsidiaries and 2 associates are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial statements of such subsidiaries and associates located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Holding Company's management. Our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of such subsidiaries and associates located outside India, is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us.

    Our opinion above on the consolidated financial statements, and our report on other legal and regulatory requirements below, are not modified in respect of the above matters with respect to our reliance on the work done by and the reports of the other auditors.

Report on Other Legal and Regulatory Requirements

13. As required by section 197(16) of the Act, we report that a subsidiary Company has paid remuneration to its whole-time director and an executive director for the year ended 31 March 2026 in excess of the limits laid down under section 197 read with Schedule V of the Act by ₹ 6.04 millions and ₹ 30.65 millions, respectively, which has also resulted in exceeding the overall limit of remuneration payable by the subsidiary company to its directors by Rs. 23.29 million. However, the subsidiary company has obtained required approvals from the Board of Directors and shareholders by way of special resolution, for aforesaid excess remuneration paid, as detailed in note 50(ii) to the accompanying financial statements.

    Further, the appointment of whole-time director of the subsidiary company is subject to approval of Form MR-2 filed with the Central Government in accordance with Section 196 read with Schedule V of the Act, which is currently pending to be received as on date.

14. As required by clause (xxi) of paragraph 3 of Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act based on the consideration of the Order reports issued till date by us and by the respective other auditors as mentioned in paragraph 12 above, of companies included in the consolidated financial statements for the year ended 31 March 2026 and covered under the Act we report that:

    Following are the qualifications/adverse remarks reported by us in the Order reports of the companies included in the consolidated financial statements for the year ended 31 March 2026 for which such Order reports have been issued till date:

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

S No	Name	CIN	Holding Company / subsidiary	Clause number of the CARO report which is qualified or adverse
1	Integris Medtech Limited	U85110DL2008PLC177230	Holding Company	Clause (iii)(e)
2	Transhealth Private Limited	U33309DL2020PTC364238	Subsidiary Company	Clause (ix)(a)
3	CPC Diagnostics Private Limited	U52599TN1991PTC021095	Subsidiary Company	Clause (ix)(d)
4	Translumina Therapeutics Private Limited	U32509DL2025PTC441712	Subsidiary Company	Clause (vii)(a)

15. As required by section 143(3) of the Act, based on our audit and on the consideration of the report of the other auditor on separate financial statements and other financial information of the subsidiary incorporated in India whose financial statements have been audited under the Act, we report, to the extent applicable, that:

    a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated financial statements;

    b) Except for the matters stated in paragraph 15(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors;

    c) The consolidated financial statements dealt with by this report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;

    d) In our opinion, the aforesaid consolidated financial statements comply with Ind AS specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015;

    e) On the basis of the written representations received from the directors of the Holding Company and its subsidiaries and taken on record by the Board of Directors of the Holding Company and its subsidiaries respectively, and the report of the statutory auditor of its subsidiary, covered under the Act, none of the directors of the Holding Company and its subsidiaries are disqualified as on 31 March 2026 from being appointed as a director in terms of section 164(2) of the Act;

    f) The qualification relating to the maintenance of accounts and other matters connected therewith with respect to the consolidated financial statements are as stated in paragraph 15(b) above on reporting under section 143(3)(b) of the Act and paragraph 15(h)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended);

    g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company, and its subsidiaries covered under the Act, and the operating

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

effectiveness of such controls, refer to our separate report in 'Annexure B' wherein we have expressed an unmodified opinion; and

h) With respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditor on separate financial statements and other financial information of the subsidiary incorporated in India, whose financial statements have been audited under the Act:

i. The consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Holding Company and its subsidiaries as detailed in Note 42(b) to the consolidated financial statements;

ii. The Holding Company and its subsidiaries did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2026;

iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company and its subsidiaries during the year ended 31 March 2026;

iv.

a. The respective managements of the Holding Company and its subsidiaries incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditor of such subsidiary respectively that, to the best of their knowledge and belief other than as disclosed in note 48(vi) to the consolidated financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or securities premium or any other sources or kind of funds) by the Holding Company or its subsidiaries to or in any person(s) or entity(ies), including foreign entities ('the intermediaries'), with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company, or any such subsidiaries ('the Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf the Ultimate Beneficiaries;

b. The respective managements of the Holding Company and its subsidiaries incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditor of such subsidiary respectively that, to the best of their knowledge and belief, as disclosed in the note 48(viii) to the accompanying consolidated financial statements, no funds have been received by the Holding Company or its subsidiaries from any person(s) or entity(ies), including foreign entities ('the Funding Parties'), with the understanding, whether recorded in writing or otherwise, that the Holding Company, or any such subsidiaries shall, whether directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

c. Based on such audit procedures performed by us and that performed by the auditors of the subsidiaries and associates, as considered reasonable and appropriate in the circumstances, nothing has come to our or other auditors' notice that has caused us or the other auditors to believe that the management representations under sub-clauses iv(a) and iv(b) above contain any material misstatement.

v. The Holding Company and its subsidiaries have not declared or paid any dividend during the year ended 31 March 2026.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

vi. As stated in Note 49 to the consolidated financial statements and based on our examination which included test checks and that performed by the auditor of the subsidiary, of the Holding Company which are companies incorporated in India and audited under the Act, except for matters mentioned below, the Holding Company and its subsidiaries, in respect of financial year commencing on 1 April 2025, have used an accounting software for maintaining their books of account and payroll records which have a feature of recording audit trail (edit log) facility and the same have been operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with other than the consequential impact of the exception given below. Furthermore, except matter mentioned below the audit trail have been preserved by the Holding Company and its subsidiaries as per the statutory requirements for record retention: -

i. The audit trail feature was not enabled at the database level for accounting software used for maintenance of books of accounts by the Holding Company and five subsidiaries to log any direct data changes.

ii. The audit trail feature was not enabled at the database level for accounting software used for maintenance of payroll records by one of the Subsidiary Company. Further, the audit trail pertaining to accounting software used for maintaining payroll records have not been preserved by the Holding Company and three subsidiaries as per the statutory requirements for record retention;

iii. In case of another subsidiary audited by other auditor, the accounting software used for maintaining its books of account did not have a feature of recording audit trail (edit log) facility.

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No.: 001076N/N500013

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Kartik Gogia
Partner
Membership No.: 512371
UDIN: 26512371IQQYQD3442

Place: Gurugram
Date: 29 June 2026

Annexure A

<u>Group</u>

Holding Company

1. Integris Medtech Limited (formerly known as Integris Health Private Limited)

Subsidiary Companies

1. Translumina Therapeutics LLP (till 25 January 2025)
2. Translumina Therapeutics Private Limited (with effect from 25 January 2025)
3. Transvalve Health Private Limited
4. Transhealth Private Limited
5. Translumina GmbH
6. Translumina France (till 31 July 2024)
7. Artic GmbH
8. Lamed Vertriebsgesellschaft mbh
9. Blue Medical Devices B.V.
10. Translumina Medical Devices Trading LLC (with effect from 24 April 2024)
11. Everlife Holdings Pte. Ltd
12. Chemoscience Pte.Ltd
13. Biofrontier Technology Pte. Ltd.
14. Scientific Resources Pte. Ltd.
15. Research Instrument Pte Ltd
16. Bio Rev Pte Ltd
17. Chemopharm Sdn Bhd
18. Medigene Sdn. Bhd.
19. Research Instruments Sdn. Bhd.
20. Chemoscience (Malaysia) Sdn. Bhd.
21. Chemoinformatics Sdn. Bhd.
22. Chemoresources Sdn. Bhd
23. Analisa Resources (M) Sdn. Bhd
24. Research Instruments Vietnam Company Limited
25. CPC Diagnostics Private Limited
26. Chemoscience Phils. Inc
27. Everlife Philippines Holding INC
28. PT Chemoscience Indonesia
29. Hausen Bernstein Co. Ltd
30. Lifeline Holdings, Inc. (from 24 June 2025)
31. Lifeline Diagnostics Supplies Inc (from 24 June 2025)
32. Neoscience Sdn Bhd
33. Nevolution Engineering Sdn Bhd

Associate Companies

1. Chemoscience (Thailand) Co., Ltd.
2. RI Technologies Limited
3. Lifeline Holdings, Inc. (till 23 June 2025)
4. Lifeline Diagnostics Supplies Inc (till 23 June 2025)
5. Laguna Tech USA, Inc. (w.e.f. 11 December 2025)

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Annexure B

Independent Auditor's Report on the internal financial controls with reference to financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the consolidated financial statements of Integris Medtech limited (formerly known as Integris Health Private Limited) ('the Holding Company'), its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates as at and for the year ended 31 March 2026, we have audited the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies, which are companies covered under the Act, as at that date.

Responsibilities of Management and Those Charged with Governance for Internal Financial Controls

2. The respective Board of Directors of the Holding Company and its subsidiary companies which are companies covered under the Act, are responsible for establishing and maintaining internal financial controls based on internal financial controls with reference to financial statements criteria established by the group considering the essential components of internal financial controls stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements

3. Our responsibility is to express an opinion on the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies, as aforesaid, based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India ('ICAI') prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

5. We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditor in terms of their report referred to in the Other Matter paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies as aforesaid.

Meaning of Internal Financial Controls with Reference to Financial Statements

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion and based on the consideration of the report of the other auditor on internal financial controls with reference to financial statements of the subsidiary company, the Holding Company and its subsidiary companies, which are companies covered under the Act, have in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2026, based on internal financial controls with reference to financial statements criteria established by the group considering the essential components of internal financial controls stated in the Guidance Note.

Other Matter

9. We did not audit the internal financial controls with reference to financial statement insofar as it relates to 1 subsidiary company, which is a company covered under the Act, whose financial statements reflect total assets of ₹ 97.82 million as at 31 March 2026, total revenues of ₹ 29.18 million and net cash inflows amounting to ₹ 10.54 million for the period ended on that date, as considered in the consolidated financial statements. The internal financial controls with reference to financial statements in so far as it relates to such subsidiary company have been audited by other auditor whose report has been furnished to us by the management and our report on the adequacy and operating effectiveness of the internal financial controls with reference to financial statements for the Holding Company and its subsidiary companies, as aforesaid, under Section 143(3)(i) of the Act in so far as it relates to such subsidiary company is based solely on the report of the auditor of such company. Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and on the report of the other auditor.

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No.: 001076N/N500013

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Kartik Gogia
Partner
Membership No.: 512371
UDIN: 26512371IQQYQD3442

Gurugram
29 June 2026

Integris Medtech Limited (formerly known as Integris Health Private Limited)
CIN: U85110DL2008PLC177230

Consolidated Balance Sheet as at 31 March 2026
(All amounts in ₹ millions except number of shares and per share data, unless otherwise stated)

Particulars	Notes	As at 31 March 2026	As at 31 March 2025
ASSETS			
Non-current assets			
Property, plant and equipment	4A	3,707.88	2,279.02
Capital work-in-progress	4B	177.38	111.68
Right-of-use-assets	4C	818.09	600.20
Goodwill	5B	11,628.47	7,233.50
Other intangible assets	5A	4,899.40	3,470.70
Intangible assets under development	5C	183.07	115.67
Investments accounted for using the equity method	6A	522.26	3,789.74
Financial assets			
(i) Loans	6B	24.38	426.35
(ii) Other financial assets	7A	180.56	111.93
Deferred tax assets (net)	34	606.34	454.90
Non-current tax assets (net)	8	171.53	65.76
Other non-current assets	9	124.96	105.60
Total non-current assets		**23,044.32**	**18,765.05**
Current assets			
Inventories	11	5,198.22	3,164.69
Financial assets			
(i) Investments	12	1,426.15	3,276.23
(ii) Trade receivables	13	7,386.05	5,333.63
(iii) Cash and cash equivalents	14	2,260.06	1,928.30
(iv) Bank balances other than (iii) above	15	1,163.99	2,972.12
(v) Loans	6C	97.13	67.81
(vi) Other financial assets	7B	373.66	296.82
Other current assets	10	1,019.31	608.70
Total current assets		**18,924.57**	**17,648.30**
Total assets		**41,968.89**	**36,413.35**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	16A	108.34	30.02
Other equity	16B	22,627.15	11,507.37
Equity attributable to owners of the Company		**22,735.49**	**11,537.39**
Non-controlling interest	16B	349.09	1,675.85
Total equity		**23,084.58**	**13,213.24**
Liabilities			
Non-current liabilities			
Financial liabilities			
(i) Borrowings	17A	4,974.36	4,914.50
(ii) Lease liabilities	18A	581.58	387.78
(iii) Other financial liabilities	21A	250.34	76.76
Other non-current liabilities	22A	24.08	42.45
Deferred tax liabilities (net)	34	1,429.89	859.44
Provisions	19A	187.30	93.51
Total non-current liabilities		**7,447.55**	**6,374.44**
Current liabilities			
Financial liabilities			
(i) Borrowings	17B	3,350.23	12,380.08
(ii) Lease liabilities	18B	199.36	129.26
(iii) Trade payables	20		
- Total outstanding dues of micro enterprises and small enterprises		64.47	15.28
- Total outstanding dues of creditors other than micro enterprises and small enterprises		3,677.67	2,008.19
(iv) Other financial liabilities	21B	2,579.06	606.49
Other current liabilities	22B	622.99	620.83
Provisions	19B	698.83	902.61
Current tax liabilities (net)	23	244.15	162.93
Total current liabilities		**11,436.76**	**16,825.67**
Total equity and liabilities		**41,968.89**	**36,413.35**
Summary of material accounting policies	3		

The accompanying notes form an integral part of the Consolidated Financial Statements.
As per our report of even date attached

For Walker Chandiok & Co LLP
Chartered Accountants
Firm's Registration No: 001076N/N500013

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Kartik Gogia
Partner
Membership No.: 512371

Place: Gurugram
Date: 29 June 2026

Probir Das
Executive Director and Group CEO
DIN : 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No. ACS 15719

Place: Noida
Date: 29 June 2026

Integris Medtech Limited (formerly known as Integris Health Private Limited)
CIN: U85110DL2008PLC177230

Consolidated Statement of Profit and Loss for the year ended 31 March 2026
(All amounts in ₹ millions except number of shares and per share data, unless otherwise stated)

Particulars	Note	For the year ended 31 March 2026	For the year ended 31 March 2025
Income			
Revenue from operations	24	25,786.00	19,024.66
Other income	25	781.62	571.18
Total income		**26,567.62**	**19,595.84**
Expenses			
Cost of materials consumed	26	1,481.91	1,315.49
Purchases of stock-in-trade	27	13,748.24	9,429.11
Changes in inventories of finished goods, stock-in-trade and work-in-progress	28	(729.61)	(81.43)
Employee benefits expense	29	4,979.77	3,491.55
Finance costs	30	614.28	686.60
Depreciation and amortisation expenses	31	2,004.95	1,345.46
Other expenses	32	2,670.26	2,080.93
Total expenses		**24,769.80**	**18,267.71**
Profit before share of net profit of investments accounted for using the equity method, exceptional items and tax		**1,797.82**	**1,328.13**
Share of profit of an associate, net of tax	38(f)	43.30	144.00
Profit before exceptional items and tax		**1,841.12**	**1,472.13**
Exceptional items	33	(1,695.01)	326.62
Profit before tax		**3,536.13**	**1,145.51**
Tax expense	34		
- Current tax (including earlier years)		671.78	538.27
- Deferred tax credit		(52.13)	(99.60)
Total tax expense		**619.65**	**438.67**
Profit for the year		**2,916.48**	**706.84**
Other comprehensive income			
Items that will not be reclassified to profit or loss:			
Re-measurements of the defined benefit plans		(1.93)	(3.41)
Income tax relating to above item		0.43	1.31
Items that will be reclassified subsequently to profit or loss:			
Exchange differences on translation of foreign operations		616.47	171.04
Total other comprehensive income for the year		**614.97**	**168.94**
Total comprehensive income for the year		**3,531.45**	**875.78**
Profit attributable to:			
Owners of the Company		2,829.87	506.95
Non-controlling interest		86.61	199.89
Total other comprehensive income attributable to:			
Owners of the Company		562.46	139.01
Non-controlling interest		52.51	29.93
Total comprehensive income attributable to:			
Owners of the Company		3,392.33	645.96
Non-controlling interest		139.12	229.82
Earnings per equity share (₹ 1 per share) attributable to owners	39		
Basic (₹)		27.16	5.82
Diluted (₹)		27.03	5.73
Summary of material accounting policies	3		

The accompanying notes form an integral part of the Consolidated Financial Statements.
As per our report of even date attached

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No: 001076N/N500013

Kartik Gogia
Partner
Membership No.: 512371

Place: Gurugram
Date: 29 June 2026

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Probir Das
Executive Director an
DIN : 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Office

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Membership No. ACS 15719

Place: Noida
Date: 29 June 2026

Consolidated Statement of Changes in Equity for the year ended 31 March 2026

(All amounts in ₹ millions except number of shares and per share data, unless otherwise stated)

A Equity share capital

Particulars	Balance as at 01 April 2024	Equity shares to be issued pursuant to business combination (refer note 46(I)(D))	Changes during the year	Balance as at 31 March 2025	Changes during the year	Balance as at 31 March 2026
Equity share capital	16.70	**10.36**	2.96	**30.02**	78.32	**108.34**
Total	**16.70**	**10.36**	**2.96**	**30.02**	**78.32**	**108.34**

B Other equity (refer note 16B)

Particulars	Equity component of compulsorily convertible preference shares	Reserves and surplus								Total other equity	Non-controlling interest		Total
		Securities premium	Retained earnings	Shared based compensation reserve	Capital reserve	Common control adjustment deficit account (refer note 46(I)(D))	Other reserve (refer note 16B(xi))	Deemed Equity (refer note 47 (d))	Foreign currency translation reserve (FCTR)		Class B preference share capital (refer note 16A(a)(iii)(c))	Other non-controlling interest	
Balance as at 01 April 2024	**634.65**	**5,652.79**	**404.54**	**-**	**-**	**-**	**-**	**-**	**19.67**	**6,711.65**	**-**	**-**	**6,711.65**
Impact of business combination under common control (refer note 46(I)(D))	-	19,990.31	(1,234.85)	18.70	0.97	(16,148.70)	1,317.01	-	702.03	**4,645.47**	2,900.38	1,436.82	**8,982.67**
Profit for the year	-	-	506.95	-	-	-	-	-	-	**506.95**	-	199.89	**706.84**
Other comprehensive income for the year (net of tax impact)	-	-	(1.89)	-	-	-	-	-	140.90	**139.01**	-	29.93	**168.94**
Total comprehensive income / (loss) for the year	**-**	**-**	**505.06**	**-**	**-**	**-**	**-**	**-**	**140.90**	**645.96**	**-**	**229.82**	**875.78**
Security premium on equity shares issued during the year	-	3,580.72	-	-	-	-	-	-	-	**3,580.72**	-	-	**3,580.72**
Transaction cost arising on issue of equity shares	-	(42.76)	-	-	-	-	-	-	-	**(42.76)**	-	-	**(42.76)**
Conversion of compulsorily convertible preference shares (refer note 17B(xiii))	(634.65)	1,399.16	-	-	-	-	-	-	-	**764.51**	-	-	**764.51**
Acquisition of stake by minorities	-	-	-	-	-	-	-	-	-	**-**	-	7.65	**7.65**
Share-based payment expenses	-	-	-	224.99	-	-	-	-	-	**224.99**	-	1.56	**226.55**
Impact of redemption of preference shares (refer note 16A(a)(iii)(c))	-	-	(3,003.44)	-	-	-	(1,317.01)	-	(702.72)	**(5,023.17)**	(2,900.38)	-	**(7,923.55)**
Balance as at 31 March 2025	**-**	**30,580.22**	**(3,328.69)**	**243.69**	**0.97**	**(16,148.70)**	**-**	**-**	**159.88**	**11,507.37**	**-**	**1,675.85**	**13,183.22**
Profit for the year	-	-	2,829.87	-	-	-	-	-	-	**2,829.87**	-	86.61	**2,916.48**
Other comprehensive income for the year (net of tax impact)	-	-	1.57	3.09	-	-	-	-	557.80	**562.46**	-	52.51	**614.97**
Total comprehensive income / (loss) for the year	**-**	**-**	**2,831.44**	**3.09**	**-**	**-**	**-**	**-**	**557.80**	**3,392.33**	**-**	**139.12**	**3,531.45**
Securities premium on equity shares issued during the year	-	11,763.09	-	-	-	-	-	-	-	**11,763.09**	-	-	**11,763.09**
Bonus shares issued during the year (refer note 16A(a)(iii)(b))		(72.22)	-	-	-	-	-	-	-	**(72.22)**		-	**(72.22)**
Impact of business combination (refer note 46(I)(C))	-	-	-	-	-	-	-	-	-	**-**	-	30.81	**30.81**
Employee stock options exercised by minorities (refer note 47(b) and (c))	-	-	(17.28)	(30.38)	-	-	-	-	-	**(47.66)**	-	154.76	**107.10**
Acquisition of stake held by minorities (refer note 16B)	-	-	(4,494.45)	5.54	-	-	-	-	268.07	**(4,220.84)**	-	(1,651.48)	**(5,872.32)**
Share-based payment expenses (refer note 47(d))	-	-	-	186.23	-	-	-	432.90	-	**619.13**	-	0.03	**619.16**
Transfer from shared based compensation reserve to retained earnings on cancellation of options (refer note 47(a))	-	-	90.25	(90.25)	-	-		-	-	**-**	-	-	**-**
Employee stock options settlement on cancellation of options (refer note 47(a))	-	-	(114.40)	-	-	-		-	-	**(114.40)**	-	-	**(114.40)**
Impact of business restructuring (refer note 16B)	-	-	(199.65)	-	-	-	-	-	-	**(199.65)**	-	-	**(199.65)**
Balance as at 31 March 2026	**-**	**42,271.09**	**(5,232.78)**	**317.92**	**0.97**	**(16,148.70)**	**-**	**432.90**	**985.75**	**22,627.15**	**-**	**349.09**	**22,976.24**

The accompanying notes form an integral part of the Consolidated Financial Statements.
As per our report of even date attached

For Walker Chandiok & Co LLP
Chartered Accountants
Firm's Registration No: 001076N/N500013

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Kartik Gogia
Partner
Membership No.: 512371

Place: Gurugram
Date: 29 June 2026

Probir Das
Executive Director and Group CEO
DIN : 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No. ACS 15719

Place: Noida
Date: 29 June 2026

Integris Medtech Limited (formerly known as Integris Health Private Limited)

CIN: U85110DL2008PLC177230

Consolidated Statement of Cash Flows for the year ended 31 March 2026

(All amounts in ₹ millions except number of shares and per share data, unless otherwise stated)

	Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
A	**Cash flow from operating activities**		
	Profit before tax	3,536.13	1,145.51
	Adjustments for:		
	Depreciation and amortisation expense	2,004.95	1,345.46
	Finance costs	614.28	686.60
	Interest income	(62.49)	(125.53)
	Share of net profit/(loss) of associates and joint venture accounted for using the equity method	(43.30)	(144.00)
	Gain on sale of property, plant and equipment	(0.76)	6.84
	Liabilities no longer required written back	(37.03)	(81.52)
	Allowance for expected credit loss on trade receivables	117.95	34.46
	Bad debts/asset written off	4.47	13.89
	Fair value gains on investment measured at fair value through profit or loss	(22.11)	(72.35)
	Gain on lease termination/modification	(5.59)	(9.50)
	Share-based payment expenses	684.86	226.55
	Gain on deemed disposal	(2,396.23)	-
	Net (profit)/loss on foreign currency transactions and translations	(443.59)	47.10
	Change in contingent consideration	372.75	-
	Gain on disposal of investment in mutual funds	(145.64)	(7.25)
	Operating profit before working capital changes	**4,178.65**	**3,066.26**
	Movement in operating assets and liabilities		
	Increase in trades payables	779.75	(15.15)
	Increase in other financial liabilities	163.52	14.88
	Decrease in provisions	(226.92)	(139.56)
	Decrease in other liabilities	(191.40)	84.77
	Increase in trade receivables	(583.21)	(424.42)
	Increase in inventories	(786.01)	(123.87)
	Decrease in financial assets	(57.10)	(120.33)
	Increase in other assets	(249.72)	(233.97)
	Cash flows from operating activities post working capital changes	**3,027.56**	**2,108.61**
	Income tax paid (net)	(717.00)	(553.18)
	Net cash flows generated from operating activities (A)	**2,310.56**	**1,555.43**
B	**Cash flows from investing activities**		
	Purchase of property, plant and equipment (including capital work-in-progress, capital advances, intangible assets, intangible assets under development and capital creditors)	(1,542.12)	(870.68)
	Proceeds from disposal of property, plant and equipment	28.66	61.58
	Acquisition through business combinations, net of cash and cash equivalents	(487.18)	-
	Purchase of additional stake from minority of a subsidiary	(680.12)	-
	Purchase of investments	-	(3,500.00)
	Sale of investments	2,017.83	303.37
	Movement in bank deposits (net)	1,906.15	(1,872.83)
	Interest received	100.82	60.60
	Investment in associate	(293.95)	-
	(Repayments) of/proceeds from loans	(11.49)	26.54
	Dividend income	-	57.71
	Payment of contingent consideration liability	(114.44)	(352.20)
	Net cash generated from investing activities (B)	**924.16**	**(6,085.91)**
C	**Cash flows from financing activities**		
	Proceeds from issue of equity share capital (net of transaction costs)	-	3,540.09
	Proceeds from non-current borrowings	69.31	4,195.88
	Repayment of non-current borrowings	(474.71)	(4,169.99)
	(Repayment) of /proceeds from current borrowings (net)	(1,755.64)	1,622.60
	Payment of principal portion of lease liabilities	(200.83)	(145.53)
	Expenses in relation to transaction with owners	(99.64)	-
	Payment of interest portion of lease liabilities	(49.35)	(31.53)
	Finance costs	(676.08)	(560.47)
	Net cash used in financing activities (C)	**(3,186.94)**	**4,451.05**
	Net increase in cash and cash equivalents (A+B+C)	**47.78**	**(79.43)**
	Cash and cash equivalents at the beginning of the year	1,928.30	1,867.16
	Effect of exchange rate changes in cash and cash equivalents	283.98	140.57
	Cash and cash equivalents at the end of the year	**2,260.06**	**1,928.30**

Cash and cash equivalents include (refer note 14)	As at 31 March 2026	As at 31 March 2025
Cash on hand	3.46	5.18
Cheques on hand	78.13	26.17
Balance with banks in current accounts	2,111.72	1,714.36
Deposits with original maturity of less than three months	66.75	182.59
	2,260.06	**1,928.30**

Notes:

(a) Reconciliation of movements of borrowings (current and non current) and interest accrued but not due to cash flows arising from financing activities

Particulars	Interest accrued but not due on borrowings	Borrowings
As at 01 April 2024	**127.12**	**8,131.03**
Cash flows	(560.47)	1,648.49
Interest expense/ adjustment	625.18	7,515.06
As at 31 March 2025	**191.83**	**17,294.58**
Cash flows	(676.08)	(2,161.04)
Interest expense/ adjustment	578.69	(6,764.02)
As at 31 March 2026	**94.44**	**8,369.52**

(b) Details of non-cash investing and financing activities

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Acquisition of right of use assets	345.21	370.24

Also, refer note 16A(a)(iii)(a), 16A(a)(iii)(c), 17B(xiii) and 46(I)(D) for details of significant non-cash transactions entered by the Group relating to financing and investing activities.

The above Consolidated Statement of Cash Flows has been prepared under the 'indirect method' as set out in Ind AS 7, 'Statement of cash flows'.

The accompanying notes form an integral part of the Consolidated Financial Statements.
As per our report of even date attached

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No: 001076N/N500013

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Kartik Gogia
Partner
Membership No.: 512371

Place: Gurugram
Date: 29 June 2026

Probir Das
Executive Director and Group CEO
DIN : 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No. ACS 15719

Place: Noida
Date: 29 June 2026

1 Group overview

Integris Medtech Limited (formerly known as Integris Health Private Limited) ('the Holding Company'), having Corporate Identification Number ('CIN') U85110DL2008PLC177230 is a public limited company domiciled in India and was incorporated on 25 April 2008. Pursuant to the approval of the shareholders in extra ordinary general meeting held on 13 June 2025, the name of the Company has been changed from Integris Health Private Limited to Integris Medtech Private Limited. Further, pursuant to approval of shareholders in extra ordinary general meeting dated 01 August 2025, the company have been converted from Integris Medtech Private Limited to Integris Medtech Limited w.e.f. 08 August 2025. Read together with details mentioned in note 46(I)(D), the Holding Company, its subsidiaries together referred to as "the Group" and its associates is engaged into business units based on its products and services and has two segments: (a) Lab solutions segment and (b) Cardiovascular segment.

The Lab solutions segment is primarily involved in the trading and distribution of chemicals, laboratory and medical equipment, in-vitro diagnostic products, and scientific instruments; it also provides technical services such as testing, analysis, and support of medical equipment, along with after-sales support for research and clinical laboratories. Additionally, it offers specialised services including the rental of laboratory and surgical instruments, as well as training and research support for biologics. The Cardiovascular segment is engaged in the manufacturing and marketing of coronary stent systems and related products, drug-eluting solutions, Percutaneous Transluminal Coronary Angioplasty ("PTCA") balloon catheters, and other innovative, high-quality cardiovascular devices, along with trading of various medical devices, coronary stents, and related cardiovascular products.The registered address of the Holding Company is located at 1st Floor, Metro Tower LSC, M.O.R Land, New Rajinder Nagar, New Delhi -110060, India.

2 Basis of preparation and statement of compliance of Consolidated Financial Statements

These consolidated financial statements (‘financial statements’) of the Company have been prepared in accordance with the Indian Accounting Standards (hereinafter referred to as the ‘Ind AS’) as notified by the Ministry of Corporate Affairs (‘MCA’) under section 133 of the Companies Act, 2013 (‘Act’) read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time.

The financial statements have been prepared on accrual and going concern basis.

The financial statements are presented in Indian Rupees (‘₹’) (its functional and presentation currency) and all values are rounded off to the nearest millions or decimals thereof, except where otherwise indicated. Wherever the amount represented ₹ ‘0’ (zero) construes value less than Rupees fifty thousand. Adding the individual figures may therefore not always result in the exact total given.

The financial statements for the year ended 31 March 2026 were authorized and approved for issue by the Board of Directors on 29 June 2026.

(i) Principles of consolidation

Subsidiary is an entity over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity. Subsidiary is fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. Statement of profit and loss (including other comprehensive income ('OCI')) of the subsidiary acquired or disposed of during the period are recognised from the effective date of acquisition, or up to the date of disposal, as applicable.
Consolidated Financial Statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If an entity of the Group uses accounting policies other than those adopted in the Consolidated Financial Statements for like transactions and events in similar circumstances, appropriate adjustments are made to that group entity’s financial statements in preparing the Consolidated Financial Statements to ensure conformity with the Group’s accounting policies.

Consolidation procedures

i. The Consolidated Financial Statements have been combined on a line-by-line basis by adding the book values of like items of assets, liabilities, income and expenses after eliminating intra-group balances/transactions and resulting elimination of unrealised profits in full. The amounts shown in respect of reserves comprise the amount of the relevant reserves as per the balance sheet of the Holding Company and its share in the post-acquisition increase in the relevant reserves of the entities consolidated;

ii. Summary of material accounting policies and other explanatory information to the Consolidated Financial Statements, represents notes involving items which are considered material and are accordingly duly disclosed. Materiality for the purpose is assessed in relation to the information contained in the Consolidated Financial Statements. Further, additional statutory information disclosed in separate financial statements of the subsidiaries companies and/or a holding company having no bearing on the true and fair view of the Consolidated Financial Statements has not been disclosed in the Consolidated Financial Statements.

Foreign operations

The assets and liabilities of foreign operations (subsidiaries) including goodwill and fair value adjustments arising on acquisition, are translated into Indian Rupees, the functional currency of the Holding company, at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into Indian Rupees at the exchange rates at the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction.

Such exchange differences are recognised in OCI and accumulated in equity (as foreign currency translation reserve), except to the extent that the exchange differences are allocated to Non-controlling interest, if any.

When a foreign operation is disposed of in its entirety or partially such that control, significant influence or joint control is lost, the cumulative amount of exchange differences related to that foreign operation recognised in OCI is reclassified to Consolidated Statement of Profit and Loss as part of the gain or loss on disposal. If the Group disposes of part of its interest in a subsidiary but retains control, then the relevant proportion of the cumulative amount is re-allocated to Non-controlling interest, if any.

Business combination and goodwill

The Group applies the acquisition method in accounting for business combinations. The cost of an acquisition is measured as the aggregate of the consideration transferred measured at acquisition date fair value and the amount of any non-controlling interests in the acquiree. For each business combination, the Group elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree’s identifiable net assets. Acquisition-related costs are expensed as incurred.

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognised at their acquisition date fair values. For this purpose, the liabilities assumed include contingent liabilities representing present obligation and they are measured at their acquisition date fair values irrespective of the fact that outflow of resources embodying economic benefits is not probable. However, deferred tax assets or liabilities, and the assets or liabilities related to employee benefit arrangements are recognised and measured in accordance with Ind AS 12 Income Tax and Ind AS 19 Employee Benefits respectively. When a liability assumed is recognised at the acquisition date but the related costs are not deducted in determining taxable profits until a later period, a deductible temporary difference arises which results in a deferred tax asset. A deferred tax asset also arises when the fair value of an identifiable asset acquired is less than its tax base.

Any contingent consideration to be transferred by the acquirer is recognised at fair value at the acquisition date. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of Ind AS 109 ‘Financial Instruments’ (“Ind AS 109”), is measured at fair value with changes in fair value recognised in the Consolidated Statement of Profit and Loss. If the contingent consideration is not within the scope of Ind AS 109, it is measured in accordance with the appropriate Ind AS. Contingent consideration that is classified as equity is not re-measured at subsequent reporting dates and subsequent its settlement is accounted for within equity.

Goodwill is initially measured as excess of the aggregate of the consideration transferred and the amount recognised for non-controlling interests, and any previous interest held, over the net identifiable assets acquired and liabilities assumed. If the fair value of the net assets acquired is in excess of the aggregate consideration transferred and where exists clear evidence of underlying reasons of classifying business combinations as bargain purchase, the difference is recognised in other comprehensive income and accumulated in equity as capital reserve. However, if there is no clear evidence of bargain purchase, the entity recognises the gain directly in equity as capital reserve, without routing the same through other comprehensive income.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group’s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

A cash generating unit to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised in Consolidated Statement of Profit and Loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

Non-controlling interest
Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of profit and loss, consolidated statement of equity and consolidated balance sheet respectively.
Consolidated Statement of Profit and Loss (including each component of OCI) is attributed to the equity holders of the Holding Company and to the non-controlling interest basis the respective ownership interests and the such balance is attributed even if this results in the non-controlling interests have a deficit balance.

The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Group. Such a change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognised within equity.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

Business Combinations - common control transactions
Business Combinations involving entities or businesses in which all the combining entities or businesses are ultimately controlled by the same party or parties both before and after the business combination, and where that control is not transitory is accounted using the pooling of interests method as enumerated below:
(i) The assets and liabilities of the combining entities are reflected at their carrying amounts.
(ii) No adjustments are made to reflect fair values, or recognise any new assets or liabilities. Adjustments are only made to harmonise accounting policies
(iii) The financial information presented in respect of prior periods is as if the business combination had occurred from the beginning of the earliest period in the financial information, irrespective of the actual date of the combination. However, where the business combination had occurred after that date, the prior period information is only from that date.
(iv) The balance of the retained earnings appearing in the Financial Information of the transferor is aggregated with corresponding balance appearing in the Financial Information of the transferee or is adjusted against capital reserve.
(v) The identity of the reserves shall be preserved and shall appear in the Financial Information of the transferee in the same form in which they appeared in the Financial Information of the transferor.
(vi) The difference, if any, between the amounts recorded as share capital issued plus any additional consideration in the form of cash or other assets and the amount of share capital of the transferor is transferred to capital reserves.

Investment in associates
An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies.

A joint venture is a type of joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint venture. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control. The considerations made in determining whether significant influence or joint control are similar to those necessary to determine control over the subsidiaries.

The Group's investments in its associate and joint venture are accounted for using the equity method. Under the equity method, the investment in an associate or a joint venture is initially recognised at cost. The carrying amount of the investment is adjusted to recognise changes in the Group's share of net assets of the associate or joint venture since the acquisition date. Goodwill relating to the associate or joint venture is included in the carrying amount of the investment and is not tested for impairment individually.

The Consolidated Statement of Profit and Loss reflects the Group's share of the results of operations of the associate or joint venture. Any change in OCI of those investees is presented as part of the Group's OCI. In addition, when there has been a change recognised directly in the equity of the associate or joint venture, the Group recognises its share of any changes, when applicable, in the investment in associate or joint venture. Unrealised gains and losses resulting from transactions between the Group and the associate or joint venture are eliminated to the extent of the interest in the associate or joint venture.

If Group's share of losses of an associate or a joint venture equals or exceeds its interest in the associate or joint venture (which includes any long term interest that, in substance, form part of the Group's net investment in the associate or joint venture), the Group discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate or joint venture. If the associate or joint venture subsequently reports profits, the Group resumes recognising its share of those profits only after its share of the profits equals the share of losses not recognised.
The aggregate of the Group's share of profit or loss of an associate and a joint venture is shown on the face of the Consolidated Statement of Profit and Loss.

The Financial Information of the associate or joint venture are prepared for the same reporting period as the Group. When necessary, adjustments are made to bring the accounting policies in line with those of the Group.

After application of the equity method, the Group determines whether it is necessary to recognise an impairment loss on its investment in its associate or joint venture. At each reporting date, the Group determines whether there is objective evidence that the investment in the associate or joint venture is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate or joint venture and its carrying value, and then recognises the loss as 'Share of profit of an associate and a joint venture' in the Consolidated Statement of Profit and Loss.

Upon loss of significant influence over the associate or joint control over the joint venture, the Group measures and recognises any retained investment at its fair value. Any difference between the carrying amount of the associate or joint venture upon loss of significant influence or joint control and the fair value of the retained investment less cost to sell is recognise in Consolidated Statement of Profit and Loss.

The Group discontinue the use of equity method from the date the investment is classified as held for sale in accordance with Ind AS 105 - Non-current Assets Held for Sale and Discontinued Operations and measures the interest in associate and joint venture held for sale at the lower of its carrying amount and fair value less cost to sell.

(ii) Historical cost convention

The Group's Consolidated Financial Statements have been prepared on an accrual basis and under the historical cost convention except for certain financial assets and liabilities, contingent consideration, defined benefit plans and share-based payments.

These Consolidated Financial Statements have been prepared in accordance with the accounting policies set out below and were consistently applied to all periods presented unless otherwise stated. They have been prepared under the assumption that the Group operates on a going concern basis, which assumes the Group will be able to discharge its liabilities as and when they fall due.

(iii) Current versus non-current classification

The Group presents assets and liabilities in the balance sheet based on current/ non-current classification. An asset is treated as current when it is:
• Expected to be realised or intended to be sold or consumed in normal operating cycle
• Held primarily for the purpose of trading
• Expected to be realised within twelve months after the reporting period, or
• Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:
• It is expected to be settled in normal operating cycle
• It is held primarily for the purpose of trading
• It is due to be settled within twelve months after the reporting period, or

There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period The Group classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Group has identified twelve months as its operating cycle.

3 Material accounting policies

The financial statements have been prepared using the material accounting policies and measurement bases summarised as below. These policies are applied consistently for all the periods presented in the financial statements.

a) Property, plant and equipment

Recognition and initial measurement

Property, plant and equipment are measured at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discount and rebates are deducted in arriving at the purchase price. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The cost of improvements to leasehold premises, if recognition criteria are met, have been capitalised and disclosed separately under leasehold improvement. All other repair and maintenance costs are recognised in Consolidated Statement of Profit and Loss.

Freehold land and buildings are measured at fair value less accumulated depreciation on buildings and impairment losses recognised after the date of the revaluation. Valuations are performed with sufficient regularity to ensure that the carrying amount does not differ materially from the fair value of the freehold land and buildings at the reporting date. Freehold land is not depreciated but are subject to impairment test if there is any indication of impairment.

Cost of property, plant and equipment not ready for use as at the reporting date are disclosed as capital work-in-progress.

Subsequent measurement (depreciation method, useful lives and residual value)

Property, plant and equipment are subsequently measured at cost less accumulated depreciation and impairment losses. Depreciation on property, plant and equipment is provided on straight line method based on estimated useful life of the asset after considering the residual value as set out in Schedule II to the Act referred above. Depreciation is calculated on pro rata basis from the date on which the asset is ready for use or till the date the asset is sold or disposed.

The estimated useful lives of items of property, plant and equipment are as follows:

S.No	Asset category	Useful life of assets
1	Buildings	20-60 Years
2	Plant and equipment (other than machinery leased to customers)	1 - 15 years
3	Plant and equipment (machinery leased to customers)	5 years
4	Furniture and fixtures	5 - 13 years
5	Vehicles	4 -10 years
6	Office equipment	5 - 7 years
7	Computers	3 - 4 years

Leasehold improvements are depreciated over the lease period on a straight line basis, commencing from the date the asset is available to the Group for its use.

The residual values, useful lives and method of depreciation are reviewed at the end of each financial year.

De-recognition

An item of property, plant and equipment and any significant component initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognized in the Consolidated Statement of Profit and Loss, when the asset is de-recognised.

b) Intangible assets

Recognition and measurement

Intangible assets that are acquired are recognised only if it is probable that the expected future economic benefits that are attributable to the asset will flow to the Group and the cost of assets can be measured reliably. The intangible assets are recorded at cost of acquisition including incidental costs related to acquisition and are carried at cost less accumulated amortisation and impairment losses, if any. Gain or losses arising from derecognition of an intangible assets are measured as the difference between the net disposal proceeds and the carrying amount of the intangible asset and are recognised in the Consolidated Statement of Profit and Loss when the asset is derecognised.

Research costs are expensed as incurred. An intangible asset arising form development expenditure that are directly attributable to the design and testing of an individual project is recognized only where the following criteria are met:

• it is technically feasible to complete the intangible asset so that it will be available for use

• management intends to complete the intangible asset and use or sell it

• there is an ability to use or sell the intangible asset

• it can be demonstrated how the intangible asset will generate probable future economic benefits

• adequate technical, financial and other resources to complete the development and to use or sell the intangible asset are available, and

• the expenditure attributable to the intangible asset during its development can be reliably measured

Amortisation

Amortisation on intangible assets is calculated to write off the cost of intangible assets less their estimated residual values over their estimated useful lives using the straight-line method, and is included in 'depreciation and amortisation expenses' head in the Consolidated Statement of Profit and Loss.

Amortisation method, useful lives and residual values are reviewed at the end of each financial year and adjusted if appropriate. Amortisation has been computed based on the following useful lives:

S.No	Asset category	Useful life
1	Trademarks	9 years
2	Customer relationships	10 years
3	Patents, computer software and others	5 years
4	Distribution Networks	5-14 years
5	Non-compete fee	2 years
6	Brand	10 years
7	Technical know-how	9.5 years

c) Revenue recognition

Revenue from contracts with customers is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. When a performance obligation is satisfied, the revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of goods sold and services rendered is net of variable consideration on account of various discounts and schemes offered by the Company as part of the contract. Revenue is only recognised to the extent that it is highly probable a significant reversal will not occur. The Group applies the revenue recognition criteria to each component of the revenue transaction as set out below:

The Group often enters into customer contracts to supply a bundle of products and services, for example, right-to-use of medical instruments along with related maintenance service and supply of reagents. The contract is then assessed to determine whether it contains a single combined performance obligation or multiple performance obligations. If applicable the total transaction price is allocated amongst the various performance obligations based on their relative stand-alone selling prices. Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price allocated to that performance obligation.

Sale of goods

Revenue from sale of goods is recognized when goods are transferred for a price, all significant risk and rewards of the ownership have been transferred to the customer, no effective control is retained with respect to goods transferred to a degree usually associated with ownership, no significant uncertainty exists regarding the amount of consideration and collectability of amount is reasonably assured. The Group considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for the goods excluding amounts collected on behalf of third parties (for example, indirect taxes).

A receivable is recognised by the Group when the control is transferred as this is the case of point in time recognition where consideration is unconditional because only the passage of time is required. When either party to a contract has performed, an entity shall present the contract in the balance sheet as a contract asset or a contract liability, depending on the relationship between the entity's performance and the payment.

Income from services

In certain contracts, the Group offers instrument rental program which provides the customers the ability to use an instrument through the contract period. These contracts may or may not contain substantive substitution rights. These agreements may also provide the customers with maintenance service of the instruments placed at customer locations. For contracts where there is no lease identified within the contact, the Group recognises revenue from providing such service over time, on a straight-line basis over the term of the contract, since the customer simultaneously receives and consumes the benefits as the entity performs such service.

Interest income

Interest income is recognised on time proportion basis considering the amount outstanding and rate applicable. For all financial assets measured at amortised cost, interest income is recorded using the effective interest rate (EIR) i.e. the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial assets.

Export incentives

Revenue in respect of export incentives is recognised when the right to receive the same is established.

Variable consideration

If the consideration in a contract includes a variable amount, the Group estimates the amount of consideration to which it will be entitled in exchange for transferring the goods to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved. Some contracts for the sale of products provide customers with discounts. The discounts give rise to variable consideration.
(i) Discounts
The Company provides discounts to certain customers. Discounts are offset against amounts payable by the customer.

Sales return

The customers have the contractual right to return goods only when authorised by the Group. An estimate is made of goods that will be returned, and a liability is recognised for this amount using a best estimate based on accumulated experience. The Group deals in various products and operates in various distribution channels.
Accordingly, the estimate of sales returns is determined primarily by the Group's historical experience in the markets in which the Group operates by considering actual sales returns, estimated shelf life and other factors.

d) Right of use assets and lease liabilities

The Group as a lessee

The Group at the inception considers whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'.

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

The Group enters into leasing arrangements for various assets. The assessment of the lease is based on several factors, including, but not limited to, transfer of ownership of leased asset at end of lease term, lessee's option to extend/purchase etc.

Right of use assets

Recognition and initial measurement

At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the group, an estimate of any costs to dismantle and remove the asset at the end of the lease (if any), and any lease payments made in advance of the lease commencement date (net of any incentives received).

Subsequent measurement

The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist.

Lease Liabilities

At lease commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group's incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed payments) and variable payments based on an index or rate. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is re-measured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is re-measured, the corresponding adjustment is reflected in the right-of-use asset.

The Group has elected to account for short-term leases using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in Consolidated Statement of Profit and Loss on a straight-line basis over the lease term.

e) Inventories

Inventories are valued at the lower of cost and net realisable value. Cost is determined on a weighted average cost method in case of lab solutions segment and on first-in-first-out method in case of cardiovascular segment.
In respect of raw materials and stores and spares, cost includes cost of purchase. Cost includes freight, taxes and duties and excludes duties and taxes that are recoverable subsequently from tax authorities.

In respect of traded goods, cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Trade discounts and rebates are deducted in determine cost of purchase.
In respect of finished goods and work In progress: cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.
Provision for slow moving/non moving inventory is estimated and made by the management, wherever necessary, based on the past experience of the Group.

f) Income taxes

Tax expense recognized in Consolidated Statement of Profit and Loss comprises the sum of deferred tax and current tax except to the extent it recognized in other comprehensive income or directly in equity.

Current tax

Current tax is measured at the amount expected to be paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the end of the reporting date in the countries where the Group operates and generates taxable income.

Current tax comprises the tax payable on taxable income for the year and any adjustment to the tax payable or receivable in respect of previous years. Current tax is computed in accordance with relevant tax regulations. The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received after considering uncertainty related to income taxes, if any. Current tax relating to items recognised outside profit or loss is recognised outside Consolidated Statement of Profit and Loss (either in other comprehensive income or in equity).

Current tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

Deferred tax

Deferred tax is recognised in respect of temporary differences between carrying amount of assets and liabilities for financial reporting purposes and corresponding amount used for taxation purposes. Deferred tax assets are recognised on unused tax loss, unused tax credits and deductible temporary differences to the extent it is probable that the future taxable profits will be available against which they can be used. This is assessed based on the Group's forecast of future operating results, adjusted for significant non-taxable income and expenses and specific limits on the use of any unused tax loss. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax is not recognised for:

- temporary differences arising on the initial recognition of assets or liabilities in a transaction that affects neither accounting nor taxable profit or loss at the time of the transaction;
- taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Group expects, at the reporting date to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously. Deferred tax relating to items recognised outside statement of profit and loss is recognised outside Consolidated Statement of Profit and Loss (either in other comprehensive income or in equity).

In the situations where the Group is entitled to a tax holiday under the Income-tax Act, 1961 enacted in India or tax laws prevailing in the respective tax jurisdictions where it operates, no deferred tax (asset or liability) is recognized in respect of timing differences which reverse during the tax holiday period, to the extent the Group's gross total income is subject to the deduction during the tax holiday period. Deferred tax in respect of timing differences which reverse after the tax holiday period is recognised in the year in which the timing differences originate. However, the Group restricts recognition of deferred tax assets to the extent that it has become reasonably certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized. For recognition of deferred taxes, the timing differences which originate first are considered to reverse first.

g) Employee benefits

Post-employment benefit plans are classified into defined benefits plans and defined contribution plans as under:

Defined contribution plan
The Group has a defined contribution plans namely provident fund and pension scheme. The contribution made by the Group in respect of these plans are charged to the Consolidated Statement of Profit and Loss in the year in which the related service is performed.

Defined benefit plan
The Group has an obligation towards gratuity, a defined benefit retirement plan covering eligible employees. Under the defined benefit plans, the amount that an employee will receive on retirement is defined by reference to the employee's length of service and last drawn salary. The liability recognised in the statement of financial position for defined benefit plans is the present value of the Defined Benefit Obligation (DBO) at the reporting date. Management estimates the DBO annually with the assistance of independent actuaries. Actuarial gains/losses resulting from re-measurements of the liability/asset are included in other comprehensive income.

The Group has a defined contribution plans namely provident fund and pension scheme. The contribution made by the Group in respect of these plans are charged to the Consolidated Statement of Profit and Loss in the year in which the related service is performed.

Defined benefit plan
Other long term benefits
The Group also provides the benefit of compensated absences to its employees which are in the nature of long-term employee benefit plan. Liability in respect of compensated absences becoming due and expected to availed after one year from the balance sheet date is estimated in the basis of an actuarial valuation performed by an independent actuary using the projected unit credit method as on the reporting date. Actuarial gains and losses arising from past experience and changes in actuarial assumptions are charged to Consolidated Statement of Profit and Loss in the year in which such gains or losses are determined.
The obligations are presented as current liabilities in the balance sheet if the group does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur.

Share-based payments
Equity-settled share-based payments to employees and others providing similar services that are granted by the Group are measured by reference to the fair value of the equity instruments at the grant date. Estimating fair value for equity-based payment transactions requires determination of the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including the expected life of the share option, volatility, risk free rate, expected dividend yield, market price and exercise price and making assumptions about them. For equity settled share-based payment transactions, the liability needs to be disclosed at the carrying amount at end of each reporting period up to the date of settlement. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 47. Change in assumptions for estimating fair value of share-based payment transactions is expected to have insignificant impact on income statement.

The fair value determined at the grant date of the equity-settled share-based payments is expensed over the vesting period, based on the Group's estimate of equity instruments that will eventually vest, with a corresponding increase in equity. At the end of each reporting period, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the equity-settled employee benefits reserve.

If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options expected to vest. Upon exercise of share options, the proceeds received, net of any directly attributable transaction costs, are allocated to share capital up to the nominal (or par) value of the shares issued with any excess being recorded as share premium.

In case of forfeiture/lapse of vested options with respect to option given to employees of the Company or the Group, the reserve amount is transferred within other equity from employee stock options reserve to retained earnings. Further, the dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

h) Initial public offer related transaction costs

The expenses pertaining to Initial Public Offer (IPO') includes expenses pertaining to fresh issue of equity shares, offer for sale by selling shareholders and listing of equity shares and has been accounted for as follows:

• Incremental costs that are directly attributable to issuing new shares has been deferred until successful consummation of IPO upon which it shall be deducted from equity;

• Incremental Costs that are not directly attributable to issuing new shares or offer for sale by selling shareholders, has been recorded as an expense in the statement of profit and loss as and when incurred; and

• Costs that relate to fresh issue of equity shares and offer for sale by selling shareholders has been allocated on a rational and consistent basis as per the agreed terms.

Any payments by the Company in relation to the issue on behalf of the selling shareholders shall be reimbursed by the selling shareholders to the Company in proportion to the equity shares being offered for sale by the selling shareholders to the issue.

i) Provisions, contingent liabilities and contingent assets

Provisions are recognized only when there is a present obligation, as a result of past events, and when a reliable estimate of the amount of obligation can be made at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates. Provisions are discounted to their present values, where the time value of money is material.

Contingent liability is disclosed for:
• Possible obligations which will be confirmed only by future events not wholly within the control of the Group; or
• Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

Contingent assets are neither recognised nor disclosed except when realisation of income is virtually certain, related asset is disclosed.

j) Impairment of non-financial assets

At each reporting date, the Group assesses whether there is any indication that an asset may be impaired. If any such indication exists, the Group estimates the recoverable amount of the asset. Recoverable amount is higher of an asset's net selling price and its value in use. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the Consolidated Statement of Profit and Loss. If at the reporting date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount, subject to a maximum of depreciated historical cost.

k) Impairment of financial assets

In accordance with Ind AS 109, the Group applies expected credit loss ('ECL') model for measurement and recognition of impairment loss for financial assets. ECL is provided for when there has been a significant increase in credit risk and then, factors historical trends and forward looking information. An impairment loss is recognised either based on the 12 months' probability of default or lifetime probability of default.

Trade receivables
In respect of trade receivables, the Group applies the simplified approach of Ind AS 109, which requires measurement of loss allowance at an amount equal to lifetime expected credit losses. Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of such receivables.

Other financial assets
In respect of its other financial assets, the Group assesses if the credit risk on those financial assets has increased significantly since initial recognition. If the credit risk has not increased significantly since initial recognition, the Group measures the loss allowance at an amount equal to 12-month expected credit losses, else at an amount equal to the lifetime expected credit losses.

l) Foreign currency transactions and translations

Functional and presentation currency
Items included in the Consolidated Financial Statements of the Group are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The Consolidated Financial Statements have been prepared and presented in Indian Rupees ('₹'), which is the Group's functional and presentation currency.

Transactions and balances
Foreign currency transactions are translated into the functional currency, by applying the exchange rates on the foreign currency amounts at the date of the transaction. Foreign currency monetary items outstanding at the balance sheet date are converted to functional currency using the closing rate. Non-monetary items denominated in a foreign currency which are carried at historical cost are reported using the exchange rate at the date of the transaction.

Exchange differences
Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the Consolidated Statement of Profit and Loss in the year in which they arise.

m) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Initial recognition and measurement
Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted for transaction costs. Subsequent measurement of financial assets and financial liabilities is described below.

Non-derivative financial assets
Subsequent measurement
Financial assets carried at amortised cost – A 'financial asset' is measured at the amortised cost if both the following conditions are met:
• The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
• Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method.

Financial assets carried at Fair value through other comprehensive income (FVOCI) - The Group accounts for financial assets at FVOCI if the assets meet the following conditions:
• They are held under a business model whose objective it is "hold to collect" the associated cash flows and sell, and
• the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding

Any gains or losses recognised in Other comprehensive income (OCI) will be recycled upon derecognition of the asset. However, there is an exception to this, which is an irrevocable option to present subsequent changes in the fair value of an investment in equity, in which case there is no recycling even at the time of derecognition, except for dividend income recognised in Consolidated Statement of Profit and Loss.

Financial Assets at Fair value through profit or loss (FVTPL) -
Financial assets held within a different business model other than 'hold to collect' or 'hold to collect and sell' are categorised at FVTPL. Further, irrespective of the business model used, financial assets whose contractual cash flows are not solely payments of principal and interest are accounted for at FVTPL.

For all equity investments, the Group accounts for the investment at FVTPL. The fair value is determined in line with the requirements of Ind AS 113 'Fair Value Measurement'.

Assets in this category are measured at fair value with gains or losses recognised in consolidated statement of profit and loss. The fair values of financial assets in this category are determined by reference to active market transactions or using a valuation technique where no active market exists.

De-recognition of financial assets

A financial asset is de-recognised when the contractual rights to receive cash flows from the asset have expired or the Group has transferred its rights to receive cash flows from the asset.

Non-derivative financial liabilities
Subsequent measurement
Subsequent to initial recognition, all non-derivative financial liabilities are measured at amortised cost using the effective interest method.

De-recognition of financial liabilities
A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the consolidated statement of profit and loss.

Offsetting of financial instruments
Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Reclassification of financial assets
The Group determines classification of financial assets and liabilities on initial recognition. After initial recognition, no reclassification is made for financial assets which are equity instruments and financial liabilities. For financial assets which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. The Group's senior management determines change in the business model as a result of external or internal changes which are significant to the Group's operations. Such changes are evident to external parties. A change in the business model occurs when the Group either begins or ceases to perform an activity that is significant to its operations. If the Group reclassifies financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in business model. The Group does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

Put Option Liability
The Group has entered into arrangements that grant counterparties the right to exercise put options requiring the Group to purchase certain equity instruments of its subsidiaries. Based on an evaluation of the contractual terms, the Group has determined that the triggering events governing the exercise of such put options are not entirely within its control.
In accordance with Ind AS 32, Financial Instruments: Presentation, such arrangements are treated as giving rise to a financial liability. Accordingly, the Group recognises a put option liability in respect of its obligation to acquire the underlying equity instruments.
The put option liability is initially recognised at the present value of the expected future cash outflows required to settle the obligation, taking into consideration the contractual terms of the arrangement and the expected timing of exercise.
The corresponding debit on initial recognition is recorded as an adjustment to equity attributable to the owners of the Group, as the arrangement represents a transaction with non-controlling interest holders. Subsequent remeasurement of the liability is recognised in the statement of profit and loss in accordance with the applicable accounting standards

n) Fair value measurement
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability; or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their best economic interest.

A fair value measurement of a non-financial asset considers a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.
Involvement of external valuers is decided upon annually by the Group. At each reporting date, the Group analyses the movements in the values of assets and liabilities which are required to be remeasured or re-assessed as per the accounting policies. For this analysis, the Group verifies the major inputs applied in the latest valuation by agreeing the information in the valuation computation to contracts and other relevant documents.

For the purpose of fair value disclosures, the Group has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

o) Cash and cash equivalents

Cash and cash equivalents for the purposes of consolidated cash flow statement comprise cash at bank and in hand, cheques in hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value and having original maturities of three months or less from the date of purchase, to be cash equivalents. Cash and cash equivalents consist of balances with banks which are unrestricted for withdrawal and usage.

p) Segment reporting
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (CODM). The chief operating decision maker is considered to be the Group Chief Executive Officer (CEO) who makes strategic decisions and is responsible for allocating resources and assessing performance of the operating segments

q) Earnings per share

Basic Earnings Per Share ('EPS') is computed by dividing the net profit attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the net profit after income tax effect of interest and other financing costs associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share and also the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue and share split that have changed the number of equity shares outstanding, without a corresponding change in resources.

Dilutive potential equity shares are deemed converted as of the beginning of the year, unless issued at a later date. In computing diluted earnings per share, only potential equity shares that are dilutive and that either reduces earnings per share or increases loss per share are included. The number of shares and potentially dilutive equity shares are adjusted retrospectively for all periods presented in case of share splits.

r) Significant management judgement in applying accounting policies and estimation uncertainty

The preparation of these Consolidated Financial Statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the related disclosures. Actual results may differ from these estimates. Continuous evaluation is done on the estimation and judgements based on historical experience and other factors, including expectations of future events that are believed to be reasonable. Revisions to accounting estimates are recognised prospectively.

Significant management judgements

Recognition of deferred tax assets – The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the Group's future taxable income against which the deferred tax assets can be utilised.

Leases – The Group evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgment. The Group uses significant judgement in assessing the lease term (including anticipated renewals) and the applicable discount rate. The Group determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Group is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Group is reasonably certain not to exercise that option. In assessing whether the Group is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Group to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The Group revises the lease term if there is a change in the non-cancellable period of a lease.

Provisions and contingent liabilities - The Group estimates the provisions that have present obligations as a result of past events and it is probable that outflow of resources will be required to settle the obligations. These provisions are reviewed at the end of each reporting period and are adjusted to reflect the current best estimates. The Group uses significant judgements to assess contingent liabilities.
Contingent liabilities are recognised when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount cannot be made. Contingent assets are neither recognised nor disclosed in the consolidated financial statements.

Significant estimates

Impairment of financial assets – At each balance sheet date, based on historical default rates observed over expected life, existing market conditions as well as forward looking estimates, the management assesses the expected credit losses on outstanding receivables and advances. Further, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with industry and country in which the customer operates.

Impairment of goodwill

The Group estimates the value-in-use of the cash generating units (CGUs) based on the future cash flows after considering current economic conditions and trends, estimated future operating results and growth rate and anticipated future economic and regulatory conditions. The estimated cash flows are developed using internal forecasts. The discount rates used for the CGUs represent the weighted average cost of capital based on the historical market returns of comparable companies.

Defined benefit obligation (DBO) – Management's estimate of the DBO is based on a number of underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.

Useful lives of depreciable/amortisable assets – Management reviews its estimate of the useful lives of depreciable/amortisable assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and economic obsolescence that may change the utilisation of assets.

Business combinations – Management uses various valuation techniques when determining the fair values of certain assets and liabilities acquired in a business combination (Refer note 2(i) and note 46). In particular, the fair value of contingent consideration is dependent on the outcome of many variables including the acquirees' future profitability.

s) Borrowing costs

Borrowing costs attributable to the acquisition or construction of a qualifying asset are capitalised as part of the cost of the asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. Other borrowing costs are recognised as an expense in the period in which they are incurred. Borrowing cost includes exchange differences to the extent regarded as an adjustment to the borrowing costs, if any.

t) Events after reporting date:

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted in the financial statements. Otherwise, events after the balance sheet date of material size or nature are only disclosed.

u) Application of New standards and amendments

The Ministry of Corporate Affairs notified new standards or amendment to existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. The Group applied following amendments for the first-time during the current year which are effective from 1 April 2025:

Lack of exchangeability – Amendments to Ind AS 21

MCA via notification dated 7 May 2025, announced amendments to Ind AS 21 "The Effects of Changes in Foreign Exchange Rates" to specify how an entity should assess whether a currency is exchangeable and how it should determine a spot exchange rate when exchangeability is lacking. The amendments also require disclosure of information that enables users of its financial statements to understand how the currency not being exchangeable into the other currency affects, or is expected to affect, the entity's financial performance, financial position and cash flows. The amendments are not expected to have a material impact on the Group's Consolidated Financial Statements.

Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants - Amendments to Ind AS 1

MCA via notification dated 13 August 2025 announced amendments to Ind AS 1 "Presentation of Financial Statements", which elaborate on guidance set out in Ind AS 1 by:
• clarifying that the right to defer settlement of a liability for at least 12 months after the reporting period; a) must have substance, and b) must exist at the end of the reporting period;
• stating that management's expectations around whether they will defer settlement or not does not impact the classification of the liability;
• including requirements for liabilities that can be settled using an entity's own instruments; and
• stating that at the reporting date, the entity does not consider covenants that will need to be complied with in the future when considering the classification of the debt as current or non current.
The amendments are not expected to have a material impact on the Group's Consolidated Financial Statements.

Supplier Finance Arrangements - Amendments to Ind AS 7 and Ind AS 107

MCA via notification dated 13 August 2025 announced amendments to Ind AS 7 "Statement of Cash Flows" and Ind AS 107 "Financial Instruments: Disclosures" which introduced disclosure requirements with the objective to enable users of financial statements to assess how supplier finance arrangements affect an entity's liabilities, cashflows and exposure to liquidity risk.
The amendments are not expected to have a material impact on the Group's financial statements.

International Tax Reform - Pillar Two Model Rules - Amendments to Ind AS 12

MCA via notification dated 13 August 2025 announced amendments to Ind AS 12 "Income Taxes" which includes:
• a temporary exception to the recognition and disclosure of deferred taxes arising from the implementation of the Pillar Two model rules; and
• additional disclosure requirements targeted at a reporting entity's exposure to income taxes in periods in which the Pillar Two Model legislation is enacted or substantively enacted but not yet in effect.
The amendments are not expected to have a material impact on the Group's financial statements.

v) Standards notified but not yet effective

The new and amended standards that are notified by the Ministry of Corporate Affairs (MCA), but not yet effective, up to the date of issuance of the Group's financial statements are disclosed below. The Group will adopt these new and amended standards, when they become effective.

(i) Amendments to Ind AS 1 - Classification of Liabilities as Current or Non-current and Non-current Liabilities with Covenants

In accordance with Ind AS 1 currently applicable, breach of an immaterial covenant is ignored deciding in current vs. non-current classification of liabilities. Also, in case of breach of a material covenant of a non-current loan on or before the reporting date, the entity can obtain waiver from the lender after the reporting date and continue to classify the loan as non-current liability.
In accordance with changes to Ind AS 1 already notified by the MCA, the above relaxations to classify loan as non-current liability will not be available from FY 2026-27 onward and need to be applied retrospectively. Consequently:
• A breach of either material or immaterial covenant will trigger current classification of liability.
• To continue classifying loan as non-current liability, entities will need to obtain waiver from the breach on or before the reporting date.

The amendments are not expected to have a material impact on the Group's financial statements.

(This space has been intentionally left blank)

4A Property, plant and equipment

Particulars	Freehold Land	Buildings	Plant and equipments	Computers	Furniture and fixtures	Vehicles	Office equipment	Leasehold improvements	Total
Gross carrying amount									
Balance as at 01 April 2024	**0.05**	**145.85**	**732.74**	**30.17**	**25.96**	**44.19**	**17.10**	**20.75**	**1,016.81**
Impact of business combination under common control (refer note 46(I)(D))	48.98	29.37	2,352.60	202.73	47.64	38.08	83.07	145.38	2,947.85
Additions during the year	-	19.02	656.27	21.09	4.41	7.59	11.28	18.57	738.23
Disposals during the year	-	(5.52)	(238.70)	(5.85)	(3.44)	(1.79)	(11.74)	(2.47)	(269.51)
Transfer to inventory	-	-	(13.25)	-	-	-	-	-	(13.25)
Exchange differences	(0.05)	0.02	211.67	15.45	4.05	2.98	8.71	11.68	254.51
Balance as at 31 March 2025	**48.98**	**188.74**	**3,701.33**	**263.59**	**78.62**	**91.05**	**108.42**	**193.91**	**4,674.64**
Impact of business combination under common control (refer note 46(I)(D))	-	-	-	-	-	-	-	-	-
Acquisition under business combination (refer note 46)	-	0.60	739.33	2.17	1.24	2.15	12.71	22.78	780.98
Additions during the year	-	61.91	955.96	46.92	17.85	1.98	15.90	29.05	1,129.57
Disposals during the year	-	-	(142.16)	(16.53)	(8.16)	(13.53)	(18.41)	(5.34)	(204.13)
Assets written off/Impairment	-	-	-	-	-	-	-	-	-
Transfer from inventory (net)	-	-	269.21	-	-	-	2.37	-	271.58
Exchange differences	-	-	674.82	43.74	11.01	9.67	23.20	33.71	796.15
Balance as at 31 March 2026	**48.98**	**251.25**	**6,198.49**	**339.89**	**100.56**	**91.32**	**144.19**	**274.11**	**7,448.79**
Accumulated depreciation									
Balance as at 01 April 2024	**-**	**11.82**	**226.30**	**17.99**	**8.15**	**6.92**	**7.63**	**5.35**	**284.16**
Impact of business combination under common control (refer note 46(I)(D))	-	9.29	1,195.96	158.50	38.65	25.99	62.00	69.72	1,560.11
Depreciation for the year (refer note 31)	-	16.90	505.41	28.80	8.90	10.01	10.64	23.54	604.20
Disposals during the year	-	(4.42)	(179.40)	(3.62)	(2.68)	(1.74)	(8.12)	(2.46)	(202.44)
Transfer to inventory	-	-	(10.55)	-	-	-	-	-	(10.55)
Exchange differences	-	-	129.33	11.30	2.93	2.13	7.63	6.82	160.14
Balance as at 31 March 2025	**-**	**33.59**	**1,867.05**	**212.97**	**55.95**	**43.31**	**79.78**	**102.97**	**2,395.62**
Depreciation for the year (refer note 31)	-	7.69	882.61	31.40	7.06	10.01	17.69	37.28	993.74
Disposals during the year	-	-	(117.78)	(16.47)	(8.15)	(11.64)	(18.02)	(5.34)	(177.40)
Transfer from inventory (net)	-	-	(0.84)	-	-	-	-	-	(0.84)
Exchange differences	-	-	436.92	35.37	9.26	6.74	20.30	21.20	529.79
Balance as at 31 March 2026	**-**	**41.28**	**3,067.96**	**263.27**	**64.12**	**48.42**	**99.75**	**156.11**	**3,740.91**
Net block as at 31 March 2025	**48.98**	**155.15**	**1,834.28**	**50.62**	**22.67**	**47.74**	**28.64**	**90.94**	**2,279.02**
Net block as at 31 March 2026	**48.98**	**209.97**	**3,130.53**	**76.62**	**36.44**	**42.90**	**44.44**	**118.00**	**3,707.88**

Notes:

(i) Refer note 42 for disclosure of contractual commitments for the acquisition of property, plant and equipment.

(ii) The Group has not revalued its property, plant and equipments during the year.

(iii) Refer note 17A and 17B for details of property, plant and equipments pledged as security.

(iv) The Group undisputedly possesses the title deeds for all immovable properties held by the Group, presented under 'Freehold land' and 'Buildings' in the above note.

(v) Plant and equipments includes certain machineries and diagnostic instruments placed at customer location. Refer note 43(e) for further details.

4B Capital work-in-progress (CWIP)

Particulars	Total
As at 01 April 2024	**58.68**
Impact of business combination under common control (refer note 46(I)(D))	2.65
Additions during the year	118.01
Capitalised during the year	(57.93)
Adjustments made during the year*	(9.66)
Exchange differences	(0.07)
As at 31 March 2025	**111.68**
Additions during the year	473.92
Capitalised during the year	(412.76)
Exchange differences	4.54
As at 31 March 2026	**177.38**

Notes :

(i) CWIP Ageing schedule as at 31 March 2026

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	156.28	13.84	7.26	-	**177.38**
	156.28	**13.84**	**7.26**	**-**	**177.38**

(ii) CWIP Ageing schedule as at 31 March 2025

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	61.94	39.23	10.51	-	**111.68**
	61.94	**39.23**	**10.51**	**-**	**111.68**

*This pertains to transfer from CWIP to inventory

(i) Details of expenses capitalised as a part of capital work in progress are disclosed in note 26, 29, 30 and 32.

(ii) There are no projects included under CWIP that are overdue or have exceeded their original Start of Production (SOP) date as compared to the approved plan, except for one project amounting to ₹ 111.34 million as on 31 March 2026. The said project was originally scheduled to be completed by 31 March 2026; however, the timeline has been revised and is now expected to complete on 31 July 2026.

(iii) Capital work in progress does not include any project temporarily suspended.

(iv) Refer note 42 for contractual commitments for constructions or acquisition of any CWIP.

4C Right-of-use assets

Particulars	Land	Buildings	Equipments	Vehicles	Total
Gross carrying amount					
Balance as at 01 April 2024	**75.20**	**122.07**	**55.77**	**40.14**	**293.18**
Impact of business combination under common control (refer note 46(I)(D))	-	282.79	-	2.61	285.40
Additions during the year	40.87	317.64	-	11.73	370.24
Disposals during the year	-	(42.51)	-	-	(42.51)
Adjustment for lease terminations/modification	-	8.16	(4.90)	-	3.26
Exchange differences	-	21.53	0.52	2.61	24.66
Balance as at 31 March 2025	**116.07**	**709.68**	**51.39**	**57.09**	**934.23**
Acquisition under business combination (refer note 46)	-	72.97	-	-	72.97
Additions during the year	-	336.94	-	8.27	345.21
Disposals during the year	-	(164.59)	(24.08)	(2.88)	(191.55)
Adjustment for lease terminations/modification	-	(25.40)	-	-	(25.40)
Exchange differences	-	77.31	5.65	7.09	90.05
Balance as at 31 March 2026	**116.07**	**1,006.91**	**32.96**	**69.57**	**1,225.51**
Accumulated depreciation					
Balance as at 01 April 2024	**3.39**	**63.42**	**41.78**	**(1.25)**	**107.34**
Impact of business combination under common control (refer note 46(I)(D))	-	108.02	-	0.84	108.86
Depreciation for the year (refer note 31)	1.08	135.17	1.43	16.91	154.59
Disposals during the year	-	(34.61)	-	-	(34.61)
Adjustment for lease terminations/modification	-	(16.70)	-	-	(16.70)
Exchange differences	-	12.46	0.44	1.65	14.55
Balance as at 31 March 2025	**4.47**	**267.76**	**43.65**	**18.15**	**334.03**
Depreciation for the year (refer note 31)	1.90	199.04	3.15	11.04	215.13
Disposals during the year	-	(150.66)	(24.08)	(2.88)	(177.62)
Adjustment for lease terminations/modification	-	(22.68)	-	-	(22.68)
Exchange differences	-	49.46	4.67	4.43	58.56
Balance as at 31 March 2026	**6.37**	**342.92**	**27.39**	**30.74**	**407.42**
Net block as at 31 March 2025	**111.60**	**441.92**	**7.74**	**38.94**	**600.20**
Net block as at 31 March 2026	**109.70**	**663.99**	**5.57**	**38.83**	**818.09**

Note:
(i) The Group has not revalued its Right-of-use assets during the year.

(This space has been intentionally left blank)

5A Other Intangible assets

Particulars	Non-compete fee	Project agreement	Brand	Technical know-how	Trademarks	Patents	Distribution network	Computer software	Customer relationships	Total
Gross carrying amount										
Balance as at 01 April 2024	**-**	**-**	**-**	**-**	**595.10**	**203.06**	**952.92**	**40.89**	**1,089.47**	**2,881.44**
Impact of business combination under common control (refer note 46(I)(D))	50.66	24.66	-	212.89	-	-	2,081.92	52.84	304.73	2,727.70
Additions during the year	-	-	-	-	-	-	-	18.40	-	18.40
Disposals during the year	-	-	-	-	-	-	-	(1.47)	-	(1.47)
Exchange differences	4.88	2.39	-	4.09	1.36	5.39	118.97	9.48	0.96	147.52
Balance as at 31 March 2025	**55.54**	**27.05**	**-**	**216.98**	**596.46**	**208.45**	**3,153.81**	**120.14**	**1,395.16**	**5,773.59**
Impact of business combination under common control (refer note 46(I)(D))	-	-	-	-	-	-	-	-	-	-
Acquisition under business combination (refer note 46)	26.50	-	521.40	-	35.00	-	279.42	0.50	906.04	1,768.86
Additions during the year	-	-	-	-	-	21.29	-	15.76	-	37.05
Disposals during the year	-	-	-	-	-	-	-	(5.49)	-	(5.49)
Exchange differences	11.60	5.66	9.06	27.75	9.09	44.69	490.80	10.92	26.74	636.31
Balance as at 31 March 2026	**93.64**	**32.71**	**530.46**	**244.73**	**640.55**	**274.43**	**3,924.03**	**141.83**	**2,327.94**	**8,210.32**
Accumulated amortisation										
Balance as at 01 April 2024	**-**	**-**	**-**	**-**	**283.80**	**42.28**	**15.92**	**35.63**	**358.19**	**735.82**
Impact of business combination under common control (refer note 46(I)(D))	37.11	24.66	-	39.22	-	-	663.16	27.17	139.70	931.02
Amortisation for the year (refer note 31)	5.98	-	-	22.73	59.67	27.66	317.51	23.33	129.79	586.67
Disposals during the year	-	-	-	-	-	-	-	(0.10)	-	(0.10)
Adjustments	-	-	-	-	-	12.99	-	-	-	12.99
Exchange differences	3.74	2.39	-	0.86	1.36	1.33	29.72	(3.55)	0.64	36.49
Balance as at 31 March 2025	**46.83**	**27.05**	**-**	**62.81**	**344.83**	**84.26**	**1,026.31**	**82.48**	**628.32**	**2,302.89**
Impact of business combination under common control (refer note 46(I)(D))	-	-	-	-	-	-	-	-	-	-
Acquisition under business combination (refer note 46)	-	-	-	-	-	-	-	-	-	-
Amortisation for the year (refer note 31)	16.71	-	41.26	24.72	62.87	44.81	381.44	13.65	210.62	796.08
Disposals during the year	-	-	-	-	-	-	-	(3.16)	-	(3.16)
Exchange differences	10.44	5.66	0.60	9.08	4.53	24.26	148.31	6.70	5.53	215.11
Balance as at 31 March 2026	**73.98**	**32.71**	**41.86**	**96.61**	**412.23**	**153.33**	**1,556.06**	**99.67**	**844.47**	**3,310.92**
Net block as at 31 March 2025	**8.71**	**-**	**-**	**154.17**	**251.63**	**124.19**	**2,127.50**	**37.66**	**766.84**	**3,470.70**
Net block as at 31 March 2026	**19.66**	**-**	**488.60**	**148.12**	**228.32**	**121.10**	**2,367.97**	**42.16**	**1,483.47**	**4,899.40**

(This space has been intentionally left blank)

5B Goodwill

Particulars	Total
Gross carrying amount	
Balance as at 01 April 2024	**3,471.22**
Impact of business combination under common control (refer note 46(I)(D))	3,770.09
Adjustments*	(18.46)
Exchange differences	173.58
Balance as at 31 March 2025	**7,396.43**
Acquisition under business combination (refer note 46)	3,587.94
Exchange differences	807.44
Balance as at 31 March 2026	**11,791.81**
Impairment	
Balance as at 01 April 2024	**77.81**
Impact of business combination under common control (refer note 46(I)(D))	85.01
Exchange differences	0.11
Balance as at 31 March 2025	**162.93**
Exchange differences	0.41
Balance as at 31 March 2026	**163.34**
Closing balance as at 31 March 2025	**7,233.50**
Closing balance as at 31 March 2026	**11,628.47**

*It represents adjustment on account of funds received by one of the subsidiary company “Hausen Bernstein Co., Ltd” on account of additional share capital issued by it to its existing shareholders as per the terms of “Share subscription and shareholder agreement”.

Impairment testing of goodwill

For the purpose of impairment testing, goodwill is allocated to a cash generating unit, representing the lowest level within the Group at which goodwill is monitored for internal management purposes and which is not higher than the Group’s operating segment.

The carrying amount of goodwill was allocated to the following Cash Generating Units ('CGUs'):

	As at 31 March 2026	As at 31 March 2025
Translumina GmbH	21.23	16.56
Translumina Therapeutics Private Limited (Converted from Translumina Therapeutics LLP)	2,624.16	2,624.16
Blue Medical Devices B.V.	283.98	240.72
LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte	634.40	537.77
Halemed Medical Private Limited (refer note (b) below)	75.23	-
Medigene Sdn Bhd (refer note 46(I)(E))	-	105.91
Chemosciences Phils. Inc.	41.96	39.32
Bio-Rev Pte. Ltd	62.27	55.21
Research Instrument Pte. Ltd	1,361.24	1,206.91
Research Instruments Sdn. Bhd	157.55	130.24
Scientific Resources Pte Ltd	249.39	221.11
Biofrontier Technology Pte. Ltd	549.70	487.39
Hausen Bernstein Co., Ltd	448.80	389.78
CPC Diagnostics Private Limited	519.17	519.18
Analisa Resources (M) Sdn Bhd	168.03	138.91
Chemopharm Sdn. Bhd. (refer note 46(I)(E))	757.54	520.33
Neoscience Sdn. Bhd. (refer note (b) below)	341.24	-
Lifeline Diagnostics Supplies Inc. (refer note (b) below)	3,332.58	-
	11,628.47	**7,233.50**

Notes:

a) During the year ended 31 March 2026 and 31 March 2025, the management has reviewed the carrying value of its goodwill against the recoverable amounts of all the CGUs identified above, using internal and external information available. The recoverable amount of goodwill for impairment testing is determined as its value in use, which is calculated using discounted projected cash flows based on management approved financial budgets and forecasts.

b) During the year ended 31 March 2026, the Group has acquired three CGU entities, namely Halemed Medical Private Limited and Lifeline Diagnostic Supplies Inc. and Neoscience Sdn. Bhd. on which goodwill of ₹ 75.23 million, ₹ 3,216.75 million and ₹ 295.96 million is generated respectively on the date of acquisition.

The Group has restated the amount of goodwill as per the requirement of IND AS 21 “The effect of changes in foreign exchange rates" as on year ended 31 March 2026 and 31 March 2025.

Following key assumptions were considered while performing impairment testing of goodwill:

Assumptions	Approach used to determine the assumption
Revenue growth rate	Annual growth rate over the forecast period based on past performance and management’s future expectations.
Discount rate	Weighted Average Cost of Capital (WACC) computed as per Capital Asset Pricing Model (CAPM) model.
Terminal growth rate	This reflects the estimated sustainable long-term growth rate of the respective company which is in line with the long-term average growth rates of the respective industry and country in which the entity operates.
Number of years for which cash flows were considered	The period of projection is based on the budgets/ forecasts and cover a maximum period of five years that is considered appropriate as per management.

Summary of key assumptions used by the management:

Assumption	31 March 2026				
	Chemopharm Sdn Bhd	CPC Diagnostics Private Limited	Analisa Resources (M) Sdn Bhd	Blue Medical Devices B.V.	LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte
Revenue growth rate	5.00%	13.40% to 14.80%	10.00%	9.70% to 21.90%	9.70% to 21.90%
Discount rate	15.60%	17.80%	13.88%	14.50%	14.50%
Terminal growth rate	5%	5.00%	4%	2.50%	2.50%
Number of years for which cash flows were considered	5 years	5 years	4 years	5 years	5 years

Assumption	31 March 2026				
	Translumina GmbH	Translumina Therapeutics Private Limited	Chemosciences Phils. Inc.	Bio-Rev Pte. Ltd	Halemed Medical Private Limited
Revenue growth rate	9.70% to 21.90%	11.70% to 32.60%	10.00% to 15.00%	5.00%	20.20% to 448.80%
Discount rate	14.50%	18.50%	13.00%	12.20%	17.79%
Terminal growth rate	2.50%	4.00%	6.00%	2.00%	5.00%
Number of years for which cash flows were considered	5 years	5 years	4 years	4 years	5 years

Assumption	31 March 2026				
	Research Instrument Pte. Ltd	Research Instruments Sdn. Bhd	Scientific Resources Pte Ltd	Biofrontier Technology Pte. Ltd	Hausen Bernstein Co., Ltd
Revenue growth rate	6.80% to 7.10%	9.00% - 12.00%	8.00%	6.00%	8.00%
Discount rate	12.40%	13.88%	14.20%	13.30%	14.10%
Terminal growth rate	2.70%	4.00%	3.00%	3.00%	3.00%
Number of years for which cash flows were considered	5 years	4 years	5 years	5 years	5 years

Assumption	31 March 2026	
	Neoscience Sdn. Bhd.	Lifeline Diagnostics Supplies Inc.
Revenue growth rate	2.00% to 10.00%	9.90%
Discount rate	27.80%	13.00%
Terminal growth rate	NA	3.00%
Number of years for which cash flows were considered	5 years	5 years

Summary of key assumptions used by the management:

Assumption	31 March 2025				
	Chemopharm Sdn Bhd	CPC Diagnostics Private Limited	Analisa Resources (M) Sdn Bhd	Blue Medical Devices B.V.	LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte
Revenue growth rate	7.80% to 9.70%	14.80% to 15.30%	15%-17%	9.00%-19.00%	6.00%- 12.50%
Discount rate	15.40%	18.10%	13.88%	22.00%	20.00%
Terminal growth rate	5%	5%	3%	2.50%	2.50%
Number of years for which cash flows were considered	5 years	5 years	5 years	5 years	5 years

Assumption	31 March 2025				
	Translumina GmbH	Translumina Therapeutics Private Limited	Chemosciences Phils. Inc.	Chemoscience Pte. Ltd	Medigene Sdn Bhd
Revenue growth rate	6.60% to 10.40%	12.20% to 26.30%	10%-22%	8.00% to 12.46%	7.00%
Discount rate	15.00%	18.50%	13.00%	12.20%	13.88%
Terminal growth rate	2.50%	4.00%	6.00%	2.00%	4.00%
Number of years for which cash flows were considered	5 years	5 years	5 years	5 years	5 years

Assumption	31 March 2025				
	Research Instrument Pte. Ltd	Research Instruments Sdn. Bhd	Scientific Resources Pte Ltd	Biofrontier Technology Pte. Ltd	Hausen Bernstein Co., Ltd
Revenue growth rate	2.80% to 8.00%	8.00% - 12.00%	2.80% to 8.00%	4.00% to 10.60%	(11.90)% to 8.00%
Discount rate	12.20%	13.88%	14.00%	13.10%	13.90%
Terminal growth rate	3.00%	4.00%	3.00%	3.00%	3.00%
Number of years for which cash flows were considered	5 years	5 years	5 years	5 years	5 years

5C Intangible assets under development

Particulars	Total
Balance as at 01 April 2024	**86.33**
Impact of business combination under common control (refer note 46(I)(D))	0.80
Additions during the year	28.48
Capitalised during the year	(1.31)
Exchange difference	1.37
Balance as at 31 March 2025	**115.67**
Acquisition under business combination (refer note 46)	9.18
Additions during the year	95.06
Adjustments made during the year*	(22.70)
Capitalised during the year	(24.42)
Exchange difference	10.28
Balance as at 31 March 2026	**183.07**

Notes :

(i) Intangible assets under development ageing schedule as at 31 March 2026

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects under development	69.38	61.89	51.80	-	183.07
	69.38	**61.89**	**51.80**	**-**	**183.07**

(ii) Intangible assets under development ageing schedule as at 31 March 2025

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects under development	28.94	86.73	-	-	115.67
	28.94	**86.73**	**-**	**-**	**115.67**

*It includes written off of intangible assets under development amounts to ₹ 17.01 million (refer note 33(vi)).
(i) There are no other projects whose completion is overdue or has exceeded its cost compared to its original plan.
(ii) Intangible assets under development does not include any project temporarily suspended.
(iii) Details of expenses capitalised as a part of intangible assets under development are disclosed in note 29.

(This space has been intentionally left blank)

6A Investments accounted for using the equity method

	As at 31 March 2026	As at 31 March 2025
Investment in unquoted equity instruments in associates*		
Lifeline Holdings Inc(Refer note 46(I)(C))	-	1,959.46
Lifeline Diagnostics Supplies Inc (Refer note 46(I)(C))	-	1,625.68
RI Technologies Limited	162.20	155.34
Chemoscience (Thailand) Company Limited	66.11	49.26
Laguna Tech USA, Inc.**	293.95	-
Total	**522.26**	**3,789.74**
Aggregate amount of quoted investments	-	-
Aggregate market value of quoted investments	-	-
Aggregate value of unquoted investments	522.26	3,789.74
Aggregate amount of impairment in value of investments	-	-

* Refer note 38 for details and disclosures related to investment in associates.

** The Group through one of its subsidiary i.e. Translumina GmbH ('TLG') has invested ₹24.34 million in Laguna Tech Inc. on 13 November 2024 and 23 April 2025 (31 March 2025: ₹ 21.81 million) under a Simple Agreement for Future Equity (SAFE). The instrument entitles the Group to convert the investment into equity shares upon a qualified financing round or other specified events. Based on the terms and conditions, the investment has been classified as a financial asset measured at fair value through OCI with Ind AS 109.
On 11 December 2025, the SAFE agreement was terminated, and the TLG received back the invested amount. Accordingly, the related financial asset was derecognised.
Subsequently, on 11 December 2025, the Company invested ₹293.95 million to acquire a 13.98% equity interest in Laguna Tech USA, Inc. by purchasing its 1,771,210 Series A Preferred Shares. The investment provides the Group with one board seat out of total 5 on the board of directors, enabling active participation in key policy making processes of Laguna Tech USA, Inc., including review of financial plans, strategic initiatives, and operational decisions. Based on these rights and representation, the management has concluded that the Group is able to exercise significant influence over Laguna Tech USA, Inc. Therefore, the investment has been accounted for using the equity method in accordance with Ind AS 28 – Investments in Associates and Joint Ventures.

6B Loans-non current

Particulars	As at 31 March 2026	As at 31 March 2025
(unsecured and considered good, valued at amortised cost)		
Loan to related parties (refer note 44)	12.22	415.44
Loan to employees	12.16	10.91
	24.38	**426.35**

Notes:

a) Loans or advances in the nature of loans are granted to promoters, directors, key managerial personnel (KMPs) and the related parties that are repayable on demand:

Type of Borrower	As at 31 March 2026		As at 31 March 2025	
	Amount of loan or advance in the nature of loan outstanding	Percentage to the total loans and advance in the nature of loan %	Amount of loan or advance in the nature of loan outstanding	Percentage to the total loans and advance in the nature of loan %
Chemoscience (Thailand) Company Limited*	12.22	50.12%	1.47	0.34%

*This loan is given for the general business purpose and carry nil interest.

b) Lifeline Holdings Inc., a related party has obtained an unsecured loan, for the purpose of general business purposes. The loan carries an interest rate of Nil and was repayable on 17 June 2028. The balance outstanding is ₹ Nil (31 March 2025: ₹ 413.97 million)

c) No loans or advances are due from directors of the Group or any of them either severally or jointly with any other person. Further, no loans or advances are due by firms or private companies in which any director is a partner, a director or a member.

6C Loans-current

Particulars	As at 31 March 2026	As at 31 March 2025
(unsecured and considered good, valued at amortised cost)		
Loans to employees	97.13	0.88
Loan to related parties (refer note 44)	-	66.93
	97.13	**67.81**

Notes:

(i) No loans or advances are due from directors of the Group or any of them either severally or jointly with any other person. Further, no loans or advances are due by firms or private companies in which any director is a partner, a director or a member, other than as disclosed above.

(ii) During the previous year, one of the subsidiary company has granted an unsecured loan to Halemed Medical Private Limited, a related party, for the purpose of general business purposes. The loan carried an interest rate of 10% per annum and was repayable on 30 September 2025. The balance outstanding as at 31 March 2026 amounts to Nil (31 March 2025: ₹ 66.93 million (Including accrued interest of ₹ 2.43 million)).

7A Other financial assets - non current

Particulars	As at 31 March 2026	As at 31 March 2025
(unsecured and considered good, valued at amortised cost)		
Security deposits	53.55	27.02
Fixed deposits with banks with maturity period of more than 12 months (refer note (a) below)	118.43	63.10
Other recoverable	8.58	-
(unsecured and considered doubtful, valued at amortised cost)		
Security deposits	0.43	-
Less: Loss allowance or expected credit loss on deposits (refer note (b) below)	(0.43)	-
(unsecured and considered good, valued at FVOCI)		
Investment in SAFE Instrument (refer note 6A)	-	21.81
	180.56	**111.93**

(a) It includes fixed deposits with a carrying amount of ₹ 10.98 million as on 31 March 2026 (31 March 2025: ₹ 9.52 million) that are pledged for earnest money deposits for various tenders and fixed deposits with a carrying amount of ₹ 35.53 million as on 31 March 2026 (31 March 2025: ₹ 10.39 million) pledged with banks as margin money for issuance of bank guarantees or borrowing facilities.

b) Movement in allowance for doubtful deposits

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Balance as at the beginning of the year	-	-
Provision recognised during the year	0.43	-
Provision utilised during the year	-	-
Balance as at the end of the year	**0.43**	**-**

7B Other financial assets-current

Particulars	As at 31 March 2026	As at 31 March 2025
(unsecured and considered good, valued at amortised cost)		
Interest accrued but not due on deposits	0.98	48.87
Security deposits	51.28	88.26
Amount due from related parties (refer note 44)	0.05	0.15
Other recoverable (refer note (b) below)	317.95	159.54
(unsecured and considered doubtful, valued at amortised cost)		
Security deposits	0.57	0.57
Less: Loss allowance or expected credit loss on deposits (refer note (a) below)	(0.57)	(0.57)
Financial assets at FVTPL		
Forward contract asset	3.40	-
	373.66	**296.82**

Notes:
a) Movement in allowance for doubtful deposits

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Balance as at the beginning of the year	0.57	-
Provision recognised during the year	-	0.57
Provision utilised during the year	-	-
Balance as at the end of the year	**0.57**	**0.57**

Notes:
b) Other recoverable mainly includes the following:

i) During the year ended 31 March 2025 and 31 March 2024, Everlife Holdings Pte. Ltd.("Everlife") declared and paid dividend on Class B preferences shares held by RT Heptagon Holdings SG Pte. Ltd. ("RT Heptagon") amounting to ₹ 59.14 million and ₹ 33.35 million. During the year ended 31 March 2026, upon identification of the fact that Everlife did not have sufficient balances in "Retained Earnings" during the above years and thus, profits of Everlife were insufficient to declare the above dividend as per the local laws, the Board of Directors of Everlife in their meeting held on 08 September 2025 have passed a resolution for revocation of the above dividend and acceptance of the dividend repayment by RT Heptagon. The same has been disclosed as recoverable amounting to ₹ 92.49 million as at 31 March 2025 which has been subsequently received on 19 February 2026.

ii) The Holding Company has incurred share issue expenses in connection with proposed public offer of equity shares amounting to ₹ 432.14 million , recoverable from selling shareholders or adjustable against securities premium portion of the Initial Public Offer (IPO) proceeds and accordingly ₹ 246.16 million (including GST recoverable from selling shareholders amounting to ₹ 30.09 million) has been included under other recoverable above and ₹ 216.07 million has been disclosed under other current assets.

8 Non-current tax assets (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Income tax assets (net of provisions for tax)	171.53	65.76
	171.53	**65.76**

9 Other non-current assets

Particulars	As at 31 March 2026	As at 31 March 2025
(Unsecured, considered good)		
Capital advances	5.89	12.14
Deposits under protest	1.28	0.76
Prepaid expenses	14.38	6.61
Balance with government authorities	92.13	83.02
Export incentive receivable	4.04	3.07
Right to recover inventory	7.24	-
	124.96	**105.60**

10 Other current assets

Particulars	As at 31 March 2026	As at 31 March 2025
(Unsecured, considered good)		
Advances to suppliers	179.39	98.91
Advances to employees	9.06	12.18
Prepaid expenses	175.56	189.14
Balance with government authorities	293.07	225.36
Export incentive receivable	7.52	7.79
Right to recover inventory	114.92	75.32
Others*	231.31	-
Deferred cost	8.48	-
	1,019.31	**608.70**

*This includes share issue expenses of ₹ 216.07 million relating to to incremental costs that are directly attributable to proposed issue of equity shares on account of Initial Public offer (IPO) (refer note 7B(b)(ii)).

11 Inventories

Particulars	As at 31 March 2026	As at 31 March 2025
(valued at lower of cost or net realisable value)		
Raw materials and components	651.60	593.23
Work-in-progress	164.74	231.09
Finished goods	658.36	260.47
Stores and spare parts	67.71	67.83
Traded goods (including stock in transit (refer note (vi) below))	4,066.57	2,218.02
	5,608.98	**3,370.64**
Less: Provision for obsolete inventory (refer note 33)	410.76	205.95
	5,198.22	**3,164.69**

Notes:

(i) The cost of inventories recognised as an expense during the year are disclosed in Note 26, 27, 28 and 33.

(ii) Inventories include ₹ 196.62 million (31 March 2025: ₹ 166.47 million) of inventory lying with third parties.

(iii) During the year, the Group has written off the inventory on account of quality issues identified through internal assessments (refer note 33).

(iv) Refer note 17A and 17B for details of inventories pledged as security.

(v) During the year ended 31 March 2026 an amount of ₹ 211.45 million (31 March 2025: ₹ 137.09 million) was charged to statement of profit and loss account on account of damage and expiry which is included as a part of cost of goods consumed.

(vi) Stock in transit forming part of traded goods and raw materials amounts to ₹ 454.17 million (31 March 2025: ₹ 59.24 million) and ₹ 8.94 million (31 March 2025: Nil) respectively.

12 Investments

Particulars	As at 31 March 2026	As at 31 March 2025
Current investments		
Investment in mutual funds (Quoted)		
Financial assets carried at fair value through profit or loss (FVTPL)		
387,368.06 (31 March 2025: 1,112,427.86) units in ABSL Money Manager Fund - Direct - Growth plan	151.91	409.01
Nil (31 March 2025: 289,126.26) units in Axis Money Market Fund - Direct - Growth plan	-	409.39
53,660.29 (31 March 2025: 53,660.29) units in HDFC Money Market Fund - Direct - Growth plan*	-	306.77
7,234.02 (31 March 2025: 68,998.38) units in Kotak Money Market Fund - Direct - Growth plan	34.32	306.73
10,128.19 (31 March 2025: 49,613.61) units in Nippon India Money Market Fund - Direct - Growth plan	-	204.50
77,554.15 (31 March 2025: 133,934.36) units in UTI Money Market Fund - Direct - Growth plan	253.32	409.34
9,835,582.55 (31 March 2025: 6,683,820.77) units in Nippon India Corporate Bond Fund - Direct - Growth plan**	640.63	410.81
10,135,691.85 (31 March 2025: 12,564,040.58) units in HDFC Corporate Bond Fund - Direct - Growth plan*	345.97	408.85
Nil (31 March 2025: 3,653,390.32) units in ABSL Corporate Bond Fund - Direct - Growth plan	-	410.83
	1,426.15	**3,276.23**
Aggregate amount of quoted investments	1,426.15	3,276.23
Aggregate market value of quoted investments	1,426.15	3,276.23
Aggregate value of unquoted investments	-	-
Aggregate amount of impairment in the value of investments	-	-

*As at 31 March 2026, mutual funds investment of the Company namely 9,122,610 units in "HDFC Corporate Bond Fund - Direct - Growth plan" (31 March 2025: 52,000 units in "HDFC Money Market Fund- Direct- Growth plan", 31 March 2024: Nil) have been pledged to HDFC Bank as a guarantee against against letter of credit amounting to ₹ 1,380.00 million to one of its wholly owned subsidiary company (Translumina GmBH) and working capital facility of ₹ 20.00 million of the Company.

** As at 31 March 2026, mutual funds investment of 2,084,000 units (31 March 2025 : Nil and March 2024: Nil) in "Nippon India Corporate Bond Fund - Direct - Growth plan" have been pledged to CITI Bank as a guarantee against working capital facility of ₹ 120.00 million. There is no outstanding balance as on 31 March 2026 for this working capital facility.

13 Trade receivables

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good	7,386.05	5,333.63
Unsecured, considered impaired	344.87	227.17
	7,730.92	**5,560.80**
Impairment allowance		
Unsecured, considered impaired	(344.87)	(227.17)
	7,386.05	**5,333.63**

Trade receivable ageing schedule as at 31 March 2026

Particulars	Outstanding for following periods from due date of payment							
	Unbilled	Not due	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed trade receivables:								
Undisputed trade receivables - considered good	53.99	3,960.57	2,709.38	383.15	245.92	22.96	10.08	7,386.05
Undisputed trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-	-
Undisputed trade receivables - credit impaired	-	20.21	57.67	44.55	57.39	45.46	100.70	325.98
Disputed trade receivables - considered good	-	-	-	-	-	-	-	-
Disputed trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-	-
Disputed trade receivables - credit impaired	-	-	0.01	-	2.72	0.01	16.15	18.89
Total	**53.99**	**3,980.78**	**2,767.06**	**427.70**	**306.03**	**68.43**	**126.93**	**7,730.92**

Trade receivable ageing schedule as at 31 March 2025

Particulars	Outstanding for following periods from due date of payment							
	Unbilled	Not due	Less than 6 months	6 months-1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed trade receivables:								
Undisputed trade receivables - considered good	10.55	3,124.08	1,907.69	145.73	127.97	14.83	2.78	5,333.63
Undisputed trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-	-
Undisputed trade receivables - credit impaired	-	7.72	14.86	15.89	25.57	9.57	139.05	212.66
Disputed trade receivables - considered good	-	-	-	-	-	-	-	-
Disputed trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	-	-
Disputed trade receivables - credit impaired	-	-	-	2.29	-	-	12.22	14.51
Total	**10.55**	**3,131.80**	**1,922.55**	**163.91**	**153.54**	**24.40**	**154.05**	**5,560.80**

Note:
(i) Trade receivables are non-interest bearing and are generally on payment terms of 0 to 180 days.
(ii) No trade or other receivable are due from directors or other officers of the Holding Company either severally or jointly with any other person. Nor any trade or other receivable are due from firms or private companies respectively in which any director is a partner, a director or a member except as disclosed in note 44.
(iii) Trade receivables include due from related parties ₹ Nil (31 March 2025: ₹ 0.86 million). Refer note 44 for details.
(iv) Refer note 35(B) for expected credit loss movement during the year.

14 Cash and cash equivalents

Particulars	As at 31 March 2026	As at 31 March 2025
Cash on hand	3.46	5.18
Cheques on hand	78.13	26.17
Balance with banks in current accounts	2,111.72	1,714.36
Deposits with original maturity of less than three months	66.75	182.59
	2,260.06	**1,928.30**

15 Bank balances other than cash and cash equivalents

Particulars	As at 31 March 2026	As at 31 March 2025
Fixed deposits with banks with original maturity period of more than 3 months but remaining maturity of less than 12 months*	1,163.24	2,972.12
Earmarked accounts - Unspent corporate social responsibility account	0.75	-
	1,163.99	**2,972.12**

* Includes fixed deposits pledged with banks as margin money for issuance of bank guarantees or borrowing facilities amounting to ₹ 789.76 million (31 March 2025: ₹ 687.75 million).

16A Share capital

(a) Equity share capital

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
i Authorised share capital				
Equity shares of ₹ 1 each (31 March 2025 : ₹ 1 each) with voting rights	17,00,00,000	170.00	4,00,00,000	40.00
	17,00,00,000	**170.00**	**4,00,00,000**	**40.00**
ii Issued, subscribed and fully paid up				
Equity shares of ₹ 1 each (31 March 2025 : ₹ 1 each) with voting rights	10,83,38,049	108.34	3,00,16,649	30.02
	10,83,38,049	**108.34**	**3,00,16,649**	**30.02**

During the year ended 31 March 2026, the authorised share capital was increased by 130 million i.e. 130 million equity shares of ₹ 1 each.
During the year ended 31 March 2025, the authorised share capital was increased by ₹ 20 million i.e. 20 million equity shares of ₹ 1 each. Further, pursuant to the approval of the shareholders in extra ordinary general meeting held on 26 April 2024, each equity share of the Company having face value of ₹ 10 per share was sub-divided into ten equity shares of face value of ₹ 1 per share.

iii Reconciliation of number of equity shares outstanding at the beginning and at the end of the year

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
Balance at the beginning of the year	**3,00,16,649**	**30.02**	**16,70,078**	**16.70**
Impact of business combination under common control (refer note 46(I)(D))	-	-	1,03,59,660	10.36
Add : Issued during the year (refer note ((a),(c) and (d) below)	60,96,034	6.10	21,25,624	2.13
Add : Issue of bonus equity shares during the year in the ratio of 2:1 (refer note (b) below)	7,22,25,366	72.22	-	-
Add : Equity shares arising on shares split from ₹ 10 to ₹ 1 per share (refer note (e) below)	-	-	1,50,30,702	-
Add : Conversion of 7% Compulsory Convertible Preference Shares into equity shares (refer note (f) below)	-	-	8,30,585	0.83
Balance at the end of the year	**10,83,38,049**	**108.34**	**3,00,16,649**	**30.02**

a. On 11 June 2025, the Holding Company through its subsidiary company, Everlife Holdings Pte. Ltd. ("Everlife") acquired an additional 25% interest in the voting shares of Chemopharm Sdn. Bhd., increasing its ownership interest in Chemopharm Sdn. Bhd. to 100%. In consideration of above, Everlife issued 10,444,446 Class C Compulsorily Convertible Preference Shares amounting to ₹ 3,856.13 million to minority stakeholders of Chemopharm Sdn. Bhd., which in turn were acquired by Holding Company via issuance of 1,997,344 equity shares of face value of ₹ 1 each having fair value of ₹ 3,856.13 million. The carrying value of the additional interest acquired at the date of acquisition was ₹ 829.30 million. The difference between the fair value of equity issued and carrying value of additional interest acquired amounting to ₹ 3,026.83 million has been debited other equity (₹ 3,194.11 million debited to retained earnings and ₹ 167.28 million credited to foreign currency translation reserve).

In addition, Everlife paid stamp duty of ₹ 14.32 million in connection with the acquisition. The stamp duty has been debited to retained earnings.

b. On 27 August 2025, pursuant to the approval of the shareholders in extra ordinary general meeting held on 26 August 2025, the company had allotted 7,22,25,366 equity shares of face value of ₹1 each through bonus share in the proportion of 2 bonus equity share for every 1 fully paid up equity share to eligible shareholders whose names appeared in the Register of Members/ Beneficial owners as on 25 August 2025, being the record date fixed for this purpose. The said bonus equity shares rank pari passu in all respects with the existing equity shares of the Company. The paid-up capital on account of bonus issue of ₹ 72.22 million has been appropriated from securities premium.

c. On 17 February 2025, one of the subsidiary company, Everlife Holdings Pte. Ltd. ("Everlife"), redeemed 12,500,000 Class B preferences shares earlier issued to ECP III Pte. Ltd. ("ECP III"), Cure Everlife Holdings ("Cure") (ECP III and Cure, both are related parties as explained in note 44) and RT Heptagon Holdings SG Pte. Ltd. ("RT Heptagon"), having carrying value of ₹ 2,900.38 million. The redemption was carried through the issuance of promissory notes amounting to ₹ 7,923.55 million, which has been classified under "Borrowings" as at 31 March 2025 under note 17B in accordance with provisions of Ind AS 109 "Financial Instruments". In connection with the redemption of above mentioned Class B preference share, Everlife had utilised the balance lying in other reserve amounting to ₹ 1,317.01 million . The difference between the value of promissory notes issued of ₹ 7,923.55 million and carrying value of Class B preferences shares and balance lying in other reserves for a sum total of ₹ 4,217.39 million, amounting to ₹ 3,003.44 million, has been debited to retained earnings and amounting to ₹ 702.72 million has been debited to foreign currency translation reserve.
On the same date 17 February 2025, ECP III and Cure assigned their respective promissory notes to Medicore Holdings Pte. Ltd. ("Medicore") (a related party) through the execution of an allonge, pursuant to which Medicore assumed all the rights and interests in these promissory notes. Further, on 11 June 2025, Everlife issued 12,859,496 and 8,572,998 Class C compulsory convertible preference shares (CCPS) of ₹ 7,913.05 million (excluding impact of foreign currency translation of ₹ 10.50 million) to Medicore and RT Heptagon Holdings SG Pte. Ltd. respectively as a consideration for its obligation to repay the above promissory notes.
On 23 June 2025, the Holding Company acquired the above Class C CCPS through issuance of 4,098,690 equity shares of face value of INR 1 each having fair value of ₹ 7,913.05 million. (refer note 44)

d. On 17 December 2024, the Holding Company issued 2,125,624 equity shares through private placement. Each equity share carries equal rights with respect to dividends, repayment of capital, and entitles the holder to one vote at the Holding Company's shareholders' meetings.

e. Pursuant to the approval of the shareholders in extra ordinary general meeting held on 26 April 2024, each equity share of the Holding Company having face value of ₹ 10 per share was sub-divided into ten equity shares of face value of ₹ 1 per share.

f. On 27 November 2024, the Company converted its 162,790 7% Compulsorily Convertible Preference Shares (CCPS) into fully paid up 830,585 equity shares in accordance with the terms of issuance (refer note 17B(xiii)).

iv Rights, preferences and restrictions attached to equity shares

The Holding Company has only one class of equity shares having the par value of ₹ 1/- per share. Each holder of equity share is entitled to one vote per share. The Company declares and pays dividend in Indian rupees. All shareholders are equally entitled to dividends.
As per the Articles of Association (the 'AOA') of the Holding Company, in the event of liquidation, dissolution or admission of winding up proceedings by an appropriate court or tribunal, either voluntary or involuntary, the Evercure Holding Pte Ltd. (the 'Investor') shall have the right in preference to any other shareholders of the Holding Company to require the Holding Company, and Mr. Gurmit Singh Chugh and Ms. Punita Sharma (the 'Founders') (on a reasonable efforts basis) to ensure that the liquidator is appointed to liquidate the Holding Company in order to distribute the proceeds from the liquidation of the Holding Company, which remains after discharging the liabilities of the Holding Company to the Investor, such that the Investor receives the Liquidation Price (as defined in the AOA) subject to applicable laws, in priority over any amounts received by any other existing shareholders of the Holding Company.
Except with the prior written consent of the Investor, the Founders shall not transfer any of the securities of the Holding Company held by them to any person, including competitor However, the shares held by the Investor shall, subject to the transferee executing a Deed of Adherence, be freely transferable without any restrictions of any nature whatsoever.

v Details of shares held by holding/ ultimate holding company and/ or their subsidiaries/ associates

Name of the equity shareholders	As at 31 March 2026		As at 31 March 2025	
	Number	%	Number	%
Evercure Holding Pte. Ltd. (Immediate Holding Company till 22 June 2025)	3,15,56,433	29.13%	1,05,18,811	35.04%
Medicore Holdings Pte. Ltd. (formerly known as Integris Holding Pte Ltd.)*	3,71,15,679	34.26%	-	0.00%

* entity having significant influence w.e.f. 23 June 2025.

vi Details of shareholder holding more than 5% share capital*

Name of the equity shareholders	As at 31 March 2026		As at 31 March 2025	
	Number	%	Number	%
Mr. Gurmit Singh Chugh	1,11,89,331	10.33%	35,06,277	11.68%
Mrs. Punita Sharma	1,11,89,331	10.33%	35,06,277	11.68%
Evercure Holding Pte. Ltd. (Immediate Holding Company till 22 June 2025)	3,15,56,433	29.13%	1,05,18,811	35.04%
Medicore Holdings Pte. Ltd. (formerly known as Integris Holding Pte Ltd.)	3,71,15,679	34.26%	-	0.00%

*As per records of the Holding Company, including its register of shareholders/members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

vii Details of equity shares held by promoter in the Holding Company as at the end of the year:

Name of the equity shareholders	As at 31 March 2026			As at 31 March 2025		
	Number	% of total shares	% of change during the year	Number	% of total shares	% of change during the year
Mr. Gurmit Singh Chugh	1,11,89,331	10.33%	(1.35)%	35,06,277	11.68%	(0.66)%
Mrs. Punita Sharma	1,11,89,331	10.33%	(1.35)%	35,06,277	11.68%	(0.66)%
Evercure Holding Pte. Ltd. (Immediate Holding Company till 22 June 2025)	3,15,56,433	29.13%	(5.92)%	1,05,18,811	35.04%	(1.99)%
Medicore Holdings Pte. Ltd. (formerly known as Integris Holding Pte Ltd.)	3,71,15,679	34.26%	34.26%	-	-	-

viii Aggregate number and class of shares allotted as fully paid up pursuant to contract(s) without payment being received in cash, by way of bonus shares and shares bought back for the period of 5 years immediately preceding the balance sheet date

Particulars	As at 31 March 2026	As at 31 March 2025
Equity share allotted as fully paid up pursuant to contract for consideration other than cash:		
- equity shares arising on shares split from ₹ 10 to ₹ 1 per share (refer note 16A(a)(iii)(e) above)	2,43,54,396	2,43,54,396
-Conversion of 7% Compulsory Convertible Preference Shares into equity shares (refer note 16A(a)(iii)(f) above)	8,30,585	8,30,585
- for acquisition of controlling stake in Everlife Holdings Pte. Ltd. (including those held by minorities) (refer note 16A(a)(iii)(a), 16A(a)(iii)(c) above and 46(I)(D))	71,32,000	-
- Issue of bonus equity shares during the year in the ratio of 2:1 (refer note 16A(a)(iii)(b) above)	7,22,25,366	-
	10,45,42,347	**2,51,84,981**

Notes:

(i) On 23 April 2019, the Holding Company had issued 641,868 bonus equity shares of face value ₹ 10 each to the shareholders whose names appeared in the register of members/beneficial owners position as on the record date, i.e., 22 April 2019 in proportion of 0.64 equity share for every 1 equity share of the Holding Company held.

(ii) The Holding Company had entered into a Share Subscription and Loan Assignment Agreement ('LAA') on 13 December 2018 with Translumina Therapeutics Private Limited (formerly known as Translumina Therapeutics LLP) ('TTLLP'), Mr. Gurmit Singh Chugh and Ms. Punita Sharma ('Assignors'). Pursuant to the said agreement and a further addendum to the agreement dated 17 April 2019, the Holding Company has issued 307,112 equity shares of face value ₹ 10 each at a premium of ₹ 5,558 per equity share amounting to ₹ 1,710 million on 17 April 2019 to the Assignors against assignment of all the rights, interest and obligation of the Assignors in connection with the loan amount advanced by the Assignors to the TTLLP. The assigned loan was converted into investment in TTLLP as mutually agreed between the parties, pursuant to terms of the LAA.

(iii) The Holding Company had entered into a Share Subscription and Partnership Interest Purchase Agreement ('PIPA') on 13 December 2018 with Translumina Therapeutics Private Limited (formerly known as Translumina Therapeutics LLP) ('TTLP'), Mr. Gurmit Singh Chugh and Ms. Punita Sharma (erstwhile Partners of TTLLP). Pursuant to the said agreement and a further addendum to the agreement dated 17 April 2019, the Company has issued 684,158 equity shares of face value ₹ 10 each at a premium of ₹ 5,558 per equity share amounting to ₹ 3,809.39 million on 18 April 2019 to the erstwhile partners of TTLLP against purchase of 99% interest in TTLLP.

(iv) Pursuant to a Share Purchase Agreement ('SPA') between the Holding Company, Promoters of the Holding Company (Mr. Gurmeet Singh Chugh and Ms. Punita Sharma) and Evercure Holding Pte. Limited ('Investor'), the Promoters have sold 60% their equity shareholding to the Investor on 10 May 2019.

(v) During the year ended 31 March 2024, shareholders have pledged 27% equity shares (pledge proportionately by existing shareholders) to HDFC Bank as a guarantee against letter of credit amounting to ₹ 115.00 million to its wholly owned subsidiary company Translumina GmBH and working capital facility of ₹ 20.00 million of the Holding Company. On 25 February 2025, the pledge on equity shares of all the existing shareholders have been released and mutual funds investment of 9.12 million units amounting to ₹ 311.30 million in "HDFC Corporate Bond Fund - Direct - Growth plan" (31 March 2025 : 0.05 million units of ₹ 297.61 million in "HDFC Money Market Fund- Direct- Growth plan") have been pledged to HDFC Bank as a guarantee against such letter of credit and working capital facility.

(b) Preference share capital

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
(i) Authorised share capital				
7% Compulsory Convertible Preference Shares of ₹8,600 each (CCPS)	1,62,790	1,399.99	1,62,790	1,399.99
	1,62,790	**1,399.99**	**1,62,790**	**1,399.99**
(ii) Issued, subscribed and fully paid up				
7% Compulsory Convertible Preference Shares of ₹8,600 each (CCPS)	-	-	-	-
	-	-	-	-

(iii) Reconciliation of number of preference shares outstanding at the beginning and at the end of the year

7% Compulsory Convertible Preference Shares - issued by the Holding Company

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
Balance at the beginning of the year	**-**	**-**	**1,62,790**	**1,399.99**
Issue of CCPS	-	-	-	-
Conversion of CCPS into equity shares (refer note 16A(a)(iii)(f))	-	-	(1,62,790)	(1,399.99)
Balance at the end of the year	**-**	**-**	**-**	**-**

(iii) Rights, preferences and restrictions attached to compulsory convertible preference shares

Compulsorily convertible cumulative preference shares were issued at par in May 2023 and each share is convertible into equity shares after a period of 10 years and can be converted at any time prior to expiry of 10 years at the option of the Company, convertible at the Fair Market Value of equity shares prevailing as on the date of conversion. The holders of these shares are entitled to fixed cumulative dividend at the rate of 7% on the capital for the time being paid-up thereon and shall be payable, as and when declared by the Board. In the event of winding up, preference shareholders have a preferential right over equity shareholders to be repaid to the extent of capital paid-up and dividend in arrears on such shares.

Except with the prior written consent of the Investor, the Founders shall not transfer any of the securities of the Company held by them to any person, including competitor However, the shares held by the Investor shall, subject to the transferee executing a Deed of Adherence, be freely transferable without any restrictions of any nature whatsoever.

(iv) No shares have been issued pursuant to contract without payment being received in cash, allotted as fully paid-up shares by way of bonus issues nor has any bought back of shares happened during the period of five years immediately preceding the reporting date.

16B Other equity

Particulars	As at 31 March 2026	As at 31 March 2025
Securities premium	42,271.09	30,580.22
Retained earnings	(5,232.78)	(3,328.69)
Foreign currency translation reserve	985.75	159.88
Shared based compensation reserve	317.92	243.69
Capital reserve	0.97	0.97
Common control adjustment deficit account	(16,148.70)	(16,148.70)
Deemed equity	432.90	-
Total Other Equity	**22,627.15**	**11,507.37**
Non-controlling Interest	349.09	1,675.85
Total Other reserves	**22,976.24**	**13,183.22**

(i) Securities premium

Particulars	As at 31 March 2026	As at 31 March 2025
Balance at the beginning of the year	**30,580.22**	**5,652.79**
Add: Impact of business combination under common control	-	19,990.31
Add: Premium on issue of equity shares (refer note 16A(a)(iii)(a) and (c))	11,763.09	3,580.72
Add: Bonus shares issued during the year (refer note 16A(a)(iii)(b)	(72.22)	-
Add: Premium on conversion of compulsorily convertible preference shares	-	1,399.16
Less: Transaction cost arising on share issues (refer note 16A(a)(iii)(d))	-	(42.76)
Balance at the end of the year	**42,271.09**	**30,580.22**

	Particulars	As at 31 March 2026	As at 31 March 2025
(ii)	**Retained earnings**		
	Balance at the beginning of the year	**(3,328.69)**	**404.54**
	Less: Impact of business combination under common control	-	(1,234.85)
	Add: Profit for the year	2,829.87	506.95
	Add: Other comprehensive income for the year, net of income tax	1.57	(1.89)
	Less: Acquisition of stake held by minorities**	(4,494.45)	-
	Less: Impact of business restructuring***	(199.65)	-
	Less:Employee stock options settlement on cancellation of options (refer note 47(a))	(114.40)	-
	Add: Transfer from shared based compensation reserve to retained earnings on cancellation of options (refer note 47(a))	90.25	-
	Less: Employee stock options exercised by minorities (refer note 47(b) and (c))	(17.28)	-
	Less: Impact of redemption of preference shares (refer note 16A(a)(iii)(c))	-	(3,003.44)
	Balance at the end of the year	**(5,232.78)**	**(3,328.69)**
(iii)	**Foreign currency translation reserve**		
	Balance at the beginning of the year	**159.88**	**19.67**
	Add: Impact of business combination under common control	-	702.03
	Add: Other comprehensive income for the year, net of income tax	557.80	140.90
	Less: Acquisition of stake held by minorities	268.07	-
	Less: Impact of redemption of preference shares (refer note 16A(a)(iii)(c))	-	(702.72)
	Balance at the end of the year	**985.75**	**159.88**
(iv)	**Equity component of compulsorily convertible preference shares***		
	Balance at the beginning of the year	**-**	**634.65**
	Add: Issued/converted during the year	-	(634.65)
	Balance at the end of the year	**-**	**-**
(v)	**Shared based compensation reserve**		
	Balance at the beginning of the year	**243.69**	**-**
	Add: Impact of business combination under common control	-	**18.70**
	Add: Share-based payment expenses for the year	186.23	224.99
	Add: Other comprehensive income for the year, net of income tax	3.09	-
	Less: Employee stock options exercised by minorities	(30.38)	-
	Add: Acquisition of stake held by minorities	5.54	-
	Less: Transfer from shared based compensation reserve to retained earnings on cancellation of options (refer note 47(a))	(90.25)	-
	Balance at the end of the year	**317.92**	**243.69**
(vi)	**Other reserve (refer note 16B(x))**		
	Balance at the beginning of the year	**-**	**-**
	Add: Impact of business combination under common control		**1,317.01**
	Less: Impact of redemption of preference shares (refer note 16A(a)(iii)(c))		**(1,317.01)**
	Balance at the end of the year	**-**	**-**
(vii)	**Capital reserve**		
	Balance at the beginning of the year	**0.97**	**-**
	Add: Impact of business combination under common control	-	0.97
	Balance at the end of the year	**0.97**	**0.97**
(viii)	**Common control adjustment deficit account**		
	Balance at the beginning of the year	**(16,148.70)**	**-**
	Add: Impact of business combination under common control (refer note 46(I)(D))	-	**(16,148.70)**
	Balance at the end of the year	**(16,148.70)**	**(16,148.70)**
(ix)	**Deemed equity**		
	Balance at the beginning of the year	**-**	**-**
	Add: Share-based payment expenses (refer note 47(d))	432.90	-
	Balance at the end of the year	**432.90**	**-**
	Total other equity [(i)+(ii)+(iii)+(iv)+(v)+(vi)+(vii)+(viii)]	**22,627.15**	**11,507.37**
(x)	**Non-controlling Interest**		
	Balance at the beginning of the year	**1,675.85**	**-**
	Add: Impact of business combination under common control (refer note 46(I)(D))	-	**4,337.20**
	Add: Profit for the year	86.61	199.89
	Add: Other comprehensive income for the year, net of income tax	52.51	29.93
	Add: Share-based payment expenses for the year	0.03	1.56
	Add: Impact of business combination (refer note 46(I)(C))	30.81	7.65
	Less: Impact of redemption of preference shares	-	(2,900.38)
	Add: Employee stock options exercised by minorities (refer note 47(b) and (c))	154.76	-
	Less: Acquisition of stake held by minorities^^^	(1,651.48)	-
	Balance at the end of the year	**349.09**	**1,675.85**

*With respect to disclosures related to compulsory convertible preference shares, refer note 17B(xiii).

** Represents ₹ 3,194.11 million (refer note 16A(a)(iii)(a)),₹ 385.90 million (refer note 21B), ₹ 562.55 million (refer note 47(c)), and ₹ 351.89 million (refer note 16B(xi)) debited to retained earnings during the year ended 31 March 2026.

*** Represents ₹ 174.78 million (refer note 46(I)(D)), ₹ 10.55 million (refer note 46(I)(C)) and ₹ 14.32 million (refer note 16A(a)(iii)(a)) debited to retained earnings during the year ended 31 March 2026.

^^^ Represents ₹ 829.30 million (refer note 16A(a)(iii)(a)),₹ 522.15 million (refer note 21B), ₹ 149.91 million (refer note 47(c)) and ₹ 150.12 million (refer note 16B(xi)) debited to Non-controlling interest during the year ended 31 March 2026.

(xi) NCI includes Class B preference shares issued by one of the subsidiary company of the Holding Company, Everlife Holdings Pte. Ltd. ("Everlife") to RT Heptagon Holdings SG Pte. Ltd., ECPIII Pte. Ltd. and Cure Everlife Holdings, details of which are as under:
During the earlier years, Everlife incorporated a wholly owned subsidiary, Everlife Philippines Holdings, Inc.("EPHI"), and acquired 40% ownership interest in Lifeline Holdings, Inc. ("LHI").
In turn, EPHI and LHI acquired 40% and 60% of the ownership interest in Lifeline Diagnostics Supplies, Inc. ("Lifeline Diagnostics"). As a result, the Group's effective ownership interest in Lifeline Diagnostics" became 64%. It was assessed that the Group exercises significant influence over Lifeline Diagnostics and accounted for it as an associate (also refer note 46).
In return, RT Heptagon Holdings SG Pte. Ltd. (related party of erstwhile owner of Lifeline Diagnostics) agreed to subscribe 5,000,000 preference shares in Everlife for a total consideration of ₹ 369.95 million. The 5,000,000 preference shares were issued at ₹ 73.99 (USD 1) per preference share whereas the other 7,500,000 preference shares issued to the existing shareholders of Everlife were issued at a share price of ₹ 337.39 (USD 4.56) per preference share. The discount of ₹ 263.40 (USD 3.56) per preference share, representing a total discount of ₹ 1,317.01 million, was recorded as part of other reserve.
Also, as part of arrangement entered into with RT Heptagon Holdings SG Pte. Ltd., Everlife , via, Director's Resolution dated 29 July 2022, declared and paid dividend amounting to ₹ 477.19 million on Class B preference share capital held by RT Heptagon Holdings SG Pte. Ltd.
The holders of preference shares are entitled to receive a cumulative preference dividend equal to the amount of dividends or distributions declared and received from Everlife Philippines and/or Lifeline Holdings.
All preference shares carry no voting rights except for circumstances to be counted for the purposes of a quorum and, in a poll thereat, to one vote in respect of each preference share held if:
(i) the resolution in question varies or abrogates the rights attached to the preference shares; or
(ii) the resolution in question is for the winding-up of the Everlife.

Details of Preference Share Capital issued by Everlife Holdings Pte. Ltd.

Issued, subscribed and fully paid up Preference Share Capital

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
Class C Compulsorily Convertible Preference Shares of USD 1 each fully paid-up	**3,25,02,819**	**2,311.18**	**3,25,02,819**	**2,311.18**
Class C Compulsorily Convertible Preference Shares of USD 4.317 each fully paid-up	3,18,76,940	11,769.18	-	-
	6,43,79,759	**14,080.36**	**3,25,02,819**	**2,311.18**

Class B Cumulative Preference Shares

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
Balance at the beginning of the year	**-**	**-**	**1,25,00,000**	**2,900.38**
Issue of shares	-	-	-	-
Redeemed during the year (refer note 16A(a)(iii)(c))	-	-	(1,25,00,000)	(2,900.38)
Balance at the end of the year	**-**	**-**	**-**	**-**

Class C Compulsorily Convertible Preference Shares

Particulars	As at 31 March 2026		As at 31 March 2025	
	Number	Amount	Number	Amount
Balance at the beginning of the year	**3,25,02,819**	**2,311.18**	**-**	**-**
Issue of shares (refer note 16A(a)(iii)(a) and (c))	3,18,76,940	11,769.18	3,25,02,819	2,311.18
Balance at the end of the year	**6,43,79,759**	**14,080.36**	**3,25,02,819**	**2,311.18**

Name of Class C Compulsorily Convertible Preference Shareholders	As at 31 March 2026			As at 31 March 2025		
	Number	% of total shares	% of change during the year	Number	% of total shares	% of change during the year
ECP III Pte. Ltd.	-	0.00%	(89.09)%	2,89,56,761	89.09%	-
Cure Everlife Holdings	-	0.00%	(10.91)%	35,46,058	10.91%	-
Integris Medtech Limited	6,43,79,759	100.00%	100.00%	-	0.00%	-

Rights, preferences and restrictions attached to Class B Cumulative Preference Shares

The holders of preference shares are entitled to receive a cumulative preference dividend equal to the amount of dividends or distributions declared and received from Everlife Philippines and/or Lifeline Holdings.

All preference shares carry no voting rights except for circumstances to be counted for the purposes of a quorum and, in a poll thereat, to one vote in respect of each preference share held if:
(i) the resolution in question varies or abrogates the rights attached to the preference shares; or
(ii) the resolution in question is for the winding-up of the Company.

The preference shares shall not confer the right to any further or other rights to participate in the profits or assets of the Company

Rights, preferences and restrictions attached to Class C Compulsorily Convertible Preferences Shares

Class C Preferences Shares carry dividend (non-cumulative) at such rate per annum as may be determined by the Directors of Everlife Holdings Pte. Ltd. on the amount paid up on each Class C Preference Share, subject to applicable laws, and provided however the rate of dividend declared shall not be less than the rate of dividend on the equity shares of Everlife Holdings Pte. Ltd.

The right of the holders of the Class C Preference Shares to receive dividend shall rank senior and prior to and in preference to the dividend rights of the holders of equity share capital of Everlife Holdings Pte. Ltd.

Each Class C Preference share shall be convertible into 1 equity share of Everlife Holdings Pte. Ltd.

Each holder of a Class C Preference Share shall have the same right as are available to holders of Ordinary Shares in the capital of Everlife Holdings Pte. Ltd., determined on an as converted basis, with respect to any question upon which holders of Ordinary Shares of Everlife Holdings Pte. Ltd. have the right to vote, and to be counted for the purposes of a quorum at such meeting and, in a poll thereat, and to receive a copy of any written resolution circulated to eligible members on the circulation date.

(xii) Acquisition of partial minority shares in CPC Diagnostics Private Limited

During the year ended 31 March 2026, pursuant to resolution dated 07 January 2026, passed by Board of Directors of the Holding Company, the Holding Company has agreed to acquire the balance 35.39% stake in CPC Diagnostics Private Limited ("CPC") forming part of Non controlling interest ("NCI") for a consideration of ₹ 1,813.92 million, consequent to which CPC shall become, directly and indirectly, wholly owned subsidiary of the Holding Company. Out of the total consideration, an amount of ₹ 502.01 million has been paid till 31 March 2026 and the balance would be paid in due course of time.

Pursuant to above, as on the date of transfer of 10.61% shares, NCI amounting to ₹ 150.12 million has been derecognised with the difference between amount derecognised and the consideration paid to NCI holders amounting to ₹ 502.01 million adjusted against retained earnings amounting to ₹ 351.89 million in the consolidated financial statements.

The above transaction resulted into an overall 75.22% stake of CPC being held by the Group and the balance 24.78% being held by NCI as on 31 March 2026.

Nature and purpose of other reserves

Securities premium
Securities premium represents premium received on issue of shares. The amount is utilised in accordance with the provisions of the Companies Act 2013.

Retained earnings
Retained earnings are used to record the profit/(loss) earned by the Group. The reserve is utilised in accordance with the provisions of the Act. It includes impact of remeasurement gain/(loss) net of taxes on defined benefit plans on account of change in actuarial assumption or experience adjustments within the plan.

Foreign currency translation reserve
Exchange differences arising on translation of the foreign operations are recognised in other comprehensive income as described in accounting policy and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the Group dispose or partially dispose off its interest in a foreign operation through sale, liquidation, repayment of share capital or abandonment of all, or part of, that entity.

Equity component of compulsorily convertible preference shares
Compulsory Convertible Preference Shares (equity component) represents the fair value of financial liability on account of net proceeds received from the issue of Compulsory Convertible Preference Shares. Refer note 21A for more details

Shared based compensation reserve
The share options-based payment reserve is used to recognise the grant date fair value of options issued to employees under Employee stock option plan.

Capital reserve
The capital reserve represents reserve arising from business combinations.

Common control adjustment deficit account
This capital reserve represents reserve arising on business combination pertaining to common control transaction (refer note 46(I)(D))

Deemed Equity
Deemed Equity represents employee stock options granted by an entity exercising significant influence to employees of the Group entity (without any crosscharge) which are recorded as share based payment expenses with a corresponding credit to Other equity.

Other reserve
Other reserve represents discount given on preference shares issued by Everlife Holdings Pte. Ltd. to the erstwhile shareholder of Lifeline Diagnostics Supplies, Inc. in exchange of the acquisition of 64% effective economic interest in Lifeline Diagnostics Supplies, Inc.

Non-controlling Interest
Non-controlling interest reserve represents the difference between the consideration paid and the carrying value of non-controlling interest acquired in subsidiaries.

17A Borrowings-non current

Particulars	As at 31 March 2026	As at 31 March 2025
Secured, at amortised cost		
Term loan from banks and financial institutions (refer note (i) below)	5,709.21	5,340.71
Vehicle loan from banks and financial institutions (refer note (ii) below)	6.71	16.29
Equipment loan from banks and financial institutions(refer note (iii) below)	56.54	53.49
Less: Current maturities of long term borrowings (refer note 17B)	(798.10)	(495.99)
	4,974.36	**4,914.50**

17B Borrowings-current

Particulars	As at 31 March 2026	As at 31 March 2025
Secured, at amortised cost		
Buyers credit (refer note (iv) below)	446.63	370.00
Bankers acceptance (refer note (v) below)	298.88	167.64
Working capital demand loan (refer note (vi) below)	220.00	160.00
Cash credit limit from bank (refer note (vii) below)	955.55	492.07
Foreign currency working capital loan (refer note (viii) below)	109.04	439.36
Term loan from banks (refer note 17A(i))	-	1,650.00
Trust receipts (refer note (ix) below)	269.91	508.36
Promissory notes (refer note (x) below and 16A(a)(iii)(c))	-	7,923.55
Add: Current maturity of long term borrowings (refer note 17A)	798.10	495.99
Unsecured, at amortised cost		
Loan from related parties (refer note (xi) below and 44)	248.23	169.89
Loan from others (refer note (xii) below)	3.89	3.22
	3,350.23	**12,380.08**

Terms and conditions of borrowings are as follows:

(i) **Term Loans**

Name of lender	Nature of Security	Terms of repayment and rate of interest	Date of Maturity	As at 31 March 2026	As at 31 March 2025
HSBC Bank	The term loan is obtained by Chemopharm Sdn. Bhd. and is secured against the below mentioned securities: (i)First ranking security over shares of Chemoscience Pte Ltd., Medigene Sdn Bhd, Research Instruments Sdn Bhd, Research Instruments Pte Ltd, Scientific Resources Pte Ltd, Biofrontier Technology Pte Ltd., Hausen Bernstein Co. Ltd. (Subsidiary Companies) and RI Technologies Limited (Associate companies), (ii)Corporate Guarantee of Everlife Holdings Pte. Ltd.	Term loan from banks is repayable as below: 8 half yearly instalments Rate of interest - 5.78% p.a for the year ended 31 March 2026 and 31 March 2025. Chemopharm Sdn Bhd (CPM) term loan facilities restrict certain defined upstream payments beyond specified threshold's, from CPM and its step down subsidiaries to its immediate holding company (Everlife Holdings Pte Ltd).	28 October 2029	2,821.94	2,365.61
HSBC Bank	The term loan is obtained by Chemopharm Sdn. Bhd. and is secured against the below mentioned securities: (i)First ranking security over shares of Chemoscience Pte Ltd., Medigene Sdn Bhd, Research Instruments Sdn Bhd, Research Instruments Pte Ltd, Scientific Resources Pte Ltd, Biofrontier Technology Pte Ltd., Hausen Bernstein Co. Ltd. (Subsidiary Companies) and RI Technologies Limited (Associate companies), (ii)Corporate Guarantee of Everlife Holdings Pte. Ltd.	Term loan from banks is repayable as below: 8 half yearly instalments Rate of interest - 7.39% p.a for the year ended 31 March 2026 and 31 March 2025. Chemopharm Sdn Bhd (CPM) term loan facilities restrict certain defined upstream payments beyond specified threshold's, from CPM and its step down subsidiaries to its immediate holding company (Everlife Holdings Pte Ltd).	28 October 2029	1,868.63	1,817.11

(i) Term Loans (Continued)

Name of lender	Nature of Security	Terms of repayment and rate of interest	Date of Maturity	As at 31 March 2026	As at 31 March 2025
Citi Bank	The term loan is obtained by CPC Diagnostic Private Limited and is charged against the movable fixed assets of the aforementioned company.	Term loan from bank is repayable as below: 20 equal quarterly instalments of ₹ 4.50 million each at each year at a rate of interest linked with T Bill 3 Month (T Bill+ 3.81%) p.a. for the year ended 31 March 2026 and 31 March 2025.	12 April 2028	22.50	40.50
Citi Bank	The term loan is obtained by Transhealth Private Limited and is secured by way of following : 1) Exclusive charge on movable property, plant and equipments of the Company by term loan proceeds. 2) First pari passu charge on present and future trade receivables of the Company. 3) Corporate Guarantee of Integris Medtech Limited and Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP) .	60 equal monthly instalments of ₹ 0.50 million each at the interest rate of 10.50% p.a.for the year ended 31 March 2026 (31 March 2025 : 7.15% p.a.).	31 March 2027	6.00	12.00
		32 equal monthly instalments of ₹ 1.86 million each at the interest rate of 8% p.a. for the year ended 31 March 2026 (31 March 2025 : 8.50% p.a.).	26 October 2026	13.02	35.34
		43 equal monthly instalments of ₹ 0.94 million each at the interest rate of 8% p.a. for the year ended 31 March 2026 (31 March 2025 : 8.50% p.a.).	26 September 2027	16.95	28.25
		48 equal monthly instalments of ₹ 0.69 million each at the interest rate of 8% p.a. for the year ended 31 March 2026 (31 March 2025 : 8.50% p.a.).	26 February 2028	15.80	24.04
		60 equal monthly instalments of ₹ 0.43 million each at the interest rate of 8.50% p.a.for the year ended 31 March 2026 and 31 March 2025.	18 June 2029	16.90	22.10
HDFC Bank	The Term Loan is obtained by Translumina GmbH and is secured by a standard letter of credit issued by the Holding Company and pledge of mutual funds investment units of 9,122,610 units in "HDFC Corporate Bond Fund - Direct - Growth plan" (31 March 2025: 52,000 units in "HDFC Money Market Fund- Direct-Growth plan").	20 equal quarterly instalment having an interest rate of 3M Euribor + 215 bps for the year ended 31 March 2026 and 31 March 2025.	24 April 2028	541.49	662.82
		10 half yearly instalment having an interest rate of 3M Euribor + 215 bps for the year ended 31 March 2026 and 31 March 2025.	21 September 2028	104.90	118.59
		20 equal quarterly instalment having an interest rate of 3M Euribor + 215 bps for the year ended 31 March 2026 and 31 March 2025.	30 September 2029	196.49	214.35
Citicorp Finance India Limited	The term loan is obtained by Translumina Therapeutics Private Limited (Formerly known as Translumina Therapeutics LLP) and is secured by fixed deposits	Loan at an interest rate of 10.23% p.a for the year ended 31 March 2025, repaid in April 2025 .	Loan is repaid in April 2025	-	1,650.00
HDFC Bank	The Term Loan is obtained by Transhealth Private Limited and is secured by way of: **Primary Security** : Fixed Deposits, Plant and machinery. **Guarantees**:Corporate guarantee from the Holding Company and Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP).	56 equal monthly instalments of ₹ 1.65 million each, having an interest rate of 8.50% p.a. for the year ended 31 March 2026.	07 November 2030	84.59	-
Total				**5,709.21**	**6,990.71**
Non-current borrowings				**5,709.21**	**5,340.71**
Current borrowings				**-**	**1,650.00**

(This space has been intentionally left blank)

(ii) Vehicle loans

Name of lender	Nature of Security	Name of Entity	Terms of repayment and rate of interest	Date of Maturity	As at 31 March 2026	As at 31 March 2025
Malayan Banking Berhad	The vehicle loans are secured by first charge by way of hypothecation over vehicles.	Medigene Sdn Bhd	36 monthly instalments at the rate of interest of 3.18% p.a. for the year ended 31 March 2026 and 31 March 2025.	January 2026 to July 2026	1.65	8.38
MBB Auto Finance		Chemopharm Sdn. Bhd.	11 monthly instalments of INR 0.08 million ((31 March 2025: 23 monthly installments of INR 0.08 million) Rate of interest is 3.25% p.a (31 March 2025: 3.25% p.a.)	23 February 2027	0.91	1.56
MBB Auto Finance		Chemopharm Sdn. Bhd.	Nil (31 March 2025: 5 monthly instalments of INR 0.02 million) Rate of interest Nil (31 March 2025 : 3.35% p.a)	30 August 2025	-	0.12
HDFC Bank		CPC Diagnostic Private Limited	Nil (31 March 2025: 48 monthly instalments of ₹ 0.08 million) Rate of interest Nil (31 March 2025 : 6.91% p.a.).	05 March 2026	-	0.94
TMBT thanachart		Hausen Bernstein Co. Ltd	48 instalments (31 March 2025 : 48 installments) Rate of interest is 2.89% p.a. (31 March 2025 : 2.34% p.a.).	16 December 2027	0.09	0.64
Metro Bank		Lifeline Diagnostic Supplies Inc.	8 instalments Rate of interest is 8.58% p.a. for year ended 31 March 2026.	01 November 2026	0.73	-
Union Bank		Lifeline Diagnostic Supplies Inc.	13 instalments Rate of interest is 8.89% p.a. for year ended 31 March 2026.	24 April 2027	1.23	-
Kotak bank		Translumina Therapeutics Private Limited	4 equal monthly instalments of ₹ 0.12 million each (31 March 2025 : 15 equal monthly instalments of ₹ 0.13 million) Rate of Interest- 7.40% p.a. (31 March 2025 : 7.35% p.a.).	24 June 2026	0.49	1.89
HDFC Bank		Translumina Therapeutics Private Limited	9-21 equal monthly installments of 0.11 million each (31 March 2025: 12-30 equal monthly installments of 0.33 million each) Rate of Interest- 7.10%-8.50% p.a. (31 March 2025 : 8.90%-7.50%).	16 December 2027	1.62	2.76
Total					**6.72**	**16.29**

(iii) Equipment loan

Name of lender	Nature of Security	Terms of repayment and rate of interest	Date of maturity	As at 31 March 2026	As at 31 March 2025
CIMB Factorlease Berhad	Equipment loans secured by first charge by way of hypothecation over equipments	Nil monthly instalments of ₹ Nil million (31 March 2025 : 1 monthly instalments of ₹ 0.83 million) Rate of interest is Nil (31 March 2025 : 3.25% p.a.)	01 April 2025	-	0.83
CIMB Factorlease Berhad		1 monthly installments of ₹ 1.18 million (31 March 2025: 13 monthly installments of 1.18 million) Rate of interest is 3.25% p.a.(31 March 2025 : 3.25% p.a.)	01 April 2025	1.44	15.52
CIMB Factorlease Berhad		7 monthly installments of ₹ 2.13 million (31 March 2025: 19 monthly installments of 1.95 million) Rate of interest is 3.25% p.a.(31 March 2025 : 3.25% p.a.)	01 October 2026	16.55	37.14
CIMB Factorlease Berhad		33 monthly installments of ₹ 1.06 million (31 March 2025: Nil monthly installments of Nil million) Rate of interest is 3.00% p.a.(31 March 2025 : Nil.)	01 December 2028	38.55	-
Total				**56.54**	**53.49**

Terms and conditions of borrowings are as follows: (continued)

(iv) Buyer's credit

(a) One of the subsidiaries (Chemopharm Sdn. Bhd.) has obtained Buyer's credit amounting to ₹ 252.90 million (31 March 2025: ₹ 172.00 million) from Standard Chartered Bank, carrying interest rates ranging from 4.43%-4.53% (31 March 2025: 3.5%-4.95%) per annum and has a tenure of upto 69-129 days (31 March 2025: upto 150 days).

(b) One of the subsidiaries (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP) from HDFC Bank has obtained Buyer's credit amounting to ₹ 193.73 million (31 March 2025: ₹ 198.00 million) at an interest rate of 3.72% (31 March 2025: 6.48%) per annum.

Primary Security : Fixed Deposits, inventory and trade receivables of group company Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP).

Collateral Security : Equitable Mortgage over property owned by Transhealth Private Limited.

Guarantees:Corporate guarantee of Integris Medtech Limited and Transhealth Private Limited.

(v) Bankers' acceptances

(a) One of the subsidiaries (Chemopharm Sdn. Bhd.) has obtained Bankers acceptance amounting to ₹ 134.93 million (31 March 2025: ₹ 90.43 million) from Commerce International Merchant Bank, carrying interest rates ranging from 4.67%-4.76% (31 March 2025:4.85%-5.04%) per annum and is redeemable within 63-79 days (31 March 2025 57-73 days) from date of issuance.

(b) One of the subsidiaries (Chemopharm Sdn. Bhd.) has obtained Bankers acceptance amounting to ₹ 142.62 million (31 March 2025 : ₹ 2.16 million) from Maybank carrying interest rates ranging from 4.45%-4.73% (31 March 2025: 5.11%) per annum and is redeemable within 42-95 days (31 March 2025: 88 days) from date of issuance.

(c) One of the subsidiaries has obtained Bankers acceptance (Research Instruments Sdn. Bhd.) from Maybank amounting to ₹ 21.33 million (31 March 2025 : ₹ 8.00 million), carrying interest rates ranging from 4.82%-5.11% (31 March 2025: 4.82%-5.11%) per annum and is redeemable within 67-93 days (31 March 2025: 73 days) from date of issuance.

(d) One of the subsidiaries (Medigene Sdn. Bhd.) from Maybank Bank has obtained Bankers acceptance amounting to ₹ Nil million (31 March 2025 : ₹ 67.05 million) interest rate ranging from Nil ((31 March 2025: 4.57% to 4.90%) per annum and is redeemable within Nil days (31 March 2025: 29 days to 69 days) from date of issuance.
Primary Security : These borrowing are secured by lien on fixed deposit of Chemopharm by MYR 4 million.

(vi) Working capital loan

One of the subsidiaries (CPC Diagnostics Private Limited) has obtained working capital loan from CITI Bank of ₹ 220.00 million (31 March 2025:₹ 160 million) an average interest rate of 6.90% (31 March 2025: 9.15%) per annum, secured by way of all immovable properties, inventories and trade receivables.

(vii) Cash credit:

(a) One of the subsidiaries (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP) is having the cash credit facility from HDFC Bank amounting to ₹ 77.52 million (31 March 2025: ₹ 122.91 million) from HDFC Bank bearing an average interest rate of 9.00% (31 March 2025: 9.75%) per annum, primary security being inventory and trade receivables, repayable on demand and is secured by way of-

Primary Security : Fixed Deposits, inventory and trade receivables of group company (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP).

Collateral Security : Equitable Mortgage over property owned by Transhealth Private Limited, plant and machinery.

Guarantees:Corporate guarantee of Integris Medtech Limited (Formerly known as Integris Health Private Limited) and Transhealth Private Limited.

(b) One of the subsidiaries (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP) is having the cash credit facility amounting to ₹ 374.83 million (31 March 2025: ₹ 167.38 million) from CITI Bank bearing an average interest rate of 9.50% per annum repayable on demand and is secured by way of-

Primary Security : First pari passu charge on the following :
i) Present and future trade receivables of the Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP).
ii) Present and future inventory of the Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP).
iii) Present and future movable property, plant and equipments of the Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP).

Collateral Security: Exclusive charge on Industrial property owned by Transhealth Pvt. Ltd.

Guarantees:Corporate guarantee of Integris Medtech Limited (Formerly known as Integris Health Private Limited).

(c) One of the subsidiaries (CPC Diagnostics Private Limited) from CITI Bank is having the cash credit facility amounting to ₹ 136.18 million (31 March 2025: ₹ 118.44 million) bearing an average interest rate of 9.00% p.a. (31 March 2025: 10.38% p.a.) and is secured by way of all immovable properties, inventories and trade receivables of CPC Diagnostics Private Limited.

(d) One of the subsidiaries (CPC Diagnostics Private Limited) is having the cash credit facility from HSBC Bank amounting to ₹ 157.90 million (31 March 2025: ₹ Nil) bearing an average interest rate of 7.25% p.a. (31 March 2025: Nil) and is secured by way of all immovable properties, inventories and trade receivables of CPC Diagnostics Private Limited.

(e) One of the subsidiaries (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP) is having the cash credit facility amounting to ₹ 61.23 million (31 March 2025: ₹ 52.03 million) from ICICI Bank bearing an average interest rate of 9.37% p.a. (31 March 2025: 9.8% p.a) and is secured by way of :

Primary Security : Fixed Deposits, Current assets and property, plant and equipments.
Guarantee: Corporate guarantee of Integris Medtech Limited (Formerly known as Integris Medtech Private Limited)

(f) One of the subsidiaries (Transhealth Private Limited) is having the cash credit facility amounting to ₹ 117.53 million (31 March 2025: ₹ 24.35 million) from CITI bank bearing an average interest rate of 9.50% per annum and is secured by way of:
i) Exclusive charge on movable property, plant and equipments of the Transhealth Private Limited by term loan proceeds.
ii) First pari passu charge on present and future trade receivables of the Transhealth Private Limited.

(g) One of the subsidiaries (Transhealth Private Limited) is having the cash credit facility amounting to ₹ 20.12 million (31 March 2025: ₹ Nil) from ICICI bank bearing an average interest rate of 9.00% p.a. is secured by way of:
i) Exclusive charge on movable property, plant and equipments of the Transhealth Private Limited by term loan proceeds.
ii) First pari passu charge on present and future trade receivables of the Transhealth Private Limited.

(h) One of the subsidiaries (Halemed Private Limited) is having the cash credit facility amounting to ₹10.24 million (31 March 2025: ₹ Nil) from Kotak Mahindra Bank bearing an average interest rate of 9.40% per annum and is secured by way of:
Primary Security : Charge on present and future current assets and movable fixed assets of the borrower
Collateral Security : Mortgage on Property owned by Mr. Gurmit Singh Chugh.

(i) Integris Medtech Limited (Holding Company) is having the cash credit facility amounting to ₹ Nil (31 March 2025 : ₹ 6.96 million) from HDFC Bank bearing an average interest rate of 8.77% per annum repayable on demand.
Primary Security : Cash collateral 15% of limit, inventory and trade receivables.

Guarantees:
1) Corporate guarantee of Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP).
2) Mutual funds investment of the Company namely 9.12 million units in "HDFC Corporate Bond Fund - Direct - Growth plan" (31 March 2025: 0.05 million units in "HDFC Money Market Fund- Direct- Growth plan").

(viii) Foreign currency working capital loan

(a) One of the subsidiaries (Transhealth Private Limited) is having the foreign currency working capital loan to ₹ Nil million (31 March 2025: ₹ 115.86 million) from CITI Bank bearing interest rate of Nil (31 March 2025: 6.48% p.a.) is secured by way of :
i) Exclusive charge on movable property, plant and equipments of the Transhealth Private Limited by term loan proceeds.
ii) First pari passu charge on present and future trade receivables of the Transhealth Private Limited.

(b) One of the subsidiaries (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP) is having the foreign currency working capital loan amounting to ₹ 109.04 million (31 March 2025: ₹ 323.50 million) from CITI Bank bearing an interest rate of 4.05% (31 March 2025: 6.48%) p.a. repayable on demand is secured by way of-

Primary Security : First pari passu charge on the following :
i) Present and future trade receivables of the (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP)).
ii) Present and future inventory of the (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP)).
iii) Present and future movable property, plant and equipments of the (Translumina Therapeutics Private Limited (converted from Translumina Therapeutics LLP)).
Collateral Security: Exclusive charge on property owned by Transhealth Private Limited.

(ix) Trust receipts:

(a) One of the subsidiaries (Chemoscience Pte. Ltd.) is having trust receipts payable amounting to ₹ Nil million (31 March 2025: ₹ 116.47 million) secured by fixed deposits and corporate guarantees furnished by the holding company (Chemopharm Sdn. Bhd) bearing, interest at the rate of SOFR Term Rate + Margin 2%.

(b) One of the subsidiaries (Research instruments Pte. Ltd.) is having trust receipts payable amounting to ₹ 124.02 million (31 March 2025: ₹ 176.49 million) for the payment of import purchase, secured by fixed deposits and bank guarantees, bearing interest at the rate of SOFR Term Rate + Margin 2%

(c) One of the subsidiaries (Hausen Bernstein Co. Ltd.) is having trust Receipts amounting to ₹ 145.89 million (31 March 2025: ₹ 215.40 million) from financial institutions secured by the pledge of bank deposits, mortgage of the land of the Company's director and guaranteed by the Company's directors (Mr. Banlang Luangwaranan, Mrs. Darat Luangwaranan, Ms.Preeya Noppakao).

(x) Promissory notes

(a) A subsidiary (Everlife Holdings Pte. Ltd.) had outstanding promissory notes amounting to ₹ Nil (31 March 2025: ₹ 7,923.55 million), which were non-interest bearing and repayable on demand. These notes were converted into Class C Compulsorily Convertible Preference Shares (CCPS) in June 2025 (refer note 16A(a)(ii)(c)).

(xi) Unsecured loan from related parties (refer note 44)

(a) One of the subsidiaries (Everlife Holdings Pte. Ltd.) has an outstanding balance of ₹ 2.18 million (31 March 2025: ₹ 2.23 million) from Cure Everlife holdings, repayable on demand and carrying an interest rate of 10.00% p.a.

(b) One of the subsidiaries (Everlife Holdings Pte. Ltd.) has an outstanding balance of ₹ 156.74 million (31 March 2025: ₹ 142.28 million) from ECP III Pte. Limited repayable on demand and carrying an interest rate of 10.00% p.a.

(c) One of the subsidiaries (Everlife Holdings Pte. Ltd.) has a non interest bearing outstanding balance of ₹ 9.43 million (31 March 2025: ₹ 25.38 million) from Cure Everlife holdings.

(d) One of the subsidiaries (Chemopharm Sdn. Bhd.) has a outstanding balance of ₹ 50.30 million (31 March 2025 : ₹ Nil) from RI Technologies Limited. This represents an unsecured loan, repayable on demand carrying an interest rate of 3% p.a.

(e) One of the subsidiaries (Chemopharm Sdn. Bhd.) has a outstanding balance of ₹ 29.58 million (31 March 2025 : ₹ Nil) from Chemoscience Thailand. This represents an unsecured loan, repayable on demand carrying an interest rate of 3% p.a.

(xii) Unsecured loan from others

(a) One of the subsidiaries (Chemopharm Sdn. Bhd.) has an outstanding balance for unsecured loan from its directors of ₹ 2.44 million (31 March 2025: ₹ 2.67 million) at an interest rate of 4% per annum repayable on demand.

(b) One of the subsidiaries, (Chemopharm Sdn. Bhd.) has an outstanding balance for unsecured loan of ₹ 1.45 million (31 March 2025 : ₹ 0.55 million) from shareholders. This represents unsecured loan taken from the shareholders at the interest rate 4.00% repayable on demand.

(xiii) Convertible Preference Shares	**As at 31 March 2026**	**As at 31 March 2025**
7% compulsory convertible preference shares (CCPS) of ₹8,600 each /- fully paid-up*	-	-
Transaction costs	-	-
Net proceeds from issue of CCPS	-	-
Liability component at date of issue (net of transaction costs)	-	-
Amount classified as equity	-	-
Liability component at date of issue (net of transaction costs)	-	-
Interest charged (using effective interest rate)	-	-
Carrying amount of liability component	-	-

* On 03 May 2023, the Holding Company had issued 1,62,790 7.00% fully and compulsorily convertible Preference Share(s) ("CCPS") at an issue price of ₹ 8,600 per share amounting to ₹ 1,399.99 million for cash at par, on a rights basis to the eligible equity shareholders of the Holding Company. CCPS are convertible into equity shares after a period of 10 years at a fair market value at the time of conversion. Alternatively, at the option of the Company CCPS can be converted prior to expiry of 10 years at the fair market value of equity shares prevailing as on the date of conversion. The shares were Issued on a rights basis to the Eligible Equity Shareholder(s) on the basis of their proportion of the equity shareholding. The net proceeds received from the issue of the CCPS had been split between the financial liability element and an equity component, representing the fair value of the financial liability.

The equity component of ₹ 634.65 million had been credited to the other equity during the year ended 31 March 2024. Further, on 27 November 2024, the same has been debited during the year ended 31 March 2025 on account of conversion to equity shares.

(xiv) The Group has undrawn facility amounting to ₹ 3,398.24 million (31 March 2025 : ₹ 2,262.32 million).

18A Lease liabilities-non current

Particulars	**As at 31 March 2026**	**As at 31 March 2025**
Lease liabilities (refer note 41)	581.58	387.78
	581.58	**387.78**

18B Lease liabilities - current

Particulars	**As at 31 March 2026**	**As at 31 March 2025**
Lease liabilities (refer note 41)	199.36	129.26
	199.36	**129.26**

19A Provisions - non-current

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for employees benefits		
- Provision for gratuity and other retirement benefits (refer note 40)	152.91	84.48
- Provision for compensated absences	8.45	9.03
- Provision for warranty (refer note 19C(c) below)	6.02	-
- Provision for sales return (refer note 19C(a) below)	19.92	-
	187.30	**93.51**

19B Provisions - current

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for employees benefits		
- Provision for gratuity and other retirement benefits (refer note 40)	12.75	6.99
- Provision for compensated absences	57.03	34.56
Other provisions		
Provision for sales return (refer note 19C(a) below)	156.23	164.51
Provision for discount (refer note 19C(b) below)	439.24	662.48
Provision for warranty (refer note 19C(c) below)	22.12	23.63
Others	11.46	10.44
	698.83	**902.61**

19C Movement in others provisions during the year

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
a) Provision for sales return		
Opening balance	**164.51**	**80.92**
Impact of business combination under common control	-	33.49
Additions during the year	176.15	164.51
Amount utilised during the year	(164.51)	(114.41)
Closing balance	**176.15**	**164.51**
b) Provision for discount		
Opening balance	**662.48**	**877.09**
Additions during the year	1,205.42	1,616.00
Amount utilised during the year	(1,428.66)	(1,830.61)
Closing balance	**439.24**	**662.48**
c) Provision for warranty		
Opening balance	**23.63**	**-**
Impact of business combination under common control	-	18.54
Additions during the year	17.38	9.58
Amount utilised during the year	(12.87)	(4.49)
Closing balance	**28.14**	**23.63**

20 Trade payables

Particulars	As at 31 March 2026	As at 31 March 2025
Total outstanding dues of micro enterprises and small enterprises	64.47	15.28
Total outstanding dues of creditors other than micro enterprises and small enterprises	3,677.67	2,008.19
	3,742.14	**2,023.47**

Trade payables ageing schedule as at 31 March 2026

	Outstanding for following periods from due date of payment						
	Unbilled	**Not due**	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Undisputed trade payables:							
Total outstanding dues of micro enterprises and small enterprises	-	51.54	12.93	-	-	-	64.47
Total outstanding dues of creditors other than micro enterprises and small enterprises	464.77	2,291.13	906.48	13.09	0.43	1.77	3,677.67
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-	-
Total	**464.77**	**2,342.67**	**919.41**	**13.09**	**0.43**	**1.77**	**3,742.14**

Trade payables ageing schedule as at 31 March 2025

Particulars	Outstanding for following periods from due date of payment						
	Unbilled	**Not due**	**Less than 1 year**	**1-2 years**	**2-3 years**	**More than 3 years**	**Total**
Undisputed trade payables:							
Total outstanding dues of micro enterprises and small enterprises	-	7.13	8.13	-	0.02	-	15.28
Total outstanding dues of creditors other than micro enterprises and small enterprises	339.84	813.38	816.82	1.75	2.64	33.76	2,008.19 -
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-	-
Total	**339.84**	**820.51**	**824.95**	**1.75**	**2.66**	**33.76**	**2,023.47**

Note:
(i) The Group does not have any disputed trade payables as on 31 March 2026 and 31 March 2025.
(ii) Trade payable include due to related parties ₹ Nil (31 March 2025: ₹ 16.13 million). Refer note 44 for details.

21A Other financial liabilities-non current

Particulars	As at 31 March 2026	As at 31 March 2025
Financial liabilities at amortised cost		
Retention money	0.68	0.68
Employee related payables*	70.51	9.14
Financial liabilities at FVTPL		
Contingent consideration (refer note 46 and 35B)	179.15	66.94
	250.34	**76.76**

* refer note 47(a)(i).

21B Other financial liabilities - current

Particulars	As at 31 March 2026	As at 31 March 2025
Financial liabilities at amortised cost		
Interest accrued but not due on borrowings(1)	94.44	191.83
Employee related payables(2)	499.23	241.82
Creditors for capital goods	9.39	9.33
Other payables(1)(4)	178.50	112.70
Payable on account of shares held by Non Controlling Interest holders acquired/ to be acquired(3)	1,371.35	-
Financial liabilities at FVTPL		
Contingent consideration (refer note 46 and 35B)	425.41	50.81
Forward contract liability	0.74	-
	2,579.06	**606.49**

(1) including interest and other payable to related parties (refer note 44).

(2) refer note 47(a).

(3) As at 31 March 2026, pursuant to put option available with the shareholders holding Non-controlling Interest in one of the subsidiary company "Hausen Bernstein Co., Ltd." ("NCI holders") and in accordance with the provisions of Ind AS 109, the balance lying in NCI pertaining to the above NCI holders amounting to ₹ 522.15 million, has been derecognised with difference between the amount derecognised and the consideration payable to these NCI holders amounting to ₹ 801.72 million (disclosed under "other financial liability") being adjusted against other equity amounting to ₹ 279.57 million (₹ 385.90 million debited to retained earnings and ₹ 106.33 million credited to foreign currency translation reserve).

Further, it includes ₹ 569.63 million payable to NCI holders of Chemopharm Sdn Bhd pursuant to Share Purchase Agreement entered with NCI holders (refer note 47(c)).

(4) includes transaction cost amounting to ₹ 100.01 million (refer note 46(I)(D).

22A Other non-current liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Deposits from customers	18.29	15.88
Statutory dues payable	5.50	14.51
Unearned income	0.29	12.06
	24.08	**42.45**

22B Other current liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Contract liabilities	401.38	308.52
Statutory dues payable	209.61	309.10
Deposits from customers	2.63	2.85
Other payables	9.37	0.36
	622.99	**620.83**

23 Current tax liabilities (net)

Particulars	As at 31 March 2026	As at 31 March 2025
Provision for income tax (net of taxes paid)	244.15	162.93
	244.15	**162.93**

(This space has been intentionally left blank)

24 Revenue from operations

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of products (refer note (a) and (b) below)		
-Finished goods	3,452.05	3,025.51
-Traded goods	21,527.97	15,590.46
Total of sale of products	**24,980.02**	**18,615.97**
Sale of services	766.16	371.00
Total revenue from contract with customers	**25,746.18**	**18,986.97**
Other operating revenues		
- Scrap sales	0.27	0.11
- Royalty income	39.55	37.58
Total revenue from operations	**25,786.00**	**19,024.66**

a) The Group offers rebates/discount to its customers on the basis of certain agreed terms and conditions. Since, such rebates/discount is not attributable to any specific product sold, for the purpose of disclosure above, rebates/discount has been attributed to sale of manufactured and traded goods respectively, on an estimate, in the ratio of gross sale value of such products, and accordingly adjusted to arrive at the reported sales, net of discount.

b) In certain cases, the Group sells some of the products in which it trades, by bundling them along with the sale of manufactured products.

c) **Disaggregation of revenue information**
Set out below is the disaggregation of the Group's revenue from contracts with customers:

Type of goods/services		
Clinical diagnostic and lifesciences	17,818.82	12,041.37
Wires/catheters	1,866.28	1,393.81
Coronary stents	2,486.73	2,888.02
Other accessories	2,808.19	2,292.77
Income from lab solutions services	766.16	371.00
Other operating revenues	39.82	37.69
Total revenue from operations	**25,786.00**	**19,024.66**
Geographical information		
- Within India	7,363.53	6,674.88
- Outside India	18,422.47	12,349.78
Total revenue from operations	**25,786.00**	**19,024.66**
Timing of revenue recognition		
Goods transferred at a point in time	24,980.29	18,616.08
Services transferred over the time	805.71	408.58
Total revenue from operations	**25,786.00**	**19,024.66**

d) **Performance obligations**
Sales of goods: Performance obligation is satisfied when control of goods is transferred to the customer, generally on delivery of the goods.
Sales of services: The performance obligation in respect of professional services is satisfied over a period of time and acceptance of the customer. In respect of these services, payment is generally due upon completion of services.

*Refer note 43 for revenue related disclosure

25 Other income

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest income earned on:		
- bank deposits (at amortised cost)	52.81	93.79
- income tax refund	0.09	-
- financial assets (at amortised cost)	9.59	31.74
Gain on foreign exchange fluctuations (net)	445.11	160.97
Profit on sale of property, plant and equipment	0.76	-
Gain on modification/termination of leases	5.59	9.50
Marketing subsidy and government grants	3.50	5.31
Export incentive	10.60	16.82
Fair value gains on investment measured at fair value through profit or loss	22.11	72.35
Liabilities no longer required written back	37.03	81.52
Gain on disposal of Investment in mutual funds	145.64	7.25
Chargeback income (refer note 44)	11.95	34.06
Miscellaneous income	36.84	57.87
	781.62	**571.18**

26 Cost of materials consumed

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Raw materials at the beginning of the year	593.23	531.99
Add: Impact of business combination under common control	-	20.01
Add: Inventory acquired under business combination (refer note 46)	7.60	-
Add: Purchase during the year	1,517.79	1,324.70
Less: Amounts capitalised under intangible assets under development	(17.34)	(2.76)
Less: Raw materials at the end of the year	(651.60)	(593.23)
	1,449.68	**1,280.71**
Exchange difference	32.23	34.78
	1,481.91	**1,315.49**

27 Purchases of stock-in-trade

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Purchase of traded goods*	13,748.24	9,429.11
	13,748.24	**9,429.11**

*Purchase during the year is netted off w.r.t. transfer to/ from property, plant and equipment to/from inventory, right to recover inventory and provision for obsolete inventory.

28 Changes in inventories of finished goods, work-in-progress and stock in trade

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Inventories at the end of the year:		
Finished goods	658.36	260.47
Work-in-progress	164.74	231.09
Traded goods (including stock in transit)	4,066.57	2,218.02
Inventories at the beginning of the year:		
Finished goods	260.47	384.26
Work-in-progress	231.09	237.93
Traded goods (including stock in transit)	2,218.02	481.49
Add: Impact of business combination under common control	-	1,510.99
Add: Inventory acquired under business combination (excluding stores and spares part of ₹ 129.42 million (31 March 2025 : ₹ Nil) (refer note 46)	1,032.58	-
Exchange differences	417.90	13.48
	(729.61)	**(81.43)**

29 Employee benefits expense*

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Salaries, wages and bonus	3,790.00	2,860.27
Gratuity expense (refer note 40)	29.32	19.72
Contributions to provident and other funds (refer note 40)	317.24	227.14
Share-based payment to employees expenses (refer note 47)	684.86	226.55
Staff welfare expenses	158.35	159.05
Subtotal	**4,979.77**	**3,492.73**
Less: Amounts capitalised in Intangible asset under development and in capital work-in-progress	-	(1.18)
	4,979.77	**3,491.55**

*Refer note 44 for remuneration to KMP.

30 Finance costs

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest expense on:		
- Lease liabilities (refer note 41)	49.34	31.53
- Financial liabilities measured at amortised cost	518.85	588.87
- Others	46.09	68.97
Less: amounts capitalised towards capital work-in-progress	-	(2.77)
	614.28	**686.60**

31 Depreciation and amortisation expense

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Depreciation on property, plant and equipment (refer note 4A)	993.74	604.20
Depreciation on right-of-use assets (refer note 4C)	215.13	154.59
Amortisation of intangible assets (refer note 5A)	796.08	586.67
	2,004.95	**1,345.46**

32 Other expenses

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Rent (refer note 41)	39.14	38.68
Power and fuel	72.94	50.01
Packaging and forwarding expenses	263.70	180.45
Rates and taxes	86.24	30.53
Commission on sales	81.11	65.40
Travelling and conveyance	450.63	374.72
Legal and professional expenses	437.10	454.05
Bank charges	38.92	48.20
Insurance charges	59.91	39.81
Repair and maintenance	252.31	190.57
Advertising and sales promotion	238.96	254.68
Communication charges	64.02	37.76
Recruitment expenses	24.94	-
Contract Labour	59.73	-
Subscription expense	0.60	3.20
Printing and stationery	49.63	43.64
Clinical trial expenditure	165.21	91.17
Loss on sale of property, plant and equipment	-	6.84
Allowance for expected credit loss on trade receivables (refer note 35(B))	117.95	34.46
Bad debts/asset written off	4.47	13.89
Charity and donation	0.16	6.96
Corporate social responsibility	13.37	2.86
Warranty	17.38	17.36
Provision of Performance Bond	1.08	-
Miscellaneous expenses	130.76	95.69
	2,670.26	**2,080.93**

	For the year ended 31 March 2026	For the year ended 31 March 2025
***Amount capitalised under intangible assets under development:**		
Legal and professional expenses	-	19.04
Clinical trial expenditure	-	3.63
Miscellaneous expenses	-	2.01
	-	**24.68**
***Amount capitalised under capital work-in-progress:**		
Legal and professional expenses	-	1.54
Power and fuel	-	0.05
Miscellaneous expenses	-	0.07
	-	**1.66**

33 Exceptional items

Particulars	**For the year ended 31 March 2026**	**For the year ended 31 March 2025**
Provision/Write off of Obsolete inventory (refer note (i) below)	72.39	133.56
Demand by tax authority (refer note (ii) below)	-	117.85
Changes in contingent consideration (refer note (iii) below)	372.75	29.43
Acquisition/diligence cost (refer note (iv) below)	55.55	45.78
Gain on deemed disposal (refer note (v) below)	(2,396.23)	-
Intangibles assets under development written off (refer note (vi) below)	13.97	-
Others (refer note (vii) below)	186.56	-
	(1,695.01)	**326.62**

Notes:

(i) (a) The Group had performed internal quality checks and had written off certain batches amounting to ₹ 9.17 million (31 March 2025: 133.56 million), which were not as per standard output and hence, considered exceptional.

(b) During the year ended 31 March 2026 one of the subsidiary company reassessed inventory post restructuring and discontinuation of catheter production. Provision for obsolete inventory of ₹ 63.22 million was recognized classified as an exceptional item as it does not arise from normal operations.

(ii) It represents, one of the subsidiary company has recognised provision for differential custom rate of tax as per demand raised by tax authority. Further, the complete demand amount has been paid to the concerned authorities on 31 May 2025 and 30 June 2025.

(iii) It represents additional contingent consideration paid/ payable by the Group in respect of acquisition of subsidiary companies pursuant to additional earn out payments made/ to be made as compared to initial estimate made at the time of acquisition of respective subsidiary.

(iv) It represents expenditure incurred on technical, commercial, tax, legal and financial due diligences on new acquisitions and existing entities in the Group.

(v) During the year ended 31 March 2026, read together with note 46(I)(C) “Background- Acquisitions of Lifeline Holdings Inc and Lifeline Diagnostic Supplies Inc.”, the change in classification w.r.t. investment in Lifeline Holdings Inc and Lifeline Diagnostic Supplies Inc constitutes a deemed disposal of the associate and a step acquisition of a subsidiary under Ind AS 103 – Business Combinations, requiring the previously held interest to be fair valued, with the resulting gain recognised in the consolidated statement of profit and loss. Accordingly, gain on deemed disposal of ₹ 2,373.19 million has been recognised in the consolidated financial statements. Also, the Group has recognised a gain in the consolidated financial statements of ₹ 17.14 million in respect of provision created in earlier years on loan given by Everlife Holding Pte Ltd to Lifeline Holding Inc.

(vi) During the year ended 31 March 2026, one of the subsidiary company, reviewed the future economic benefits of certain intangible assets under development and consequently wrote off an amount of ₹ 17.01 million. After considering the eligible input tax credit available in respect of the said expenditure, net amount of ₹ 13.97 has been recognised and disclosed as an exceptional item.

(vii) (a) During the year ended 31 March 2026, one-time payment of ₹ 125.90 million, approved by one of the subsidiary company (i.e., Lifeline Diagnostics Supplies Inc.) has been paid to one of its directors who has transitioned and stepped down from being an executive (President to the subsidiary company) to non-executive role in recognition of his legacy, past services and contributions to the said subsidiary company.

(b) On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed the incremental impact of these changes amounting to ₹ 17.74 million towards gratuity and other employee benefits for the year ended 31 March 2026, on the basis of best information available, consistent with the guidance provided by Institute of Chartered Accountants of India.Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such incremental impact under "Exceptional Items" for the year ended 31 March 2026.
The Group continues to monitor the finalisation of Central/State Rules and clarifications from the Government on other aspects of the Labour Codes and would provide the appropriate accounting effect on the basis of such developments needed.

(c) During the year ended 31 March 2026, expenses amounting to ₹ 6.17 million primarily include advertising and promotional expenses, website development and maintenance charges, branding and marketing expenses, and other related costs incurred for IPO preparedness and investor outreach activities that are non-recurring in nature.

(d) During the year ended 31 March 2026, an amount of ₹ 36.75 million has been paid to Securities and Exchange Board of India (SEBI), National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in relation to proposed listing of equity shares of the Company.

34. Tax expense

(a) Amounts recognised in the statement of profit and loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Current tax (including earlier years)	671.78	538.27
Deferred tax	(52.13)	(99.60)
Tax expense for the year	**619.65**	**438.67**

(b) Amounts recognised in other comprehensive income

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Re-measurement of defined benefit obligations	0.43	1.31
	0.43	**1.31**

(c) Reconciliation of effective tax rate

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Accounting profit before income tax	**3,536.13**	**1,145.51**
Tax using the Company's domestic tax rate	25.17%	25.17%
Expected tax expense at India's statutory income tax rate	889.97	288.32
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:		
Expenses not deductible for tax purposes	173.08	144.58
Income not chargeable to tax	(656.89)	8.24
Under/Over provision of tax expense in prior years	51.11	17.46
Current year losses for which no deferred tax asset is created	101.82	72.39
Impact of different tax rates across	68.31	(25.81)
Share of results of associates	(11.22)	(33.27)
Others	3.47	(33.24)
Income tax expense	**619.65**	**438.67**

(d) (i) Changes in deferred tax assets and liabilities from 01 April 2025 to 31 March 2026:

Particulars	Balance as at 01 April 2025	Acquired through business combination	Recognised in profit or loss	Recognised in other comprehensive income	Balance as at 31 March 2026
Property, plant and equipment	(243.35)	1.78	(187.86)	-	(429.43)
Intangible assets recognised on business combination	(583.67)	(422.17)	213.47	-	(792.37)
Lease liabilities/ROU assets	2.88	8.00	(0.66)	-	10.22
Allowance for expected credit loss	41.60	11.70	20.53	-	73.83
Provision for customer rebate/schemes	84.81	-	(10.17)	-	74.64
Provision for employee benefits	33.91	15.09	22.01	0.43	71.44
Provision for stock obsolescence	34.39	1.51	26.90	-	62.80
Provision for decline in inventories	-	-	-	-	-
Provision for custom	29.66	-	-	-	29.66
Business losses and unabsorbed depreciation	176.13	12.59	39.28	-	228.00
Other temporary differences	19.10	-	(71.37)	-	(52.27)
Unrealised foreign exchange loss	-	-		-	(100.07)
Total	**(404.54)**	**(371.50)**	**52.13**	**0.43**	**(823.55)**

(ii) Changes in deferred tax assets and liabilities from 01 April 2024 to 31 March 2025:

Particulars	Balance as at 01 April 2024	Acquired through business combination	Recognised in profit or loss	Recognised in other comprehensive income	Balance as at 31 March 2025
Property, plant and equipment	(327.56)	-	84.21	-	(243.35)
Intangible assets recognised on business combination	(619.01)	-	35.34	-	(583.67)
Lease liabilities/ROU	2.49	-	0.39	-	2.88
Allowance for expected credit loss	42.43	-	(0.83)	-	41.60
Provision for customer rebate/schemes	124.95	-	(40.14)	-	84.81
Provision for employee benefits	28.12	-	4.48	1.31	33.91
Provision for stock obsolescence	20.58	-	13.81	-	34.39
Provision for custom	-	-	29.66	-	29.66
Business losses and unabsorbed depreciation	166.23	-	9.90	-	176.13
Other temporary differences	64.96	-	(37.22)	-	27.74
Unrealised foreign exchange gain/(loss)	-	-	-	-	(8.64)
Net deferred tax asset/(liability)	**(496.81)**	**-**	**99.60**	**1.31**	**(404.54)**

Disclosed in consolidated financial statements:	As at 31 March 2026	As at 31 March 2025
Deferred tax assets (net)	606.34	454.90
Deferred tax liabilities (net)	1,429.89	859.44

Note: It includes unused tax losses, unabsorbed capital allowances, unabsorbed depreciation and other deductible temporary differences of the Group as at 31 March 2026 amounting to ₹ 407.15 million (31 March 2025: ₹ 381.80 million) for which no deferred tax asset has been recognised in the books of accounts. The unutilised business tax losses of the Group expire to be utilised between 2029 to 2033, while unabsorbed capital allowances, unabsorbed depreciation and other deductible temporary differences can be carried forwarded indefinitely.

35 Financial Instruments

A Financial risk management objective and policies

The Group's principal financial liabilities comprises borrowings, lease liabilities, trade and other payables. The main purpose of these financial liabilities is to finance the Group's operations. The Group's principal financial assets includes investment, trade and other receivables, and cash and cash equivalents that are derived directly from its operations.

The Group's financial risk management is an integral part of how to plan and execute its business strategies. The Group is exposed to market risk, credit risk and liquidity risk.

The Group's senior management oversees the management of these risks. The senior professionals working to manage the financial risks and the appropriate financial risk governance framework for the Group are accountable to the Board of Directors and Audit Committee. This process provides assurance to Group's senior management that the Group's financial risk-taking activities are governed by appropriate policies and procedures and that financial risk are identified, measured and managed in accordance with Group policies and Group risk objective.

Financial assets and liabilities

The accounting classification of each category of financial instruments, and their carrying amounts, are set out below:

Particulars	As at 31 March 2026	As at 31 March 2025
Financial assets		
Amortised Cost		
Trade receivables	7,386.05	5,333.63
Cash and cash equivalents	2,260.06	1,928.30
Other bank balances	1,163.99	2,972.12
Loans	121.51	494.16
Other financial assets	550.82	386.94
	11,482.43	**11,115.15**
FVTOCI		
Investment in SAFE Instrument	-	21.81
	-	**21.81**
FVTPL		
Investment in unquoted securities		-
Investment in quoted securities	1,426.15	3,276.23
Forward contract asset	3.40	-
	1,429.55	**3,276.23**
Total financial assets	**12,911.98**	**14,413.19**
Financial liabilities		
Amortised Cost		
Borrowings	8,324.59	17,294.58
Trade payables	3,742.14	2,023.47
Lease liabilities	780.94	517.04
Other financial liabilities	852.75	565.50
	13,700.42	**20,400.59**
FVTPL		
Contingent consideration	604.56	117.75
Payable on account of share acquired/ to be acquired	1,371.35	-
Forward contract liability	0.74	-
	1,976.65	**117.75**
Total financial liabilities	**15,677.07**	**20,518.34**

B Fair value measurements

The management assessed that cash and cash equivalents, trade receivables, trade payables, and other investments, other current financial assets and other current financial liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments.
The fair value of investments classify as FVOCI approximates their carrying values.
The fair value of the other financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.
The following methods and assumptions were used to estimate the fair values:

1) The fair value of unquoted instruments, loans from banks, other non-current financial assets and non-current financial liabilities is estimated by discounting future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities. The valuation requires management to use unobservable inputs in the model, of which the significant unobservable inputs are disclosed in the tables below. Management regularly assesses a range of reasonably possible alternatives for those significant unobservable inputs and determines their impact on the total fair value.

2) Fair value hierarchy
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).
Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

Particulars	Fair Value as at		Fair value hierarchy (level)	Valuation Technique and key inputs
	31 March 2026	31 March 2025		
Financial assets				
Investment in quoted securities	1,426.15	3,276.23	1	See note (i) below
Investment in SAFE Instrument	-	21.81	3	See note (ii) below
Forward contract asset	3.40	-	2	
Total financial assets	**1,429.55**	**3,298.04**		
Financial liabilities				
Contingent consideration	604.56	117.75	3	See note (iii) below
Payable on account of share acquired/ to be acquired	1,371.35	-	3	See note (iv) below
Forward contract liability	0.74	-	2	
Total financial liabilities	**1,976.65**	**117.75**		

(i) Investment in mutual funds traded in active markets are determined by reference to quotes from the financial institutions; for example: Net asset value (NAV) for investments in mutual funds declared by mutual funds declared by mutual fund house.

(ii) Transaction price of investment in SAFE instrument represents fair value as there were no material changes in market conditions.
(iii) The management has determined the fair value of contingent consideration using monte- carlo simulation.

(iv) The management has unconditional Share Purchase Agreement requiring it to acquire/settle shares at pre-determined prices, resulting in a contract liability that is measured at fair value through profit or loss in accordance with Ind AS 109.

Fair value measurement using significant unobservable inputs (level 3)

The following table represents the changes in level 3 items for the year ended 31 March 2026 and 31 March 2025

Particulars	Contingent consideration	Total
As at 01 April 2024	**413.83**	**413.83**
Fair value change in contingent consideration (refer note 33)	29.43	29.43
Contingent consideration paid	(352.20)	(352.20)
Exchange difference	26.69	26.69
As at 31 March 2025	**117.75**	**117.75**
Acquisition under business combination (refer note 46)	162.13	162.13
Fair value change in contingent consideration (refer note 33)	372.75	372.75
Contingent consideration paid	(114.44)	(114.44)
Exchange difference	66.37	66.37
As at 31 March 2026	**604.56**	**604.56**

Financial instruments risk

The Group is exposed to various risks in relation to financial instruments. The main types of financial risks are market risk, credit risk and liquidity risk.

The respective management of the Holding Company and other subsidiary companies comprising the Group monitors and manages the financial risks relating to the operations of the respective Companies on a continuous basis.

The Group does not engage in the trading of financial assets for speculative purposes. The most significant financial risks to which the Group is exposed are described below.

(i) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. The Group is exposed to market risk through its use of financial instruments and specifically to interest rate risk, foreign currency risk and commodity price risk which result from its operating, investing and financing activities.

(a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group is exposed to changes in market interest rates as some borrowings are at floating interest rates.

The following table illustrates the sensitivity of restated profit and equity to a reasonably possible change in interest rates of +/- 1%. These changes are considered to be reasonably possible based on management's assessment. The calculations are based on a change in the average market interest rate for each period, and the financial instruments held at each reporting date that are sensitive to changes in interest rates. All other variables are held constant.

Particulars	Amount of borrowings	Profit/(loss) for the year		Equity	
		+1%	-1%	+1%	-1%
31 March 2026	3,304.70	(33.05)	33.05	(33.05)	33.05
31 March 2025	1,375.09	(13.75)	13.75	(13.75)	13.75

(b) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The functional currency of the Holding Company is Indian Rupees ('₹'). Most of the transactions of the Holding Company and other companies are carried out in the respective local currency. Exposures to currency exchange rates mainly arise from the overseas operations.

The Company has limited exposure to foreign currency risk and outstanding foreign currency exposures are not being hedged against adverse currency fluctuation.

Foreign currency risk exposure:

Particulars	Currency	Amount in foreign currency (in million)		Amount in ₹ (in million)	
		As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Receivables					
Trade receivables	USD	1.01	0.67	92.65	57.54
	EUR	2.42	1.22	263.68	112.82
	THB	0.02	-	0.06	-
	AED	0.39	-	9.95	-
	SGD	0.00	-	0.06	-
Other receivables	EUR	3.68	1.18	401.82	109.51
	USD	12.35	0.00	192.12	0.10
	SGD	0.01		0.76	
Loans	USD	0.11	0.02	10.71	1.45
	EUR	11.64	-	1,268.77	-
	MYR	44.86	-	1,045.25	-
Cash and cash equivalents	USD	0.33	0.08	30.82	6.72
	SGD	0.19	0.03	14.02	1.63
	EUR	0.00	0.00	0.09	0.12
	GBP	0.00	0.00	0.53	0.46
Payables					
Trade payables	USD	12.45	4.33	1,198.05	370.78
	JPY	25.53	22.88	15.09	16.82
	EUR	5.72	4.08	619.15	380.16
	CHF	0.04	0.08	4.25	7.52
	SGD	3.71	1.65	274.26	106.13
	MYR	0.75	0.01	16.46	0.27
	THB	4.69	-	12.81	-
	IDR	965.21	-	5.18	-
	GBP	-	0.00	0.13	0.02
Borrowings	USD	24.91	21.00	2,407.19	1,798.39
	SGD	3.50	-	262.98	-
	CHF	-	0.00	-	-
	THB	112.00	0.00	338.14	-
	MYR	44.86	-	1,045.25	-
Other payables	USD	0.24	0.05	23.16	3.88
	MYR	0.04	0.00	0.83	0.00
	SGD	0.29	0.00	21.38	0.00
	THB	1.89	0.00	5.70	0.00
Buyers credit / FCNR	EUR	2.78	6.90	302.77	637.35

The Group has entered into foreign exchange forward contracts to buy EUR 790,647 (31 March 2025: Nil).

Sensitivity
The foreign currency sensitivity of profit and equity in regards to the Group's financial assets and financial liabilities considering 'all other things being equal' and ignoring the impact of taxation. It assumes a +/- 1% change of the respective countries exchange rates (i.e. local currency to foreign currency) for the year ended at 31 March 2026 and 31 March 2025.The sensitivity analysis includes only outstanding foreign currency denominated monetary items at end of each period reported upon. A positive number indicates an increase in profit or equity and vice-versa.

If the ₹ had strengthened against the below currencies by 1% the following would have been the impact:

Currency	Profit/(loss) for the year		Equity	
	For the year ended 31 March 2026	For the year ended 31 March 2025	For the year ended 31 March 2026	For the year ended 31 March 2025
USD	33.02	21.07	33.02	21.07
EUR	(10.12)	7.95	(10.12)	7.95
MYR	0.17	0.00	0.17	0.00
SGD	5.44	1.05	5.44	1.05
GBP	(0.00)	(0.00)	(0.00)	(0.00)
JPY	0.15	0.17	0.15	0.17
CHF	0.04	0.08	0.04	0.08
THB	3.57	0.00	3.57	0.00
VND	-	0.00	-	0.00
AED	(0.10)	-	(0.10)	-
IDR	0.05	-	0.05	-

(c) Commodity price risk

The Group is affected by the price volatility of certain commodities. Its operating activities require the ongoing purchase and manufacture of cardio vascular products and therefore require a continuous supply of cobalt chromium, stainless steel, hypotube and Ballon. The Group's Board of Directors has developed and enacted a risk management strategy regarding commodity price risk and its mitigation.

Commodity price sensitivity
The following tables shows the effect of price change in raw material Cobalt Chromium, Stainless Steel, Hypo tube and Ballon purchased by the Holding company.

Particulars	Change in yearly average price		Effect on profit before tax		Effect on equity	
31 March 2026						
Cobalt Chromium	+1%	-1%	(6.49)	6.49	(6.49)	6.49
Stainless Steel	+1%	-1%	(1.25)	1.25	(1.25)	1.25
Hypo tube	+1%	-1%	(0.11)	0.11	(0.11)	0.11

Particulars	Change in yearly average price		Effect on profit before tax		Effect on equity	
31 March 2025						
Cobalt Chromium	+1%	-1%	(7.90)	7.90	(7.90)	7.90
Stainless Steel	+1%	-1%	(0.59)	0.59	(0.59)	0.59
Hypo tube	+1%	-1%	(1.03)	1.03	(1.03)	1.03
Ballon	+1%	-1%	(0.27)	0.27	(0.27)	0.27

(d) Other price sensitivity
The Group manages surplus funds through investments in mutual fund plans. The NAV declared by Asset Management Companies (AMC) has generally remained constant on the mutual fund plans taken by the Group. However, if the NAV of the fund is increased/decreased by 5%, the sensitivity analysis has been mentioned below :

Particulars	As at	Closing Balance	Increase in profit or loss	
			5% increase	5% decrease
Investments in mutual funds (Impact on profit and loss)	31 March 2026	1,426.15	71.31	(71.31)
Investments in mutual funds (Impact on profit and loss)	31 March 2025	3,276.23	163.81	(163.81)

(ii) Credit risk
Credit risk is the risk that a counterparty fails to discharge an obligation to the Group. The Group is operating through a network of distributors and other distribution partners based at different locations. The Group is exposed to this risk for various financial instruments, for example receivables from customers, deposits placed etc. The Group's maximum exposure to credit risk is limited to the carrying amount of financial assets recognised at end of each reporting period, as summarised below:

Particulars	As at 31 March 2026	As at 31 March 2025
Loans	121.51	494.16
Trade receivables	7,386.05	5,333.63
Cash and cash equivalents	2,260.06	1,928.30
Other bank balances	1,163.99	2,972.12
Other financial assets	554.22	408.75
	11,485.83	**11,136.96**

The Group continuously monitors receivables and defaults of customers and other counterparties, and incorporates this information into its credit risk controls.
The credit risk for cash and cash equivalents, other bank balance is considered negligible, since the counterparties are reputable banks.

Trade receivables
The Group closely monitors the credit-worthiness of customers, thereby, limiting the credit risk. The Group uses a simplified approach (lifetime expected credit loss model) for the purpose of computation of expected credit loss for trade receivables (refer note 35).

Cash and cash equivalents and other bank balances
Credit risk related to cash and cash equivalents and bank deposits is managed by only diversifying bank deposits and accounts in different banks. Credit risk is considered low because the Group deals with reputed banks.

Loans and other financial assets
Loans and other financial assets measured at amortized cost includes security deposits and other receivables. Credit risk related to these financial assets is managed by monitoring the recoverability of such amounts continuously. Credit risk is considered low because the Group is in possession of the underlying asset. Further, the Group creates provision by assessing individual financial asset for expectation of any credit loss basis expected credit loss model.

a) Credit risk exposure

Credit Risk is the risk that the counter party will not meet its obligation under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks, foreign exchange transactions and other financial instruments.

The Group provides for 12 month expected credit losses for following financial assets:

As at 31 March 2026

Particulars	Gross carrying amount	Expected credit losses	Net carrying amount
Cash and cash equivalents	2,260.06	-	2,260.06
Other bank balances	1,163.99	-	1,163.99
Trade receivables	7,730.92	(344.87)	7,386.05
Loans	121.51	-	121.51
Other financial assets	555.22	(1.00)	554.22

As at 31 March 2025

Particulars	Gross carrying amount	Expected credit losses	Net carrying amount
Cash and cash equivalents	1,928.30	-	1,928.30
Other bank balances	2,972.12	-	2,972.12
Trade receivables	5,560.80	(227.17)	5,333.63
Loans	494.16	-	494.16
Other financial assets	409.32	(0.57)	408.75

Reconciliation of expected credit loss

Particulars	Trade receivables
Expected credit loss as on 01 April 2024	**53.96**
Impact of business combination under common control	129.94
Expected credit loss created/(reversed) during the year	34.46
Exchange differences	8.81
Expected credit loss as on 31 March 2025	**227.17**
Acquisition under business combination (refer note 46)	141.15
Expected credit loss created/(reversed) during the year	117.95
Provisions utilised/written off during the year	(119.33)
Exchange differences	(22.07)
Expected credit loss as on 31 March 2026	**344.87**

b) Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group 's approach to managing liquidity is to ensure as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due.

Maturities of financial liabilities

The tables below analyse the Group financial liabilities into relevant maturity groupings based on their undiscounted contractual maturities.

31 March 2026	Less than 1 year	1 - 5 years	More than 5 years	Total
Borrowings	3,350.23	5,018.35	-	**8,368.58**
Trade payable	3,742.14	-	-	**3,742.14**
Lease liabilities	254.49	756.14	-	**1,010.63**
Other financial liabilities	2,579.06	250.34	-	**2,829.40**
Total	**9,925.92**	**6,024.83**	**-**	**15,950.75**

31 March 2025	Less than 1 year	1 - 5 years	More than 5 years	Total
Borrowings	12,380.08	4,962.12	-	**17,342.20**
Trade payable	2,023.47	-	-	**2,023.47**
Lease liabilities	168.48	518.90	-	**687.38**
Other financial liabilities	606.49	76.76	-	**683.25**
Total	**15,178.52**	**5,557.78**	**-**	**20,736.30**

36 Capital Management

The Group's objective when managing capital is to maintain positive cash flow position. The Group's strategy is to maintain a reasonable current ratio. The current ratio is as follows:

Particulars	As at 31 March 2026	As at 31 March 2025
Non-current borrowings	4,974.36	4,914.50
Current borrowings	3,350.23	12,380.08
Lease liabilities	780.94	517.04
Interest accrued and due on borrowings	94.44	191.83
Less: Cash and cash equivalents	(2,260.06)	(1,928.30)
Less: Other bank balances	(1,163.99)	(2,972.12)
Net debt (A)	**5,775.92**	**13,103.03**
Equity	23,084.58	13,213.24
Equity and net debt (B)	**28,860.50**	**26,316.27**
Gearing ratio (A/B)	**20.01%**	**49.79%**

In order to achieve overall objective, the Group's capital management, amongst other things, aims to ensure that is meets financial covenants attached to interest-bearing loans and borrowings that define capital structure requirements. No change were made in the objectives, policies or process for managing capital during the year ended 31 March 2026 and 31 March 2025. There's no breaches in the financials covenants of the borrowing that would permit the banks to immediately call loans and borrowings in the reporting periods.

37 Additional information to the consolidated financial statements, as required under Schedule III of the Companies Act, 2013 of entities consolidated as subsidiaries/associates/Joint ventures

Following is the share of net assets and the profit or loss of the entities which have been consolidated for preparation of the consolidated financial statements of Integris Medtech Limited for the financial year ended 31 March 2026:

Name of the entity	Net assets (Total assets minus Total liabilities)		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
	As a % of consolidated net assets	Amount	As a % of consolidated profit or loss	Amount	As a % of consolidated profit or loss	Amount	As a % of consolidated profit or loss	Amount
Integris Medtech Limited	192.35	44,403.55	12.76	372.13	0.02	0.13	10.54	372.26
Indian Subsidiaries (Group's share)								
Translumina Therapeutics Private Limited	1.92	443.41	5.69	165.84	0.55	3.36	4.79	169.20
Transhealth Private Limited	0.99	228.42	0.61	17.81	(0.04)	(0.22)	0.50	17.59
Transvalve Health Private Limited	0.03	7.82	(0.30)	(8.77)	-	-	(0.25)	(8.77)
CPC Diagnostics Private Limited	5.57	1,285.60	4.34	126.62	0.22	1.38	3.62	128.00
Halemed Medical Private Limited	(0.61)	(141.17)	(2.15)	(62.83)	(0.02)	(0.15)	(1.78)	(62.98)
Foreign subsidiaries								
Translumina GmbH	5.50	1,269.12	(3.72)	(108.51)	-	-	(3.07)	(108.51)
Artic GmbH	0.10	23.04	(0.09)	(2.72)	-	-	(0.08)	(2.72)
Blue Medical Devices B.V.	1.64	377.94	6.12	178.49	-	-	5.05	178.49
LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte	1.08	250.43	8.58	250.20	-	-	7.08	250.20
Translumina Medical Devices Trading L.L.C	(0.08)	(18.66)	(0.41)	(11.82)	-	-	(0.33)	(11.82)
Everlife Holdings Pte. Ltd.	61.54	14,207.24	(23.22)	(677.19)	-	-	(19.18)	(677.19)
Analisa Resources (M) Sdn Bhd	1.54	356.29	4.84	141.09	-	-	4.00	141.09
Chemopharm Sdn Bhd	19.15	4,421.32	42.76	1,247.10	-	-	35.31	1,247.10
Everlife Philippines Holdings Inc	2.48	571.83	(1.15)	(33.63)	-	-	(0.95)	(33.63)
Chemoscience Pte. Ltd	2.49	574.52	5.06	147.46	-	-	4.18	147.46
Bio-Rev Pte. Ltd.	0.08	18.92	(0.01)	(0.23)	-	-	(0.01)	(0.23)
Research Instrument Pte. Ltd	1.93	446.37	7.61	221.90	-	-	6.28	221.90
Chemoinformatics Sdn. Bhd	0.44	102.55	0.52	15.10	-	-	0.43	15.10
Chemoresources Sdn. Bhd	(0.25)	(57.44)	(0.31)	(8.99)	-	-	(0.25)	(8.99)
Chemoscience (Malaysia) Sdn. Bhd	0.07	16.56	-	0.10	-	-	-	0.10
Chemoscience Phills. Inc.	0.84	193.51	0.34	9.97	-	-	0.28	9.97
Medigene Sdn Bhd	0.88	203.96	0.61	17.91	-	-	0.51	17.91
Biofrontier Technology Pte. Ltd	0.55	128.02	2.31	67.28	-	-	1.91	67.28
PT Chemoscience Indonesia	0.11	24.66	0.24	7.11	0.11	0.69	0.22	7.80
Research Instruments Sdn. Bhd	0.15	33.67	1.55	45.07	-	-	1.28	45.07
Research Instruments Vietnam Company Limited	1.04	241.02	2.72	79.32	-	-	2.25	79.32
Scientific Resources Pte Ltd	0.80	184.11	4.15	121.08	-	-	3.43	121.08
Hausen Bernstein Co., Ltd	6.61	1,526.01	2.58	75.25	-	-	2.13	75.25
Lifeline Holdings Inc.	4.83	1,115.97	(0.75)	(21.97)	-	-	(0.62)	(21.97)
Lifeline Diagnostics Supplies Inc.	9.59	2,212.69	5.14	149.78	(1.09)	(6.71)	4.05	143.07
Neoscience Sdn Bhd (including Nevolution Engineering Sdn Bhd)	2.94	679.56	4.60	134.11	-	-	3.80	134.11
Foreign Associates (as per equity method)								
Chemoscience (Thailand) Co Ltd	-	-	0.30	8.87	-	-	0.25	8.87
RI Technologies Limited	-	-	(0.32)	(9.43)	-	-	(0.27)	(9.43)
Lifeline Holdings Inc.(refer note 46)	-	-	(0.11)	(3.19)	-	-	(0.09)	(3.19)
Laguna Tech USA, Inc.	-	-	-	0.00	-	-	-	0.00
Lifeline Diagnostics Supplies Inc. (refer note 46)	-	-	1.61	47.05	-	-	1.33	47.05
Eliminations								
Inter-company eliminations and consolidation adjustments	(227.86)	(52,595.35)	4.54	132.51	91.71	563.98	19.70	696.49
Non controlling interests	1.51	349.09	2.96	86.61	8.54	52.51	3.96	139.12
Total	**99.95**	**23,084.58**	**100.00**	**2,916.48**	**100.00**	**614.97**	**100.00**	**3,531.45**

37 Additional information to the consolidated financial statements, as required under Schedule III of the Companies Act, 2013 of entities consolidated as subsidiaries/associates/Joint ventures

Following is the share of net assets and the profit or loss of the entities which have been consolidated for preparation of the consolidated financial statements of Integris Medtech Limited for the financial year ended 31 March 2025:

Name of the entity	Net assets (Total assets minus Total liabilities)		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
	As a % of consolidated net assets	Amount	As a % of consolidated profit or loss	Amount	As a % of consolidated profit or loss	Amount	As a % of consolidated profit or loss	Amount
Integris Medtech Limited	92.07	12,165.55	50.14	354.42	(0.08)	(0.13)	40.45	354.29
<u>Indian subsidiaries (group's share)</u>								
Translumina Therapeutics LLP*	-	-	19.63	138.72	(1.24)	(2.10)	15.60	136.62
Translumina Therapeutics Private Limited	2.17	286.97	(6.90)	(48.77)	(0.15)	(0.25)	(5.60)	(49.02)
Transhealth Private Limited	1.60	210.77	10.49	74.12	0.52	0.88	8.56	75.00
Transvalve Health Private Limited	0.13	16.59	(0.14)	(1.01)	-	-	(0.12)	(1.01)
CPC Diagnostics Private Limited	8.46	1,118.34	20.32	143.61	(0.32)	(0.54)	16.34	143.07
Foreign subsidiaries								
Translumina GmbH	5.30	700.34	(5.32)	(37.57)	-	-	(4.29)	(37.57)
Artic GmbH	0.17	22.00	(0.31)	(2.18)	-	-	(0.25)	(2.18)
Translumina France	-	-	-	-	-	-	-	-
Blue Medical Devices B.V.	1.20	158.98	11.36	80.32	-	-	9.17	80.32
LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte	1.50	198.36	29.36	207.54	-	-	23.70	207.54
Translumina Medical Devices Trading L.L.C	(0.04)	(5.54)	(1.11)	(7.88)	-	-	(0.90)	(7.88)
Everlife Holdings Pte. Ltd.	2.39	315.84	(31.47)	(222.41)	-	-	(25.40)	(222.41)
Analisa Resources (M) Sdn Bhd	1.41	185.80	7.30	51.57	-	-	5.89	51.57
Chemopharm Sdn Bhd	18.35	2,424.83	61.04	431.45	-	-	49.26	431.45
Everlife Philippines Holdings Inc	3.69	487.77	(4.88)	(34.48)	-	-	(3.94)	(34.48)
Chemoscience Pte. Ltd	3.28	432.87	14.20	100.40	-	-	11.46	100.40
Research Instrument Pte. Ltd	2.64	348.26	23.46	165.80	-	-	18.93	165.80
Chemoinformatics Sdn. Bhd	0.79	104.68	2.12	14.99	-	-	1.71	14.99
Chemoresources Sdn. Bhd	(0.30)	(39.32)	(1.04)	(7.35)	-	-	(0.84)	(7.35)
Chemoscience (Malaysia) Sdn. Bhd	0.17	22.39	0.03	0.21	-	-	0.02	0.21
Chemoscience Phills. Inc.	0.96	127.20	0.95	6.68	-	-	0.76	6.68
Medigene Sdn Bhd	1.89	249.52	3.28	23.18	-	-	2.65	23.18
Biofrontier Technology Pte. Ltd	1.04	136.98	8.68	61.38	-	-	7.01	61.38
Bio-Rev Pte. Ltd	0.13	16.80	(0.14)	(1.00)	-	-	(0.11)	(1.00)
PT Chemoscience Indonesia	0.10	13.30	0.76	5.40	0.19	0.32	0.65	5.72
Research Instruments Sdn. Bhd	0.70	92.79	4.00	28.29	-	-	3.23	28.29
Research Instruments Vietnam Company Limited	0.96	127.25	8.20	57.98	-	-	6.62	57.98
Scientific Resources Pte Ltd	1.16	152.97	12.51	88.42	-	-	10.10	88.42
Hausen Bernstein Co., Ltd	9.51	1,256.07	12.40	87.66	-	-	10.01	87.66
Foreign Associates (as per equity method)								
Chemoscience (Thailand) Co Ltd	-	-	2.01	14.22	-	-	1.62	14.22
RI Technologies Limited	-	-	(0.34)	(2.37)	-	-	(0.27)	(2.37)
Lifeline Holdings Inc	-	-	(1.78)	(12.59)	-	-	(1.44)	(12.59)
Lifeline Diagnostics Supplies Inc	-	-	20.48	144.74	-	-	16.53	144.74
Eliminations				-		-		-
Inter-company eliminations and consolidation adjustments	(74.11)	(9,790.97)	(197.57)	(1,396.54)	83.36	140.83	(143.35)	(1,255.71)
Non controlling interests	12.68	1,675.85	28.28	199.89	17.72	29.93	26.24	229.82
Total	**100.00**	**13,213.24**	**100.00**	**706.84**	**100.00**	**168.94**	**100.00**	**875.78**

* W.e.f. 25 January 2025, Translumina Therapeutics LLP has converted from a Limited Liability Partnership to a Private Limited Company in accordance with the applicable legal and regulatory provisions, with no material impact on its operations or financial position.

38 Disclosure of interest in Subsidiaries/Associates and Non Controlling Interest

(a) Subsidiaries

The Group has following subsidiaries held directly and indirectly by the Parent Company i.e. Integris Medtech Limited, which operate around the world. Following are the details of shareholdings in the subsidiaries :

S.No	Name of Company	Principal activities	Immediate holding company	Country of Incorporation	Proportion of Ownership Interest and Voting power held by the Group	
					As at 31 March 2026	As at 31 March 2025
1	Translumina Therapeutics Private Limited (Converted from Translumina Therapeutics LLP on 25 January 2025)	Manufacturing and trading of coronary stent systems, and related products	Integris Medtech Limited	India	100%	100%
2	Transhealth Private Limited	Manufacturing and marketing of coronary stents and related products	Integris Medtech Limited	India	100%	100%
3	Transvalve Health Private Limited	Manufacturing and marketing of coronary stents and related products	Integris Medtech Limited	India	100%	100%
4	Translumina GmbH	Manufacturing and marketing of coronary stents and related products	Integris Medtech Limited	Germany	100%	100%
5	Artic GmbH	Generating royalty income from patents	Integris Medtech Limited	Germany	100%	100%
6	Blue Medical Devices B.V.	Manufacturing innovative high-quality drug eluting solutions, PTCA balloon catheters and coronary stent systems	Translumina Gmbh	Netherlands	100%	100%
7	LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte	Trading of medical devices including endovascular products, patches, haemostasis, catheters, surgical tools, meshes and staple seam sealing.	Translumina Gmbh	Germany	100%	100%
8	Translumina Medical Devices Trading L.L.C (incorporated w.e.f. 24 April 2024)	Trading of medical and surgical articles.	Translumina Gmbh	Dubai	100%	100%
9	Analisa Resources (M) Sdn. Bhd.(refer note (a) below)	Trading of scientific instruments and chemicals	Everlife Holdings Pte. Ltd.	Malaysia	100%	100%
10	Biofrontier Technology Pte. Ltd (refer note (a) below)	Technical testing, analysis and distribution of medical equipment	Chemopharm Sdn Bhd	Singapore	100%	100%
11	Bio-Rev Pte. Ltd (refer note (a) below)	Trading and distribution of scientific and life sciences products	Chemoscience Pte. Ltd	Singapore	100%	100%
12	Chemoinformatics Sdn. Bhd (refer note (a) below)	Agents and distributors of data processing, equipment, consulting and advisory services for automated data processing systems	Chemopharm Sdn Bhd	Malaysia	100%	100%
13	Chemopharm Sdn Bhd (refer note (a) and (g) below	Trading and distribution of chemicals, laboratory and medical supplies	Everlife Holdings Pte. Ltd.	Malaysia	96.28%	75%
14	Chemoresearch Sdn. Bhd (refer note (a) and (d) below)	Distribution, marketing and after sales support of high-end research equipment for research and development, quality control, quality assurance and clinical research laboratories	Chemopharm Sdn Bhd	Malaysia	0%	100%
15	Chemoresources Sdn. Bhd (refer note (a) below)	Manufacturing, assembling and trading of laboratory furniture and related products	Chemopharm Sdn Bhd	Malaysia	100%	100%
16	Chemoscience (Malaysia) Sdn. Bhd (refer note (a) and (h) below)	Trading, distribution and renting out of laboratory instruments, laboratory furniture, surgical instruments and materials handling equipment	Chemopharm Sdn Bhd	Malaysia	100%	100%
17	Chemoscience Pte. Ltd (refer note (a) below)	Trading laboratory equipment and spare	Chemopharm Sdn Bhd	Singapore	100%	100%
18	Chemoscience Philippines Inc.(refer note (a) below)	Buying, selling, distributing, marketing of laboratory equipment, chemicals, laboratory furniture, medical devices and reagents	Chemopharm Sdn Bhd	Philippines	100%	100%
19	CPC Diagnostics Private Limited (refer note (a) and (j) below)	Trading and distribution of in-vitro diagnostics products	Everlife Holdings Pte. Ltd. (64.61%) Integris Medtech Limited (10.61%)	India	75.22%	65%
20	Lifeline Holdings Inc. (refer note (b) and (e) below) (w.e.f. 23 June 2025)	Investment holding	Translumina Gmbh	Philippines	40%	0%
21	Lifeline Diagnostics Supplies Inc.(refer note (b) and (e) below) (w.e.f. 23 June 2025)	Trading of hospital and laboratory reagents, equipment and supplies on wholesale/retail basis	Lifeline Holdings Inc	Philippines	64%	0%
22	Everlife Philippines Holding Inc (w.e.f. 23 June 2025)	Investment holding	Translumina Gmbh	Philippines	100%	0%
23	Everlife Philippines Holding Inc(refer note (a) below) (till 22 June 2025)	Investment holding	Everlife Holdings Pte. Ltd.	Philippines	0%	100%
24	Medigene Sdn Bhd (refer note (a) below)	Supply of medical and genetic tools and provision of management and consultancy services	Chemopharm Sdn Bhd	Malaysia	0%	100%
25	PT Chemoscience Indonesia (refer note (a) below)	Trading in pharmacy, chemical laboratory and material handling equipment	Chemopharm Sdn Bhd	Indonesia	100%	100%

38 Disclosure of interest in Subsidiaries/Associates and Non Controlling Interest

(a) Subsidiaries (continued)

S.No	Name of Company	Principal activities	Immediate holding company	Country of Incorporation	Proportion of Ownership Interest and Voting power held by the Group	
					As at 31 March 2026	As at 31 March 2025
26	Research Instrument Pte. Ltd (refer note (a) below)	Trading in scientific and industrial equipment, chemical and materials	Chemopharm Sdn Bhd	Singapore	100%	100%
27	Research Instruments Sdn. Bhd (refer note (a) below)	Trading in scientific instruments and providing its related services	Chemopharm Sdn Bhd	Malaysia	100%	100%
28	Research Instruments Vietnam Company Limited (refer note (a) below)	Trading and services	Research Instrument Pte. I	Vietnam	100%	100%
29	Scientific Resources Pte Ltd (refer note (a) below)	Dealers in industrial chemical and scientific laboratory equipment	Chemopharm Sdn Bhd	Singapore	100%	100%
30	Hausen Bernstein Co., Ltd.(refer note (a) and (i) below)	Trading of reagents, tools and equipment in laboratory	Chemopharm Sdn Bhd	Thailand	70%	70%
31	Neoscience Sdn Bhd (refer note (a) below) (w.e.f. 24 June 2025)	Trading in laboratory equipment, pharmaceutical and medical goods.	Analisa Resources (M) Sdn. Bdn.	Malaysia	100%	0%
32	Nevolution Engineering Sdn Bhd (refer note (b) below) (w.e.f. 24 June 2025)	Trading in laboratory equipment, pharmaceutical and medical goods.	Neoscience Sdn Bhd	Malaysia	100%	0%
33	Everlife Holdings Pte. Ltd.(refer note (b) below)	Investment holding	Integris Medtech Limited	Singapore	100%	100%
34	Halemed Medical Private Limited (refer note (b) below) (w.e.f. 24 June 2025)	Manufacturing and marketing of medical consumables including infusion and transfusion, cardiac surgery equipment, respiratory and general consumables.	Integris Medtech Limited	India	100%	0%

(b) Details of Non-Wholly Owned Subsidiaries that have material Non Controlling Interest

Set out below are the details of the Non Controlling interests that are material to the Group:

S.No	Name of the Subsidiary	Principal activities	Principal place of business	Proportion of Ownership Interest and voting rights held by non controlling interests	
				As at 31 March 2026	As at 31 March 2025
1	CPC Diagnostics Private Limited (refer note (a) and (j) below)	Trading and distribution of in-vitro diagnostics products	India	24.78%	35%
2	Hausen Bernstein Co., Ltd (refer note (a) and (i) below)	Trading of reagents, tools and equipment in laboratory	Thailand	30%	30%
3	Chemopharm Sdn Bhd (refer note (a) and (g) below)	Trading and distribution of chemicals, laboratory and medical supplies	Malaysia	3.72%	25%
4	Lifeline Holdings Inc. (refer note (a) below) (w.e.f. 23 June 2025)	Investment holding	Philippines	60%	0%
5	Lifeline Diagnostics Supplies, Inc. (refer note (a) below) (w.e.f. 23 June 2025)	Trading of hospital and laboratory reagents, equipment and supplies on wholesale/retail basis	Philippines	36%	0%

(c) Associates

Set out below are the associates of the group which, in the opinion of the management are material to the Group. Percentage of ownership interest as exercised by the Group is as follows-:

S.No	Associates	Principal activities	Country of incorporation	Ownership Interest	
				As at 31 March 2026	As at 31 March 2025
1	Lifeline Holdings Inc.(refer note (a),(c) and (e) below)	Investment holding	Philippines	0%	40%
2	Lifeline Diagnostics Supplies, Inc. (refer note (a),(b),(c) and (e) below)	Trading of hospital and laboratory reagents, equipment and supplies on wholesale/retail basis	Philippines	0%	64%
3	R I Technologies Limited (refer note (a) and (c) below)	Selling of instruments for research in laboratories and to render the service for training and research for biologics	Thailand	49%	36%
4	Chemoscience (Thailand) Co Ltd (refer note (a) and (c) below)	Import and distribution of laboratorial tools and equipment	Thailand	49%	36%
5	Laguna Tech USA, Inc.(refer note (f) below)	Research, development, manufacturing and selling of transcatheter aortic valve and delivery systems	State of Delaware, USA	13.98%	0%

(a) Subsidiaries, associates and joint ventures of Everlife Holdings Pte. Ltd.
(b) Refer note 46
(c) Refer note 44
(d) Chemoresearch Sdn Bhd has been dissolved/strike off w.e.f. 06 January 2025.
(e) Lifeline Holdings Inc. and Lifeline Diagnostics Supplies, Inc. become subsidiary w.e.f. 23 June 2025 (refer note 46(I)(C)).
(f) Refer note 6A.
(g) Refer note 47(c).
(h) The management of Chemoscience (Malaysia) Sdn. Bhd is planning to submit an application to the concerned authorities for striking off. Accordingly, the financial statements of subsidiary have been prepared on liquidation basis, wherein all the assets have been recognised at their net realisable value.
(i) Refer note 21B
(j) Refer note 16B(xii)

38 Disclosure of interest in Subsidiaries/Associates/Joint Ventures and interest of Non Controlling Interest

d) Summary of Non Controlling Interest (other than Class C Preference shares separately disclosed under note no. 16B(x))

Particulars	**Balance Sheet**		**Profit for the year ended**		**Total other comprehensive income for the year ended**		**Total comprehensive income for the year ended**	
Name of the Company	**As at 31 March 2026**	**As at 31 March 2025**	**31 March 2026**	**31 March 2025**	**31 March 2026**	**31 March 2025**	**31 March 2026**	**31 March 2025**
Lifeline Diagnostics Supplies Inc.	10.71	-	19.16	-	(39.27)	-	(20.11)	-
Lifeline Holdings Inc.	(14.31)	-	(13.18)		(1.12)		(14.30)	
CPC Diagnostics Private Limited	352.69	465.56	31.35	38.62	1.01	(0.34)	32.36	38.28
Hausen Bernstein Co. Ltd	-	439.92	14.74	19.39	66.86	33.09	81.60	52.48
Chemopharm Sdn Bdn	-	770.37	34.54	141.88	25.03	(2.82)	59.57	139.06
Total	**349.09**	**1,675.85**	**86.61**	**199.89**	**52.51**	**29.93**	**139.12**	**229.82**

Particulars	**For the year ended 31 March 2026**	**For the year ended 31 March 2025**
Opening balance of Non controlling interest (other than Class C Preference shares separately disclosed under note no. 16B(x))	1,675.85	-
Impact of business combination under common control	-	1,436.82
Total comprehensive income for the year	139.12	229.82
Impact of business combination	30.81	
Acquisition of stake held by minorities	(1,651.48)	7.65
Share-based payment expenses	0.03	1.56
Issue of shares to minority	154.76	
Closing balance of Non controlling interest (other than Class C Preference shares separately disclosed under note no. 16B(x))	**349.09**	**1,675.85**

e) The table shows summarized financial information of subsidiary of the Group that have material non-controlling interests before intra group eliminations.

Particulars (Balance sheet)	**Lifeline Diagnostics Supplies Inc.***		**Lifeline Holdings Inc.***		**CPC Diagnostics Private Limited**		**Hausen Bernstein Co. Ltd**		**Chemopharm Sdn Bdn**	
	As at 31 March 2026	**As at 31 March 2025**	**As at 31 March 2026**	**As at 31 March 2025**	**As at 31 March 2026**	**As at 31 March 2025**	**As at 31 March 2026**	**As at 31 March 2025**	**As at 31 March 2026**	**As at 31 March 2025**
Current assets	2,405.56	-	0.83	-	1,889.18	1,420.33	-	1,255.77	-	4,853.10
Non current assets	634.17	-	1,490.30	-	901.16	750.07	-	480.35	-	5,257.25
Current liabilities	763.29	-	37.95	-	1,360.34	877.20	-	433.27	-	2,222.79
Non current liabilities	63.75	-	337.21	-	144.40	135.74	-	46.78	-	4,458.36
Total equity before acquisition adjustments	**2,212.69**	**-**	**1,115.97**	**-**	**1,285.60**	**1,157.46**	**-**	**1,256.07**	**-**	**3,429.20**
Share of equity of Hausen Bernstein Co. Ltd disclosed separately	-	-	-	-	-	-	-	-	-	439.92
Intangible assets acquired through business combination	-	-	-	-	162.50	214.49	-	262.91	-	117.65
Property, Plant and Equipment acquired through business combination	-	-	-	-	46.11	46.67	-	-	-	-
Deferred tax liabilities created on above	-	-	-	-	70.93	88.79	-	52.58	-	25.47
Reversal of other liabilities (net of deferred tax)	-	-	-	-	-	0.33	-	-	-	-
Total equity	**2,212.69**	**-**	**-**	**-**	**1,423.28**	**1,330.16**	**-**	**1,466.40**	**-**	**3,081.46**
Attributable to owners of the Holding Company	2,201.98	-	1,130.27	-	1,070.59	864.60	-	1,026.48	-	2,311.10
Attributable to owners of the non controlling interest	10.71	-	(14.31)	-	352.69	465.56	-	439.92	-	770.37

** also refer note 46(I)(C)*

Particulars (Profit or loss)	**Lifeline Diagnostics Supplies Inc.***		**Lifeline Holdings Inc.***		**CPC Diagnostics Private Limited**		**Hausen Bernstein Co. Ltd**		**Chemopharm Sdn Bdn**	
	For the year ended 31 March 2026	**For the year ended 31 March 2025**	**For the year ended 31 March 2026**	**For the year ended 31 March 2025**	**For the year ended 31 March 2026**	**For the year ended 31 March 2025**	**For the year ended 31 March 2026**	**For the year ended 31 March 2025**	**For the year ended 31 March 2026**	**For the year ended 31 March 2025**
Revenue	3,157.99	-	-	-	3,227.31	2,743.60	1,558.06	1,780.55	1,905.55	9,099.45
Other income	3.93	-	-	-	12.89	10.68	8.52	8.55	66.69	182.87
Expenses	(2,950.13)	-	21.97	-	(3,071.64)	(2,551.29)	(1,470.69)	(1,673.46)	(1,777.60)	(8,448.59)
Share of profit/(loss) of an associate, net of tax	-	-	-	-	-	-	-	-	(3.18)	11.85
Tax expense	(62.01)	-	-	-	(41.94)	(57.96)	(20.64)	(28.02)	(45.55)	(241.36)
Depreciation/ amortisation of property, plant and equipment/ intangible assets (net of deferred tax)	(96.55)	-	-	-	(34.68)	(34.68)	(26.13)	(22.99)	(3.66)	(17.31)
Share of equity of Hausen Bernstein Co. Ltd disclosed separately	-	-	-	-	-	-	-	-	(4.08)	(19.39)
Profit for the year	**53.23**	**-**	**21.97**	**-**	**91.94**	**110.35**	**49.12**	**64.63**	**138.17**	**567.52**
Profit attributable to the owners of the Holding Company	34.07	-	(8.79)	-	60.59	71.73	34.38	45.24	103.63	425.64
Profit attributable to the non controlling interest	19.16	-	(13.18)	-	31.35	38.62	14.74	19.39	34.54	141.88
Profit for the year	**53.23**	**-**	**(21.97)**	**-**	**91.94**	**110.35**	**49.12**	**64.63**	**138.17**	**567.52**
Items that will not be reclassified to profit and loss:										
Re-measurements of the defined benefit plans (net of tax)	(6.71)	-			2.95	(0.83)	-	-	0.07	0.32
Items that will be reclassified subsequently to profit or loss:			-	-						
Exchange differences on translation of foreign operations (net of tax)	(102.37)	-	(1.87)	-	-	(0.13)	222.88	110.29	100.05	(11.60)
Other comprehensive income/(loss)	**(109.08)**	**-**	**(1.87)**	**-**	**2.95**	**(0.96)**	**222.88**	**110.29**	**100.12**	**(11.28)**
Other comprehensive income/(loss) attributable to the owners of the Holding Company	(69.81)	-	(0.75)	-	1.91	(0.62)	156.02	77.20	75.09	(8.46)
Other comprehensive income/(Loss) attributable to the non controlling interest	(39.27)	-	(1.12)	-	1.01	(0.34)	66.86	33.09	25.03	(2.82)
Other comprehensive income/(loss)	**(109.08)**	**-**	**(1.87)**	**-**	**2.92**	**(0.96)**	**222.88**	**110.29**	**100.12**	**(11.28)**
Total comprehensive income/(loss) attributable to the owners of the Holding Company	(35.74)	-	(9.53)	-	62.50	71.11	190.40	122.44	178.72	417.18
Total comprehensive income/loss) attributable to the non controlling interest	(20.11)	-	(14.29)	-	32.36	38.28	81.60	52.48	59.57	139.06
Total comprehensive income/(loss)	**(55.85)**	**-**	**(23.82)**	**-**	**94.86**	**109.39**	**272.00**	**174.92**	**238.29**	**556.24**
Net cash flow from/ (used in) operating activities	193.68	-	10.91	-	61.90	67.31	327.80	288.05	-	1,007.85
Net cash flow used in investing activities	(135.90)	-	-	-	(226.25)	(233.42)	(398.79)	(67.78)	-	(601.91)
Net cash flow from/ (used in) financing activities	(66.37)	-	(10.40)	-	(18.96)	67.61	(113.00)	(70.15)	-	(544.84)
Net Cash inflow (outflow)	**(8.59)**	**-**	**0.51**	**-**	**(183.31)**	**(98.50)**	**(183.99)**	**150.12**	**-**	**(138.90)**

** also refer note 46(I)(C)*

38 Disclosure of interest in Subsidiaries/Associates/Joint Ventures and interest of Non Controlling Interest

f) The table shows summarized financial information of associates that are material to the Holding Company before intra group eliminations.

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Share of profit/(loss) of associates (net of tax)		
Lifeline Holdings Inc.	(3.19)	(12.59)
RI Technologies Limited	(9.43)	(2.37)
Chemoscience (Thailand) Company Limited	8.87	14.22
Laguna Tech USA, Inc.	0.00	-
Lifeline Diagnostics Supplies, Inc.	47.05	144.74
Total	**43.30**	**144.00**

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Movement of investment in material associates	**3,585.14**	**3,409.30**
Balance at the beginning of the year		
Share of profit of associates (net of tax)	43.86	132.15
Deemed investment in associate	86.70	
Impact of deemed disposal of investment in associates*	(3,732.96)	-
Foreign currency translation reserve	17.26	43.69
Closing amount of investment in associates	**-**	**3,585.14**

* Impact of deemed disposal of investment in associates includes cumulative impact of foreign currency translation reserve of ₹ 98.23 million.

Particulars (Balance sheet)	Lifeline Holdings Inc. (Stake held by Group: 40%)		Lifeline Diagnostics Supplies, Inc. (through Everlife Philippines Holdings Inc.) (Stake held by Group: 40%)	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Current Assets	-	0.78	-	2,047.85
Investment in Lifeline Diagnostics Supplies, Inc.	-	2,041.99	-	-
Non Current Assets	-	-	-	675.35
Current Liabilities	-	400.62	-	747.52
Non Current Liabilities	-	1,302.07	-	83.88
Total equity before acquisition adjustments	**-**	**340.08**	**-**	**1,891.80**
Group's share of equity @ 40%	-	136.03	-	756.72
Goodwill	-	1,823.43	-	582.60
Intangible assets acquired through business combination	-	-	-	286.36
Group's carrying amount of investment	**-**	**1,959.46**	**-**	**1,625.68**

Particulars (Profit or loss)	Lifeline Holdings Inc. (Stake held by Group: 40%)		Lifeline Diagnostics Supplies, Inc. (through Everlife Philippines Holdings Inc.) (Stake held by Group: 40%)	
	For the year ended 31 March 2026	For the year ended 31 March 2025	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue	-	-	1,014.33	3,394.17
Other Income	-	0.01	1.53	0.77
Purchases of traded goods	-	-	(759.18)	(2,160.45)
Changes in inventories	-	-	155.81	126.36
Employee benefits expense	-	-	(106.49)	(348.93)
Finance costs	(7.49)	(28.02)	(5.03)	(15.07)
Depreciation and amortisation expense	-		(74.35)	(250.06)
Other expenses	(0.50)	(3.46)	(97.73)	(328.99)
Amortisation of intangible assets (net of deferred tax)	-		(23.66)	(91.05)
Profit before tax	**(7.99)**	**(31.47)**	**105.23**	**326.75**
Tax expense	-	-	(31.71)	(100.60)
Profit for the year	**(7.99)**	**(31.47)**	**73.52**	**226.15**
Items that will not be reclassified to profit or loss				
Re-measurements of the defined benefit plans (net of tax)	-	-	-	-
Other comprehensive income/(loss)	**-**	**-**	**-**	**-**
Total other comprehensive income/(loss)	**(7.99)**	**(31.47)**	**73.52**	**226.15**
Group’s share of profit/(loss) excluding dividend income disclosed above	**(3.19)**	**(12.59)**	**47.05**	**144.74**

** also refer note 46(I)(C)*

39 Earnings per share

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Calculation of Basic EPS		
Profit attributable to equity holders of the parent	**2,829.87**	**506.95**
Interest on compulsory convertible preference shares (CCPS)	-	-
Adjusted profit attributable to equity holders of the parent (A)	**2,829.87**	**506.95**
Nominal value of equity shares (₹)	1.00	1.00
Weighted average number of equity shares	3,47,26,462	2,79,56,368
Add: Number of equity shares under bonus issue (2 bonus shares for each equity share)	6,94,52,923	5,59,12,736
Add: Weighted average number of potential equity share to be issued on account of conversion of Compulsory Convertible Preference Shares (including bonus shares) at the end of year^	-	32,11,200
Total weighted average number of equity shares outstanding (B)*	**10,41,79,385**	**8,70,80,304**
Basic earning per share (A/B)	**27.16**	**5.82**
Calculation of Diluted EPS		
Adjusted profit attributable to equity holders of the parent (C)	**2,829.87**	**506.95**
Weighted average number of equity shares	3,47,26,462	2,79,56,368
Add: Number of equity shares under bonus issue (2 bonus shares for each equity share)	6,94,52,923	5,59,12,736
Add: Weighted average number of potential equity share to be issued on account of conversion of Compulsory Convertible Preference Shares (including bonus shares) at the end of year^	-	32,11,200
Add: Weighted average number of shares from share-based payment arrangements (including bonus shares)	5,16,708	13,21,790
Total weighted average number of equity shares (D)*	**10,46,96,093**	**8,84,02,094**
Diluted earnings per share (C/D)	**27.03**	**5.73**

*weighted average number of shares outstanding have been retrospective adjusted to give impact of the issuance of bonus shares and stock split in accordance with Ind AS 33- Earnings Per Share.

^ Calculated on the basis of fair value on the date of issue of Compulsory Convertible Preference Shares.

40 Employee benefit plans

(i) Contribution to Defined Contribution Plan, recognised as expense for the period is as under:

The Group's contribution to the Employees Provident Fund is deposited with the Regional Provident Fund Commissioner for qualifying employees. Under the scheme, the Group is required to contribute a specified percentage of payroll cost to the retirement benefit plan to fund the benefits.

During the year, the Group has recognised ₹ 317.24 million (31 March 2025: ₹ 227.14 million) for Employer's contributions to the Provident Fund, Employee State Insurance, National Pension Scheme and others contribution in the Consolidated Statement of Profit and Loss. The contributions payable to the plan by the Group is at the rate specified in rules to the scheme.

(ii) Defined benefit plan:

Gratuity

The Group provides for gratuity obligations through a defined benefit retirement plan (the 'Gratuity Plan') covering all employees. The Gratuity Plan provides a lump sum payment to vested employees at retirement/termination of employment or death of an employee, based on the respective employees' salary and years of employment with the Group. In respect of certain employees of the foreign subsidiaries, the gratuity benefit is accrued on the basis of their current salary and length of service as per the extant rules of the particular jurisdiction where such subsidiaries operate.

The gratuity plan in one of the subsidiary company, CPC Diagnostics Private Limited, is funded through annual contributions to Life Insurance Corporation of India (LIC), whereas others are unfunded.

Salary Inflation risk:	Actual salary increases will increase the plan's liability. Increase in salary increase rate assumption in future valuations will also increase the liability.
Discount rate:	The present value of the defined benefit liability is calculated using a discount rate determined by reference to market yields of Government bonds. The estimated term of the bonds is consistent with the estimated term of the defined benefit obligation (DBO). A decrease in market yield on Government bonds will increase the Group's defined benefit liability, although it is expected that this would be offset partially by an increase in the fair value of the plan assets.
Mortality & disability:	Actual deaths and disability cases proving lower or higher than assumed in the valuation can impact the liabilities.
Withdrawals:	Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can impact plan's liability.

A. Amounts recognised in the balance sheet:

Particulars	As at 31 March 2026	As at 31 March 2025
Current liability	12.75	6.99
Non-current liability	152.91	84.48
Total	**165.66**	**91.47**

B. Expenses recognised in the statement of profit and loss

Particulars	For the year ended 31 March 2026		For the year ended 31 March 2025	
	Funded Plan	Unfunded Plan	Funded Plan	Unfunded Plan
Current service cost	10.25	15.25	3.80	12.95
Past service cost vested benefits (refer note 33)	10.86	6.88	-	-
Interest cost	(0.60)	4.42	(0.16)	3.13
Cost recognised during the year	**20.51**	**26.55**	**3.64**	**16.08**

C. (Gain)/loss recognised in other comprehensive income:

Particulars	For the year ended 31 March 2026		For the year ended 31 March 2025	
	Funded Plan	Unfunded Plan	Funded Plan	Unfunded Plan
Actuarial gain for the year on projected benefit obligation	-	(5.31)	1.31	2.30
Return on plan assets excluding interest income	7.24	-	(0.20)	-
Recognised in other comprehensive income	**7.24**	**(5.31)**	**1.11**	**2.30**

D. Movement in the liability recognised in the balance sheet is as under:

Particulars	Funded Plan	Unfunded Plan	Funded Plan	Unfunded Plan
	As at 31 March 2026	As at 31 March 2026	As at 31 March 2025	As at 31 March 2025
Present value of defined benefit obligation at the beginning of the year	32.91	86.38	-	28.33
Impact of business combination under common control	-	-	26.23	36.84
Liability of subsidiary acquired	97.39	-	-	-
Current service cost	10.25	15.25	3.80	12.95
Past service cost	-	6.88	-	-
Interest cost	4.58	4.42	1.52	3.13
Transfer in	10.86	-	1.08	-
Actuarial gain	5.77	(5.31)	1.31	2.30
Benefits paid	(3.19)	(1.64)	(1.03)	(0.53)
Exchange differences	0.05	7.31	-	3.36
Present value of defined benefit obligation at the end of the year	**158.62**	**113.29**	**32.91**	**86.38**

Movement in the fair value of the plan assets are as follows:

Particulars	Funded Plan	
	As at 31 March 2026	As at 31 March 2025
Opening fair value of plan asset	27.82	-
Impact of business combination under common control	-	22.50
Assets of subsidiaries acquired	71.26	-
Return on plan assets excluding interest income	0.17	0.20
Interest income	5.18	1.68
Transfer in fund	-	1.08
Exchange difference	(0.09)	-
Contribution by employer	6.75	3.39
Actuarial gain (net)	(1.65)	-
Benefits paid	(3.19)	(1.03)
Closing fair value of plan asset	**106.25**	**27.82**

E. For determination of the liability of the Group the following actuarial assumptions were used:

Particulars	As at 31 March 2026	As at 31 March 2025
Discount rate	2.47%-6.82%	2.47%-7.25%
Salary escalation rate	4% to 5%	4% to 10%
Retirement age (years)	55-60 Years	55-60 Years
Decremented remaining adjusted life (Years)	7 Years	7 Years
Mortality table	IALM (2012-14)	IALM (2012-14)
Withdrawal rate	1.91%-22.92% PA	1.91%-22.92% PA
Weighted average duration of defined benefit obligation	6-16 years	6-12 years

These assumptions were developed by management with the assistance of independent actuaries. Discount factors are determined close to each year-end by reference to market yields of government bonds that are denominated in the currency in which the benefits will be paid and that have terms to maturity approximating to the terms of the related defined benefit obligation. Other assumptions are based on current actuarial benchmarks and management's historical experience.

F. Maturity profile of undiscounted defined benefit obligation

Particulars	As at 31 March 2026	As at 31 March 2025
Within the next 12 months	30.57	18.45
Between 2 and 5 years	124.12	83.20
More than 5 years	299.85	93.30

G. Sensitivity analysis for gratuity liability:
Increase / (decrease) on present value of defined benefits obligation at the end of the year*

Particulars	As at 31 March 2026	As at 31 March 2025
a) Impact of the change in discount rate		
Impact due to increase of 1.00 %	31.42	(30.56)
Impact due to decrease of 1.00 %	74.57	41.24
b) Impact of the change in salary increase		
Impact due to increase of 1.00 %	73.69	40.37
Impact due to decrease of 1.00 %	31.64	(30.58)

*The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting year.

41 Lease related disclosures

The Group has executed lease arrangements for land, equipment, vehicles and business premises. With the exception of short-term leases and leases with variable lease payments, each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. Variable lease payments which do not depend on an index or a rate are excluded from the initial measurement of the lease liability and right of use assets. The Group classifies its right-of-use assets in a consistent manner to its property, plant and equipment.

Each lease generally imposes a restriction that, unless there is a contractual right for the Group to sublet the asset to another party, the right-of-use asset can only be used by the Group. Leases are either non-cancellable or may only be cancelled by incurring a substantive termination fee. Some leases contain an option to extend the lease for a further term. The Group is prohibited from selling or pledging the underlying leased assets as security against the Group's other debts and liabilities. For leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease. The Group is required to insure items of property, plant and equipment and incur maintenance fees on such items in accordance with the lease contracts. Further, the Group and the Company are restricted from assigning and subleasing the leased assets.

The Group has considered automatic extension option available for the property leases in lease period assessment since the Group can enforce its right to extend the lease beyond the initial lease period as the Group is likely to be benefited by exercising the extension option.

A Set out below are the carrying amounts of lease liabilities and the movements during the year:

Particulars	As at 31 March 2026	As at 31 March 2025
Opening Balance	517.04	137.34
Impact of business combination under common control (refer note 46(I)(D))	-	181.38
Additions during the year	343.68	328.63
Acquisition under business combination (refer note 46)	105.80	-
Lease terminations/modification	(22.24)	10.46
Interest expense on lease liabilities	49.34	31.53
Payments	(250.17)	(177.06)
Exchange differences	37.49	4.76
Closing balance	**780.94**	**517.04**
- Current	199.36	129.26
- Non Current	581.58	387.78

B Lease liabilities

i) Lease liabilities are presented in the balance sheet as follows:

Particulars	As at 31 March 2026	As at 31 March 2025
Current	199.36	129.26
Non-current	581.58	387.78
Total	**780.94**	**517.04**

ii) The following are amounts recognised in the statement of profit and loss:

Particulars	As at 31 March 2026	As at 31 March 2025
Depreciation on right-of-use assets	215.13	154.59
Interest expense on lease liabilities	49.34	31.53
Rent expense related to short-term leases	39.14	38.68
Total	**303.61**	**224.80**

C The Group has elected not to recognise a lease liability for short term leases (leases with an expected term of 12 months or less) or for leases of low value assets. Payments made under such leases are expensed on a straight-line basis. In addition, certain variable lease payments are not permitted to be recognised as lease liabilities and are expensed as incurred.

D Maturity of lease liabilities

As at 31 March 2026	Minimum lease payments due				
	Within 1 year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	254.49	184.31	120.24	451.59	1,010.63
Interest expense	55.13	43.57	35.60	95.39	229.69
Net present values	**199.36**	**140.74**	**84.64**	**356.20**	**780.94**

As at 31 March 2025	Minimum lease payments due				
	Within 1 year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	168.48	130.52	79.88	308.50	687.38
Interest expense	39.22	30.76	24.59	75.77	170.34
Net present values	**129.26**	**99.76**	**55.29**	**232.73**	**517.04**

E Total cash outflow of leases

Particulars	As at 31 March 2026	As at 31 March 2025
Total cash outflow of leases	250.17	177.06

42 Contingent liabilities and commitments

	Particulars	As at 31 March 2026	As at 31 March 2025
a)	**Commitments**		
	Estimated amount of contracts remaining to be executed on capital account and not provided for (net of capital advances)	96.36	96.71
	Export obligation on account of concessional rate of custom duty availed under EPCG license under scheme on import of capital goods	267.62	192.86

b) Contingent liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Claim against the group not acknowledged as debts		
(i) Value Added Tax (VAT)	-	6.01
(ii) All taxes (except VAT)	8.75	9.92

The Group and its associates has certain ongoing litigations for which amounts are not quantifiable. Based on the assessment of these litigations, the management believes that no material liability will devolve on the Group.

43 Revenue from contracts with customers

The Group deals into coronary stent system and related products and lab solution products. The revenue is recognised in respect of the Goods at a point in time basis when the control of goods is transferred to the customer and revenue in respect of services is recognised over the time.

a) Assets related to contracts with customer:

Particulars	As at 31 March 2026	As at 31 March 2025
Trade receivables (refer note 13)	7,386.05	5,333.63

b) Reconciliation of revenue recognised in statement of Profit and loss with contract price:

Description	As at 31 March 2026	As at 31 March 2025
Contract price	27,348.41	21,341.09
Less: discounts, rebates, credits etc.	(1,602.23)	(2,354.12)
Total	**25,746.18**	**18,986.97**

c) The information about contract liabilities from contract with customers:

Particulars	As at 31 March 2026	As at 31 March 2025
Contract liabilities (refer note 22B)	401.38	308.52

d) Revenue recognised in the reporting period included in contract liability:

Particulars	As at 31 March 2026	As at 31 March 2025
Opening balance	308.52	294.57
Advance from customers acquired under business combination (refer note 46)	64.65	196.05
Addition during the year	401.38	308.52
Revenue recognised during the year	(373.17)	(490.62)
Closing balance	**401.38**	**308.52**

e) The Group enters into instrument rental arrangements with customers wherein diagnostic instruments are placed at customer locations without upfront consideration and free of cost maintenance service over the period of the contract. Under these agreements, customers commit to purchasing reagents exclusively from the Group over a specified period and the recovery for the said implicit services is bundled with the consideration received for the supply of reagents.

The Group has determined that the performance obligations of transferring the use of instruments over the contract period, its maintenance and supply of reagents are separate performance obligations in the context of the contract as each such performance obligation is promised to be delivered to the customer individually.

Basis evaluation at the contract inception date, either the arrangements do not contain a lease component or where the substitution rights are not substantive for a specified non-cancellable period, such instrument rental arrangements are predominantly classified as operating leases with variable lease payments. In both cases, revenue is to be recognised over time over the contract period. Considering the contract is for supply of reagents uniformly over the contract period, the income for aforesaid 'right to use' and maintenance components is recognised as and when the reagents are supplied to the customer. Further, considering the aforesaid service components are not material to the contract values and do not impact the timing of revenue recognition, additional disclosures with respect to service income/lease income have not been considered necessary.

f) The Group has not incurred any cost for obtaining contracts except administrative cost and the same is charged to the consolidated statement of profit and loss.

g) No single external customer amounts to 10% or more of the Group's revenue from operations.

(This space has been intentionally left blank)

44 Information on related party transactions pursuant to Ind AS 24 - Related Party Disclosures

In accordance with the requirements of Ind AS 24, 'Related Party Disclosures', the names of the related party where control/ significant influence exists, along with the transactions and year end balances with them as identified and certified by the management are given below:

A Names of related parties and related party relationship

Name of the related party	
(i) Ultimate Holding Company	Everstone Capital Partners III LP
(ii) Intermediate Holding Company	ECP III Pte. Ltd., Singapore
(iii) Entities having significant influence over the Holding Company	Medicore Holdings Pte. Ltd. (formerly known as Integris Holding Pte Ltd.) (w.e.f. 23 June 2025) Evercure Holding Pte. Ltd., Singapore (Immediate Holding Company till 22 June 2025)
(iv) Directors and Key Management Personnel (KMP)	Ms. Punita Sharma, Director Mr. Gurmit Singh Chugh, Director Mr. Vishal Sharma, Director (till 07 March 2025) Mr. Avnish Mehra, Director Mr. Arjun Oberoi, Director (refer note (l) below) Mr. Vishal Omprakash Goenka, Director Mr. Puggera Mandappa Devaiah, Director (w.e.f. 07 March 2025 till 21 July 2025) Mr. Amit Manocha, Director (w.e.f. 07 March 2025 till 21 July 2025) Mr. Indranil Mukherjee, Director (till 09 June 2025) Mr. Kewal Jindal, Chief Financial Officer (till 25 August 2025) Mr. Probir Das, (Executive Director - w.e.f. 10 June 2025 and Group CEO - w.e.f. 18 November 2024) Mr. Hemant Sultania, Chief Financial Officer (w.e.f. 25 August 2025) Ms. Rajani Kesari, Independent Director (w.e.f. 01 August 2025) Mr. Ramesh Subrahmanian, Independent Director (w.e.f. 01 August 2025) Mr. Annaswamy Vaidheesh, Independent Director (w.e.f. 26 August 2025) Ms. Sonia, Company Secretary (w.e.f. 20 September 2024 till 09 March 2025) Mr. Darpan Batra, Group General Counsel and Company Secretary (w.e.f. 26 September 2025)
(v) Entities under the control, joint control or significant influence of KMP or their relatives	Halemed Medical Private Limited (till 23 June 2025)
(vi) Subsidiaries	Translumina Therapeutics Private Limited (Converted from Translumina Therapeutics LLP on 25 January 2025) Transhealth Private Limited Transvalve Health Private Limited Translumina GmbH Artic GmbH Translumina France (refer note (k) below) Blue Medical Devices B.V. LAMED Vertriebsgesellschaft mbH für medizintechnische Produkte Translumina Medical Devices Trading L.L.C (incorporated w.e.f. 24 April 2024) Analisa Resources (M) Sdn. Bhd.(refer note (a) below) Biofrontier Technology Pte. Ltd (refer note (a) below) Bio-Rev Pte. Ltd (refer note (a) below) Chemoinformatics Sdn. Bhd (refer note (a) below) Chemopharm Sdn Bhd (refer note (a) and (g) below Chemoresearch Sdn. Bhd (refer note (a) and (d) below) Chemoresources Sdn. Bhd (refer note (a) below) Chemoscience (Malaysia) Sdn. Bhd (refer note (a) and (h) below) Chemoscience Pte. Ltd (refer note (a) below) Chemoscience Philippines Inc.(refer note (a) below) CPC Diagnostics Private Limited (refer note (a) and (j) below) Lifeline Holdings Inc. (refer note (b) and (e) below) (w.e.f. 23 June 2025) Lifeline Diagnostics Supplies Inc.(refer note (b) and (e) below) (w.e.f. 23 June 2025) Everlife Philippines Holding Inc (refer note (a) below) Medigene Sdn Bhd (refer note (a) below) PT Chemoscience Indonesia (refer note (a) below) Research Instrument Pte. Ltd (refer note (a) below) Research Instruments Sdn. Bhd (refer note (a) below) Research Instruments Vietnam Company Limited (refer note (a) below) Scientific Resources Pte Ltd (refer note (a) below) Hausen Bernstein Co., Ltd.(refer note (a) and (i) below) (w.e.f. 21 February 2024) Neoscience Sdn Bhd (refer note (b) below) (w.e.f. 24 June 2025) Nevolution Engineering Sdn Bhd (refer note (b) below) (w.e.f. 24 June 2025) Everlife Holdings Pte Ltd.(refer note (b) below) Halemed Medical Private Limited (refer note (b) below) (w.e.f. 24 June 2025)
(vii) Associate company	Lifeline Holdings Inc.(refer note (b) and (e) below) (till 22 June 2025) Lifeline Diagnostics Supplies Inc (refer note (b) and (e) below) (till 22 June 2025) R I Technologies Limited (refer note (a) below) Chemoscience (Thailand) Co Ltd (refer note (a) below) Laguna Tech USA, Inc. (refer note (f) below) (w.e.f. 11 December 2025)
(viii) Fellow subsidiaries/entities under common management/under which director is interested with whom there are transactions	'Cure Everlife Holdings, Mauritius

(a) Subsidiaries, associates and joint ventures of Everlife Holdings Pte. Ltd.
(b) Refer note 46
(c) Refer note 44
(d) Chemoresearch Sdn Bhd has been dissolved/strike off w.e.f. 06 January 2025.
(e) Lifeline Holdings Inc. and Lifeline Diagnostics Supplies, Inc. become subsidiary w.e.f. 23 June 2025 (refer note 46(I)(C)).
(f) Refer note 6A.
(g) Refer note 47(c).
(h) The management of Chemoscience (Malaysia) Sdn. Bhd is planning to submit an application to the concerned authorities for striking off the Company. Accordingly, the financial statements of subsidiary have been prepared on liquidation basis, wherein all the assets have been recognised at their net realisable value.
(i) Refer note 21B
(j) Refer note 16B(xii)
(k) Translumina France has been dissolved/strike off w.e.f. 31 July 2024.
(l) Mr. Arjun Oberoi resigned on 07 March 2025 from the position of Director however subsequently resumed his position effective 21 July 2025.

B The following transactions were carried out with related parties in the ordinary course of business

	Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
i)	**Key management personnel**		
	Ms. Punita Sharma		
	Interest expense on lease liability	0.22	0.60
	Depreciation on ROU	0.42	0.83
	Rent expense	0.16	-
	Issue of equity shares	7.01	-
	Equity shares issued on conversion of CCPS#	-	280.00
	Gurmit Singh Chugh		
	Interest on lease Liability	0.21	0.57
	Depreciation on ROU Asset	0.41	0.88
	Rent Expense	0.16	-
	Issue of Equity shares	7.01	-
	Equity shares issued on conversion of CCPS#	-	280.00
	Remuneration to Key Management Personnel		
	Short term employee benefits	128.33	81.47
	Share based payment expense	37.30	135.44
	Independent director remuneration and sitting fees	9.64	-
	* The above remuneration excludes provision for gratuity and compensated absences as employee-wise detailed in actuarial valuations are not available.		
(ii)	**Associate companies**		
	Chemoscience (Thailand) Co. Ltd		
	Loan taken	27.85	-
	Expense paid on behalf of Co.	5.61	-
	Other expense	0.67	-
	Purchases	-	1.24
	Sales	-	0.14
	Loan repaid	-	18.73
	RI Technologies Limited		
	Loan taken	47.35	-
	Chargeback income	0.04	0.04
	Expense paid on behalf of Co.	6.92	
	Interest expense	1.14	-
	Purchase	-	0.03
	Lifeline Diagnostics Supplies Inc.		
	Freight charges	-	0.01
	Chargeback expense	11.55	34.01
	Purchase	-	13.74
	Reimbursement paid on behalf of Lifeline Holdings, Inc.	0.20	-
	Reimbursement paid on behalf of Everlife Holdings Pte. Ltd.	0.70	-
	Reimbursement paid on behalf of Everlife Philippines Holding Inc	0.09	0.29
	Rental expense	0.05	0.09
	Sales	2.83	0.86
	Reimbursement received on behalf of Everlife Philippines Holding Inc	-	1.33
	Lifeline Holdings, Inc.		
	Interest income	7.49	30.78
	Reimbursement paid on behalf of Lifeline Diagnostics Supplies Inc	0.19	-
	Loan repaid	-	86.53
	Rental income	0.02	-
	Laguna Tech Inc, USA		
	Investment in equity component	293.95	-
	Repaid on termination of SAFE instrument	44.64	-
(iii)	**Intermediate Holding Company**		
	ECP III Pte. Limited		
	Interest expense	15.72	50.60
	Loan repaid	66.21	-
	Loan taken	66.21	-
	Redemption of preference share capital issued by Everlife Holdings Pte. Ltd.	-	2,254.36
	Issue of promissory note by Everlife Holdings Pte. Ltd.	-	4,235.45
	Conversion of promissory note into Class C preferences shares	4,235.45	-
	Acquisition of Class C preference shares by Holding Company via issuance of equity share capital	4,229.84	-
(iv)	**Entities having significant influence over the Holding Company**		
	Medicore Holdings Pte. Ltd.		
	Share based payment expenses	432.90	-
	Issue of Equity Shares	38.46	
	Evercure Holding Pte. Ltd.		
	Issue of Equity Shares	21.04	-
	Equity shares issued on conversion of CCPS#	-	840.00
(v)	**Fellow subsidiaries/entities under common management/under which director is interested**		
	Cure Everlife Holdings		
	Loan repaid	17.33	-
	Interest paid	-	0.52
	Redemption of preference share capital issued by Everlife Holdings Pte. Ltd.	-	276.07
	Issue of promissory note by Everlife Holdings Pte. Ltd.	-	518.67
(vi)	**Entities under the control, joint control or significant influence of KMP or their relatives**		
	Halemed Medical Private Limited		
	Loan given	-	64.50
	Interest Income on loan given	-	2.43
	Sale of Products	-	3.15

C The following balances were outstanding as at with related parties in the ordinary course of business:

	Particulars	As at 31 March 2026	As at 31 March 2025
i)	**Key management personnel**		
	Mr. Gurmit Singh Chugh		
	Lease liabilities	-	2.00
	Ms. Punita Sharma		
	Lease liabilities	-	1.25
	Directors and Key Managerial Personnel		
	Short term employee benefits payable	46.23	-
	Independent director remuneration and sitting fees	3.33	-
ii)	**Associate Companies**		
	Lifeline Holdings, Inc.		
	Loan given	-	413.97
	Investment in equity component	-	1,959.46
	Lifeline Diagnostics Supplies Inc		
	Investment in equity component	-	1,625.68
	Trade receivable	-	0.86
	Other payable	-	5.57
	Trade payable	-	15.99
	Chemoscience (Thailand) Co. Ltd		
	Investment in equity component	66.11	49.26
	Loan given	12.21	-
	Other payable	6.19	-
	Other recoverable	0.05	0.10
	Loan taken	29.55	1.47
	Trade payables	-	0.14
	RI Technologies Limited		
	Other recoverable	-	0.05
	Other payable	8.14	-
	Investment in equity component	162.20	155.34
	Loan taken	50.23	-
	Laguna Tech Inc, USA		
	Investment in equity component	293.95	-
iii)	**Ultimate Holding Company**		
	ECP III Pte. Limited		
	Loan taken	156.74	142.28
	Interest payable	56.90	168.70
(iv)	**Fellow subsidiaries/entities under common management/under which director is interested**		
	Cure Everlife Holdings		
	Loan taken	11.61	27.61
	Interest payable	0.49	-
(vi)	**Entities under the control, joint control or significant influence of KMP or their relatives**		
	Halemed Medical Private Limited		
	Loan given	-	64.50
	Trade receivables	-	0.81
	Interest accrued	-	2.43

*refer note 33(ii)
#refer note 17(xiv)

Notes

a) All the transactions with related parties are made on the terms equivalent to those that prevails in arm's length transactions and within the ordinary course of business. Outstanding balances at respective year ends are unsecured and settlement is generally done in cash.
b) The above information has been determined to the extent such parties have been identified on the basis of information available with the Group and relied upon by the auditors.
c) Liabilities for gratuity are provided on an actuarial basis for the Group as a whole, the amounts pertaining to the key management personnel is not included.
d) Outstanding balances are net of TDS and including GST as applicable.
e) Also refer note 16(a)(iii)(a),(c), 46(I)(B), 46(I)(D), 17B, 17(xiii), 21 B and 47(c) for related party transactions and balances.

45 Segment information

For management purposes, the Group is organised into business units based on its products and services and has two reportable segments, as follows:
a. Lab solutions segment and
b. Cardiovascular segment.

The Lab solutions segment is majorly involved in
- trading and distribution of chemicals, laboratory and medical equipment's, in-vitro diagnostics products, scientific instruments,
- technical services such as testing, analysis and support of medical equipment along with after sales support for research and clinical labs,
- specialised services such as renting of lab and surgical instruments and training and research support for biologics

The Cardiovascular segment is majorly engaged in manufacturing & marketing of coronary stent systems and related products, drug-eluting solutions, Percutaneous Transluminal Coronary Angioplasty ("PTCA") balloon catheters, innovative, high-quality cardiovascular devices and trading of various medical devices, coronary stent and related cardiovascular products.

No operating segments have been aggregated to form the above reportable operating segments.

The Group Chief Executive Officer is the Chief Operating Decision Maker (CODM) and monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the consolidated financial statements. However, the performance of Group's joint venture and associate companies is evaluated using proportionate consolidation. Also, the Group's financing (including finance costs and finance income) and income taxes are managed on a Group basis and are not allocated to operating segments.

Transfer prices between operating segments are on an arm's length basis in a manner similar to transactions with third parties.
The Group has operations in India, Europe and Southeast Asia and has identified two Geographical Segments namely, 'Within India' and 'Outside India'.
Segment assets include all operating assets that are employed by a segment in its operating activities, including goodwill and that either are directly attributable to the segment or can be allocated to the segment on a reasonable basis. Segment assets do not include income tax assets.

A. Segment revenue:
Financial information about geographical segments is presented below:

Particulars	Within India	Outside India	Total
Revenue from operations			
31 March 2026	7,363.53	18,422.47	25,786.00
31 March 2025	6,674.88	12,349.78	19,024.66

B. Other information:
Financial information about geographical segments is presented below:

Particulars	Within India	Outside India	Total
Non-current assets (other than financial instruments and deferred tax asset)			
31 March 2026	5,824.03	16,409.01	22,233.04
31 March 2025	1,876.02	15,895.85	17,771.87

C. Category wise:
Financial information about category wise segments is presented below:

Particulars	Lab solutions	Cardiovascular	Total
Revenue:			
31 March 2026	18,585.25	7,200.75	25,786.00
31 March 2025	12,412.48	6,612.18	19,024.66

Particulars	Lab solutions		Cardiovascular	
	For the year ended 31 March 2026	For the year ended 31 March 2025	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue from operations	18,585.25	12,412.48	7,200.75	6,612.18
Other income	363.47	245.75	418.15	325.43
Segment revenue	**18,948.72**	**12,658.23**	**7,618.90**	**6,937.61**
Cost of materials consumed	157.84	41.13	1,324.07	1,274.36
Purchases of stock-in-trade	11,340.53	7,456.50	2,407.71	1,972.61
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(441.84)	(139.37)	(287.77)	57.94
Employee benefits expenses	3,254.55	2,078.93	1,725.22	1,412.62
Finance costs	406.90	447.83	207.38	238.77
Depreciation and amortisation expenses	1,573.34	982.17	431.61	363.29
Other expenses	1,424.51	1,006.75	1,245.75	1,074.18
Total expenses	**17,715.83**	**11,873.94**	**7,053.97**	**6,393.77**
Profit before share of net profit of investments accounted for using the equity method, exceptional items and tax	1,232.89	784.29	564.93	543.84
Share of profit of an associate, net of tax	43.30	144.00	-	-

Particulars	Lab solutions		Cardiovascular	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Segment assets	24,185.81	18,239.90	17,783.08	18,173.45
Segment liabilities	13,131.36	16,397.50	5,752.95	6,802.61

46 Business Combination

(I) Acquisitions during the year ended 31 March 2026

(A) Acquisition of Neoscience Group

On 24 June 2025, the Group acquired 100% of the issued share capital of Neoscience Sdn Bhd ("Neoscience") and Nevolution Engineering Sdn. Bhd ("Nevolution", subsidiary of Neoscience) (Neoscience and Nevolution collectively referred as "Neoscience Group"). Neoscience Group is engaged in trading of laboratory equipment, pharmaceuticals, and medical goods.

Assets acquired and liabilities assumed

The fair values of the identifiable assets and liabilities of Neoscience Group as at the date of acquisition were:

	Fair value recognised on acquisition
Assets	
Property, plant and equipment	161.24
Right of use assets	2.97
Distribution agreements	245.23
Cash and cash equivalents	250.56
Other bank balances	60.34
Trade receivables	94.93
Inventories	123.74
Other current financial assets	18.68
Other current assets	14.28
Total Assets	**971.97**
Liabilities	
Deferred tax liabilities (net)	(62.23)
Lease liabilities	(3.01)
Trade payables	(55.91)
Other current financial liabilities	(3.03)
Other current liabilities	(61.49)
Current tax liabilities (net)	(11.05)
Total liabilities	**(196.72)**
Total identifiable net assets at fair value	**775.25**
Goodwill arising on acquisition (refer note 5B)	295.96
Purchase consideration transferred	**1,071.21**

Analysis of cash flows on acquisition

Particulars	**Amount**
Cash and cash equivalents paid	(909.08)
Cash and cash equivalents acquired with the subsidiary	250.56
Net cash flow/(paid) on acquisition	**(658.52)**
Fair value of contingent consideration	(162.13)

<u>Goodwill arising on acquisition</u>

The goodwill of ₹ 295.96 million comprises the value of strengthening the Group's market position in the area of technical testing, analysis services including certification of products and services expected to arise from the acquisition.

<u>Impact of the acquisition on profit or loss</u>

From the acquisition date, Neoscience Group contributed ₹ 671.88 million of revenue and a profit before tax of ₹ 153.62 million to the Group's profit before tax for the year. If the combination had taken place at the beginning of the year ended 31 March 2026, revenue from operations would have been higher by ₹180.75 million and the profit before tax for the Group would have been higher by ₹ 40.51 million.

Notes:

a) The acquisition date fair value of the trade receivables amounts to ₹ 94.93 million. The gross amount of trade receivables is ₹ 94.93 million. However, none of the trade receivables is credit impaired and it is expected that the full contractual amounts can be collected.

b) The Group measured the acquired lease liabilities using the present value of the remaining lease payments at the date of acquisition. The right-of-use assets were measured at an amount equal to the lease liabilities and adjusted to reflect the favourable terms of the lease relative to market terms.

c) As part of Share Purchase Agreement with the previous owners of Neoscience Group, a contingent consideration has been agreed. There will be additional cash payments to the previous owner of Neoscience Group, if the adjusted audited earning before interest and tax of Neoscience Group for each of the calendar years ending 31 December 2025 and 31 December 2026 is at least 107% of the adjusted audited earning before interest and tax of Neoscience Group of the respective preceding year. Further, the above additional cash payments shall vary in case the adjusted audited earning before interest and tax of Neoscience Group is higher than above minimum threshold of 107%. The deferred consideration payable will be paid in June 2026 and 2027.

As at the acquisition date, the fair value of the contingent consideration has been estimated to be ₹ 163.13 million (RM 8.00 million) using fair valuation report obtained by the management from external expert wherein value has been determined using monte- Carlo simulation. The contingent consideration is classified as other financial liability (refer note 21B).

Significant increase/ (decrease) in the earning before interest and tax of Neoscience Group would result in higher/ (lower) fair value of the contingent consideration liability.
As at 31 March 2026, the key performance indicators of Neoscience Group show that it is highly probable that the target will be achieved due to a significant expansion of the business and the synergies realised. The fair value of the contingent consideration determined at 31 March 2026 reflects this development, amongst other factors.

(B) Acquisitions of Halemed Medical Private Limited

On 24 June 2025, the Group acquired 100% of the issued share capital of Halemed Medical Private Limited, engaged in the manufacturing and marketing of medical consumables including infusion and transfusion, Cardiac surgery equipments, Respiratory and general consumables.

Assets acquired and liabilities assumed

The fair values of the identifiable assets and liabilities of Halemed as at the date of acquisition were:

	Fair value recognised on acquisition
Assets	
Property, plant and equipments	14.75
Intangibles	0.06
Right of use assets	10.50
Inventory	25.70
Trade receivables	45.30
Cash and cash equivalents	1.20
Other current assets	5.96
Deferred tax assets	14.11
Other current financial assets	0.48
Trademark	35.00
Non-Compete	26.50
Intangible assets under development	9.18
Total Assets	**188.74**
Liabilities	
Borrowings	(169.23)
Trade payables	(11.90)
Other current financial liabilities	(10.07)
Provisions	(1.68)
Lease liability	(12.95)
Total liabilities	**(205.83)**
Total identifiable net assets at fair value (A)	**(17.09)**
Purchase consideration transferred (B)	**42.66**
Goodwill arising on acquisition (refer note 5B) (C) (B-A)	59.75
Deferred tax liability on fair value adjustments and newly identified assets (D)	15.48
Total Goodwill (C+D)	**75.23**

Analysis of cash flows on acquisition

Particulars	**Amount**
Cash and cash equivalents paid	(42.66)
Cash and cash equivalents acquired with the subsidiary	1.20
Net cash flow/(paid) on acquisition	**(41.46)**

Goodwill arising on acquisition

The goodwill of ₹ 75.23 million comprises the value of strengthening the Group's market position in the area of reagents expected to arise from the acquisition.

Impact of the acquisition on profit or loss

From the acquisition date, Halemed Medical Private Limited contributed ₹ 29.18 million of revenue and a loss before tax of ₹ (45.80) million to the Group's profit before tax for the year. If the combination had taken place at the beginning of the year ended 31 March 2026, revenue from operations would have been higher by ₹14.64 million and the profit before tax for the Group would have been lower by ₹ 10.88 million.

Notes:

The acquisition date fair value of the trade receivables amounts to ₹ 45.30 million. The gross amount of trade receivables is ₹ 45.30 million. However, none of the trade receivables is credit impaired and it is expected that the full contractual amounts can be collected.

The Group measured the acquired lease liabilities using the present value of the remaining lease payments at the date of acquisition. The right-of-use assets were measured at an amount equal to the lease liabilities and adjusted to reflect the favourable terms of the lease relative to market terms.

(C) Acquisitions of Lifeline Holdings Inc and Lifeline Diagnostic Supplies Inc.

On 23 June 2025, the Holding Company through its wholly owned subsidiary gained control over Lifeline Holdings Inc and its subsidiary Lifeline Diagnostics Supplies Inc by virtue of removal of commercial restrictions from exercise of call option for 60% voting rights in Lifeline Holdings Inc and additional board seat in its only operating subsidiary Lifeline Diagnostics Supplies Inc, in conjunction to the pre-existing rights & interests, which earlier resulted in significant influence. The additional board seat was acquired by way of a contractual agreement where certain put rights were given to majority shareholder of Lifeline Holdings Inc. The transaction is accounted for as a business combination achieved in stages (step acquisition) under Ind AS 103 “Business Combinations”.
After the transaction, the Holding Company along with its subsidiary holds 40% voting interest in Lifeline Holdings Inc along with holding a substantive call option to purchase the remaining 60% voting interest.

The purpose of this transaction is to significantly enlarge the range of distribution of medical devices, laboratory equipment's and supplies to its clients in the region of Philippines.

Assets acquired and liabilities assumed

The fair values of the identifiable assets and liabilities as at the date of acquisition were:

	Lifeline Diagnostics Supplies Inc. and Lifeline Holdings Inc.
	Fair Value
Assets	
Property, plant and equipment's	604.99
Intangibles	0.44
Right of use assets	59.50
Inventory	890.62
Trade receivables	1,196.86
Cash and cash equivalents	212.80
Other current assets	122.20
Deferred tax assets	36.45
Other current financial assets	18.99
Customer relationship	906.03
Brand	521.40
Distribution agreement	34.19
Total assets	**4,604.47**
Liabilities	
Borrowings	(162.94)
Trade payables	(728.99)
Other current financial liabilities	(50.24)
Deferred tax liabilities	(344.46)
Lease liabilities	(89.84)
Other current liabilities	(11.30)
Provisions	(34.76)
Total liabilities	**(1,422.53)**
Total identifiable net assets at fair value (A)	**3,181.94**
Carrying value of existing stake in associate (after requisite reversal of foreign currency translation reserve pursuant to above restructuring of ₹ 157.61 million).	3,988.80
Gain on business combination achieved in stages	2,379.08
Non-controlling interests measured at fair value	30.81
Total (B)	**6,398.69**
Goodwill arising on acquisition (refer note 5B) (C = B-A)	**3,216.75**

The consideration paid to gain control of above companies was the fair value of previously held interest and fair value of 2% Put rights given to the other shareholder. The previously held equity interest was remeasured to fair value at the acquisition date, and a gain of ₹ 2,379.08 million was recognized in the consolidated statement of profit and loss as an "Exceptional item". Also, the Group has recognised a gain of ₹ 17.14 million in respect of provision created in earlier years on loan given by Everlife Holding Pte Ltd to Lifeline Holding Inc.

Pursuant to above acquisition, Lifeline Holdings, Inc. has incurred transaction cost pertaining to stamp duty charges and taxes payable amounting to ₹ 10.55 million which has been adjusted with retained earnings considering the same to have been incurred as transaction with owners.

Analysis of cash flows on acquisition

Particulars	**Lifeline Diagnostics Supplies Inc. and Lifeline Holdings Inc.**
Cash and cash equivalents paid	-
Cash and cash equivalents acquired with the subsidiary	212.80
Net cash flow/(paid) on acquisition	**212.80**

Goodwill arising on acquisition

The goodwill of ₹ 3,216.75 million comprises the value of strengthening the Group's market position in the area of reagents expected to arise from the acquisition. None of the goodwill recognised is expected to be deductible for income tax purposes.

Impact of the acquisition on profit or loss

From the acquisition date, these companies have contributed ₹ 3,157.99 million of revenue and a profit before tax of ₹ 162.72 million to the Group's profit before tax for the respective period. If the combination had taken place at the beginning of the year ended 31 March 2026, revenue from operations would have been higher by 1,017.87 million and the profit before tax for the Group would have been higher by 126.76 million.

Notes:

(i) The acquisition date fair value of the trade receivables amounts to ₹ 1,196.86 million. The gross amount of trade receivables is ₹ 1,196.86 million. However, none of the trade receivables is credit impaired and it is expected that the full contractual amounts can be collected.

(ii) The Group has elected to measure the non-controlling interests in these Philippines acquiree companies at fair value amounting to ₹ 30.81 million. The fair value of the Non-controlling is valued using market approach after considering the rights of obligations of other instruments including call options, right of first refusal with the Company and redeemable preference shares.

(D) Acquisition of Everlife Holdings Pte. Ltd.

On 23 June 2025, pursuant to the Amended and Restated Shareholders' Agreement entered into between the Company, Evercure Holdings Pte. Ltd. and other parties (the "Amended RSA"), and the Share Subscription and Purchase Agreement dated 12 June 2025 (the "SSPA") entered into amongst the Company, Everlife Holdings Pte. Ltd. ("Everlife Holdings"), Integris Holdings Pte. Ltd. (now known as Medicore Holdings Pte. Ltd.) ("IHPL"), RT Heptagon Holdings SG Pte. Ltd. ("RT Heptagon"), and certain individual shareholders (collectively referred to as the "Minority Shareholders"), (IHPL, RT Heptagon and the Minority Shareholders collectively referred to as the "Sellers"), read together with the Share Swap Agreements dated 18 June 2025 executed between the Company and the Sellers, the Company completed the acquisition of 100% of the equity share capital of Everlife Holdings Pte. Ltd. ("Everlife") controlled by the Parent Company (ECP III) of the Holding Company

Everlife Holdings Pte Ltd is primarily involved in the lab solution segment which includes trading and distribution of chemicals, laboratory and medical equipment, in-vitro diagnostic products, and scientific instruments; it also provides technical services such as testing, analysis, and support of medical equipment, along with after-sales support for research and clinical laboratories. Additionally, it offers specialised services including the rental of laboratory and surgical instruments, as well as training and research support for biologics.

The acquisition has been effected through issuance of 16,455,694 equity shares of the Company, aggregating to a total consideration of ₹ 31,769.86 million.

Out of the total shares issued as consideration, 10,359,660 equity shares, amounting to ₹ 20,000.67 million (consists of equity share capital amounting to ₹10.36 millions and securities premium amounting to ₹ 19,990.31 millions), pertain to transactions considered as common control transactions, as the underlying interest in such shares was outstanding as at 1 April 2024. Accordingly, such portion of the acquisition has been accounted for in accordance with the applicable guidance for common control transactions.

The above acquisition has been accounted for as business combination under common control as per the provisions of Appendix C of Ind AS 103 "Business Combinations". Pursuant to the above, all the assets, liabilities and reserves of have been accounted for from the beginning of the earliest period presented in these in these consolidated financial statements, i.e., 1 April 2024, as under:

(i) The Company has recorded all the assets and liabilities of Everlife Holdings as at the carrying values as appearing in the consolidated financial statements of Everlife Holdings.
(ii) The identity of the reserves pertaining to Everlife Holdings have been preserved and the Company has recorded them in the same form and at the carrying values as appearing in the consolidated financial statements of Everlife Holdings.

(iii) The value of equity share capital and securities premium thereon issued by the Company as consideration of above acquisition has been disclosed as "equity share capital to be issued pursuant to business combination" and "securities premium" respectively.

iv) The difference between the value of assets, liabilities and reserves of Everlife Holdings taken over by the Company and the value of equity share capital and securities premium accounted for has been disclosed as "Common control adjustment deficit account ".

(a) Below are the details of assets, liabilities and reserves taken over of Everlife Holdings as on 01 April 2024 :

Assets taken over (A)	**Amount**
Non-current assets	
Property, plant and equipment	1,387.74
Capital work-in-progress	2.65
Right of use assets	176.54
Goodwill	3,685.08
Other intangible assets	1,796.68
Intangible assets under development	0.80
Financial assets	
Investments in associates	3,578.50
Loans	481.89
Other financial assets	47.63
Deferred tax assets (net)	125.06
Non-current tax assets (net)	28.88
Other non-current assets	2.95
Inventories	1,428.37
Financial assets	
(i) Trade receivables	1,995.07
(ii) Cash and cash equivalents	1,719.81
(iii) Bank balances other than (ii) above	446.48
(v) Other financial assets	137.71
Other current assets	225.55
Total assets	**17,267.39**
Liabilities taken over (B)	
Financial liabilities	
(i) Borrowings	2,298.60
(ii) Lease liabilities	103.30
Other long-term liabilities	34.29
Provisions	46.07
Deferred tax liabilities (net)	359.62
(i) Borrowings	2,809.37
(ii) Lease liabilities	78.09
- Total outstanding dues of micro enterprises and small enterprises	4.39
- Total outstanding dues of creditors other than micro enterprises and small enterprises	1,278.28
(iv) Other financial liabilities	754.85
Other current liabilities	327.57
Provisions	60.38
Current tax liabilities (net)	119.55
Total liabilities	**8,274.36**
Reserves taken over (C)	
Other equity	803.86
Other non-controlling interest	1,436.82
Class B preference share capital	2,900.38
Total reserves	**5,141.06**
Net Assets Taken over (D) (D=A-B-C)	**3,851.97**
Equity share capital issued (E)	**10.36**
Securities premium (F)	**19,990.31**
Capital reserve pursuant to business combination G=(D-E-F)	**(16,148.70)**

also refer note 44

Reconciliation of other equity on account of restatement

Particulars	**01 April 2024**
As reported in previous periods	6,711.65
Adjustments:	
Securities premium	19,990.31
Retained earnings	(1,234.85)
Shared based compensation reserve	18.70
Capital reserve	0.97
Common control adjustment deficit account	(16,148.70)
Other reserve	1,317.01
Foreign currency translation reserve (FCTR)	702.03
Total adjustments	**4,645.47**
As restated	**11,357.12**

Change in assets, liabilities, income, expense, profit and cash flows:

Particulars	Reported number in 31 March 2025	Restated number in 31 March 2025	Increase/ (decrease)	Change %
Total assets	18,172.83	36,413.35	18,240.52	100%
Total liabilities	6,802.59	23,200.11	16,397.52	241%
Total income	6,947.50	19,595.84	12,648.34	182%
Total expenses (including exceptional items)	6,716.12	18,594.33	11,878.21	177%
Share/(loss) of profit from associate	-	144.00	144.00	100%
Profit before tax	231.38	1,145.51	914.13	395%
Total comprehensive income	114.39	875.78	761.39	666%
Cashflow from operating activities	416.87	1,555.43	1,138.56	273%
Cashflow from investing activities	(5,008.97)	(6,085.91)	(1,076.94)	22%
Cashflow from financing activities	4,840.61	4,451.05	(389.56)	(8)%

(b) The details of assets, liabilities, and reserves taken over from Everlife as at 1 April 2023 are presented below. This disclosure has been included for the purpose of the restated financial statements, wherein the earliest period presented is 1 April 2023:

Assets taken over (A)	Amount
Non-current assets	
Property, plant and equipment	803.50
Capital work-in-progress	9.60
Right of use assets	116.32
Goodwill	3,364.33
Other intangible assets	1,853.06
Intangible assets under development	1.51
Financial assets	
Investments in Associates	3,613.36
Investment	410.56
Loans	510.06
Other financial assets	27.14
Deferred tax assets (net)	63.34
Non-current tax assets (net)	32.49
Other non-current assets	5.69
Inventories	1,153.99
Financial assets	
(i) Trade receivables	1,442.96
(ii) Cash and cash equivalents	1,717.00
(iii) Bank balances other than (ii) above	382.44
(iv) Other financial assets	347.52
Other current assets	218.31
Total assets	**16,073.18**
Liabilities taken over (B)	
Financial liabilities	
(i) Borrowings	2,659.68
(ii) Lease liabilities	59.52
Other long-term liabilities	27.06
Provisions	14.96
Deferred tax liabilities (net)	394.96
Financial liabilities	
(i) Borrowings	1,642.01
(ii) Lease liabilities	62.19
(iii) Trade payables	
- Total outstanding dues of micro enterprises and small enterprises	5.99
- Total outstanding dues of creditors other than micro enterprises and small enterprises	1,124.97
(iv) Other financial liabilities	1,197.45
Other current liabilities	295.51
Provisions	46.57
Current tax liabilities (net)	95.53
Total liabilities	**7,626.40**
Reserves taken over (C)	
Other equity	743.08
Other non-controlling interest	951.35
Class B preference share capital	2,900.38
Total reserves	**4,594.81**
Net assets taken over (D) (D=A-B-C)	**3,851.97**
Equity share capital issued (E)	**10.36**
Securities premium (F)	**19,990.31**
Capital reserve pursuant to business combination G=(D-E-F)	**(16,148.70)**

Pursuant to above acquisition, Everlife Holdings Pte. Ltd. has incurred transaction costs pertaining to stamp duty charges and taxes payable amounting to ₹ 174.78 million which has been adjusted with retained earnings considering the same to have been incurred as transaction with owners, out of which ₹ 100.01 million is payable as at 31 March 2026 (disclosed under the head 'other financial liabilities-current') for which the Everlife Holdings Pte. Ltd. is contesting with the relevant government authorities.

(E) Transfer of Medigene Sdn Bhd to Chemopharm Sdn Bhd

During the year ended 31 March 2026, the Board of one of the subsidiaries, Chemopharm Sdn Bhd, the immediate holding company of Medigene Sdn Bhd, approved an intragroup restructuring under which all business operations, customer contracts, distribution agreements, employees, and the remaining assets and liabilities of Medigene Sdn Bhd will be gradually transferred to Chemopharm Sdn Bhd. This transaction represents a common control group reorganisation in accordance with Ind AS 103 – Business Combinations (Appendix C). Accordingly, the transfer has been accounted for at existing book values, and no adjustments have been made to the carrying amounts of the assets and liabilities relating to Medigene Sdn Bhd in the consolidated financial statements of the Group, as the reorganisation does not result in any change in the Group's economic substance. Following the Group's reorganisation, Medigene Sdn Bhd previously assessed as a separate CGU has been integrated into the Chemopharm Sdn Bhd CGU for goodwill impairment assessment.

47 Share-based payments

a) Holding Company Employee Stock Option Scheme - 2024

Under the Employee Stock Option Scheme, 2024 (ESOP), stock options of the Holding Company are granted to employees of the Holding Company and eligible employees of subsidiary companies (group employees) as defined under Employee Stock Options Scheme, 2024 which is administered by the Nomination and Remuneration Committee of the Board of the Company. The maximum number of Shares which shall be subject to Options under the Scheme shall not exceed 10% (ten per cent) of the issued, subscribed and paid-up share capital of the Holding Company, as of the Effective Date ("Ceiling"). The maximum number of Options that may be Granted in the aggregate under this Scheme shall not exceed 5,870,097.

The ESOPs provide a right to its holders (i.e., Group employees) to purchase one (Integris Medtech Limited - IML) share for each option at a pre-determined exercise price on the expiry of the vesting period. The stock options granted will not vest until performance condition is not met i.e., service. The ESOP hence represents an option that provides a right but not an obligation to the group employees to exercise the option by paying the exercise price at any time on completion of the vesting period, subject to an outer boundary on the exercise period.

The Company has granted ESOPs under the the plan to its employees and employees of the subsidiaries(group employees) on an equity-settled basis. The fair value of the share options is estimated at the grant date using a Black Scholes pricing model, taking into account the terms and conditions upon which the share options were granted. Further, there are no cash settlement alternatives with respect to these options.

The vesting of options is subject to the employee's continued employment with the IMPL group. The ESOPs shall vest in a graded manner over a period of 3 to 5 years.

The expense recognised for employee services received during the year is shown in the following table:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Share based payment expenses*	251.84	222.03

There were no cancellations or modifications to the awards other than as disclosed below.

*Share based payment expenses recovered from subsidiaries

<u>Movements during the year</u>

The following table illustrates the number and weighted average exercise prices (WAEP) of, and movements in, share options during the year:

Particulars	Number of options	Weighted average exercise price
Outstanding at 01 April 2024	-	-
Granted during the year	12,25,691	990.89
Outstanding at 31 March 2025	**12,25,691**	**990.89**
Granted during the year	94,996	1,879.06
Forfeiture/ cancellation during the year (refer note below)	(9,30,888)	389.79
Bonus issue during the year	23,81,394	-
Outstanding at 31 March 2026	**27,71,193**	**371.75**

The following principal assumptions were used at the time of grant in the valuation:

Particulars	Grant I	Grant II	Grant III	Grant IV
Grant date	31 May 2024	21 February 2025	14 July 2025	25 Aug 2025
Vesting period ends	30 September 2027	17 November 2028 and 04 February 2029	31 March 2028 ad 31 March 2029	25 August 2030
Fair value per Option at grant date (in ₹)	301.35 - 758.72	269.52 - 688.82	555.98 - 874.25	441.97 - 911.89
Exercise price at date of grant	551 and 1125	1688	1688	1930
Risk–free interest rate (%)	6.75% - 6.82%	6.60% - 6.66%	5.42%-5.84%	5.42%-5.84%
Time to Expiration (years)	1.83 -3.84	1.50 -5.24	1.50 - 4.22	1.50 - 5.50
Dividend yield (%)	0%	0%	0%	0%
Expected volatility (%)	35%	45%	40%	40%
Share price at date of grant (in ₹)	1,168.59	1,423.47	1,930.63	1,931.22

Note:

(i) Indranil Mukherjee resigned from the position of Chief Executive Officer (Cardiovascular) of Translumina Therapeutics Private Limited ("TTPL"), a subsidiary of the Company.
Pursuant to the approval of the Nomination and Remuneration Committee of Integris Medtech Limited on 24 January 2026, the Company approved the cancellation of all vested employee stock options held by Indranil Mukherjee as at the resignation date. In lieu of such cancellation, TTPL entered into an agreement (including an addendum thereto) with Mr. Mukherjee, under which TTPL agreed to pay a one-time ESOP settlement amounting to ₹ 114.40 million, payable in two tranches.
Accordingly, the settlement amount has been recognised as at 31 March 2026 and presented under employee-related payables within other financial liabilities (current).
Consequent to the above, the Company has transferred an amount of ₹ 90.25 million, representing the cumulative expense recognised in respect of vested employee stock options (i.e. 3,94,455 options), from the Share Based Payment Reserve to Retained Earnings. Further, an amount of ₹ 114.40 million has been charged directly to Retained Earnings within Other Equity, in accordance with the principles of Ind AS 102 – Share-based Payment.

(ii) One of the employee of a Subsidiary entity, has been granted ESOPs as per the Company's ESOP scheme. That employee has also been provided a right whereby the Company may allot additional stock options, or Subsidiary entity will pay a cash bonus, to ensure that the employee's total gain from exercising the stock options is not less than the annual bonus entitlement for the three years ending on 31 March 2025, 31 March 2026, and 31 March 2027.
Consequent to the above, the Holding Company has recognized an expense of ₹ 65.71 million under share based payment expense and has recorded a corresponding liability under employee related payables within other financial liabilities (non current).

b) CPC Diagnostics Private Limited Employee stock compensation - Employee stock option plan

In April 15, 2021, the Board of Directors of CPC Diagnostics Private Limited approved the 2021 Employee Stock Option Plan (ESOP) to its employees. The vesting conditions include service and performance terms for the employees. Exercise price of options is ₹ 100. The options under this grant would vest to the employees as per below terms:

- generally over 4 year vesting period as 20% for the first three years and thereafter 40% for the last one year from the date of grant commencement date, respectively.

Particulars	For the year ended 31 March 2026		For the year ended 31 March 2025	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Outstanding at the beginning of the year	3,684.00	100.00	3,684.00	100.00
Less: Exercised during the year	(3,684.00)	(100.00)	-	-
Outstanding at the end of the year	**-**	**-**	**3,684.00**	**100.00**
Exercisable at the end of the year	-	-	2,210.00	100.00

Fair value of ESOP options was determined using Black Scholes option pricing model with the following assumptions:

Particulars	Grant I
Grant date	30-Apr-21
Vesting period ends	30-Apr-25
Share price at date of grant	3,201
Volatility (s)	0.56
Expected Option Life	4 years
Dividend Yield	0.00%
Risk-free Investment Rate	6.03%
Exercise Price	100
Weighted average share price	3,201
Weighted average remaining contractual life*	-

*The exercise date for all the outstanding options depends on execution of future event (Liquidity event- Change in shareholding of the Holding Company or ultimate holding Company). As there is no fixed time limit for the future event, weighted average remaining contractual life cannot be determined.

During the year ended 31 March 2026, all of the above 3,684 ESOPs granted by CPC Diagnostics Private Limited ("CPC") have been exercised by its employees. Consequently the percentage shareholding Everlife Holdings Pte. Ltd.in CPC has reduced from 65% to 64.61%.
The impact of the additional NCI arising from the above amounts to ₹ 4.85 million, as compared to the proceeds received from employees and corresponding balance of share based compensation reserve, resulting in a credit to retained earnings of ₹ 3.74 million.

The expense recognised for employee services received during the year is shown in the following table:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Expense arising from equity-settled share-based payment transactions	0.07	4.30

c) Employee Share Option Plan (ESOP)-Chemopharm Sdn. Bhd.

On February 15, 2019, the Board of Directors of Chemopharm Sdn Bhd ("the Company") approved the Chemopharm Sdn. Bhd. Limited Employees Stock Option Plan 2019 (ESOP) to its employees. The maximum number of Shares which shall be subject to Options under the ESOP will be restricted to 10% (Ten percent) of the total paid up Share Capital of the Company on a Fully Diluted Basis at the time of the first inception of implementation of the ESOP (Ceiling limit), which may be increased or decreased with the written consent of the Board. The ESOPs provide a right to its holders (i.e.,employees) one share of the Company for each option at a pre-determined exercise price on the expiry of the vesting period. According to the scheme, The vesting conditions include service and performance terms for the employees. There would be graded vesting on annual basis for the next 4 years as 20% for the first three years and thereafter 40% for the last one year from the date of grant commencement date, respectively. The contractual life (comprising the vesting period and the exercise period) of options granted is from the date of such grant till the resignation of the employee.

The following are the number and weighted average exercise prices (WAEP) of, and movements in, share options during the year:

Particulars	For the year ended 31 March 2026		For the year ended 31 March 2025	
	No. of options***	Weighted average exercise price*	No. of options***	Weighted average exercise price*
Outstanding at the beginning of the year	2,48,500	395.25	2,48,500	360.34
Granted during the year	-		-	-
Exercised during the year	(2,48,500)	424.63	-	-
Outstanding at the end of the year	-	-	2,48,500	395.25
Exercisable at the end of the year	-	-	2,47,500	395.25

The fair value of the stock options are estimated using Black-Scholes pricing model considering the following inputs for grant dates mentioned above:

Particulars	Grant I	Grant II	Grant III	Grant IV
Grant date	01-Apr-19	01-Nov-19	31-Dec-20	31-Mar-22
Vesting period ends	31-Mar-23	31-Oct-23	31-Dec-24	31-Mar-26
Share price at date of grant	14.62	14.62	20.78	23.9
Volatility	40.80%	39.30%	33.40%	40.10%
Option Life	5 years	5 years	5 years	5 years
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Risk-free Investment Rate	3.50%	3.30%	2.10%	3.40%
1.5x return on investment	29.98	29.98	29.98	29.98
Weighted average share price	32.66	31.69	29.67	40.17
Exercise Price *	20.46	20.46	20.46	20.46
Weighted average remaining contractual life**	-	-	-	-

*The exercise price is denominated in MYR currency and the weighted average exercise price is MYR 20.46 as at 31 March 2025. The difference in weighted average exercise price in INR is on account of foreign exchange rates.

** The exercise date for all the outstanding options (Grant I, Grant II, Grant III and Grant IV) depends on execution of future event (Liquidity event- Change in shareholding of the Holding Company or ultimate holding Company and 1.5x return on investment of Holding Company). As there is no fixed time limit for the future event, weighted average remaining contractual life cannot be determined.

***As set out in the table above, during the year ended 31 March 2026, all 248,500 Employee Stock Options (ESOPs) granted by Chemopharm Sdn. Bhd. (“CPM”) were exercised by its employees. The impact of the additional NCI arising from the above amounts to ₹ 149.91 million, as compared to the proceeds received from employees and corresponding balance of share based compensation reserve, resulting in a debit to retained earnings of ₹ 21.03 million. Subsequently, Everlife Holding Pte. Ltd. (“Everlife”) and CPM entered into Share Purchase Agreements (“SPAs”) with the respective employees for the acquisition of all 248,500 equity shares so exercised.

The total purchase consideration under the SPAs amounts to ₹ 712.46 million (USD 8.05 million), of which the first tranche payment of ₹ 178.11 million (USD 2.01 million) has been made. The balance ₹ 534.35 million (reinstated amount as at 31 March 2026 : ₹ 569.63 million, USD 6.04 million), representing consideration payable to employees, has been recognised as “Payable on account of share acquired/to be acquired” under “Other financial liabilities – current” in these consolidated financial statements.

As of 31 March 2026, Everlife has completed the acquisition of 28,000 equity shares of CPM from one employee. The remaining 220,500 equity shares have not yet been acquired pending fulfilment of certain closing conditions under the SPAs. These conditions are procedural and administrative in nature. As Everlife has entered into a binding obligation to purchase these shares at a pre-determined price, the SPAs have been accounted for as forward contracts in accordance with Ind AS 32 – Financial Instruments: Presentation and Ind AS 109 – Financial Instruments.

Consequently, although Everlife legally holds 96.28% of CPM’s equity as at 31 March 2026, in substance Everlife has acquired (and has committed to acquire) the entire remaining equity interest from employees. Accordingly, the transaction has been accounted for as if Everlife held a 100% ownership interest in CPM as of that date.

In relation to the above transaction, the carrying value of the equity interest acquired was ₹ 149.91 million. The difference between the fair value of consideration paid and carrying value of equity interest amounting to ₹ 562.55 million has been debited in retained earnings

The expense recognised for employee services received during the year is shown in the following table:

Particulars	**For the year ended 31 March 2026**	**For the year ended 31 March 2025**
Expense arising from equity-settled share-based payment transactions	0.05	0.22

d) Employee Share Option Plan (ESOP)-Medicore Holdings Pte. Ltd.

On 23 October 2025, the board of Medicore Holdings Pte. Ltd. (“Medicore”), a shareholder of Integris Medtech Limited, granted 69,992 employee stock options under the MHPL Employee Stock Option Scheme - 2026 to certain employees of Everlife Holdings Pte. Ltd. (“Everlife”), a subsidiary of the Group. Each option carries the right to acquire one Class D ordinary share of Medicore at an exercise price of USD 1. Under the terms of the grant, the share options relating to one employee vested fully on the grant date, while for the remaining two employees, vesting occurs in tranches as follows: 25% on the grant date, 37.5% on 31 March 2026, and 37.5% on 30 September 2026, after which vested options may be exercised at any time in accordance with the grant conditions. The options are non-transferable, non-assignable, and may be exercised only by the respective recipients, subject to the conditions and transfer restrictions specified in their grant letters. Medicore also holds a Purchase Right, enabling it to cancel, buy back and/or require the transfer of up to all Class D shares held by the employee, as per the terms of the grant letter. Under these arrangements, Everlife has no obligation to make any payment to either the employees or Medicore. Accordingly, the Group accounts for the award as an equity-settled share-based payment in accordance with Ind AS 102, recognising a share-based payment expense over the vesting period with a corresponding credit to deemed equity (capital contribution from a shareholder) in the Restated Consolidated financial Information.On 23 October 2025, the Board of Medicore Holdings Pte Ltd approved equity-settled Class D options for selected employees of Everlife Holding Pte. Ltd.. Each option entitles the holder to subscribe one Class D share at an exercise price of USD 1.0. Class D shares do not carry voting rights other than in limited circumstances and are subject to transfer restrictions (pre-IPO) and buy-back (post-IPO). Vesting is service-based only. As per the terms of the grant, share options in respect of one employee have been fully vested as on the grant date, while for the other two employees, vesting shall happen in tranches as follows: 25% on the grant date, 37.5% on 31 March 2026, and the balance 37.5% on 30 September 2026.

The following are the number and weighted average exercise prices (WAEP) of, and movements in, share options during the year:

Particulars	For the year ended 31 March 2026	
	No. of options	Weighted average exercise price
Outstanding at the beginning of the year	-	-
Granted during the year	69,956	88.50
Exercised during the year	-	-
Outstanding at the end of the year	69,956	94.34
Exercisable at the end of the year	61,212	94.34

The fair value of the stock options are estimated using Black-Scholes-Merton option pricing model considering the following inputs for grant dates mentioned above:

Particulars	Grant I
Grant date	23-Oct-25
Vesting period ends	30-Sep-26
Share price at date of grant	79.7
Volatility	41.20% - 52.30%
Option Life	0.40 - 0.90
Dividend Yield	0.00%
Risk-free Investment Rate	1.40%
Fair value per option (USD)	78.7
Weighted average share price	88.50
Exercise Price #	1
Weighted average remaining contractual life ##	-

#The exercise price is denominated in USD currency and the weighted average exercise price is USD 1 as at 31 March 2026. The difference in weighted average exercise price in INR is on account of foreign exchange rates.

The exercise period for all the outstanding options depends on the Administering Authority which has the power to determine the time period within which the grantee may exercise the vested options.. As there is no specified time limit for exercise period, weighted average remaining contractual life cannot be determined.

The expense recognised for employee services received during the year is shown in the following table:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Expense arising from equity-settled share-based payment transactions*	432.90	-

* Since the equity shares to the employees of the group shall be issued by the share holders of the holding company, the above expense has been recognised with corresponding credit to "Deemed Equity" in the consolidated financial statements.

48 Other statutory information :

(i) The Group does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.

(ii) The Group has not traded or invested in crypto currency or Currency during the year ended 31 March 2026 and 31 March 2025.

(iii) The Group has not been declared a wilful defaulter by any bank or financial institution or other lender (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India.

(iv) The Group does not have any transaction with struck off companies under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956.

(v) The Group does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory year.

(vi) The Holding Company has not advanced or loaned or invested funds to any other person or entity, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Holding Company (Ultimate Beneficiaries); or
(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(vii) The Group has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

(viii) The Holding Company has not received any fund from any person or entity, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Holding Company shall:
(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or
(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(viii) The Group does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

(ix) The Holding Company has complied with the relevant provisions of the Foreign Exchange Management Act, 1999 (Paragraph 42 of 1999) and Companies Act for transactions disclosed and the transactions are not violative of the Prevention of Money-Laundering Act, 2002 (Paragraph 15 of 2003).

49 As per Section 128 of the Companies Act, 2013 read with proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 with reference to use of accounting software by the Group Companies for maintaining its books of account, has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such change were made and ensuring that the audit trail cannot be disabled is applicable with effect from the financial year beginning on 1 April 2023. Further the audit trail shall be preserved by the Company as per the statutory requirements for record retention.

The Group Companies, in respect of financial period commencing on 1 April 2025, has used an accounting software for maintaining its books of account which have a feature of recording audit trail (edit log) facility and the same have been operated throughout the period for all relevant transactions recorded in the software except that the audit trail feature was not enabled at the database level for accounting software to log any direct data changes. Further, in respect of one Subsidiary, the accounting software did not have a feature of recording audit trail, used for maintenance of all accounting records.

The Group Companies uses another accounting software for maintenance of payroll records which is operated by a third-party software service provider. As per the 'Independent Service Auditor's Report on a Description of the Service Organization's System and the Suitability of the Design and Operating Effectiveness of Controls' SOC 2 Report, the audit trail (edit log) feature for any direct changes made at the database level and changes made at application level was operating throughout the period for all relevant transactions recorded in the software. Further, in respect of one Subsidiary, audit trail feature was not enabled at the database leve for the accounting software used for maintenance of payroll records.

Furthermore, there were no instances of audit trail feature being tampered with and the audit trail has been preserved by the Group Companies except for one subsidiary as per the statutory requirements for record retention for all accounting softwares. Additionally, with respect to the accounting software used for maintaining the Company's payroll records, the audit trail has not been preserved.

50 Subsequent events

(i) The Board has approved the grant of 180,000 stock options w.e.f 01 April 2026, under the Employee Stock Option Plan Scheme 2024, in accordance with the applicable terms and conditions.

(ii) During the year ended 31 March 2026, the Subsidiary Company paid remuneration to its whole time director and an executive director in excess of the limits prescribed under Section 197 read with Schedule V of the Companies Act, 2013 ('the Act') by ₹ 6.04 million and ₹ 30.65 million, respectively, which has also resulted in exceeding the overall limit of remuneration paid/ payable by the Company to its directors by ₹ 23.29 million. The Company has obtained Board of Directors approval for excess remuneration paid to the whole-time director and executive director in the meetings held on 30 January 2026 and 20 June 2026, respectively.

Subsequent to year ended 31 March 2026, the Subsidiary Company has also obtained shareholders' approval by way of special resolution at the extraordinary general meetings held on 7 April 2026 and 20 June 2026, respectively, with respect to the excess remuneration paid to the whole-time director and the executive director, as required under Section 197 of the Act.

Further, the Subsidiary Company has filed Form MR 2 for seeking approval of the Central Government for appointment of its whole time director in accordance with the requirements of Section 196 read with Schedule V of the Companies Act, 2013. The management expects the requisite approval to be received in due course of time.

(This space has been intentionally left blank)

51 Per transfer pricing legislation under section 92-92F of the Income Tax Act 1961, the Group is required to use certain specific methods in computing arm's length price of international transactions with associated enterprises and maintains adequate documentation in this respect. The legislations require that such information and documentation to be contemporaneous in nature. The Group has appointed independent consultants for conducting the Transfer Pricing Study to determine whether the transactions with associated enterprises undertake during the financial year are on an "arm's length basis". The Group is in the process of conducting a transfer pricing study for the current financial year and expects such records to be in existence latest by the due date as required by law. However, in the opinion of the management the update would not have a material impact on these financial statements. Accordingly, these financial statements do not include any adjustments for the transfer pricing implications, if any.

As per our report of even date

For **Walker Chandiok & Co LLP**
Chartered Accountants
Firm's Registration No: 001076N/N500013

Kartik Gogia
Partner
Membership No.: 512371

Place: Gurugram
Date: 29 June 2026

For and on behalf of the Board of Directors of
Integris Medtech Limited (formerly known as Integris Health Private Limited)

Probir Das
Executive Director and Group CEO
DIN : 06588579

Place: London
Date: 29 June 2026

Vishal Omprakash Goenka
Director
DIN: 10084887

Place: Zermatt, Switzerland
Date: 29 June 2026

Hemant Sultania
Chief Financial Officer

Place: Gurugram
Date: 29 June 2026

Darpan Batra
Company Secretary
Membership No. ACS 15719

Place: Noida
Date: 29 June 2026